Adhesion molecules

ABSTRACT

This invention discloses and claims novel proteins, termed KIAA0301, G7c, KIAA0564, NG37, CAB01991.1 and Rv0368c, herein identified as adhesion molecules. Also disclosed and claimed are methods of use of these proteins, and nucleic acid sequences from the encoding genes, in the diagnosis, prevention and treatment of disease.

REFERENCE TO RELATED APPLICATIONS

[0001] This application is a continuation-in-part application of International Patent Application PCT/GB01/03318, filed Jul. 24, 2001 which published as WO 02/08423 on Jan. 31, 2002, and which claims priority to United Kingdom Patent Applications 0018126.3 filed Jul. 24, 2000 and 0025447.4 filed Oct. 17, 2000.

[0002] Each of the foregoing applications and patents, each foregoing publication, and each document cited or referenced in each of the foregoing applications and patents, including during the prosecution of each of the foregoing applications and patents (“application and article cited documents”), and any manufacturer's instructions or catalogues for any products cited or mentioned in each of the foregoing applications and patents and articles and in any of the application and article cited documents, are hereby incorporated herein by reference. Furthermore, all documents cited in this text, and all documents cited or referenced in documents cited in this text, and any manufacturer's instructions or catalogues for any products cited or mentioned in this text or in any document hereby incorporated into this text, are hereby incorporated herein by reference. Documents incorporated by reference into this text or any teachings therein may be used in the practice of this invention. Documents incorporated by reference into this text are not admitted to be prior art.

[0003] This invention relates to novel proteins, termed KIAA0301, G7c, KIAA0564, NG37, CAB01991.1, and Rv0368c, herein identified as adhesion molecules and to the use of these proteins and nucleic acid sequences from the encoding genes in the diagnosis, prevention and treatment of disease.

[0004] All publications, patents and patent applications cited herein are incorporated in full by reference.

BACKGROUND

[0005] The process of drug discovery is presently undergoing a fundamental revolution as the era of functional genomics comes of age. The term “functional genomics” applies to an approach utilising bioinformatics tools to ascribe function to protein sequences of interest. Such tools are becoming increasingly necessary as the speed of generation of sequence data is rapidly outpacing the ability of research laboratories to assign functions to these protein sequences.

[0006] As bioinformatics tools increase in potency and in accuracy, these tools are rapidly replacing the conventional techniques of biochemical characterisation. Indeed, the advanced bioinformatics tools used in identifying the present invention are now capable of outputting results in which a high degree of confidence can be placed.

[0007] Various institutions and commercial organisations are examining sequence data as they become available and significant discoveries are being made on an on-going basis. However, there remains a continuing need to identify and characterise further genes and the polypeptides that they encode, as targets for research and for drug discovery.

[0008] Recently, a remarkable tool for the evaluation of sequences of unknown function has been developed by the Applicant for the present invention. This tool is a database system, termed the Biopendium search database, that is the subject of co-pending International Patent Application No. PCT/GB01/01105. This database system consists of an integrated data resource created using proprietary technology and containing information generated from an all-by-all comparison of all available protein or nucleic acid sequences.

[0009] The aim behind the integration of these sequence data from separate data resources is to combine as much data as possible, relating both to the sequences themselves and to information relevant to each sequence, into one integrated resource. All the available data relating to each sequence, including data on the three-dimensional structure of the encoded protein, if this is available, are integrated together to make best use of the information that is known about each sequence and thus to allow the most educated predictions to be made from comparisons of these sequences. The annotation that is generated in the database and which accompanies each sequence entry imparts a biologically relevant context to the sequence information.

[0010] This data resource has made possible the accurate prediction of protein function from sequence alone. Using conventional technology, this is only possible for proteins that exhibit a high degree of sequence identity (above about 20%-30% identity) to other proteins in the same functional family. Accurate predictions are not possible for proteins that exhibit a very low degree of sequence homology to other related proteins of known function.

[0011] Introduction to Adhesion Molecules

[0012] Adhesion molecules are involved in a range of biological processes, including: embryogenesis (Martin-Bermudo, M. D. et al, Development. 2000 127(12):2607-15; Chen, L. M., et al., J Neurosci. 2000 20(10):3776-84; Zweegman, S., et al, Exp Hematol. 2000 28(4):401-10; Darribere, T., et al., Biol Cell. 2000 92(1):5-25), maintenance of tissue integrity (Eckes, B., et al., J Cell Sci. 2000 113(Pt 13):2455-2462; Buckwalter, J. A., et al., Instr Course Lect. 2000 49:481-9; Frenette, P. S., et al.,. J Exp Med. 2000 191(8):1413-22; Delmas, V., et al, Dev Biol. 1999 216(2):491-506; Humphries, M. J., et al., Trends Pharmacol Sci. 2000 21(1):29-32; Miosge, N., et al, Lab Invest. 1999 79(12):1591-9; Nagaoka T, et al. Am J Pathol 2000 Jul 157:1 237-47; Nwariaku F E, et al. J Trauma 1995 39(2): 285-8; Zhu X, et al. Zhonghua Zheng Xing Shao Shang Wai Ke Za Zhi 1999 15(1): 53-5), leukocyte extravasation/inflammation (Lim, L. H., et al. Am J Respir Cell Mol Biol. 2000 22(6):693-701; Johnston, B., et al., Microcirculation. 2000 7(2):109-18; Mertens, A. V., et al., Clin Exp Allergy. 1993 23(10):868-73; Chcialowski, A., et al., Pol Merkuriusz Lek. 2000 7(43):13-7; Rojas, A. I., et al, Crit Rev Oral Biol Med. 1999 10(3):337-58; Marinova-Mutafchieva, L., et al., Arthritis Rheum. 2000 43(3):638-44; Vijayan, K. V., et al, J Clin Invest. 2000 105(6):793-802; Currie, A. J., et al,. J Immunol. 2000 164(7):3878-86; Rowin, M. E., et al., Inflammation. 2000 24(2):157-73; Johnston, B., et al., J Immunol. 2000 164(6):3337-44; Gerst, J. L., et al., J Neurosci Res. 2000 59(5):680-4; Kagawa, T. F., et al., Proc Natl Acad Sci USA. 2000 97(5):2235-40; Hillan, K. J., et al., Liver. 1999 19(6):509-18; Panes, J., 1999 22(10):514-24; Arao, T., et al., J Clin Endocrinol Metab. 2000 85(1):382-9; Souza, H. S., et al., Gut. 1999 45(6):856-63; Grunstein, M. M., et al., Am J Physiol Lung Cell Mol Physiol. 2000 278(6):L1154-63; Mertens, A. V., et al., Clin Exp Allergy. 1993 23(10):868-73; Berends, C., et al., Clin Exp Allergy. 1993 23(11):926-33; Fernvik, E., et al., Inflammation. 2000 24(1):73-87; Bocchino, V., et al., J Allergy Clin Immunol. 2000 105(1 Pt 1):65-70; Jones S C, et al, Gut 1995 36(5):724-30; Liu C M, et al, Ann Allergy Asthma Immunol 1998 81(2):176-80; McMurray R W Semin Arthritis Rheum 1996 25(4):215-33; Takahashi H, et al Eur J Immunol 1992 22(11): 2879-85; Carlos T, et al J Heart Lung Transplant 1992 11(6): 1103-8; Fabrega E, et al, Transplantation 2000 69(4): 569-73; Zohrens G, et al, Hepatology 1993 18(4): 798-802; Montefort S, et al. Am J Respir Crit Care Med 1994 149(5): 1149-52), oncogenesis (Orr, F. W., et al., Cancer. 2000 88(S12):2912-2918; Zeller, W., et al., J Hematother Stern Cell Res. 1999 8(5):539-46; Okada, T., et al., Clin Exp Metastasis. 1999 17(7):623-9; Mateo, V., et al., Nat Med. 1999 5(11):1277-84; Yamaguchi, K., et al., J Exp Clin Cancer Res. 2000 19(1):113-20; Maeshima, Y., et al., J Biol Chem. 2000 275(28):21340-8; Van Waes, C., et al, Int J Oncol. 2000 16(6):1189-95; Damiano, J. S., et al., Leuk Lymphoma. 2000 38(1-2):71-81; Seftor, R. E., et al, Cancer Metastasis Rev. 1999 18(3):359-75; Shaw, L. M., J Mammary Gland Biol Neoplasia. 1999 4(4):367-76; Weyant, M. J., et al., Clin Cancer Res. 2000 6(3):949-56), angiogenesis (Koch A E, et al Nature 1995 376 (6540): 517-9; Wagener C & Ergun S. Exp Cell Res 2000 261(1): 19-24; Ergun S, et al. Mol Cell 2000 5(2): 311-20), bone resorption (Hartman G D, & Duggan M E. Expert Opin Investig Drugs 2000 9(6): 1281-91; Tanaka Y, et al. J Bone Miner Res 1995 10(10): 1462-9; Lark M W, et al. J Pharmacol Exp Ther 1999 291(2): 612-7; Raynal C, et al Endocrinology 1996 137(6):2347-54; Ilvesaro J M, et al. Exp Cell Res 1998 242(1): 75-83), neurological dysfunction (Ossege L M, et al. Int Immunopharmacol 2001 1:1085-100; Bitsch A, et al, Stroke 1998 29:2129-35; Iadecola C & Alexander M. Curr Opin Neurol 2001 14:89-94; Becker K, et al Stroke 2001 32(1): 206-11; Relton J K, et al Stroke 2001 32(1): 199-205; Hamada Y, et al J Neurochem 1996 66:1525-31), thrombogenesis (Wang, Y. G., et al., J Physiol (Lond). 2000 526(Pt 1):57-68; Matsuno, H., et al., Nippon Yakurigaku Zasshi. 2000 115(3):143-50; Eliceiri, B. P., et al., Cancer J Sci Am. 2000 6(Suppl 3):S245-9; von Beckerath, N., et al., Blood. 2000 95(11):3297-301; Topol, E. J., et al., Am Heart J. 2000 139(6):927-33; Kroll, H., et al., Thromb Haemost. 2000 83(3):392-6), and invasion/adherence of bacterial pathogens to the host cell (Dersch P, et al. EMBO J 1999 18(5): 1199-1213).

[0013] The detailed characterisation of the structure and function of several adhesion-receptor families has led to active programs by a number of pharmaceutical companies to develop adhesion molecule antagonists for use in the treatment of diseases involving inflammation, oncology, neurology, immunology and cardiovascular function. Adhesion receptors are involved in virtually every aspect of biology from embryogenesis to apoptosis. They are essential to the structural integrity and homeostatic functioning of most tissues. It is therefore not surprising that defects in adhesion receptors cause disease and that many diseases involve modulation of adhesion molecule function.

[0014] The Adhesion molecule family in fact represent at least four distinct families which are unified by their function rather than their structure. Of the four families, three are of pharmaceutical interest due to small molecule tractibility. They are;

[0015] 1.The integrin family is a superfamily of α and β heterodimeric transmembrane glycoproteins and is the family which has attracted most pharmaceutical interest. Its members are large, heavily glycosylated, heterodimeric proteins composed of one of at least 15 distinct α-subunits in non-covalent linkage with one of at least 8 β-subunits. Adhesion receptors bind ligands expressed on cell surfaces, extracellular matrix molecules, and soluble molecules. Integrins are subcategorised based on their β-subunit usage. The members of this family are summarised below in Table 1.

[0016] 2.Selectins are a small family of three members P, E and L selectin. They are glycoproteins, selectively expressed on cells related to the vasculature, and contain a lectin-binding domain. The members of this family are described below in Table 2.

[0017] 3.The immunoglobulin family represents the counter receptor for the integrins and includes the intracellular adhesion molecules (ICAMs) and vascular cell adhesion molecules (VCAMs). Members are composed of variable numbers of globular, immunoglobulin-like, extracellular domains. Some members of the family, for example, PECAM-1 (CD31) and NCAM, mediate homotypic adhesion. Some members of the family, for example ICAM-1 and VCAM-1, mediate adhesion via interactions with integrins. The members of this family are described below in Table 3.

[0018] The fourth family of adhesion molecules is the cadherins, which although is not small molecule tractable (currently), it may become tractable in the near future and is certainly a candidate for antibody targeting:

[0019] 4.The cadherins all contain multiple tandem repeats of the Ca²⁺ binding “Cadherin domain”. The first cadherins to be identified (such as Epithelial/E-Cadherin) are referred to as the classical cadherins and mediate Ca²⁺-dependent cell adhesion. However, more recently identified non-classical members of the Cadherin family are known to be involved in a diverse range of biological processes, such as cell recognition, cell signalling, cell communication, morphogenesis, angiogenesis, and possibly even neurotransmission (Angst B D, et al. J Cell Sci 2001 114(4): 629-639) (See Table 5).

[0020] Adhesion molecules have been shown to play a role in diverse physiological functions, many of which can play a role in disease processes. Alteration of their activity is a means to alter the disease phenotype and, as such, the identification of novel adhesion molecules is highly relevant as they may play a role in many diseases, particularly inflammatory disease, oncology, cardiovascular disease and bacterial infection.

[0021] A further need in the art is, of course, to treat and prevent the incidence of diseases that are caused by bacterial pathogens. Adhesion molecule-like proteins are expressed in pathogenic organisms where they function in mammalian target cell adherence and penetration. In Yersinia pseudotuberculosis, the cell adhesion molecule-like protein Invasin is required for efficient entry into mammalian cells (Dersch P, et al. EMBO J 1999 18(5): 1199-1213). A family of proteins called Intimins (which are highly similar to Invasins) are involved in the attachment of a variety of related Gram-negative enteric pathogens to host cells (Jerse A E, et al. Proc Natl Acad Sci USA 1990 87:7839-7843; Schauer D B, et al. Infect Immun 1993 61:4654-4661) (See Table 6). Therapeutic or diagnostic agents that are specific for the adhesion molecule-like proteins that are expressed in pathogenic organisms would be of great value in the diagnosis and treatment of diseases caused by these organisms. TABLE 1 Integrins: Integrin Receptor Ligand Distribution β1 (CD29) α1β1 Laminin, Collagen Activated T cells, fibroblasts α2β1 Collagen, Laminin Activated T cells, endothelial cells, platelets, basophils. α3β1 Laminin, Collagen, Basement membrane Fibronectin α4β1 VCAM-1 (domains 1 and Lymphocytes, monocytes, eosinophils, 4), Fibronectin (CS-1basophils, mast cells, NK cells domain), MadCAM-1 α5β1 Fibronectin Lymphocytes, monocytes, endothelial cells, basophils, mast cells, fibroblasts α6β1 Laminin Platelets, T cells, eosinophils, monocytes, endothelial cells α9β1 Tenascin, VCAM-1, Airway epithelial cells, smooth muscle cells, Osteopontin neutrophils αVβ1 Vitronectin, fibronectin Platelets, B cells. β2(CD18) LFA-1 ICAM-1, 2, 3 All leukocytes (CD11a/CD18) Mac-1 ICAM-1, Fibrinogen, LPS Granulocytes, monocytes (CD11b/CD18) αD ICAM-3, VCAM-1 Tissue macrophages, monocytes, CD8+ T cells eosinophils β3(CD61) GpIIb/IIIa Fibrinogen, Vitronectin, Platelets, endothelial cells Fibronectin, vWF αV/IIIa Vitronectin, Fibrinogen, Platelets, vWF, Laminin, Thrombospondin, Osteopontin β7 α4β7 MAdCAM-1, VCAM-1, Subset of memory T cells, eosinophils, (LPAM-1) Firbonectin (CS-1basophils, endothelial cells domain) αEβ7 E-cadherin Intestinal intraepithelial lymphocytes.

[0022] TABLE 2 Selectins: Receptor Ligand Distribution E-selectin Sialyl-LewisX, L- Activated endothelial cells selectin, LFA-1, ESL-1, PSGL-1 L-selectin GlyCAM-1, MAdCAM-1, Resting leukocytes CD34, Sialyl LewisX, E-selectin, P-selectin P-selectin Sialyl-LewisX, L- Activated endothelial cells, activated platelets selectin, PSGL-1

[0023] TABLE 3 Immunoglobulin superfamily: Receptor Ligand Distribution ICAM-1 LFA-1 (CD11a/CD18) Widespread, endothelial cells, fibroblasts, 5 Ig domains Mac-1 (CD 11b/CD18), epithelium, monocytes, lymphocytes, dendritic CD43 cells, chondrocytes. ICAM-2 LFA-1 (CD11b) endothelial cells (high): lymphocytes, 2 Ig domains monocytes, basophils, platelets (low). ICAM-3 LFA-1 (αd/CD18) Lymphocytes, monocytes, neutrophils, 5 Ig domains eosinophils, basophils. VCAM-1 α4β1, α4β7 Endothelial cells, monocytes, fibroblasts, 6 or 7 Ig dendritic cells, bone marrow stromal cells, domains myoblasts. LFA-3 CD2 Endothelial cells, leukocytes, epithelial cells 6 Ig domains PECAM-1 CD31, heparin Endothelial cells (at EC-EC junctions), T cell (CD3l) subsets, platelets, neutrophils, eosinophils, monocytes, smooth muscle cells, bone marrow stem cells. NCAM NCAM, heparin SO₄ Neural cells, muscle MadCAM-1 α4β7, L-selectin Peyer's patch, mesenteric lymph nodes, 4 Ig domains mucosal endothelial cells, spleen. CD2 CD58, CD59, CD48 T lymphocytes

[0024] TABLE 4 Cadherin Superfamily Receptor Ligand Distribution Classical Cadherins E-Cadherin/ Homotypic: E-Cadherin Embryo, epithelium Epithelial Cadherin/ Uvomorulin N-Cadherin/ Homotypic: N-Cadherin Neural and muscle tissue Neural Cadherin VE-Cadherin Homotypic: VE Cadherin Endothelial, adherens junctions P-Cadherin Homotypic: P-Cadherin Mouse placenta Desmasomal Cadherins Desmocollin Homo- and Heterotpypic Epithelium, epidervis, myocardium, desmosomes Desmoglein Homo- and Heterotpypic Epithelium, epidervis, myocardium, desmosomes ProtoCadherins μ-Cadberin Embryo CNR Cadherin Nervous system Other Cadherins 7-TM Homotypic: 7-TM Cadherin -Cadherin Flamingo T-Cadherin Fat Human epithelium

[0025] TABLE 6 Invasins/Intimins Receptor Ligand Distribution Invasin Integrins Yersinia pseudotuberulosis Intimin Gram-negative bacterium (including Eseherichia coli)

THE INVENTION

[0026] The invention is based on the discovery that the KIAA0301 protein, G7c protein, KIAA0564 protein, NG37 protein, CAB01991.1 protein and Rv0368c protein function as adhesion molecules.

[0027] Cell adhesion molecules mediate cell-cell adhesion. Cell adhesion molecules bind cells together by one of three possible mechanisms:

[0028] (1) Adhesion molecules on one cell bind adhesion molecules of an identical type on adjacent cells (homotypic adhesion);

[0029] (2) Adhesion molecules on one cell bind adhesion molecules of a different type on adjacent cells (heterotypic adhesion);

[0030] (3) Adhesion molecules on adjacent cells are linked to one another by secreted multivalent linker molecules.

[0031] When a molecule is described herein as possessing activity as an adhesion molecule, this is intended to mean that the described molecules mediate cell-cell adhesion by one or more of these mechanisms.

[0032] For the KIAA0301 protein, it has been found that a region including residues 1832-2036 of this protein sequence adopts an equivalent fold to residues 4 to 193 of the α2 Integrin I-domain (PDB code 1AOX:A). α2 Integrin is known to function as an adhesion molecule, and the I-domain is critical for this function. Furthermore, the divalent metal ion binding residues Ser153, Ser155 and Asp254 of the α2 Integrin I-domain are conserved as Ser1843, Ser 1845 and Asp1948 in KIAA0301, respectively. This relationship is not just to the α2 Integrin I-domain, but rather to the I-domain family as a whole. It has been found that a region whose boundaries extend between, at the most, residue 1832 and residue 2036, and at the least, residue 1836 and residue 1950 of KIAA0301 adopts an equivalent fold to to a range of other I-domains including the MAC-1 (PDB code: 1IDO) and LFA-1 (PDB code: 1ZOO:A) I-domains. Furthermore, the divalent metal ion binding residues Ser139, Ser141 and Asp239 of the LFA-1 I-domain (1ZOO:A) are conserved as Ser1843, Ser 1845 and Asp1948 in KIAA0301, respectively. Thus, by reference to the Genome Threader™ alignment of KIAA0301 with the α2 Integrin (1AOX:A) and LFA-1 (1ZOO:A) I-domains, Ser1843, Ser1845 and Asp1948 of KIAA0301 are predicted to form a metal ion binding triad. KIAA0301 also shows conservation of residues to the metal ion binding triad of the MAC-1 I-domain (1IDO). The MAC-1 (1IDO) triad differs from the triad found in the α2 Integrin (1AOX:A) and LFA-1 (1ZOO:A) I-domains because the third metal ion ligand is a Threonine rather than an Aspartate. Nonetheless, by reference to the Genome Threader™ alignment of KIAA0301 with MAC-1 (1IDO), the MAC-1 (1IDO) triad Ser142, Ser144 and Thr201 is conserved as Ser1843, Ser1845 and Thr1912 in KIAA0301. Thus KIAA0301 has two non-mutually exclusive metal ion binding triads predicted; (Ser1843, Ser1845 and Asp1948) and (Ser1843, Ser1845 and Thr1912).

[0033] The combination of equivalent fold and conservation of divalent metal ion binding residues allows the functional annotation of this region of KIAA0301, and therefore proteins that include this region, as possessing adhesion molecule activity.

[0034] For the G7c protein, it has been found that a region including residues 10-126 of this protein sequence adopts an equivalent fold to residues 3 to 119 of the LFA-1 I-domain (PDB code 1LFA:B). LFA-1 is known to function as an adhesion molecule, and the I-domain is critical for this function. Furthermore, the divalent metal ion binding residues Ser139, Ser141 and Asp239 of the LFA-1 I-domain are conserved as Thr25 (conservative substitution), Ser27 and Asp119 in G7c, respectively. This relationship is not just to the LFA-1 I-domain, but rather to the I-domain family as a whole. It has been found that a region whose boundaries extend between, at the most, residue 10 and residue 126, and at the least, residue 20 and residue 105 of G7c adopts an equivalent fold to to a range of other I-domains including the MAC-1 I-domain (PDB code 1JLM). Furthermore the divalent metal ion binding residues of the MAC-1 I-domain are conserved as Thr25 (conservative substitution), Ser27 and Asp119 in G7c. Thus by reference to the Genome Threader™ alignment with LFA-1 (1LFA:B) and MAC-1 (1JLM), residues Thr25, Ser27 and Asp119 of G7c are predicted to form a metal ion binding triad. The combination of equivalent fold and conservation of divalent metal ion binding residues allows the functional annotation of this region of G7c, and therefore proteins that include this region, as possessing adhesion molecule activity.

[0035] For the KIAA0564 protein, it has been found that a region including residues 1248-1403 of this protein sequence adopts an equivalent fold to residues 2 to 140 of the LFA-1 I-domain (PDB code 1LFA:A). LFA-1 is known to function as an adhesion molecule, and the I-domain is critical for this function. Furthermore, the divalent metal ion binding residues Ser139, Ser141 and Asp239 of the LFA-1 I-domain are conserved as Ser1258, Ser1260 and Asp1367 in KIAA0564, respectively. This relationship is not just to the LFA-1 I-domain, but rather to the I-domain family as a whole. It has been found that a region whose boundaries extend between, at the most, residue 1248 and residue 1432, and at the least, residue 1253 and residue 1403 of KIAA0564 adopts an equivalent fold to to a range of other I-domains including the MAC-1 I-domain (PDB code 1BHO:2). Furthermore the divalent metal ion binding residues of the MAC-1 I-domain (1BHO:2) are conserved as Ser1258, Ser1260 and Asp1367 in KIAA0564. Thus by reference to the Genome Threader™ alignment with LFA-1 (1LFA:A) and MAC-1 (1BHO:2), residues Ser1258, Ser1260 and Asp1367 of KIAA0564 are predicted to form a metal ion binding triad. The combination of equivalent fold and conservation of divalent metal ion binding residues allows the functional annotation of this region of KIAA0564, and therefore proteins that include this region, as possessing adhesion molecule activity.

[0036] For the NG37 protein, it has been found that a region including residues 308-424 of this protein sequence adopts an equivalent fold to residues 3 to 119 of the LFA-1 I-domain (PDB code 1CQP:A). LFA-1 is known to function as an adhesion molecule, and the I-domain is critical for this function. Furthermore, the divalent metal ion binding residues Ser139, Ser141 and Asp239 of the LFA-1 I-domain are conserved as Thr323 (conservative substitution), Ser325 and Asp417 in NG37, respectively. The combination of equivalent fold and conservation of divalent metal ion binding residues allows the functional annotation of this region of NG37, and therefore proteins that include this region, as possessing adhesion molecule activity.

[0037] For the CAB01991.1 protein, it has been found that a region including residues 484-646 of this protein sequence adopts an equivalent fold to residues 5 to 179 of the LFA-1 I-domain (PDB code 1CQP:A). LFA-1 is known to function as an adhesion molecule, and the I-domain is critical for this function. Furthermore, the divalent metal ion binding residues Ser139, Ser141 and Asp239 of the LFA-1 I-domain are conserved as Ser491, Ser493 and Asp579 in CAB01991.1, respectively. This relationship is not just to the LFA-1 I-domain, but rather to the I-domain family as a whole. It has been found that a region whose boundaries extend between, at the most, residue 482 and residue 646, and at the least, residue 484 and residue 646 of CAB01991.1 adopts an equivalent fold to to a range of other I-domains including the MAC-1 I-domain (PDB code 1BHO:2). Furthermore the divalent metal ion binding residues of the MAC-1 I-domain (1BHO:2) are conserved as Ser491, Ser493 and Asp579 in CAB01991.1. Thus by reference to the Genome Threader™ alignment with LFA-1 (1CQP:A) and MAC-1 (1BHO:2), residues Ser491, Ser493 and Asp579 of CAB01991.1 are predicted to form a metal ion binding triad. The combination of equivalent fold and conservation of divalent metal ion binding residues allows the functional annotation of this region of CAB01991.1, and therefore proteins that include this region, as possessing adhesion molecule activity.

[0038] For the Rv0368c protein, it has been found that a region including residues 230-370 of this protein sequence adopts an equivalent fold to residues 8 to 157 of the α2 Integrin I-domain (PDB code 1AOX:A). The α2 Integrin is known to function as an adhesion molecule, and the I-domain is critical for this function. Furthermore, the divalent metal ion binding residues Ser153, Ser155 and Asp254 of the α2 Integrin I-domain are conserved as Ser237, Ser239 and Asp330 in Rv0368c, respectively. This relationship is not just to the α2 Integrin I-domain, but rather to the I-domain family as a whole. It has been found that a region whose boundaries extend between, at the most, residue 230 and residue 370, and at the least, residue 230 and residue 339 of Rv0368c adopts an equivalent fold to to a range of other I-domains including the LFA-1 (1DGQ:A), α1 Integrin (1QC5:A), and MAC-1 (1IDO) I-domains.

[0039] Furthermore, the divalent metal ion binding residues Ser139, Ser141 and Asp239 of the LFA-1 I-domain (1DGQ:A) are conserved as Ser237, Ser 239 and Asp330 in Rv0368c, respectively. Furthermore, the divalent metal ion binding residues Ser542, Ser544 and Asp143 of the α1 Integrin (1QC5:A) are conserved as Ser237, Ser 239 and Asp330 in Rv0368c, respectively. Thus, by reference to the Genome Threader™ alignment of Rv0368c with the α2Integrin (1AOX:A), LFA-1 (1DGQ:A) and α1 Integrin (1QC5:A) I-domains, Ser237, Ser239 and Asp330 of Rv0368c are predicted to form a metal ion binding triad. Rv0368c also shows conservation of residues to the metal ion binding triad of the MAC-1 I-domain (1IDO). The MAC-1 (1IDO) triad differs from the triad found in the α2Integrin (1AOX:A), LFA-1 (1DGQ:A) and α1 Integrin (1QC5:A) I-domains because the third metal ion ligand is a Threonine rather than an Aspartate. Nonetheless, by reference to the Genome Threader™ alignment of Rv0368c with MAC-1 (1IDO), the MAC-1 (1IDO) triad Ser142, Ser144 and Thr201 is conserved as Ser237, Ser239 and Thr302 in Rv0368c. Thus Rv0368c has two non-mutually exclusive metal ion binding triads predicted; (Ser237, Ser239 and Asp330) and (Ser237, Ser239 and Thr302).

[0040] The combination of equivalent fold and conservation of divalent metal ion binding residues allows the functional annotation of this region of Rv0368c, and therefore proteins that include this region, as possessing adhesion molecule activity.

[0041] In a first aspect, the invention provides a polypeptide, which polypeptide:

[0042] (i) has the amino acid sequence as recited in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, or SEQ ID NO:12;

[0043] (ii) is a fragment thereof having adhesion molecule activity or having an antigenic determinant in common with the polypeptides of (i); or

[0044] (iii) is a functional equivalent of (i) or (ii).

[0045] The polypeptide having the sequence recited in SEQ ID NO:2 is referred to hereafter as “the AD1 polypeptide”.

[0046] According to this aspect of the invention, a preferred polypeptide fragment according to part ii) above includes the region of the AD1 polypeptide that is predicted as that responsible for adhesion molecule activity (hereafter, the “AD1 adhesion molecule region”), or is a variant thereof that possesses the divalent metal ion binding trio (Ser1843, Ser1845 and Asp1912, or equivalent residues) or the trio (Ser1843, Ser1845 and Thr1912, or equivalent residues). As defined herein, the AD1 adhesion molecule region is considered to extend between, at the most, residue 1832 and residue 2036, and at the least, residue 1836 and residue 1950 of the AD1 polypeptide sequence.

[0047] The polypeptide having the sequence recited in SEQ ID NO:4 is referred to hereafter as “the AD2 polypeptide”.

[0048] According to this aspect of the invention, a preferred polypeptide fragment according to part ii) above includes the region of the AD2 polypeptide that is predicted as that responsible for adhesion molecule activity (hereafter, the “AD2 adhesion molecule region”), or is a variant thereof that possesses the divalent metal ion binding residues Thr25, Ser27 and Asp119, or equivalent residues. As defined herein, the AD2 adhesion molecule region is considered to extend between, at the most, residue 10 and residue 126, and at the least, residue 20 and residue 105 of the AD2 polypeptide sequence.

[0049] The polypeptide having the sequence recited in SEQ ID NO:6 is referred to hereafter as “the AD3 polypeptide”.

[0050] According to this aspect of the invention, a preferred polypeptide fragment according to part ii) above includes the region of the AD3 polypeptide that is predicted as that responsible for adhesion molecule activity (hereafter, the “AD3 adhesion molecule region”), or is a variant thereof that possesses the divalent metal ion binding residues Ser1258, Ser1260 and Asp1367, or equivalent residues. As defined herein, the AD3 adhesion molecule region is considered to extend between, at the most, residue 1248 and residue 1432, and at the least, residue 1253 and residue 1403 of the AD3 polypeptide sequence.

[0051] The polypeptide having the sequence recited in SEQ ID NO:8 is referred to hereafter as “the AD4 polypeptide”.

[0052] According to this aspect of the invention, a preferred polypeptide fragment according to part ii) above includes the region of the AD4 polypeptide that is predicted as that responsible for adhesion molecule activity (hereafter, the “AD4 adhesion molecule region”), or is a variant thereof that possesses the divalent metal ion binding residues Thr323, Ser325 and Asp417, or equivalent residues. As defined herein, the AD4 adhesion molecule region is considered to extend between residue 308 and residue 424 of the AD4 polypeptide sequence.

[0053] The polypeptide having the sequence recited in SEQ ID NO:10 is referred to hereafter as “the AD5 polypeptide”.

[0054] According to this aspect of the invention, a preferred polypeptide fragment according to part ii) above includes the region of the AD5 polypeptide that is predicted as that responsible for adhesion molecule activity (hereafter, the “AD5 adhesion molecule region”), or is a variant thereof that possesses the divalent metal ion binding residues Ser491, Ser493 and Asp579, or equivalent residues. As defined herein, the AD5 adhesion molecule region is considered to extend between, at the most, residue 482 and residue 646, and at the least, residue 484 and residue 646 of the AD5 polypeptide sequence.

[0055] The polypeptide having the sequence recited in SEQ ID NO:12 is referred to hereafter as “the AD6 polypeptide”.

[0056] According to this aspect of the invention, a preferred polypeptide fragment according to part ii) above includes the region of the AD6 polypeptide that is predicted as that responsible for adhesion molecule activity (hereafter, the “AD6 adhesion molecule region”), or is a variant thereof that possesses either the trio of divalent metal ion binding residues: Ser237, Ser239 and Asp330, or equivalent residues; or the trio of Ser237, Ser239 and Thr302, or equivalent residues. As defined herein, the AD6 adhesion molecule region is considered to extend between, at the most, residue 230 and residue 370, and at the least, residue 230 and residue 339 of the AD6 polypeptide sequence.

[0057] This aspect of the invention also includes fusion proteins that incorporate polypeptide fragments and variants of these polypeptide fragments as defined above, provided that said fusion proteins possess activity as an adhesion molecule.

[0058] In a second aspect, the invention provides a purified nucleic acid molecule that encodes a polypeptide of the first aspect of the invention. Preferably, the purified nucleic acid molecule has the nucleic acid sequence as recited in SEQ ID NO:1 (encoding the AD1 polypeptide), SEQ ID NO:3 (encoding the AD2 polypeptide), SEQ ID NO:5 (encoding the AD3 polypeptide), SEQ ID NO:7 (encoding the AD4 polypeptide), in SEQ ID NO:9 (encoding the AD5 polypeptide), or SEQ ID NO:11 (encoding the AD6 polypeptide) or is a redundant equivalent or fragment of any one of these sequences. A preferred nucleic acid fragment is one that encodes a polypeptide fragment according to part ii) above, preferably a polypeptide fragment that includes the AD1 adhesion molecule region, the AD2 adhesion molecule region, the AD3 adhesion molecule region, the AD4 adhesion molecule region, the AD5 adhesion molecule region or the AD6 adhesion molecule region, or that encodes a variant of these fragments as this term is defined above.

[0059] In a third aspect, the invention provides a purified nucleic acid molecule which hydridizes under high stringency conditions with a nucleic acid molecule of the second aspect of the invention.

[0060] In a fourth aspect, the invention provides a vector, such as an expression vector, that contains a nucleic acid molecule of the second or third aspect of the invention.

[0061] In a fifth aspect, the invention provides a host cell transformed with a vector of the fourth aspect of the invention.

[0062] In a sixth aspect, the invention provides a ligand which binds specifically to, and which preferably inhibits the adhesion molecule activity of, a polypeptide of the first aspect of the invention.

[0063] In a seventh aspect, the invention provides a compound that is effective to alter the expression of a natural gene which encodes a polypeptide of the first aspect of the invention or to regulate the activity of a polypeptide of the first aspect of the invention.

[0064] A compound of the seventh aspect of the invention may either increase (agonise) or decrease (antagonise) the level of expression of the gene or the activity of the polypeptide. Importantly, the identification of the function of the region defined herein as the AD1, AD2, AD3, AD4, AD5 and AD6 adhesion molecule regions of the AD1, AD2, AD3, AD4, AD5 and AD6 polypeptides, respetively, allows for the design of screening methods capable of identifying compounds that are effective in the treatment and/or diagnosis of diseases in which adhesion molecules are implicated.

[0065] In an eighth aspect, the invention provides a polypeptide of the first aspect of the invention, or a nucleic acid molecule of the second or third aspect of the invention, or a vector of the fourth aspect of the invention, or a ligand of the fifth aspect of the invention, or a compound of the sixth aspect of the invention, for use in therapy or diagnosis. These molecules may also be used in the manufacture of a medicament for the treatment of cardiovascular diseases including atherosclerosis, ischaemia, restenosis, reperfusion injury, sepsis, haematological diseases such as leukaemia, blood clotting disorders, such as thrombosis, cancer including lung, prostate, breast, colorectal and brain tumours, metastasis, inflammatory diseases such as rhinitis, gastrointestinal diseases, including inflammatory bowel disease, ulcerative colitis, Crohn's disease, respiratory diseases including asthma, chronic obstructive pulmonary disease (COPD), respiratory distress syndrome, pulmonary fibrosis, immune disorders, including autoimmune diseases, rheumatoid arthritis, transplant rejection, allergy, liver diseases such as cirrhosis, endocrine diseases, such as diabetes, bone diseases such as osteoporosis, neurological diseases including stroke, multiple sclerosis, spinal cord injury, burns and wound healing, bacteria infections, particularly Mycobacterium tuberculosis infection, and virus infections.

[0066] In a ninth aspect, the invention provides a method of diagnosing a disease in a patient, comprising assessing the level of expression of a natural gene encoding a polypeptide of the first aspect of the invention or the activity of a polypeptide of the first aspect of the invention in tissue from said patient and comparing said level of expression or activity to a control level, wherein a level that is different to said control level is indicative of disease. Such a method will preferably be carried out in vitro. Similar methods may be used for monitoring the therapeutic treatment of disease in a patient, wherein altering the level of expression or activity of a polypeptide or nucleic acid molecule over the period of time towards a control level is indicative of regression of disease.

[0067] The adhesion molecules whose sequences are presented in SEQ ID NO:10 and SEQ ID NO:12 are implicated herein in the pathogenicity of the organism Mycobacterium tuberculosis. Accordingly, ligands to this polypeptide, and in particular, to the AD5 and AD6 adhesion molecule regions, of the AD5 and AD6 polypeptides respectively, as these regions are defined herein, are likely to be effective in controlling disease caused by this organism. Furthermore, these polypeptides, and in particular, polypeptide fragments including the AD5 or AD6 adhesion molecule regions of the AD5 and AD6 polypeptide sequences provide a potential component for a vaccine against this organism and the diseases that it causes.

[0068] A preferred method for detecting polypeptides of the first aspect of the invention comprises the steps of: (a) contacting a ligand, such as an antibody, of the sixth aspect of the invention with a biological sample under conditions suitable for the formation of a ligand-polypeptide complex; and (b) detecting said complex.

[0069] A number of different such methods according to the ninth aspect of the invention exist, as the skilled reader will be aware, such as methods of nucleic acid hybridization with short probes, point mutation analysis, polymerase chain reaction (PCR) amplification and methods using antibodies to detect aberrant protein levels. Similar methods may be used on a short or long term basis to allow therapeutic treatment of a disease to be monitored in a patient. The invention also provides kits that are useful in these methods for diagnosing disease.

[0070] In a tenth aspect, the invention provides for the use of a polypeptide of the first aspect of the invention as an adhesion molecule. The invention also provides for the use of a nucleic acid molecule according to the second or third aspects of the invention to express a protein that possesses adhesion molecule activity. The invention also provides a method for effecting cell-cell adhesion, said method utilising a polypeptide of the first aspect of the invention.

[0071] In an eleventh aspect, the invention provides a pharmaceutical composition comprising a polypeptide of the first aspect of the invention, or a nucleic acid molecule of the second or third aspect of the invention, or a vector of the fourth aspect of the invention, or a ligand of the sixth aspect of the invention, or a compound of the seventh aspect of the invention, in conjunction with a pharmaceutically-acceptable carrier.

[0072] In a twelfth aspect, the present invention provides a polypeptide of the first aspect of the invention, or a nucleic acid molecule of the second or third aspect of the invention, or a vector of the fourth aspect of the invention, or a ligand of the sixth aspect of the invention, or a compound of the seventh aspect of the invention, for use in the manufacture of a medicament for the diagnosis or treatment of a disease, such as herpes virus infection.

[0073] In a thirteenth aspect, the invention provides a method of treating a disease in a patient comprising administering to the patient a polypeptide of the first aspect of the invention, or a nucleic acid molecule of the second or third aspect of the invention, or a vector of the fourth aspect of the invention, or a ligand of the sixth aspect of the invention, or a compound of the seventh aspect of the invention.

[0074] For diseases in which the expression of a natural gene encoding a polypeptide of the first aspect of the invention, or in which the activity of a polypeptide of the first aspect of the invention, is lower in a diseased patient when compared to the level of expression or activity in a healthy patient, the polypeptide, nucleic acid molecule, ligand or compound administered to the patient should be an agonist. Conversely, for diseases in which the expression of the natural gene or activity of the polypeptide is higher in a diseased patient when compared to the level of expression or activity in a healthy patient, the polypeptide, nucleic acid molecule, ligand or compound administered to the patient should be an antagonist. Examples of such antagonists include antisense nucleic acid molecules, ribozymes and ligands, such as antibodies.

[0075] In a fourteenth aspect, the invention provides transgenic or knockout non-human animals that have been transformed to express higher, lower or absent levels of a polypeptide of the first aspect of the invention. Such transgenic animals are very useful models for the study of disease and may also be using in screening regimes for the identification of compounds that are effective in the treatment or diagnosis of such a disease.

[0076] A summary of standard techniques and procedures which may be employed in order to utilise the invention is given below. It will be understood that this invention is not limited to the particular methodology, protocols, cell lines, vectors and reagents described. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only and it is not intended that this terminology should limit the scope of the present invention. The extent of the invention is limited only by the terms of the appended claims.

[0077] Standard abbreviations for nucleotides and amino acids are used in this specification.

[0078] The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology, microbiology, recombinant DNA technology and immunology, which are within the skill of the those working in the art.

[0079] Such techniques are explained fully in the literature. Examples of particularly suitable texts for consultation include the following: Sambrook Molecular Cloning; A Laboratory Manual, Second Edition (1989); DNA Cloning, Volumes I and II (D. N. Glover ed. 1985); Oligonucleotide Synthesis (M. J. Gait ed. 1984); Nucleic Acid Hybridization (B. D. Hames & S. J. Higgins eds. 1984); Transcription and Translation (B. D. Hames & S. J. Higgins eds. 1984); Animal Cell Culture (R. I. Freshney ed. 1986); Immobilized Cells and Enzymes (IRL Press, 1986); B. Perbal, A Practical Guide to Molecular Cloning (1984); the Methods in Enzymology series (Academic Press, Inc.), especially volumes 154 & 155; Gene Transfer Vectors for Mammalian Cells (J. H. Miller and M. P. Calos eds. 1987, Cold Spring Harbor Laboratory); Immunochemical Methods in Cell and Molecular Biology (Mayer and Walker, eds. 1987, Academic Press, London); Scopes, (1987) Protein Purification: Principles and Practice, Second Edition (Springer Verlag, N.Y.); and Handbook of Experimental Immunology, Volumes I-IV (D. M. Weir and C. C. Blackwell eds. 1986).

[0080] As used herein, the term “polypeptide” includes any peptide or protein comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds, i.e. peptide isosteres. This term refers both to short chains (peptides and oligopeptides) and to longer chains (proteins).

[0081] The polypeptide of the present invention may be in the form of a mature protein or may be a pre-, pro- or prepro- protein that can be activated by cleavage of the pre-, pro- or prepro- portion to produce an active mature polypeptide. In such polypeptides, the pre-, pro- or prepro- sequence may be a leader or secretory sequence or may be a sequence that is employed for purification of the mature polypeptide sequence. The polypeptide of the first aspect of the invention may form part of a fusion protein. For example, it is often advantageous to include one or more additional amino acid sequences which may contain secretory or leader sequences, pro-sequences, sequences which aid in purification, or sequences that confer higher protein stability, for example during recombinant production. Alternatively or additionally, the mature polypeptide may be fused with another compound, such as a compound to increase the half-life of the polypeptide (for example, polyethylene glycol).

[0082] Polypeptides may contain amino acids other than the 20 gene-encoded amino acids, modified either by natural processes, such as by post-translational processing or by chemical modification techniques which are well known in the art. Among the known modifications which may commonly be present in polypeptides of the present invention are glycosylation, lipid attachment, sulphation, gamma-carboxylation, for instance of glutamic acid residues, hydroxylation and ADP-ribosylation. Other potential modifications include acetylation, acylation, amidation, covalent attachment of flavin, covalent attachment of a haeme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulphide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, GPI anchor formation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination.

[0083] Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. In fact, blockage of the amino or carboxyl terminus in a polypeptide, or both, by a covalent modification is common in naturally-occurring and synthetic polypeptides and such modifications may be present in polypeptides of the present invention.

[0084] The modifications that occur in a polypeptide often will be a function of how the polypeptide is made. For polypeptides that are made recombinantly, the nature and extent of the modifications in large part will be determined by the post-translational modification capacity of the particular host cell and the modification signals that are present in the amino acid sequence of the polypeptide in question. For instance, glycosylation patterns vary between different types of host cell.

[0085] The polypeptides of the present invention can be prepared in any suitable manner. Such polypeptides include isolated naturally-occurring polypeptides (for example purified from cell culture), recombinantly-produced polypeptides (including fusion proteins), synthetically-produced polypeptides or polypeptides that are produced by a combination of these methods.

[0086] The functionally-equivalent polypeptides of the first aspect of the invention may be polypeptides that are homologous to the AD1, AD2, AD3, AD4, AD5 or AD6 polypeptides. Two polypeptides are said to be “homologous”, as the term is used herein, if the sequence of one of the polypeptides has a high enough degree of identity or similarity to the sequence of the other polypeptide. “Identity” indicates that at any particular position in the aligned sequences, the amino acid residue is identical between the sequences. “Similarity” indicates that, at any particular position in the aligned sequences, the amino acid residue is of a similar type between the sequences. Degrees of identity and similarity can be readily calculated (Computational Molecular Biology, Lesk, A. M., ed., Oxford University Press, New York, 1988; Biocomputing. Informatics and Genome Projects, Smith, D. W., ed., Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part 1, Griffin, A. M., and Griffin, H. G., eds., Humana Press, New Jersey, 1994; Sequence Analysis in Molecular Biology, von Heinje, G., Academic Press, 1987; and Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991).

[0087] Homologous polypeptides therefore include natural biological variants (for example, allelic variants or geographical variations within the species from which the polypeptides are derived) and mutants (such as mutants containing amino acid substitutions, insertions or deletions) of the AD1, AD2, AD3, AD4, AD5 or AD6 polypeptides. Such mutants may include polypeptides in which one or more of the amino acid residues are substituted with a conserved or non-conserved amino acid residue (preferably a conserved amino acid residue) and such substituted amino acid residue may or may not be one encoded by the genetic code. Typical such substitutions are among Ala, Val, Leu and Ile; among Ser and Thr; among the acidic residues Asp and Glu; among Asn and Gln; among the basic residues Lys and Arg; or among the aromatic residues Phe and Tyr. Particularly preferred are variants in which several, i.e. between 5 and 10, 1 and 5, 1 and 3, 1 and 2 or just 1 amino acids are substituted, deleted or added in any combination. Especially preferred are silent substitutions, additions and deletions, which do not alter the properties and activities of the protein. Also especially preferred in this regard are conservative substitutions.

[0088] Such mutants also include polypeptides in which one or more of the amino acid residues includes a substituent group;

[0089] Typically, greater than 30% identity between two polypeptides (preferably, over a specified region) is considered to be an indication of functional equivalence. Preferably, functionally equivalent polypeptides of the first aspect of the invention have a degree of sequence identity with the AD1, AD2, AD3, AD4, AD5 or AD6 polypeptide, or with active fragments thereof, of greater than 30%. More preferred polypeptides have degrees of identity of greater than 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98% or 99%, respectively with the AD1, AD2, AD3, AD4, AD5 or AD6 polypeptide, or with active fragments thereof.

[0090] Percentage identity, as referred to herein, is as determined using BLAST version 2.1.3 using the default parameters specified by the NCBI (the National Center for Biotechnology Information; http://www.ncbi.nlm.nih.gov/) [Blosum 62 matrix; gap open penalty=11 and gap extension penalty=1.

[0091] In the present case, preferred active fragments of the AD1 polypeptide are those that include the AD1 adhesion molecule region and which possess either the metal binding trio of residues Ser1843, Ser1845 and Asp1948, or the alternative trio of Ser1843, Ser1845 and Thr1912, or equivalent residues. By “equivalent residues” is meant residues that are equivalent to the residues that bind the divalent metal ion may replace one or more of the three metal ion binding residues, provided that the adhesion molecule region retains activity as an adhesion molecule. For example Ser1843 or Ser1845 may be replaced by a Threonine. Asp1948 may be replaced by a Glutamate. Thr1912 may be replaced by a Serine. Accordingly, this aspect of the invention includes polypeptides that have degrees of identity of greater than 30%, preferably, greater than 40%, 50%, 60%, 70%, 80%,90%, 95%, 98% or 99%, respectively, with the adhesion molecule region of the AD1 polypeptide and which possess either the trio of Ser1843, Ser1845 and Asp1948 or the alternative trio Ser1843, Ser1845 and Thr1912, or equivalent residues. As discussed above, the AD1 adhesion molecule region is considered to extend between, at the most, residue 1832 and residue 2036, and at the least, residue 1836 and residue 1950 of the AD1 polypeptide sequence.

[0092] In the present case, preferred active fragments of the AD2 polypeptide are those that include the AD2 adhesion molecule region and which possess the metal binding residues Thr25, Ser27 and Asp119 or equivalent residues. By “equivalent residues” is meant residues that are equivalent to the residues that bind the divalent metal ion may replace one or more of the three metal ion binding residues, provided that the adhesion molecule region retains activity as an adhesion molecule. For example, Thr25 may be replaced by a Serine. Ser27 may be replaced by a Threonine. Asp119 may be replaced by a Glutamate. Accordingly, this aspect of the invention includes polypeptides that have degrees of identity of greater than 30%, preferably, greater than 40%, 50%, 60%, 70%, 80%,90%, 95%, 98% or 99%, respectively, with the AD2 adhesion molecule region and which possess the metal binding residues Thr25, Ser27 and Asp119, or equivalent residues. As discussed above, the AD2 adhesion molecule region is considered to extend between, at the most, residue 10 and residue 126, and at the least, residue 20 and residue 105 of the AD2 polypeptide sequence.

[0093] In the present case, preferred active fragments of the AD3 polypeptide are those that include the AD3 adhesion molecule region and which possess the metal binding residues Ser1258, Ser1260 and Asp1367 or equivalent residues. By “equivalent residues” is meant residues that are equivalent to the residues that bind the divalent metal ion may replace one or more of the three metal ion binding residues, provided that the adhesion molecule region retains activity as an adhesion molecule. For example, Ser1258 or Ser1260, or both may be replaced by a Threonine. Asp1367 may be replaced by a Glutamate. Accordingly, this aspect of the invention includes polypeptides that have degrees of identity of greater than 30%, preferably, greater than 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98% or 99%, respectively, with the AD3 adhesion molecule region and which possess the metal binding residues Ser1258, Ser1260 and Asp1367, or equivalent residues. As discussed above, the AD3 adhesion molecule region is considered to extend between, at the most, residue 1248 and residue 1432, and at the least, residue 1253 and residue 1403 of the AD3 polypeptide sequence.

[0094] In the present case, preferred active fragments of the AD4 polypeptide are those that include the AD4 adhesion molecule region and which possess the metal binding residues Thr323, Ser325 and Asp417 or equivalent residues. By “equivalent residues” is meant residues that are equivalent to the residues that bind the divalent metal ion may replace one or more of the three metal ion binding residues, provided that the adhesion molecule region retains activity as an adhesion molecule. For example Thr323 may be replaced by a Serine. Ser325 may be replaced by a Threonine. Asp417 may be replaced by a Glutamate. Accordingly, this aspect of the invention includes polypeptides that have degrees of identity of greater than 30%, preferably, greater than 40%, 50%, 60%, 70%, 80%,90%, 95%, 98% or 99%, respectively, with AD4 the adhesion molecule region and which possess the metal binding residues Thr323, Ser325 and Asp417, or equivalent residues. As discussed above, the AD4 adhesion molecule region is considered to extend between residue 308 and residue 424 of the AD4 polypeptide sequence.

[0095] In the present case, preferred active fragments of the AD5 polypeptide are those that include the AD5 adhesion molecule region and which possess the metal binding residues Ser491, Ser493 and Asp579 or equivalent residues. By “equivalent residues” is meant residues that are equivalent to the residues that bind the divalent metal ion may replace one or more of the three metal ion binding residues, provided that the adhesion molecule region retains activity as an adhesion molecule. For example, Ser491 or Ser493 or both may be replaced by a Threonine. Asp579 may be replaced by a Glutamate. Accordingly, this aspect of the invention includes polypeptides that have degrees of identity of greater than 30%, preferably, greater than 40%, 50%, 60%, 70%, 80%,90%, 95%, 98% or 99%, respectively, with the AD5 adhesion molecule region and which possess the metal binding residues Ser491, Ser493 and Asp579, or equivalent residues. As discussed above, the AD5 adhesion molecule region is considered to extend between, at the most, residue 482 and residue 646, and at the least, residue 484 and residue 646 of the AD5 polypeptide sequence.

[0096] In the present case, preferred active fragments of the AD6 polypeptide are those that include the AD6 adhesion molecule region and which possess the trio of metal binding residues Ser237, Ser239 and Asp330 or the alternative trio of Ser237, Ser239 and Thr302, or equivalent residues. By “equivalent residues” is meant residues that are equivalent to the residues that bind the divalent metal ion may replace one or more of the three metal ion binding residues, provided that the adhesion molecule region retains activity as an adhesion molecule. For example, Ser237 or Ser239 or both may be replaced by a Threonine. Asp330 may be replaced by a Glutamate. Thr302 may be replaced by a Serine. Accordingly, this aspect of the invention includes polypeptides that have degrees of identity of greater than 30%, preferably, greater than 40%, 50%, 60%, 70%, 80%,90%, 95%, 98% or 99%, respectively, with the AD6 adhesion molecule region and which possess the trio of metal binding residues Ser237, Ser239 and Asp330 or the alternative trio of Ser237, Ser239 and Thr302, or equivalent residues As discussed above, the AD6 adhesion molecule region is considered to extend between, at the most, residue 230 and residue 370, and at the least, residue 230 and residue 339 of the AD6 polypeptide sequence.

[0097] The functionally-equivalent polypeptides of the first aspect of the invention may also be polypeptides which have been identified using one or more techniques of structural alignment. For example, the Inpharmatica Genome Threader™ technology that forms one aspect of the search tools used to generate the Biopendium search database may be used (see co-pending International patent application PCT/GB01/01105) to identify polypeptides of presently-unknown function which, while having low sequence identity as compared to the AD1, AD2, AD3, AD4, AD5 or AD6 polypeptides, are predicted to have adhesion molecule activity, by virtue of sharing significant structural homology with the AD1, AD2, AD3, AD4, AD5 or AD6 polypeptide sequences.

[0098] By “significant structural homology” is meant that the Inpharmatica Genome Threader™ predicts two proteins, or protein regions, to share structural homology with a certainty of 80% and above. The certainty value of the Inpharmatica Genome Threader™ is calculated as follows. A set of comparisons was initially performed using the Inpharmatica Genome Threader™ exclusively using sequences of known structure. Some of the comparisons were between proteins that were known to be related (on the basis of structure). A neural network was then trained on the basis that it needed to best distinguish between the known relationships and known not-relationships taken from the CATH structure classification (www.biochem.ucl.ac.uk/bsm/cath). This resulted in a neural network score between 0 and 1. However, again as the number of proteins that are related and the number that are unrelated were known, it was possible to partition the neural network results into packets and calculate empirically the percentage of the results that were correct. In this manner, any genuine prediction in the Biopendium search database has an attached neural network score and the percentage confidence is a reflection of how successful the Inpharmatica Genome Threader™ was in the training/testing set.

[0099] Structural homologues of AD1 should share structural homology with the AD1 adhesion molecule region and possess the metal binding trio Ser1843, Ser1845 and Asp1948 or the alternative trio Ser1843, Ser1845 and Thr1912, or equivalent residues. Such structural homologues are predicted to have adhesion molecule activity by virtue of sharing significant structural homology with this polypeptide sequence and possessing the metal ion binding residues.

[0100] Structural homologues of AD2 should share structural homology with the AD2 adhesion molecule region and possess the metal binding trio Thr25, Ser27 and Asp119, or equivalent residues. Such structural homologues are predicted to have adhesion molecule activity by virtue of sharing significant structural homology with this polypeptide sequence and possessing the metal ion binding residues.

[0101] Structural homologues of AD3 should share structural homology with the AD3 adhesion molecule region and possess the metal binding trio Ser1258, Ser1260 and Asp1367, or equivalent residues. Such structural homologues are predicted to have adhesion molecule activity by virtue of sharing significant structural homology with this polypeptide sequence and possessing the metal ion binding residues.

[0102] Structural homologues of AD4 should share structural homology with the AD4 adhesion molecule region and possess the metal binding trio Thr323, Ser325 and Asp417, or equivalent residues. Such structural homologues are predicted to have adhesion molecule activity by virtue of sharing significant structural homology with this polypeptide sequence and possessing the metal ion binding residues.

[0103] Structural homologues of AD5 should share structural homology with the AD5 adhesion molecule region and possess the metal binding trio Ser491, Ser493 and Asp579, or equivalent residues. Such structural homologues are predicted to have adhesion molecule activity by virtue of sharing significant structural homology with this polypeptide sequence and possessing the metal ion binding residues.

[0104] Structural homologues of AD6 should share structural homology with the AD6 adhesion molecule region and possess the metal binding trio Ser237, Ser239 and Asp330 or the alternative trio of Ser237, Ser239 and Thr302, or equivalent residues. Such structural homologues are predicted to have adhesion molecule activity by virtue of sharing significant structural homology with this polypeptide sequence and possessing the metal ion binding residues.

[0105] The polypeptides of the first aspect of the invention also include fragments of the AD1, AD2, AD3, AD4, AD5 and AD6 polypeptides, functional equivalents of the fragments of the AD1, AD2, AD3, AD4, AD5 and AD6 polypeptides, and fragments of the functional equivalents of the AD1, AD2, AD3, AD4, AD5 and AD6 polypeptides, provided that those functional equivalents and fragments retain adhesion molecule activity or have an antigenic determinant in common with the AD1, AD2, AD3, AD4, AD5 or AD6 polypeptides.

[0106] As used herein, the term “fragment” refers to a polypeptide having an amino acid sequence that is the same as part, but not all, of the amino acid sequence of the AD1, AD2, AD3, AD4, AD5 or AD6 polypeptides or one of its functional equivalents. The fragments should comprise at least n consecutive amino acids from the sequence and, depending on the particular sequence, n preferably is 7 or more (for example, 8, 10, 12, 14, 16, 18, 20 or more). Small fragments may form an antigenic determinant.

[0107] Preferred polypeptide fragments according to this aspect of the invention are fragments that include a region defined herein as the AD1, AD2, AD3, AD4, AD5 or AD6 adhesion molecule region of the AD1, AD2, AD3, AD4, AD5 and AD6 polypeptides, respectively. These regions are the regions that have been annotated as adhesion molecules. For the AD1 polypeptide, this region is considered to extend between, at the most, residue 1832 and residue 2036, and at the least, residue 1836 and residue 1950. This region of the AD2 polypeptide is considered to extend between, at the most, residue 10 and residue 126, and at the least, residue 20 and residue 105. This region of the AD3 polypeptide is considered to extend between, at the most, residue 1248 and residue 1432, and at the least, residue 1253 and residue 1403. This region of the AD4 polypeptide is considered to extend between residue 308 and residue 424. This region of the AD5 polypeptide is considered to extend between, at the most, residue 482 and residue 646, and at the least, residue 484 and residue 646. This region of the AD6 polypeptide is considered to extend between, at the most, residue 230 and residue 370, and at the least, residue 230 and residue 339.

[0108] Variants of this fragment are included as embodiments of this aspect of the invention, provided that these variants possess activity as an adhesion molecule.

[0109] In one respect, the term “variant” is meant to include extended or truncated versions of this polypeptide fragment.

[0110] For extended variants, it is considered highly likely that the adhesion molecule region of the AD1, AD2, AD3, AD4, AD5 and AD6 polypeptide will fold correctly and show adhesion molecule activity if additional residues C terminal and/or N terminal of these boundaries in the AD1, AD2, AD3, AD4, AD5 or AD6 polypeptide sequences are included in the polypeptide fragment. For example, an additional 5, 10, 20, 30, 40 or even 50 or more amino acid residues from the AD1, AD2, AD3, AD4, AD5 or AD6 polypeptide sequence, or from a homologous sequence, may be included at either or both the C terminal and/or N terminal of the boundaries of the adhesion molecule regions of the AD1, AD2, AD3, AD4, AD5 or AD6 polypeptide, without prejudicing the ability of the polypeptide fragment to fold correctly and exhibit adhesion molecule activity.

[0111] For truncated variants of the AD1 polypeptide, one or more amino acid residues may be deleted at either or both the C terminus or the N terminus of the adhesion molecule region of the AD1 polypeptide, although the metal ion binding trio (Ser1843, Ser1845 and Asp1948) or the alternative trio (Ser1843, Ser1845 and Thr1912), or equivalent residues should be maintained intact; deletions should not extend so far into the polypeptide sequence that any of these residues are deleted.

[0112] For truncated variants of the AD2 polypeptide, one or more amino acid residues may be deleted at either or both the C terminus or the N terminus of the adhesion molecule region of the AD2 polypeptide, although the metal ion binding residues (Thr25, Ser27 and Asp119, or equivalent residues) should be maintained intact; deletions should not extend so far into the polypeptide sequence that any of these residues are deleted.

[0113] For truncated variants of the AD3 polypeptide, one or more amino acid residues may be deleted at either or both the C terminus or the N terminus of the adhesion molecule region of the AD3 polypeptide, although the metal ion binding residues (Ser1258, Ser1260 and Asp1367, or equivalent residues) should be maintained intact; deletions should not extend so far into the polypeptide sequence that any of these residues are deleted.

[0114] For truncated variants of the AD4 polypeptide, one or more amino acid residues may be deleted at either or both the C terminus or the N terminus of the adhesion molecule region of the AD4 polypeptide, although the metal ion binding residues (Thr323, Ser325 and Asp417, or equivalent residues) should be maintained intact; deletions should not extend so far into the polypeptide sequence that any of these residues are deleted.

[0115] For truncated variants of the AD5 polypeptide, one or more amino acid residues may be deleted at either or both the C terminus or the N terminus of the adhesion molecule region of the AD5 polypeptide, although the metal ion binding residues (Ser491, Ser493 and Asp579, or equivalent residues) should be maintained intact; deletions should not extend so far into the polypeptide sequence that any of these residues are deleted.

[0116] For truncated variants of the AD6 polypeptide, one or more amino acid residues may be deleted at either or both the C terminus or the N terminus of the adhesion molecule region of the AD6 polypeptide, although the metal ion binding trio (Ser237, Ser239 and Asp330) or the alternative trio (Ser237, Ser239 and Thr302), or equivalent residues should be maintained intact; deletions should not extend so far into the polypeptide sequence that any of these residues are deleted.

[0117] In a second respect, the term “variant” includes homologues of the polypeptide fragments described above, that possess significant sequence homology with the adhesion molecule region of the AD1 polypeptide and which possess the metal ion binding trio (Ser1843, Ser1845 and Asp1948) or the alternative trio (Ser1843, Ser1845 and Thr1912), or equivalent residues, provided that said variants retain activity as an adhesion molecule.

[0118] The term “variant” also includes homologues of the polypeptide fragments described above, that possess significant sequence homology with the adhesion molecule region of the AD2 polypeptide and which possess the metal ion binding residues (Thr25, Ser27 and Asp119 or equivalent residues), provided that said variants retain activity as an adhesion molecule.

[0119] The term “variant” also includes homologues of the polypeptide fragments described above, that possess significant sequence homology with the adhesion molecule region of the AD3 polypeptide and which possess the metal ion binding Ser1258, Ser1260 and Asp1367 or equivalent residues), provided that said variants retain activity as an adhesion molecule.

[0120] The term “variant” also includes homologues of the polypeptide fragments described above, that possess significant sequence homology with the adhesion molecule region of the AD4 polypeptide and which possess the metal ion binding Thr323, Ser325 and Asp417 or equivalent residues), provided that said variants retain activity as an adhesion molecule.

[0121] The term “variant” also includes homologues of the polypeptide fragments described above, that possess significant sequence homology with the adhesion molecule region of the AD5 polypeptide and which possess the metal ion Ser491, Ser493 and Asp579 or equivalent residues), provided that said variants retain activity as an adhesion molecule.

[0122] The term “variant” also includes homologues of the polypeptide fragments described above, that possess significant sequence homology with the adhesion molecule region of the AD6 polypeptide and which possess the metal ion binding trio (Ser237, Ser239 and Asp330) or the alternative trio (Ser237, Ser239 and Thr302), or equivalent residues, provided that said variants retain activity as an adhesion molecule.

[0123] Homologues include those polypeptide molecules that possess greater than 30% identity with the AD1, AD2, AD3, AD4, AD5 or AD6 adhesion molecule regions, of the AD1, AD2, AD3, AD4, AD5 and AD6 polypeptides, respectively. Percentage identity is as determined using BLAST version 2.1.3 using the default parameters specified by the NCBI (the National Center for Biotechnology Information; http://www.ncbi.nlm.nih.gov/) [Blosum 62 matrix; gap open penalty=11 and gap extension penalty=1]. Preferably, variant homologues of polypeptide fragments of this aspect of the invention have a degree of sequence identity with the AD1, AD2, AD3, AD4, AD5 or AD6 adhesion molecule regions, of the AD1, AD2, AD3, AD4, AD5 and AD6 polypeptides, resepctively, of greater than 40%. More preferred variant polypeptides have degrees of identity of greater than 50%, 60%, 70%, 80%, 90%, 95%, 98% or 99%, respectively with the AD], AD2, AD3, AD4, AD5 or AD6 adhesion molecule regions of the AD1, AD2, AD3, AD4, AD5 or AD6 polypeptides, provided that said variants retain activity as an adhesion molecule. Variant polypeptides also include homologues of the truncated forms of the polypeptide fragments discussed above, provided that said variants retain activity as an adhesion molecule.

[0124] The polypeptide fragments of the first aspect of the invention may be polypeptide fragments that exhibit significant structural homology with the structure of the polypeptide fragment defined by the AD1, AD2, AD3, AD4, AD5 or AD6 adhesion molecule regions, of the AD1, AD2, AD3, AD4, AD5, or AD6 polypeptide sequences, for example, as identified by the Inpharmatica Genome Threader™. Accordingly, polypeptide fragments that are structural homologues of the polypeptide fragments defined by the AD1, AD2, AD3, AD4, AD5 or AD6 adhesion molecule regions of the AD1, AD2, AD3, AD4, AD5, and AD6 polypeptide sequences should adopt the same fold as that adopted by this polypeptide fragment, as this fold is defined above.

[0125] Structural homologues of the polypeptide fragment defined by the AD1 adhesion molecule region should also retain the metal ion binding trio (Ser1843, Ser1845 and Asp1948) or the alternative trio (Ser1843, Ser1845 and Thr1912), or equivalent residues.

[0126] Structural homologues of the polypeptide fragment defined by the AD2 adhesion molecule region should also retain the metal ion binding residues Thr25, Ser27 and Asp 119 or equivalent residues.

[0127] Structural homologues of the polypeptide fragment defined by the AD3 adhesion molecule should also retain the metal ion binding residues Ser1258, Ser1260 and Asp1367 or equivalent residues.

[0128] Structural homologues of the polypeptide fragment defined by the AD4 adhesion molecule region should also retain the metal ion binding residues Thr323, Ser325 and Asp417 or equivalent residues.

[0129] Structural homologues of the polypeptide fragment defined by the AD5 adhesion molecule region should also retain the metal ion binding residues Ser491, Ser493 and Asp579 or equivalent residues.

[0130] Structural homologues of the polypeptide fragment defined by the AD6 adhesion molecule region should also retain the metal ion binding trio (Ser237, Ser239 and Asp330) or the alternative trio (Ser237, Ser239 and Thr302), or equivalent residues.

[0131] Such fragments may be “free-standing”, i.e. not part of or fused to other amino acids or polypeptides, or they may be comprised within a larger polypeptide of which they form a part or region. When comprised within a larger polypeptide, the fragment of the invention most preferably forms a single continuous region. For instance, certain preferred embodiments relate to a fragment having a pre - and/or pro- polypeptide region fused to the amino terminus of the fragment and/or an additional region fused to the carboxyl terminus of the fragment. However, several fragments may be comprised within a single larger polypeptide.

[0132] The polypeptides of the present invention or their immunogenic fragments (comprising at least one antigenic determinant) can be used to generate ligands, such as polyclonal or monoclonal antibodies, that are immunospecific for the polypeptides. Such antibodies may be employed to isolate or to identify clones expressing the polypeptides of the invention or to purify the polypeptides by affinity chromatography. The antibodies may also be employed as diagnostic or therapeutic aids, amongst other applications, as will be apparent to the skilled reader.

[0133] The term “immunospecific” means that the antibodies have substantially greater affinity for the polypeptides of the invention than their affinity for other related polypeptides in the prior art. As used herein, the term “antibody” refers to intact molecules as well as to fragments thereof, such as Fab, F(ab′)2 and Fv, which are capable of binding to the antigenic determinant in question. Such antibodies thus bind to the polypeptides of the first aspect of the invention.

[0134] If polyclonal antibodies are desired, a selected mammal, such as a mouse, rabbit, goat or horse, may be immunised with a polypeptide of the first aspect of the invention. The polypeptide used to immunise the animal can be derived by recombinant DNA technology or can be synthesized chemically. If desired, the polypeptide can be conjugated to a carrier protein. Commonly used carriers to which the polypeptides may be chemically coupled include bovine serum albumin, thyroglobulin and keyhole limpet haemocyanin. The coupled polypeptide is then used to immunise the animal. Serum from the immunised animal is collected and treated according to known procedures, for example by immunoaffinity chromatography.

[0135] Monoclonal antibodies to the polypeptides of the first aspect of the invention can also be readily produced by one skilled in the art. The general methodology for making monoclonal antibodies using hybridoma technology is well known (see, for example, Kohler, G. and Milstein, C., Nature 256: 495-497 (1975); Kozbor et al., Immunology Today 4: 72 (1983); Cole et al., 77-96 in Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc. (1985).

[0136] Panels of monoclonal antibodies produced against the polypeptides of the first aspect of the invention can be screened for various properties, i.e., for isotype, epitope, affinity, etc. Monoclonal antibodies are particularly useful in purification of the individual polypeptides against which they are directed. Alternatively, genes encoding the monoclonal antibodies of interest may be isolated from hybridomas, for instance by PCR techniques known in the art, and cloned and expressed in appropriate vectors.

[0137] Chimeric antibodies, in which non-human variable regions are joined or fused to human constant regions (see, for example, Liu et al., Proc. Natl. Acad. Sci. USA, 84, 3439 (1987)), may also be of use.

[0138] The antibody may be modified to make it less immunogenic in an individual, for example by humanisation (see Jones et al., Nature, 321, 522 (1986); Verhoeyen et al., Science, 239: 1534 (1988); Kabat et al., J. Immunol., 147: 1709 (1991); Queen et al., Proc. Natl Acad. Sci. USA, 86, 10029 (1989); Gorman et al., Proc. Natl Acad. Sci. USA, 88: 34181 (1991); and Hodgson et al., Bio/Technology 9: 421 (1991)). The term “humanised antibody”, as used herein, refers to antibody molecules in which the CDR amino acids and selected other amino acids in the variable domains of the heavy and/or light chains of a non-human donor antibody have been substituted in place of the equivalent amino acids in a human antibody. The humanised antibody thus closely resembles a human antibody but has the binding ability of the donor antibody.

[0139] In a further alternative, the antibody may be a “bispecific” antibody, that is an antibody having two different antigen binding domains, each domain being directed against a different epitope.

[0140] Phage display technology may be utilised to select genes which encode antibodies with binding activities towards the polypeptides of the invention either from repertoires of PCR amplified V-genes of lymphocytes from humans screened for possessing the relevant antibodies, or from naive libraries (McCafferty, J. et al., (1990), Nature 348, 552-554; Marks, J. et al., (1992) Biotechnology 10, 779-783). The affinity of these antibodies can also be improved by chain shuffling (Clackson, T. et al., (1991) Nature 352, 624-628).

[0141] Antibodies generated by the above techniques, whether polyclonal or monoclonal, have additional utility in that they may be employed as reagents in immunoassays, radioimmunoassays (RIA) or enzyme-linked immunosorbent assays (ELISA). In these applications, the antibodies can be labelled with an analytically-detectable reagent such as a radioisotope, a fluorescent molecule or an enzyme.

[0142] Preferred nucleic acid molecules of the second and third aspects of the invention are those which encode the polypeptide sequences recited in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10 or SEQ ID NO:12, and functionally equivalent polypeptides, including active fragments of the AD1, AD2, AD3, AD4, AD5, and AD6 polypeptides, such as a fragment including the AD1, AD2, AD3, AD4, AD5, or AD6 adhesion molecule regions of the AD1, AD2, AD3, AD4, AD5, and AD6 polypeptide sequences, or a homologue thereof.

[0143] Nucleic acid molecules encompassing these stretches of sequence form a preferred embodiment of this aspect of the invention.

[0144] These nucleic acid molecules may be used in the methods and applications described herein. The nucleic acid molecules of the invention preferably comprise at least n consecutive nucleotides from the sequences disclosed herein where, depending on the particular sequence, n is 10 or more (for example, 12, 14, 15, 18, 20, 25, 30, 35, 40 or more).

[0145] The nucleic acid molecules of the invention also include sequences that are complementary to nucleic acid molecules described above (for example, for antisense or probing purposes).

[0146] Nucleic acid molecules of the present invention may be in the form of RNA, such as mRNA, or in the form of DNA, including, for instance cDNA, synthetic DNA or genomic DNA. Such nucleic acid molecules may be obtained by cloning, by chemical synthetic techniques or by a combination thereof. The nucleic acid molecules can be prepared, for example, by chemical synthesis using techniques such as solid phase phosphoramidite chemical synthesis, from genomic or cDNA libraries or by separation from an organism. RNA molecules may generally be generated by the in vitro or in vivo transcription of DNA sequences.

[0147] The nucleic acid molecules may be double-stranded or single-stranded. Single-stranded DNA may be the coding strand, also known as the sense strand, or it may be the non-coding strand, also referred to as the anti-sense strand.

[0148] The term “nucleic acid molecule” also includes analogues of DNA and RNA, such as those containing modified backbones ,and peptide nucleic acids (PNA). The term “PNA”, as used herein, refers to an antisense molecule or an anti-gene agent which comprises an oligonucleotide of at least five nucleotides in length linked to a peptide backbone of amino acid residues, which preferably ends in lysine. The terminal lysine confers solubility to the composition. PNAs may be pegylated to extend their lifespan in a cell, where they preferentially bind complementary single stranded DNA and RNA and stop transcript elongation (Nielsen, P. E. et al. (1993) Anticancer Drug Des. 8:53-63).

[0149] A nucleic acid molecule which encodes the polypeptide of SEQ ID NO:2, or an active fragment thereof, may be identical to the coding sequence of the nucleic acid molecule shown in SEQ ID NO:1. These molecules also may have a different sequence which, as a result of the degeneracy of the genetic code, encodes the polypeptide SEQ ID NO:2, or an active fragment of the AD1 polypeptide, such as a fragment including the AD1 adhesion molecule region, or a homologue thereof. The AD1 adhesion molecule region is considered to extend between, at most residue 1832 and 2036, and at least, residue 1836 and residue 1950 of the AD1 polypeptide sequence. In SEQ ID NO:1 the AD1 adhesion molecule region is thus encoded by, at the most, a nucleic acid molecule including nucleotide 5495 to nucleotide 6109 and, at the least, by a nucleic acid molecule including nucleotide 5507 to 5851. Nucleic acid molecules encompassing this stretch of sequence, and homologues of this sequence, form a preferred embodiment of this aspect of the invention.

[0150] A nucleic acid molecule which encodes the polypeptide of SEQ ID NO:4, or an active fragment thereof, may be identical to the coding sequence of the nucleic acid molecule shown in SEQ ID NO:3. These molecules also may have a different sequence which, as a result of the degeneracy of the genetic code, encodes the polypeptide SEQ ID NO:4, or an active fragment of the AD2 polypeptide, such as a fragment including the AD2 adhesion molecule region, or a homologue thereof. The AD2 adhesion molecule region is considered to extend between, at most residue 10 and 126, and at least, residue 20 and residue 105 of the AD2 polypeptide sequence. In SEQ ID NO:3 the AD2 adhesion molecule region is encoded by, at the most, a nucleic acid molecule including nucleotide 30 to nucleotide 380 and, at the least, by a nucleic acid molecule including nucleotide 60 to 317. Nucleic acid molecules encompassing this stretch of sequence, and homologues of this sequence, form a preferred embodiment of this aspect of the invention.

[0151] A nucleic acid molecule which encodes the polypeptide of SEQ ID NO:6, or an active fragment thereof, may be identical to the coding sequence of the nucleic acid molecule shown in SEQ ID NO:5. These molecules also may have a different sequence which, as a result of the degeneracy of the genetic code, encodes the polypeptide SEQ ID NO:6, or an active fragment of the AD3 polypeptide, such as a fragment including the AD3 adhesion molecule region, or a homologue thereof. The AD3 adhesion molecule region is considered to extend between, at most residue 1248 and 1432, and at least, residue 1253 and residue 1403 of the AD3 polypeptide sequence. In SEQ ID NO:5 the AD3 adhesion molecule region is encoded by, at the most, a nucleic acid molecule including nucleotide 3744 to nucleotide 4298 and, at the least, by a nucleic acid molecule including nucleotide 3759 to 4211. Nucleic acid molecules encompassing this stretch of sequence, and homologues of this sequence, form a preferred embodiment of this aspect of the invention.

[0152] A nucleic acid molecule which encodes the polypeptide of SEQ ID NO:8, or an active fragment thereof, may be identical to the coding sequence of the nucleic acid molecule shown in SEQ ID NO:7. These molecules also may have a different sequence which, as a result of the degeneracy of the genetic code, encodes the polypeptide SEQ ID NO:8, or an active fragment of the AD4 polypeptide, such as a fragment including the AD4 adhesion molecule region, or a homologue thereof. The AD4 adhesion molecule region is considered to extend between residue 308 and 424 of the AD4 polypeptide sequence. In SEQ ID NO:7 the AD4 adhesion molecule region is encoded by a nucleic acid molecule including nucleotide 922 to nucleotide 1272. Nucleic acid molecules encompassing this stretch of sequence, and homologues of this sequence, form a preferred embodiment of this aspect of the invention.

[0153] A nucleic acid molecule which encodes the polypeptide of SEQ ID NO:10, or an active fragment thereof, may be identical to the coding sequence of the nucleic acid molecule shown in SEQ ID NO:9. These molecules also may have a different sequence which, as a result of the degeneracy of the genetic code, encodes the polypeptide SEQ ID NO:10, or an active fragment of the AD5 polypeptide, such as a fragment including the AD5 adhesion molecule region of the AD5 polypeptide sequence, or a homologue thereof. The AD5 adhesion molecule region is considered to extend between, at most residue 482 and 646, and at least, residue 484 and residue 646 of the AD5 polypeptide sequence. In SEQ ID NO:9 the AD5 adhesion molecule region is encoded by, at the most, a nucleic acid molecule including nucleotide 1444 to nucleotide 1938 and, at the least, by a nucleic acid molecule including nucleotide 1450 to 1938. Nucleic acid molecules encompassing this stretch of sequence, and homologues of this sequence, form a preferred embodiment of this aspect of the invention.

[0154] A nucleic acid molecule which encodes the polypeptide of SEQ ID NO:12, or an active fragment thereof, may be identical to the coding sequence of the nucleic acid molecule shown in SEQ ID NO:11. These molecules also may have a different sequence which, as a result of the degeneracy of the genetic code, encodes the polypeptide SEQ ID NO:12, or an active fragment of the AD6 polypeptide, such as a fragment including the AD6 adhesion molecule region, or a homologue thereof. The AD6 adhesion molecule region is considered to extend between, at most residue 230 and 370, and at least, residue 230 and 339 of the AD6 polypeptide sequence. In SEQ ID NO:11 the AD6 adhesion molecule region is encoded by, at the most, a nucleic acid molecule including nucleotide 688 to nucleotide 1110 and, at the least, by a nucleic acid molecule including nucleotide 688 to 1017. Nucleic acid molecules encompassing this stretch of sequence, and homologues of this sequence, form a preferred embodiment of this aspect of the invention.

[0155] Such nucleic acid molecules that encode the polypeptide of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10 or SEQ ID NO:12 may include, but are not limited to, the coding sequence for the mature polypeptide by itself; the coding sequence for the mature polypeptide and additional coding sequences, such as those encoding a leader or secretory sequence, such as a pro-, pre- or prepro- polypeptide sequence; the coding sequence of the mature polypeptide, with or without the aforementioned additional coding sequences, together with further additional, non-coding sequences, including non-coding 5′ and 3′ sequences, such as the transcribed, non-translated sequences that play a role in transcription (including termination signals), ribosome binding and mRNA stability. The nucleic acid molecules may also include additional sequences which encode additional amino acids, such as those which provide additional functionalities.

[0156] The nucleic acid molecules of the second and third aspects of the invention may also encode the fragments or the functional equivalents of the polypeptides and fragments of the first aspect of the invention.

[0157] As discussed above, a preferred fragment of the AD1 polypeptide is a fragment including the AD1 adhesion molecule region, or a homologue thereof. The adhesion molecule region is encoded by, at the most, a nucleic acid molecule including nucleotide 5495 to nucleotide 6109 of SEQ ID NO:1 and, at the least, by a nucleic acid molecule including nucleotide 5507 to 5851 of SEQ ID NO:1.

[0158] A preferred fragment of the AD2 polypeptide is a fragment including the AD2 adhesion molecule region, or a homologue thereof. The AD2 adhesion molecule region is encoded by, at the most, a nucleic acid molecule including nucleotide 30 to nucleotide 380 of SEQ ID NO:3 and, at the least, by a nucleic acid molecule including nucleotide 60 to 317 of SEQ ID NO:3.

[0159] A preferred fragment of the AD3 polypeptide is a fragment including the AD3 adhesion molecule region, or a homologue thereof. The AD3 adhesion molecule region is encoded by, at the most, a nucleic acid molecule including nucleotide 3744 to nucleotide 4298 of SEQ ID NO:5 and, at the least, by a nucleic acid molecule including nucleotide 3759 to 4211 of SEQ ID NO:5.

[0160] A preferred fragment of the AD4 polypeptide is a fragment including the AD4 adhesion molecule region, or a homologue thereof. The AD4 adhesion molecule region is encoded by a nucleic acid molecule including nucleotide 922 to nucleotide 1272 of SEQ ID NO:7.

[0161] A preferred fragment of the AD5 polypeptide is a fragment including the AD5 adhesion molecule region, or a homologue thereof. The AD5 adhesion molecule region is encoded by, at the most, a nucleic acid molecule including nucleotide 1444 to nucleotide 1938 of SEQ ID NO:9 and, at the least, by a nucleic acid molecule including nucleotide 1450 to 1938 of SEQ ID NO:9.

[0162] A preferred fragment of the AD6 polypeptide is a fragment including the AD6 adhesion molecule region, or a homologue thereof. The AD6 adhesion molecule region is encoded by, at the most, a nucleic acid molecule including nucleotide 688 to nucleotide 1110 of SEQ ID NO:9 and, at the least, by a nucleic acid molecule including nucleotide 688 to 1017 of SEQ ID NO:11.

[0163] Functionally equivalent nucleic acid molecules according to the invention may be naturally-occurring variants such as a naturally-occurring allelic variant, or the molecules may be a variant that is not known to occur naturally. Such non-naturally occurring variants of the nucleic acid molecule may be made by mutagenesis techniques, including those applied to nucleic acid molecules, cells or organisms.

[0164] Among variants in this regard are variants that differ from the aforementioned nucleic acid molecules by nucleotide substitutions, deletions or insertions. The substitutions, deletions or insertions may involve one or more nucleotides. The variants may be altered in coding or non-coding regions or both. Alterations in the coding regions may produce conservative or non-conservative amino acid substitutions, deletions or insertions.

[0165] The nucleic acid molecules of the invention can also be engineered, using methods generally known in the art, for a variety of reasons, including modifying the cloning, processing, and/or expression of the gene product (the polypeptide). DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides are included as techniques which may be used to engineer the nucleotide sequences. Site-directed mutagenesis may be used to insert new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, introduce mutations and so forth.

[0166] Nucleic acid molecules which encode a polypeptide of the first aspect of the invention may be ligated to a heterologous sequence so that the combined nucleic acid molecule encodes a fusion protein. Such combined nucleic acid molecules are included within the second or third aspects of the invention. For example, to screen peptide libraries for inhibitors of the activity of the polypeptide, it may be useful to express, using such a combined nucleic acid molecule, a fusion protein that can be recognised by a commercially-available antibody. A fusion protein may also be engineered to contain a cleavage site located between the sequence of the polypeptide of the invention and the sequence of a heterologous protein so that the polypeptide may be cleaved and purified away from the heterologous protein.

[0167] The nucleic acid molecules of the invention also include antisense molecules that are partially complementary to nucleic acid molecules encoding polypeptides of the present invention and that therefore hybridize to the encoding nucleic acid molecules (hybridization). Such antisense molecules, such as oligonucleotides, can be designed to recognise, specifically bind to and prevent transcription of a target nucleic acid encoding a polypeptide of the invention, as will be known by those of ordinary skill in the art (see, for example, Cohen, J. S., Trends in Pharm. Sci., 10, 435 (1989), Okano, J. Neurochem. 56, 560 (1991); O'Connor, J. Neurochem 56, 560 (1991); Lee et al., Nucleic Acids Res 6, 3073 (1979); Cooney et al., Science 241, 456 (1988); Dervan et al., Science 251, 1360 (1991).

[0168] The term “hybridization” as used here refers to the association of two nucleic acid molecules with one another by hydrogen bonding. Typically, one molecule will be fixed to a solid support and the other will be free in solution. Then, the two molecules may be placed in contact with one another under conditions that favour hydrogen bonding. Factors that affect this bonding include: the type and volume of solvent; reaction temperature; time of hybridization; agitation; agents to block the non-specific attachment of the liquid phase molecule to the solid support (Denhardt's reagent or BLOTTO); the concentration of the molecules; use of compounds to increase the rate of association of molecules (dextran sulphate or polyethylene glycol); and the stringency of the washing conditions following hybridization (see Sambrook et al. [supra]).

[0169] The inhibition of hybridization of a completely complementary molecule to a target molecule may be examined using a hybridization assay, as known in the art (see, for example, Sambrook et al [supra]). A substantially homologous molecule will then compete for and inhibit the binding of a completely homologous molecule to the target molecule under various conditions of stringency, as taught in Wahl, G. M. and S. L. Berger (1987; Methods Enzymol. 152:399-407) and Kimmel, A. R. (1987; Methods Enzymol. 152:507-511).

[0170] “Stringency” refers to conditions in a hybridization reaction that favour the association of very similar molecules over association of molecules that differ. High stringency hybridisation conditions are defined as overnight incubation at 42° C. in a solution comprising 50% formamide, 5×SSC (150 mM NaCl, 15 mM trisodium citrate), 50 mM sodium phosphate (pH7.6), 5× Denhardts solution, 10% dextran sulphate, and 20 microgram/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1× SSC at approximately 65° C. Low stringency conditions involve the hybridisation reaction being carried out at 35° C. (see Sambrook et al. [supra]). Preferably, the conditions used for hybridization are those of high stringency.

[0171] Preferred embodiments of this aspect of the invention are nucleic acid molecules that are at least 70% identical over their entire length to a nucleic acid molecule encoding the AD1 polypeptide (SEQ ID NO:2), AD2 polypeptide (SEQ ID NO:4), AD3 polypeptide (SEQ ID NO:6), AD4 polypeptide (SEQ ID NO:8), AD5 polypeptide (SEQ ID NO:10), or AD6 polypeptide (SEQ ID NO:12), and nucleic acid molecules that are substantially complementary to such nucleic acid molecules. A preferred active fragment is a fragment that includes an AD1, AD2, AD3, AD4, AD5 or AD6 adhesion molecule region of the AD1, AD2, AD3, AD4, AD5, and AD6 polypeptide sequences, resepctively. Accordingly, preferred nucleic acid molecules include those that are at least 70% identical over their entire length to a nucleic acid molecule encoding the adhesion molecule region of the AD1, AD2, AD3, AD4, AD5, and AD6 polypeptide sequence.

[0172] Percentage identity, as referred to herein, is as determined using BLAST version 2.1.3 using the default parameters specified by the NCBI (the National Center for Biotechnology Information; http://www.ncbi.nlm.nih.gov/).

[0173] Preferably, a nucleic acid molecule according to this aspect of the invention comprises a region that is at least 80% identical over its entire length to the nucleic acid molecule having the sequence given in SEQ ID NO:1, to a region including nucleotides 5495-6109 of this sequence, to a region including nucleotides 5507-5851 of this sequence, or a nucleic acid molecule that is complementary to any one of these regions of nucleic acid. In this regard, nucleic acid molecules at least 90%, preferably at least 95%, more preferably at least 98% or 99% identical over their entire length to the same are particularly preferred. Preferred embodiments in this respect are nucleic acid molecules that encode polypeptides which retain substantially the same biological function or activity as the AD1 polypeptide.

[0174] Preferably, a nucleic acid molecule according to this aspect of the invention comprises a region that is at least 80% identical over its entire length to the nucleic acid molecule having the sequence given in SEQ ID NO:3, to a region including nucleotides 30-380 of this sequence, to a region including nucleotides 60-317 of this sequence, or a nucleic acid molecule that is complementary to any one of these regions of nucleic acid. In this regard, nucleic acid molecules at least 90%, preferably at least 95%, more preferably at least 98% or 99% identical over their entire length to the same are particularly preferred. Preferred embodiments in this respect are nucleic acid molecules that encode polypeptides which retain substantially the same biological function or activity as the AD2 polypeptide.

[0175] Preferably, a nucleic acid molecule according to this aspect of the invention comprises a region that is at least 80% identical over its entire length to the nucleic acid molecule having the sequence given in SEQ ID NO:5, to a region including nucleotides 3744-4298 of this sequence, to a region including nucleotides 3759-4211 of this sequence, or a nucleic acid molecule that is complementary to any one of these regions of nucleic acid. In this regard, nucleic acid molecules at least 90%, preferably at least 95%, more preferably at least 98% or 99% identical over their entire length to the same are particularly preferred. Preferred embodiments in this respect are nucleic acid molecules that encode polypeptides which retain substantially the same biological function or activity as the AD3 polypeptide.

[0176] Preferably, a nucleic acid molecule according to this aspect of the invention comprises a region that is at least 80% identical over its entire length to the nucleic acid molecule having the sequence given in SEQ ID NO:7, to a region including nucleotides 922-1272 of this sequence, or a nucleic acid molecule that is complementary to any one of these regions of nucleic acid. In this regard, nucleic acid molecules at least 90%, preferably at least 95%, more preferably at least 98% or 99% identical over their entire length to the same are particularly preferred. Preferred embodiments in this respect are nucleic acid molecules that encode polypeptides which retain substantially the same biological function or activity as the AD4 polypeptide.

[0177] Preferably, a nucleic acid molecule according to this aspect of the invention comprises a region that is at least 80% identical over its entire length to the nucleic acid molecule having the sequence given in SEQ ID NO:9, to a region including nucleotides 1444-1938 of this sequence, to a region including nucleotides 1450-1938 of this sequence, or a nucleic acid molecule that is complementary to any one of these regions of nucleic acid. In this regard, nucleic acid molecules at least 90%, preferably at least 95%, more preferably at least 98% or 99% identical over their entire length to the same are particularly preferred. Preferred embodiments in this respect are nucleic acid molecules that encode polypeptides which retain substantially the same biological function or activity as the AD5 polypeptide.

[0178] Preferably, a nucleic acid molecule according to this aspect of the invention comprises a region that is at least 80% identical over its entire length to the nucleic acid molecule having the sequence given in SEQ ID NO:11, to a region including nucleotides 688-1110 of this sequence, to a region including nucleotides 688-1017 of this sequence, or a nucleic acid molecule that is complementary to any one of these regions of nucleic acid. In this regard, nucleic acid molecules at least 90%, preferably at least 95%, more preferably at least 98% or 99% identical over their entire length to the same are particularly preferred. Preferred embodiments in this respect are nucleic acid molecules that encode polypeptides which retain substantially the same biological function or activity as the AD6 polypeptide.

[0179] The invention also provides a process for detecting a nucleic acid molecule of the invention, comprising the steps of: (a) contacting a nucleic probe according to the invention with a biological sample under hybridizing conditions to form duplexes; and (b) detecting any such duplexes that are formed.

[0180] As discussed additionally below in connection with assays that may be utilised according to the invention, a nucleic acid molecule as described above may be used as a hybridization probe for RNA, cDNA or genomic DNA, in order to isolate full-length cDNAs and genomic clones encoding the AD1, AD2, AD3, AD4, AD5 or AD6 polypeptides and to isolate cDNA and genomic clones of homologous or orthologous genes that have a high sequence similarity to the gene encoding this polypeptide.

[0181] In this regard, the following techniques, among others known in the art, may be utilised and are discussed below for purposes of illustration. Methods for DNA sequencing and analysis are well known and are generally available in the art and may, indeed, be used to practice many of the embodiments of the invention discussed herein. Such methods may employ such enzymes as the Klenow fragment of DNA polymerase 1, Sequenase (US Biochemical Corp, Cleveland, Ohio), Taq polymerase (Perkin Elmer), thermostable T7 polymerase (Amersham, Chicago, Ill.), or combinations of polymerases and proof-reading exonucleases such as those found in the ELONGASE Amplification System marketed by Gibco/BRL (Gaithersburg, Md.). Preferably, the sequencing process may be automated using machines such as the Hamilton Micro Lab 2200 (Hamilton, Reno, Nev.), the Peltier Thermal Cycler (PTC200; MJ Research, Watertown, Mass.) and the ABI Catalyst and 373 and 377 DNA Sequencers (Perkin Elmer).

[0182] One method for isolating a nucleic acid molecule encoding a polypeptide with an equivalent function to that of the AD1, AD2, AD3, AD4, AD5 or AD6 polypeptides, particularly with an equivalent function to the AD1, AD2, AD3, AD4, AD5 or AD6 adhesion molecule region of the AD1, AD2, AD3, AD4, AD5 or AD6 polypeptides, is to probe a genomic or cDNA library with a natural or artificially-designed probe using standard procedures that are recognised in the art (see, for example, “Current Protocols in Molecular Biology”, Ausubel et al. (eds). Greene Publishing Association and John Wiley Interscience, New York, 1989,1992). Probes comprising at least 15, preferably at least 30, and more preferably at least 50, contiguous bases that correspond to, or are complementary to, nucleic acid sequences from the appropriate encoding gene (SEQ ID NO:1), particularly a region from nucleotides 5495-6109, or from nucleotides 5507-5851 of SEQ ID NO: 1, are particularly useful probes.

[0183] Probes comprising at least 15, preferably at least 30, and more preferably at least 50, contiguous bases that correspond to, or are complementary to, nucleic acid sequences from the appropriate encoding gene (SEQ ID NO:3), particularly a region from nucleotides 30-380, or from nucleotides 60-317 of SEQ ID NO:3, are particularly useful probes.

[0184] Probes comprising at least 15, preferably at least 30, and more preferably at least 50, contiguous bases that correspond to, or are complementary to, nucleic acid sequences from the appropriate encoding gene (SEQ ID NO:5), particularly a region from nucleotides 3744-4298, or from nucleotides 3759-4211 of SEQ ID NO:5, are particularly useful probes.

[0185] Probes comprising at least 15, preferably at least 30, and more preferably at least 50, contiguous bases that correspond to, or are complementary to, nucleic acid sequences from the appropriate encoding gene (SEQ ID NO:7), particularly a region from nucleotides 922-1272 of SEQ ID NO:7, are particularly useful probes.

[0186] Probes comprising at least 15, preferably at least 30, and more preferably at least 50, contiguous bases that correspond to, or are complementary to, nucleic acid sequences from the appropriate encoding gene (SEQ ID NO:9), particularly a region from nucleotides 1444-1938, or from nucleotides 1450-1938 of SEQ ID NO:9, are particularly useful probes.

[0187] Probes comprising at least 15, preferably at least 30, and more preferably at least 50, contiguous bases that correspond to, or are complementary to, nucleic acid sequences from the appropriate encoding gene (SEQ ID NO:11), particularly a region from nucleotides 688-1110, or from nucleotides 688-1017 of SEQ ID NO:11, are particularly useful probes.

[0188] Such probes may be labelled with an analytically-detectable reagent to facilitate their identification. Useful reagents include, but are not limited to, radioisotopes, fluorescent dyes and enzymes that are capable of catalysing the formation of a detectable product. Using these probes, the ordinarily skilled artisan will be capable of isolating complementary copies of genomic DNA, cDNA or RNA polynucleotides encoding proteins of interest from human, mammalian or other animal sources and screening such sources for related sequences, for example, for additional members of the family, type and/or subtype.

[0189] In many cases, isolated cDNA sequences will be incomplete, in that the region encoding the polypeptide will be cut short, normally at the 5′ end. Several methods are available to obtain full length cDNAs, or to extend short cDNAs. Such sequences may be extended utilising a partial nucleotide sequence and employing various methods known in the art to detect upstream sequences such as promoters and regulatory elements. For example, one method which may be employed is based on the method of Rapid Amplification of cDNA Ends (RACE; see, for example, Frohman et al., Proc. Natl. Acad. Sci. USA (1988) 85: 8998-9002). Recent modifications of this technique, exemplified by the Marathon™ technology (Clontech Laboratories Inc.), for example, have significantly simplified the search for longer cDNAs. A slightly different technique, termed “restriction-site” PCR, uses universal primers to retrieve unknown nucleic acid sequence adjacent a known locus (Sarkar, G. (1993) PCR Methods Applic. 2:318-322). Inverse PCR may also be used to amplify or to extend sequences using divergent primers based on a known region (Triglia, T., et al. (1988) Nucleic Acids Res. 16:8186). Another method which may be used is capture PCR which involves PCR amplification of DNA fragments adjacent a known sequence in human and yeast artificial chromosome DNA (Lagerstrom, M. et al. (1991) PCR Methods Applic. 1: 111-119). Another method which may be used to retrieve unknown sequences is that of Parker, J. D. et al. (1991); Nucleic Acids Res. 19:3055-3060). Additionally, one may use PCR, nested primers, and PromoterFinder™ libraries to walk genomic DNA (Clontech, Palo Alto, Calif.). This process avoids the need to screen libraries and is useful in finding intron/exon junctions.

[0190] When screening for full-length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. Also, random-primed libraries are preferable, in that they will contain more sequences that contain the 5′ regions of genes. Use of a randomly primed library may be especially preferable for situations in which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries may be useful for extension of sequence into 5′ non-transcribed regulatory regions.

[0191] In one embodiment of the invention, the nucleic acid molecules of the present invention may be used for chromosome localisation. In this technique, a nucleic acid molecule is specifically targeted to, and can hybridize with, a particular location on an individual human chromosome. The mapping of relevant sequences to chromosomes according to the present invention is an important step in the confirmatory correlation of those sequences with the gene-associated disease. Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data are found in, for example, V. McKusick, Mendelian Inheritance in Man (available on-line through Johns Hopkins University Welch Medical Library). The relationships between genes and diseases that have been mapped to the same chromosomal region are then identified through linkage analysis (coinheritance of physically adjacent genes). This provides valuable information to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once the disease or syndrome has been crudely localised by genetic linkage to a particular genomic region, any sequences mapping to that area may represent associated or regulatory genes for further investigation. The nucleic acid molecule may also be used to detect differences in the chromosomal location due to translocation, inversion, etc. among normal, carrier, or affected individuals.

[0192] The nucleic acid molecules of the present invention are also valuable for tissue localisation. Such techniques allow the determination of expression patterns of the polypeptide in tissues by detection of the mRNAs that encode them. These techniques include in situ hybridization techniques and nucleotide amplification techniques, such as PCR. Results from these studies provide an indication of the normal functions of the polypeptide in the organism. In addition, comparative studies of the normal expression pattern of mRNAs with that of mRNAs encoded by a mutant gene provide valuable insights into the role of mutant polypeptides in disease. Such inappropriate expression may be of a temporal, spatial or quantitative nature.

[0193] The vectors of the present invention comprise nucleic acid molecules of the invention and may be cloning or expression vectors. The host cells of the invention, which may be transformed, transfested or transduced with the vectors of the invention may be prokaryotic or eukaryotic.

[0194] The polypeptides of the invention may be prepared in recombinant form by expression of their encoding nucleic acid molecules in vectors contained within a host cell. Such expression methods are well known to those of skill in the art and many are described in detail by Sambrook et al (supra) and Fernandez & Hoeffler (1998, eds. “Gene expression systems. Using nature for the art of expression”. Academic Press, San Diego, London, Boston, New York, Sydney, Tokyo, Toronto).

[0195] Generally, any system or vector that is suitable to maintain, propagate or express nucleic acid molecules to produce a polypeptide in the required host may be used. The appropriate nucleotide sequence may be inserted into an expression system by any of a variety of well-known and routine techniques, such as, for example, those described in Sambrook et al., (supra). Generally, the encoding gene can be placed under the control of a control element such as a promoter, ribosome binding site (for bacterial expression) and, optionally, an operator, so that the DNA sequence encoding the desired polypeptide is transcribed into RNA in the transformed host cell.

[0196] Examples of suitable expression systems include, for example, chromosomal, episomal and virus-derived systems, including, for example, vectors derived from: bacterial plasmids, bacteriophage, transposons, yeast episomes, insertion elements, yeast chromosomal elements, viruses such as baculoviruses, papova viruses such as SV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, or combinations thereof, such as those derived from plasmid and bacteriophage genetic elements, including cosmids and phagemids. Human artificial chromosomes (HACs) may also be employed to deliver larger fragments of DNA than can be contained and expressed in a plasmid.

[0197] Particularly suitable expression systems include microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with virus expression vectors (for example, baculovirus); plant cell systems transformed with virus expression vectors (for example, cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or with bacterial expression vectors (for example, Ti or pBR322 plasmids); or animal cell systems. Cell-free translation systems can also be employed to produce the polypeptides of the invention.

[0198] Introduction of nucleic acid molecules encoding a polypeptide of the present invention into host cells can be effected by methods described in many standard laboratory manuals, such as Davis et al., Basic Methods in Molecular Biology (1986) and Sambrook et al., [supra]. Particularly suitable methods include calcium phosphate transfection, DEAE-dextran mediated transfection, transvection, microinjection, cationic lipid-mediated transfection, electroporation, transduction, scrape loading, ballistic introduction or infection (see Sambrook et al., 1989 [supra]; Ausubel et al., 1991 [supra]; Spector, Goldman & Leinwald, 1998). In eukaryotic cells, expression systems may either be transient (for example, episomal) or permanent (chromosomal integration) according to the needs of the system.

[0199] The encoding nucleic acid molecule may or may not include a sequence encoding a control sequence, such as a signal peptide or leader sequence, as desired, for example, for secretion of the translated polypeptide into the lumen of the endoplasmic reticulum, into the periplasmic space or into the extracellular environment. These signals may be endogenous to the polypeptide or they may be heterologous signals. Leader sequences can be removed by the bacterial host in post-translational processing.

[0200] In addition to control sequences, it may be desirable to add regulatory sequences that allow for regulation of the expression of the polypeptide relative to the growth of the host cell. Examples of regulatory sequences are those which cause the expression of a gene to be increased or decreased in response to a chemical or physical stimulus, including the presence of a regulatory compound or to various temperature or metabolic conditions. Regulatory sequences are those non-translated regions of the vector, such as enhancers, promoters and 5′ and 3′ untranslated regions. These interact with host cellular proteins to carry out transcription and translation. Such regulatory sequences may vary in their strength and specificity. Depending on the vector system and host utilised, any number of suitable transcription and translation elements, including constitutive and inducible promoters, may be used. For example, when cloning in bacterial systems, inducible promoters such as the hybrid lacZ promoter of the Bluescript phagemid (Stratagene, LaJolla, Calif.) or pSport1™ plasmid (Gibco BRL) and the like may be used. The baculovirus polyhedrin promoter may be used in insect cells. Promoters or enhancers derived from the genomes of plant cells (for example, heat shock, RUBISCO and storage protein genes) or from plant viruses (for example, viral promoters or leader sequences) may be cloned into the vector. In mammalian cell systems, promoters from mammalian genes or from mammalian viruses are preferable. If it is necessary to generate a cell line that contains multiple copies of the sequence, vectors based on SV40 or EBV may be used with an appropriate selectable marker.

[0201] An expression vector is constructed so that the particular nucleic acid coding sequence is located in the vector with the appropriate regulatory sequences, the positioning and orientation of the coding sequence with respect to the regulatory sequences being such that the coding sequence is transcribed under the “control” of the regulatory sequences, i.e., RNA polymerase which binds to the DNA molecule at the control sequences transcribes the coding sequence. In some cases it may be necessary to modify the sequence so that it may be attached to the control sequences with the appropriate orientation; i.e., to maintain the reading frame.

[0202] The control sequences and other regulatory sequences may be ligated to the nucleic acid coding sequence prior to insertion into a vector. Alternatively, the coding sequence can be cloned directly into an expression vector that already contains the control sequences and an appropriate restriction site.

[0203] For long-term, high-yield production of a recombinant polypeptide, stable expression is preferred. For example, cell lines which stably express the polypeptide of interest may be transformed using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells may be allowed to grow for 1-2 days in an enriched media before they are switched to selective media. The purpose of the selectable marker is to confer resistance to selection, and its presence allows growth and recovery of cells that successfully express the introduced sequences. Resistant clones of stably transformed cells may be proliferated using tissue culture techniques appropriate to the cell type.

[0204] Mammalian cell lines available as hosts for expression are known in the art and include many immortalised cell lines available from the American Type Culture Collection (ATCC) including, but not limited to, Chinese hamster ovary (CHO), HeLa, baby hamster kidney (BHK), monkey kidney (COS), C127, 3T3, BHK, HEK 293, Bowes melanoma and human hepatocellular carcinoma (for example Hep G2) cells and a number of other cell lines.

[0205] In the baculovirus system, the materials for baculovirus/insect cell expression systems are commercially available in kit form from, inter alia, Invitrogen, San Diego Calif. (the “MaxBac” kit). These techniques are generally known to those skilled in the art and are described fully in Summers and Smith, Texas Agricultural Experiment Station Bulletin No. 1555 (1987). Particularly suitable host cells for use in this system include insect cells such as Drosophila S2 and Spodoptera Sf9 cells.

[0206] There are many plant cell culture and whole plant genetic expression systems known in the art. Examples of suitable plant cellular genetic expression systems include those described in U.S. Pat. No. 5,693,506; U.S. Pat. No. 5,659,122; and U.S. Pat. No. 5,608,143. Additional examples of genetic expression in plant cell culture has been described by Zenk, (1991) Phytochemistry 30, 3861-3863.

[0207] In particular, all plants from which protoplasts can be isolated and cultured to give whole regenerated plants can be utilised, so that whole plants are recovered which contain the transferred gene. Practically all plants can be regenerated from cultured cells or tissues, including but not limited to all major species of sugar cane, sugar beet, cotton, fruit and other trees, legumes and vegetables.

[0208] Examples of particularly preferred bacterial host cells include streptococci, staphylococci, E. coli, Streptomyces and Bacillus subtilis cells.

[0209] Examples of particularly suitable host cells for fungal expression include yeast cells (for example, S. cerevisiae) and Aspergillus cells.

[0210] Any number of selection systems are known in the art that may be used to recover transformed cell lines. Examples include the herpes simplex virus thymidine kinase (Wigler, M. et al. (1977) Cell 11:223-32) and adenine phosphoribosyltransferase (Lowy, I. et al. (1980) Cell 22:817-23) genes that can be employed in tk− or aprt± cells, respectively.

[0211] Also, antimetabolite, antibiotic or herbicide resistance can be used as the basis for selection; for example, dihydrofolate reductase (DHFR) that confers resistance to methotrexate (Wigler, M. et al. (1980) Proc. Natl. Acad. Sci. 77:3567-70); npt, which confers resistance to the aminoglycosides neomycin and G-418 (Colbere-Garapin, F. et al (1981) J. Mol. Biol. 150:1-14) and als or pat, which confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively. Additional selectable genes have been described, examples of which will be clear to those of skill in the art.

[0212] Although the presence or absence of marker gene expression suggests that the gene of interest is also present, its presence and expression may need to be confirmed. For example, if the relevant sequence is inserted within a marker gene sequence, transformed cells containing the appropriate sequences can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding a polypeptide of the invention under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem gene as well.

[0213] Alternatively, host cells that contain a nucleic acid sequence encoding a polypeptide of the invention and which express said polypeptide may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations and protein bioassays, for example, fluorescence activated cell sorting (FACS) or immunoassay techniques (such as the enzyme-linked immunosorbent assay [ELISA] and radioimmunoassay [RIA]), that include membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or protein (see Hampton, R. et al. (1990) Serological Methods, a Laboratory Manual, APS Press, St Paul, Minn.) and Maddox, D. E. et al. (1983) J. Exp. Med, 158, 1211-1216).

[0214] A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labelled hybridization or PCR probes for detecting sequences related to nucleic acid molecules encoding polypeptides of the present invention include oligolabelling, nick translation, end-labelling or PCR amplification using a labelled polynucleotide. Alternatively, the sequences encoding the polypeptide of the invention may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesise RNA probes in vitro by addition of an appropriate RNA polymerase such as T7, T3 or SP6 and labelled nucleotides. These procedures may be conducted using a variety of commercially available kits (Pharmacia & Upjohn, (Kalamazoo, Mich.); Promega (Madison Wis.); and U.S. Biochemical Corp., Cleveland, Ohio)).

[0215] Suitable reporter molecules or labels, which may be used for ease of detection, include radionuclides, enzymes and fluorescent, chemiluminescent or chromogenic agents as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

[0216] Nucleic acid molecules according to the present invention may also be used to create transgenic animals, particularly rodent animals. Such transgenic animals form a further aspect of the present invention. This may be done locally by modification of somatic cells, or by germ line therapy to incorporate heritable modifications. Such transgenic animals may be particularly useful in the generation of animal models for drug molecules effective as modulators of the polypeptides of the present invention.

[0217] The polypeptide can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulphate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. High performance liquid chromatography is particularly useful for purification. Well known techniques for refolding proteins may be employed to regenerate an active conformation when the polypeptide is denatured during isolation and or purification.

[0218] Specialised vector constructions may also be used to facilitate purification of proteins, as desired, by joining sequences encoding the polypeptides of the invention to a nucleotide sequence encoding a polypeptide domain that will facilitate purification of soluble proteins. Examples of such purification-facilitating domains include metal chelating peptides such as histidine-tryptophan modules that allow purification on immobilised metals, protein A domains that allow purification on immobilised immunoglobulin, and the domain utilised in the FLAGS extension/affinity purification system (Immunex Corp., Seattle, Wash.). The inclusion of cleavable linker sequences such as those specific for Factor XA or enterokinase (Invitrogen, San Diego, Calif.) between the purification domain and the polypeptide of the invention may be used to facilitate purification. One such expression vector provides for expression of a fusion protein containing the polypeptide of the invention fused to several histidine residues preceding a thioredoxin or an enterokinase cleavage site. The histidine residues facilitate purification by IMAC (immobilised metal ion affinity chromatography as described in Porath, J. et al. (1992) Prot. Exp. Purif. 3: 263-281) while the thioredoxin or enterokinase cleavage site provides a means for purifying the polypeptide from the fusion protein. A discussion of vectors which contain fusion proteins is provided in Kroll, D. J. et al. (DNA Cell Biol. 199312:441-453).

[0219] If the polypeptide is to be expressed for use in screening assays, generally it is preferred that it be produced at the surface of the host cell in which it is expressed. In this event, the host cells may be harvested prior to use in the screening assay, for example using techniques such as fluorescence activated cell sorting (FACS) or immunoaffinity techniques. If the polypeptide is secreted into the medium, the medium can be recovered in order to recover and purify the expressed polypeptide. If polypeptide is produced intracellularly, the cells must first be lysed before the polypeptide is recovered.

[0220] The polypeptide of the invention can be used to screen libraries of compounds in any of a variety of drug screening techniques. Such compounds may activate (agonise) or inhibit (antagonise) the level of expression of the gene or the activity of the polypeptide of the invention and form a further aspect of the present invention. Preferred compounds are effective to alter the expression of a natural gene which encodes a polypeptide of the first aspect of the invention or to regulate the activity of a polypeptide of the first aspect of the invention.

[0221] Agonist or antagonist compounds may be isolated from, for example, cells, cell-free preparations, chemical libraries or natural product mixtures. These agonists or antagonists may be natural or modified substrates, ligands, enzymes, receptors or structural or functional mimetics. For a suitable review of such screening techniques, see Coligan et al., Current Protocols in Immunology 1(2):Chapter 5 (1991).

[0222] Compounds that are most likely to be good antagonists are molecules that bind to the polypeptide of the invention without inducing the biological effects of the polypeptide upon binding to it. Potential antagonists include small organic molecules, peptides, polypeptides and antibodies that bind to the polypeptide of the invention and thereby inhibit or extinguish its activity. In this fashion, binding of the polypeptide to normal cellular binding molecules may be inhibited, such that the normal biological activity of the polypeptide is prevented.

[0223] The polypeptide of the invention that is employed in such a screening technique may be free in solution, affixed to a solid support, borne on a cell surface or located intracellularly. In general, such screening procedures may involve using appropriate cells or cell membranes that express the polypeptide that are contacted with a test compound to observe binding, or stimulation or inhibition of a functional response. The functional response of the cells contacted with the test compound is then compared with control cells that were not contacted with the test compound. Such an assay may assess whether the test compound results in a signal generated by activation of the polypeptide, using an appropriate detection system. Inhibitors of activation are generally assayed in the presence of a known agonist and the effect on activation by the agonist in the presence of the test compound is observed.

[0224] Alternatively, simple binding assays may be used, in which the adherence of a test compound to a surface bearing the polypeptide is detected by means of a label directly or indirectly associated with the test compound or in an assay involving competition with a labelled competitor. In another embodiment, competitive drug screening assays may be used, in which neutralising antibodies that are capable of binding the polypeptide specifically compete with a test compound for binding. In this manner, the antibodies can be used to detect the presence of any test compound that possesses specific binding affinity for the polypeptide.

[0225] Assays may also be designed to detect the effect of added test compounds on the production of mRNA encoding the polypeptide in cells. For example, an ELISA may be constructed that measures secreted or cell-associated levels of polypeptide using monoclonal or polyclonal antibodies by standard methods known in the art, and this can be used to search for compounds that may inhibit or enhance the production of the polypeptide from suitably manipulated cells or tissues. The formation of binding complexes between the polypeptide and the compound being tested may then be measured.

[0226] Another technique for drug screening which may be used provides for high throughput screening of compounds having suitable binding affinity to the polypeptide of interest (see International patent application WO84/03564). In this method, large numbers of different small test compounds are synthesised on a solid substrate, which may then be reacted with the polypeptide of the invention and washed. One way of immobilising the polypeptide is to use non-neutralising antibodies. Bound polypeptide may then be detected using methods that are well known in the art. Purified polypeptide can also be coated directly onto plates for use in the aforementioned drug screening techniques.

[0227] The polypeptide of the invention may be used to identify membrane-bound or soluble receptors, through standard receptor binding techniques that are known in the art, such as ligand binding and crosslinking assays in which the polypeptide is labelled with a radioactive isotope, is chemically modified, or is fused to a peptide sequence that facilitates its detection or purification, and incubated with a source of the putative receptor (for example, a composition of cells, cell membranes, cell supernatants, tissue extracts, or bodily fluids). The efficacy of binding may be measured using biophysical techniques such as surface plasmon resonance and spectroscopy. Binding assays may be used for the purification and cloning of the receptor, but may also identify agonists and antagonists of the polypeptide, that compete with the binding of the polypeptide to its receptor. Standard methods for conducting screening assays are well understood in the art.

[0228] The invention also includes a screening kit useful in the methods for identifying agonists, antagonists, ligands, receptors, substrates, enzymes, that are described above.

[0229] The invention includes the agonists, antagonists, ligands, receptors, substrates and enzymes, and other compounds which modulate the activity or antigenicity of the polypeptide of the invention discovered by the methods that are described above.

[0230] The invention also provides pharmaceutical compositions comprising a polypeptide, nucleic acid, ligand or compound of the invention in combination with a suitable pharmaceutical carrier. These compositions may be suitable as therapeutic or diagnostic reagents, as vaccines, or as other immunogenic compositions, as outlined in detail below.

[0231] According to the terminology used herein, a composition containing a polypeptide, nucleic acid, ligand or compound [X] is “substantially free of” impurities [herein, Y] when at least 85% by weight of the total X+Y in the composition is X. Preferably, X comprises at least about 90% by weight of the total of X+Y in the composition, more preferably at least about 95%, 98% or even 99% by weight.

[0232] The pharmaceutical compositions should preferably comprise a therapeutically effective amount of the polypeptide, nucleic acid molecule, ligand, or compound of the invention. The term “therapeutically effective amount” as used herein refers to an amount of a therapeutic agent needed to treat, ameliorate, or prevent a targetted disease or condition, or to exhibit a detectable therapeutic or preventative effect. For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, for example, of neoplastic cells, or in animal models, usually mice, rabbits, dogs, or pigs. The animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

[0233] The precise effective amount for a human subject will depend upon the severity of the disease state, general health of the subject, age, weight, and gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy. This amount can be determined by routine experimentation and is within the judgement of the clinician. Generally, an effective dose will be from 0.01 mg/kg to 50 mg/kg, preferably 0.05 mg/kg to 10 mg/kg. Compositions may be administered individually to a patient or may be administered in combination with other agents, drugs or hormones.

[0234] A pharmaceutical composition may also contain a pharmaceutically acceptable carrier, for administration of a therapeutic agent. Such carriers include antibodies and other polypeptides, genes and other therapeutic agents such as liposomes, provided that the carrier does not itself induce the production of antibodies harmful to the individual receiving the composition, and which may be administered without undue toxicity. Suitable carriers may be large, slowly metabolised macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers and inactive virus particles.

[0235] Pharmaceutically acceptable salts can be used therein, for example, mineral acid salts such as hydrochlorides, hydrobromides, phosphates, sulphates, and the like; and the salts of organic acids such as acetates, propionates, malonates, benzoates, and the like. A thorough discussion of pharmaceutically acceptable carriers is available in Remington's Pharmaceutical Sciences (Mack Pub. Co., N.J. 1991).

[0236] Pharmaceutically acceptable carriers in therapeutic compositions may additionally contain liquids such as water, saline, glycerol and ethanol. Additionally, auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, and the like, may be present in such compositions. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.

[0237] Once formulated, the compositions of the invention can be administered directly to the subject. The subjects to be treated can be animals; in particular, human subjects can be treated.

[0238] The pharmaceutical compositions utilised in this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal or transcutaneous applications (for example, see WO98/20734), subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, intravaginal or rectal means. Gene guns or hyposprays may also be used to administer the pharmaceutical compositions of the invention. Typically, the therapeutic compositions may be prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection may also be prepared.

[0239] Direct delivery of the compositions will generally be accomplished by injection, subcutaneously, intraperitoneally, intravenously or intramuscularly, or delivered to the interstitial space of a tissue. The compositions can also be administered into a lesion. Dosage treatment may be a single dose schedule or a multiple dose schedule.

[0240] If the activity of the polypeptide of the invention is in excess in a particular disease state, several approaches are available. One approach comprises administering to a subject an inhibitor compound (antagonist) as described above, along with a pharmaceutically acceptable carrier in an amount effective to inhibit the function of the polypeptide, such as by blocking the binding of ligands, substrates, enzymes, receptors, or by inhibiting a second signal, and thereby alleviating the abnormal condition. Preferably, such antagonists are antibodies. Most preferably, such antibodies are chimeric and/or humanised to minimise their immunogenicity, as described previously.

[0241] In another approach, soluble forms of the polypeptide that retain binding affinity for the ligand, substrate, enzyme, receptor, in question, may be administered. Typically, the polypeptide may be administered in the form of fragments that retain the relevant portions.

[0242] In an alternative approach, expression of the gene encoding the polypeptide can be inhibited using expression blocking techniques, such as the use of antisense nucleic acid molecules (as described above), either internally generated or separately administered. Modifications of gene expression can be obtained by designing complementary sequences or antisense molecules (DNA, RNA, or PNA) to the control, 5′ or regulatory regions (signal sequence, promoters, enhancers and introns) of the gene encoding the polypeptide. Similarly, inhibition can be achieved using “triple helix” base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA have been described in the literature (Gee, J. E. et al. (1994) In: Huber, B. E. and B. I. Carr, Molecular and Immunologic Approaches, Futura Publishing Co., Mt. Kisco, N.Y.). The complementary sequence or antisense molecule may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes. Such oligonucleotides may be administered or may be generated in situ from expression in vivo.

[0243] In addition, expression of the polypeptide of the invention may be prevented by using ribozymes specific to its encoding mRNA sequence. Ribozymes are catalytically active RNAs that can be natural or synthetic (see for example Usman, N, et al., Curr. Opin. Struct. Biol (1996) 6(4), 527-33). Synthetic ribozymes can be designed to specifically cleave mRNAs at selected positions thereby preventing translation of the mRNAs into functional polypeptide. Ribozymes may be synthesised with a natural ribose phosphate backbone and natural bases, as normally found in RNA molecules. Alternatively the ribozymes may be synthesised with non-natural backbones, for example, 2′-O-methyl RNA, to provide protection from ribonuclease degradation and may contain modified bases.

[0244] RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5′ and/or 3′ ends of the molecule or the use of phosphorothioate or 2′ O -methyl rather than phosphodiesterase linkages within the backbone of the molecule. This concept is inherent in the production of PNAs and can be extended in all of these molecules by the inclusion of non-traditional bases such as inosine, queosine and butosine, as well as acetyl-, methyl-, thio- and similarly modified forms of adenine, cytidine, guanine, thymine and uridine which are not as easily recognised by endogenous endonucleases.

[0245] For treating abnormal conditions related to an under-expression of the polypeptide of the invention and its activity, several approaches are also available. One approach comprises administering to a subject a therapeutically effective amount of a compound that activates the polypeptide, i.e., an agonist as described above, to alleviate the abnormal condition. Alternatively, a therapeutic amount of the polypeptide in combination with a suitable pharmaceutical carrier may be administered to restore the relevant physiological balance of polypeptide.

[0246] Gene therapy may be employed to effect the endogenous production of the polypeptide by the relevant cells in the subject. Gene therapy is used to treat permanently the inappropriate production of the polypeptide by replacing a defective gene with a corrected therapeutic gene.

[0247] Gene therapy of the present invention can occur in vivo or ex vivo. Ex vivo gene therapy requires the isolation and purification of patient cells, the introduction of a therapeutic gene and introduction of the genetically altered cells back into the patient. In contrast, in vivo gene therapy does not require isolation and purification of a patient's cells.

[0248] The therapeutic gene is typically “packaged” for administration to a patient. Gene delivery vehicles may be non-viral, such as liposomes, or replication-deficient viruses, such as adenovirus as described by Berkner, K. L., in Curr. Top. Microbiol. Immunol., 158, 39-66 (1992) or adeno-associated virus (AAV) vectors as described by Muzyczka, N., in Curr. Top. Microbiol. Immunol., 158, 97-129 (1992) and U.S. Pat. No. 5,252,479. For example, a nucleic acid molecule encoding a polypeptide of the invention may be engineered for expression in a replication-defective retroviral vector. This expression construct may then be isolated and introduced into a packaging cell transduced with a retroviral plasmid vector containing RNA encoding the polypeptide, such that the packaging cell now produces infectious viral particles containing the gene of interest. These producer cells may be administered to a subject for engineering cells in vivo and expression of the polypeptide in vivo (see Chapter 20, Gene Therapy and other Molecular Genetic-based Therapeutic Approaches, (and references cited therein) in Human Molecular Genetics (1996), T Strachan and A P Read, BIOS Scientific Publishers Ltd).

[0249] Another approach is the administration of “naked DNA” in which the therapeutic gene is directly injected into the bloodstream or muscle tissue.

[0250] In situations in which the polypeptides or nucleic acid molecules of the invention are disease-causing agents, the invention provides that they can be used in vaccines to raise antibodies against the disease causing agent.

[0251] Vaccines according to the invention may either be prophylactic (ie. to prevent infection) or therapeutic (ie. to treat disease after infection). Such vaccines comprise immunising antigen(s), immunogen(s), polypeptide(s), protein(s) or nucleic acid, usually in combination with pharmaceutically-acceptable carriers as described above, which include any carrier that does not itself induce the production of antibodies harmful to the individual receiving the composition. Additionally, these carriers may function as immunostimulating agents (“adjuvants”). Furthermore, the antigen or immunogen may be conjugated to a bacterial toxoid, such as a toxoid from diphtheria, tetanus, cholera, H. pylori, and other pathogens.

[0252] Since polypeptides may be broken down in the stomach, vaccines comprising polypeptides are preferably administered parenterally (for instance, subcutaneous, intramuscular, intravenous, or intradermal injection). Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the recipient, and aqueous and non-aqueous sterile suspensions which may include suspending agents or thickening agents.

[0253] The vaccine formulations of the invention may be presented in unit-dose or multi-dose containers. For example, sealed ampoules and vials and may be stored in a freeze-dried condition requiring only the addition of the sterile liquid carrier immediately prior to use. The dosage will depend on the specific activity of the vaccine and can be readily determined by routine experimentation.

[0254] This invention also relates to the use of nucleic acid molecules according to the present invention as diagnostic reagents. Detection of a mutated form of the gene characterised by the nucleic acid molecules of the invention which is associated with a dysfunction will provide a diagnostic tool that can add to, or define, a diagnosis of a disease, or susceptibility to a disease, which results from under-expression, over-expression or altered spatial or temporal expression of the gene. Individuals carrying mutations in the gene may be detected at the DNA level by a variety of techniques.

[0255] Nucleic acid molecules for diagnosis may be obtained from a subject's cells, such as from blood, urine, saliva, tissue biopsy or autopsy material. The genomic DNA may be used directly for detection or may be amplified enzymatically by using PCR, ligase chain reaction (LCR), strand displacement amplification (SDA), or other amplification techniques (see Saiki et al., Nature, 324, 163-166 (1986); Bej, et al., Crit. Rev. Biochem. Molec. Biol., 26, 301-334 (1991); Birkenmeyer et al., J. Virol. Meth., 35, 117-126 (1991); Van Brunt, J., Bio/Technology, 8, 291-294 (1990)) prior to analysis.

[0256] In one embodiment, this aspect of the invention provides a method of diagnosing a disease in a patient, comprising assessing the level of expression of a natural gene encoding a polypeptide according to the invention and comparing said level of expression to a control level, wherein a level that is different to said control level is indicative of disease. The method may comprise the steps of:

[0257] a) contacting a sample of tissue from the patient with a nucleic acid probe under stringent conditions that allow the formation of a hybrid complex between a nucleic acid molecule of the invention and the probe;

[0258] b) contacting a control sample with said probe under the same conditions used in step a);

[0259] c) and detecting the presence of hybrid complexes in said samples;

[0260] wherein detection of levels of the hybrid complex in the patient sample that differ from levels of the hybrid complex in the control sample is indicative of disease.

[0261] A further aspect of the invention comprises a diagnostic method comprising the steps of:

[0262] a) obtaining a tissue sample from a patient being tested for disease;

[0263] b) isolating a nucleic acid molecule according to the invention from said tissue sample; and,

[0264] c) diagnosing the patient for disease by detecting the presence of a mutation in the nucleic acid molecule which is associated with disease.

[0265] To aid the detection of nucleic acid molecules in the above-described methods, an amplification step, for example using PCR, may be included.

[0266] Deletions and insertions can be detected by a change in the size of the amplified product in comparison to the normal genotype. Point mutations can be identified by hybridizing amplified DNA to labelled RNA of the invention or alternatively, labelled antisense DNA sequences of the invention. Perfectly-matched sequences can be distinguished from mismatched duplexes by RNase digestion or by assessing differences in melting temperatures. The presence or absence of the mutation in the patient may be detected by contacting DNA with a nucleic acid probe that hybridises to the DNA under stringent conditions to form a hybrid double-stranded molecule, the hybrid double-stranded molecule having an unhybridised portion of the nucleic acid probe strand at any portion corresponding to a mutation associated with disease; and detecting the presence or absence of an unhybridised portion of the probe strand as an indication of the presence or absence of a disease-associated mutation in the corresponding portion of the DNA strand.

[0267] Such diagnostics are particularly useful for prenatal and even neonatal testing.

[0268] Point mutations and other sequence differences between the reference gene and “mutant” genes can be identified by other well-known techniques, such as direct DNA sequencing or single-strand conformational polymorphism, (see Orita et al., Genomics, 5, 874-879 (1989)). For example, a sequencing primer may be used with double-stranded PCR product or a single-stranded template molecule generated by a modified PCR. The sequence determination is performed by conventional procedures with radiolabelled nucleotides or by automatic sequencing procedures with fluorescent-tags. Cloned DNA segments may also be used as probes to detect specific DNA segments. The sensitivity of this method is greatly enhanced when combined with PCR. Further, point mutations and other sequence variations, such as polymorphisms, can be detected as described above, for example, through the use of allele-specific oligonucleotides for PCR amplification of sequences that differ by single nucleotides.

[0269] DNA sequence differences may also be detected by alterations in the electrophoretic mobility of DNA fragments in gels, with or without denaturing agents, or by direct DNA sequencing (for example, Myers et al., Science (1985) 230:1242). Sequence changes at specific locations may also be revealed by nuclease protection assays, such as RNase and S1 protection or the chemical cleavage method (see Cotton et al., Proc. Natl. Acad. Sci. USA (1985) 85: 4397-4401).

[0270] In addition to conventional gel electrophoresis and DNA sequencing, mutations such as microdeletions, aneuploidies, translocations, inversions, can also be detected by in situ analysis (see, for example, Keller et al., DNA Probes, 2nd Ed., Stockton Press, New York, N.Y., USA (1993)), that is, DNA or RNA sequences in cells can be analysed for mutations without need for their isolation and/or immobilisation onto a membrane. Fluorescence in situ hybridization (FISH) is presently the most commonly applied method and numerous reviews of FISH have appeared (see, for example, Trachuck et al., Science, 250: 559-562 (1990), and Trask et al., Trends, Genet. 7:149-154 (1991)).

[0271] In another embodiment of the invention, an array of oligonucleotide probes comprising a nucleic acid molecule according to the invention can be constructed to conduct efficient screening of genetic variants, mutations and polymorphisms. Array technology methods are well known and have general applicability and can be used to address a variety of questions in molecular genetics including gene expression, genetic linkage, and genetic variability (see for example: M.Chee et al., Science (1996) 274: 610-613).

[0272] In one embodiment, the array is prepared and used according to the methods described in PCT application WO95/11995 (Chee et al); Lockhart, D. J. et al. (1996) Nat. Biotech. 14: 1675-1680); and Schena, M. et al. (1996) Proc. Natl. Acad. Sci. 93: 10614-10619). Oligonucleotide pairs may range from two to over one million. The oligomers are synthesized at designated areas on a substrate using a light-directed chemical process. The substrate may be paper, nylon or other type of membrane, filter, chip, glass slide or any other suitable solid support. In another aspect, an oligonucleotide may be synthesized on the surface of the substrate by using a chemical coupling procedure and an ink jet application apparatus, as described in PCT application W095/251116 (Baldeschweiler et al). In another aspect, a “gridded” array analogous to a dot (or slot) blot may be used to arrange and link cDNA fragments or oligonucleotides to the surface of a substrate using a vacuum system, thermal, UV, mechanical or chemical bonding procedures. An array, such as those described above, may be produced by hand or by using available devices (slot blot or dot blot apparatus), materials (any suitable solid support), and machines (including robotic instruments), and may contain 8, 24, 96, 384, 1536 or 6144 oligonucleotides, or any other number between two and over one million which lends itself to the efficient use of commercially-available instrumentation.

[0273] In addition to the methods discussed above, diseases may be diagnosed by methods comprising determining, from a sample derived from a subject, an abnormally decreased or increased level of polypeptide or mRNA. Decreased or increased expression can be measured at the RNA level using any of the methods well known in the art for the quantitation of polynucleotides, such as, for example, nucleic acid amplification, for instance PCR, RT-PCR, RNase protection, Northern blotting and other hybridization methods.

[0274] Assay techniques that can be used to determine levels of a polypeptide of the present invention in a sample derived from a host are well-known to those of skill in the art and are discussed in some detail above (including radioimmunoassays, competitive-binding assays, Western Blot analysis and ELISA assays). This aspect of the invention provides a diagnostic method which comprises the steps of: (a) contacting a ligand as described above with a biological sample under conditions suitable for the formation of a ligand-polypeptide complex; and (b) detecting said complex.

[0275] Protocols such as ELISA, RIA, and FACS for measuring polypeptide levels may additionally provide a basis for diagnosing altered or abnormal levels of polypeptide expression. Normal or standard values for polypeptide expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, preferably humans, with antibody to the polypeptide under conditions suitable for complex formation The amount of standard complex formation may be quantified by various methods, such as by photometric means.

[0276] Antibodies which specifically bind to a polypeptide of the invention may be used for the diagnosis of conditions or diseases characterised by expression of the polypeptide, or in assays to monitor patients being treated with the polypeptides, nucleic acid molecules, ligands and other compounds of the invention. Antibodies useful for diagnostic purposes may be prepared in the same manner as those described above for therapeutics. Diagnostic assays for the polypeptide include methods that utilise the antibody and a label to detect the polypeptide in human body fluids or extracts of cells or tissues. The antibodies may be used with or without modification, and may be labelled by joining them, either covalently or non-covalently, with a reporter molecule. A wide variety of reporter molecules known in the art may be used, several of which are described above.

[0277] Quantities of polypeptide expressed in subject, control and disease samples from biopsied tissues are compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing disease. Diagnostic assays may be used to distinguish between absence, presence, and excess expression of polypeptide and to monitor regulation of polypeptide levels during therapeutic intervention. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials or in monitoring the treatment of an individual patient.

[0278] A diagnostic kit of the present invention may comprise:

[0279] (a) a nucleic acid molecule of the present invention;

[0280] (b) a polypeptide of the present invention; or

[0281] (c) a ligand of the present invention.

[0282] In one aspect of the invention, a diagnostic kit may comprise a first container containing a nucleic acid probe that hybridises under stringent conditions with a nucleic acid molecule according to the invention; a second container containing primers useful for amplifying the nucleic acid molecule; and instructions for using the probe and primers for facilitating the diagnosis of disease. The kit may further comprise a third container holding an agent for digesting unhybridised RNA.

[0283] In an alternative aspect of the invention, a diagnostic kit may comprise an array of nucleic acid molecules, at least one of which may be a nucleic acid molecule according to the invention.

[0284] To detect polypeptide according to the invention, a diagnostic kit may comprise one or more antibodies that bind to a polypeptide according to the invention; and a reagent useful for the detection of a binding reaction between the antibody and the polypeptide.

[0285] Such kits will be of use in diagnosing a disease or susceptibility to disease, particularly cardiovascular diseases including atherosclerosis, ischaemia, restenosis, reperfusion injury, sepsis, haematological diseases such as leukaemia, blood clotting disorders, such as thrombosis, cancer including lung, prostate, breast, colorectal and brain tumours, metastasis, inflammatory diseases such as rhinitis, gastrointestinal diseases, including inflammatory bowel disease, ulcerative colitis, Crohn's disease, respiratory diseases including asthma, chronic obstructive pulmonary disease (COPD), respiratory distress syndrome, pulmonary fibrosis, immune disorders, including autoimmune diseases, rheumatoid arthritis, transplant rejection, allergy, liver diseases such as cirrhosis, endocrine diseases, such as diabetes, bone diseases such as osteoporosis, neurological diseases including stroke, multiple sclerosis, spinal cord injury, burns and wound healing, bacteria infections, particularly Mycobacterium tuberculosis infection, and virus infections.

[0286] Various aspects and embodiments of the present invention will now be described in more detail by way of example, with particular reference to the AD1, AD2, AD3, AD4, AD5 and AD6 polypeptides.

[0287] It will be appreciated that modification of detail may be made without departing from the scope of the invention.

BRIEF DESCRIPTION OF THE FIGURES

[0288]FIG. 1: Front page of the Biopendium™. Search initiated using 1LFA:A.

[0289]FIG. 2A: Inpharmatica Genome Threader™ results of search using 1LFA:A. The arrow points to “Not Given”, the BAA20761.1 protein,

[0290]FIG. 2B: PSI-Blast results from search using 1LFA:A.

[0291]FIG. 3: Redundant Sequence Display page for BAA20761.1.

[0292]FIG. 4: NCBI protein report for BAA20761.1 (KIAA0301; AD1).

[0293]FIG. 5: PFAM search results for BAA20761.1 (AD1).

[0294]FIG. 6A: Inpharmatica Genome Threader™ results of search using BAA20761.1 (AD1) as the query sequence.

[0295]FIG. 6B: PSI-Blast results from search using BAA20761.1 (AD1).

[0296]FIG. 7A: Genome Threader™ alignment of BAA20761.1 (KIAA0301; AD1) and 1IDO, 1AOX:B, and 1AOX:A.

[0297]FIG. 7B: Genome Threader™ alignment of CAB8660.1 (CAB8660.1 is an alternative identifier for BAA20761.1, KIAA0301; AD1) and 1ZOO:A.

[0298]FIG. 8A: LigEye for 1AOX:A which illustrates the sites of interaction of the magnesium ion and 1AOX:A.

[0299]FIG. 8B: RasMol view of 1AOX:A, the I domain of integrin alpha2-beta1 in complex with a magnesium ion. The coloured balls represent the amino acids in 1AOX that directly interact with the divalent cation and are conserved in BAA20761.1 (KIAA0301; AD1).

[0300]FIG. 8C: RasMol view of 1AOX:A, The I-domain of integrin alpha2-beta1 in complex with a magnesium ion. The coloured balls represent the amino acids in 1AOX are conserved in BAA20761.1 (KIAA0301; AD1) as well.

[0301]FIG. 8D: Identification of model organism homologues of BAA20761.1

[0302]FIG. 8E: Sequence alignment of BAA20761.1 with model organism sequences CAA97671.1, AAF58612.1 and the structure 1AOX:B.

[0303]FIG. 9: UniGene report for BAA20761.1 (KIAA0301; AD1).

[0304]FIG. 10: SAGE library list.

[0305]FIG. 11A: SAGE results for BAA20761.1 (KIAA0301;AD1).

[0306]FIG. 11B: InterPro search results for BAA20761.1 (KIAA0301; AD1) as of Jul. 24, 2001.

[0307]FIG. 11C: InterPro search results for residues 1832-2036 of BAA20761.1 (KIAA0301; AD1) as of Jul. 24, 2001.

[0308]FIG. 11D: The PROSITE profile PS50079 for bipartite nuclear localisation signals has a high false positive rate.

[0309]FIG. 11E: The PROSITE profile PS50234 for von Willebrand factor/I-domains only became available in September 2000.

[0310]FIG. 11F: NCBI CDD search results for BAA20761.1 (KIAA0301; AD1) as of Jul. 24, 2001.

[0311]FIG. 11G: NCBI CDD search results for residues 1832-2036 of BAA20761.1 (KIAA0301; AD1) as of Jul. 24, 2001.

[0312]FIG. 11H: The smart profile smart00327 for von Willebrand factor/I-domains only became available on Jun. 30, 2001.

[0313]FIG. 12: Front page of the Biopendium™. Search initiated using 1LFA:A

[0314]FIG. 13A: Inpharmatica Genome Threader™ results of search using 1LFA:A. The arrow points to G7c (AD2), the protein CAB52192.1

[0315]FIG. 13B: PSI-Blast results from search using 1LFA:A.

[0316]FIG. 14: Redundant Sequence Display page for CAB52192.1 (AD2).

[0317]FIG. 15A: NCBI protein report for G7c (CAB52192.1; AD2)

[0318]FIG. 15B: J Immunol report detailing major histocompatibility recombinational hot spot in G7c (AD2) gene

[0319]FIG. 16: PFAM search results for CAB52192.1 (AD2).

[0320]FIG. 17A: Inpharmatica Genome Threader™ results of search using CAB52192.1 (AD2) as the query sequence.

[0321]FIG. 17B: PSI-Blast results from search using CAB52192.1 (AD2). The arrow points to the model organism homologue CAA87336.1.

[0322]FIG. 18A: Genome Threader™ alignment of CAB52192.1 (AD2) and 1LFA:B.

[0323]FIG. 18B: Alignment of CAB52192.1 (AD2) to CAA87336.1, 1CQP:A and 1CQP:B. 1CQP represents LFA-1 co-crystallised with lovostatin.

[0324]FIG. 18C: Genome Threader™ alignment of CAB52192.1 (AD2) and 1JLM.

[0325]FIG. 19A: LigEye for 1CQP which illustrates the sites of interaction of the magnesium ion and 1CQP.

[0326]FIG. 19B: RasMol view of 1CQP, the I domain of lymphocyte function-associated antigen in complex with a magnesium ion. The coloured balls represent the amino acids in 1CQP that directly interact with the divalent cation.

[0327]FIG. 19C: RasMol view of 1CQP, the I domain of lymphocyte function-associated antigen in complex with a magnesium ion. The coloured balls represent the amino acids in 1CQP which are conserved in CAB52192.1 (AD2) as well.

[0328]FIG. 20: SAGE library list.

[0329]FIG. 21A: SAGE results for CAB52192.1 (AD2).

[0330]FIG. 21B: InterPro search results for CAB52192.1 (G7c; AD2) as of Jul. 24, 2001.

[0331]FIG. 21C: InterPro search results for residues 10-126 of CAB52192.1 (G7c; AD2) as of Jul. 24, 2001.

[0332]FIG. 21D: NCBI CDD search results for CAB52192.1 (G7c; AD2) as of Jul. 24, 2001.

[0333]FIG. 21E: NCBI CDD search results for residues 10-126 of CAB52192.1 (G7c; AD2) as of Jul. 24, 2001.

[0334]FIG. 22: Front page of the Biopendium™ Target Mining Interface. Search initiated using 1LFA:A.

[0335]FIG. 23A: Inpharmatica Genome Threader™ only results of search using 1LFA:A. The arrow points to KIAA0594.

[0336]FIG. 23B: PSI-Blast results from search using 1LFA:A.

[0337]FIG. 24: Redundant Sequence Display page for KIAA0564.

[0338]FIG. 25: NCBI protein report for KIAA0564 (AD3).

[0339]FIG. 26: PFAM search results for KIAA0564 (AD3).

[0340]FIG. 27A: Inpharmatica Genome Threader™ only results of search using KIAA0564 (AD3). The arrows point to LFA.

[0341]FIG. 27B: PSI-Blast results from search using KIAA0564 (AD3).

[0342]FIG. 28A: Genome Threader™ alignment of KIAA0564 (BAA25490.1; AD3) and LFA.

[0343]FIG. 28B: Genome Threader™ alignment of KIAA0564 (BAA25490.1; AD3) and 1BHO:2.

[0344]FIG. 29A: LigEye for 1LFA:A, which illustrates the sites of interaction of the magnesium ion, and 1LFA:A.

[0345]FIG. 29B: RasMol view of 1LFA:A, the I domain of integrin CD11 alpha in complex with a magnesium ion. The coloured balls represent the amino acids in 1 LFA that comprise the MIDAS divalent cation site and are conserved in KIAA0564 (AD3).

[0346]FIG. 29C: RasMol view of 1LFA:A, the I domain of integrin CD11 alpha in complex with a magnesium ion. The coloured balls represent the amino acids in 1 LFA that are conserved in KIAA0564 (AD3).

[0347]FIG. 30A: SAGE results for KIAA0564 (AD3).

[0348]FIG. 30B: NCBI CDD search results for KIAA0564 (AD3) as of Jul. 24, 2001.

[0349]FIG. 30C: NCBI CDD search results for residues 1248-1432 of KIAA0564 (AD3) as of Jul. 24, 2001.

[0350]FIG. 31: Front page of the Biopendium™ Target Mining Interface. Search initiated using 1BHO:1.

[0351]FIG. 32A: Inpharmatica Genome Threader™ only results of search using 1BHO:1. The arrow points to NG37.

[0352]FIG. 32B: PSI-Blast results from search using 1BHO:1.

[0353]FIG. 33: Redundant Sequence Display page for NG37.

[0354]FIG. 34: NCBI protein report for NG37 (AD4).

[0355]FIG. 35: PFAM search results for NG37 (AD4).

[0356]FIG. 36A: Inpharmatica Genome Threader™ only results of search using NG37 (AD4) as the query sequence, arrow points to 1LFA. Reverse maximised Psi-Blast identifies a model organism homologue, arrow points to CAA87336.1.

[0357]FIG. 36B: PSI-Blast results from search using NG37 (AD4).

[0358]FIG. 37: Genome Threader™ alignment of NG37.1 (AD4), CAA87336.1, 1CQP:A, and 1CQP:B.

[0359]FIG. 38A: LigEye for 1CQP:A, which illustrates the sites of interaction of the magnesium ion, and 1CQP:A.

[0360]FIG. 38B: RasMol view of 1CQP:A, the I domain of integrin CD11 beta in complex with a magnesium ion. The coloured balls represent the amino acids in 1CQP that comprise the MIDAS divalent cation site and are conserved in NG37 (AD4).

[0361]FIG. 38C: RasMol view of 1CQP:A, the I domain of integrin CD11 beta in complex with a magnesium ion. The coloured balls represent the amino acids in 1CQP that are conserved in NG37 (AD4).

[0362]FIG. 38D: InterPro search results for NG37 (AD4) as of Jul. 24, 2001.

[0363]FIG. 38E: InterPro search results for residues 308-424 of NG37 (AD4) as of Jul. 24, 2001.

[0364]FIG. 38F: NCBI CDD search results for NG37 (AD4) as of Jul. 24, 2001.

[0365]FIG. 38G: NCBI CDD search results for residues 308-424 of NG37 (AD4) as of Jul. 24, 2001.

[0366]FIG. 39: Front page of the Biopendium™ Target Mining Interface. Search initiated using 1AOX:A.

[0367]FIG. 40A: Inpharmatica Genome Threader™ only results of search using 1AOX:A. The arrow points to CAB01991.1.

[0368]FIG. 40B: PSI-Blast results from search using 1AOX:A.

[0369]FIG. 41: Redundant Sequence Display page for CAB01991.1.

[0370]FIG. 42: NCBI protein report for CAB01991.1 (AD5).

[0371]FIG. 43: PFAM search results for CAB01991.1 (AD5).

[0372]FIG. 44A: Inpharmatica Genome Threader™ only results of search using CAB01991.1 (AD5). The arrows point to 1AOX. Reverse maximised Psi-Blast identifies a homologue, AAF11936.1.

[0373]FIG. 44B: PSI-Blast results from search using CAB01991.1 (AD5).

[0374]FIG. 45A: Sequence alignment of CAB01991.1 (AD5), and AAF11936.1, 1CQP:A and 1CQP:B.

[0375]FIG. 45B: Alignment of P71551 (P71551 is another identifier for CAB01991.1; AD5) and 1BHO:2.

[0376]FIG. 46A: LigEye for 1CQP:A, which illustrates the sites of interaction of the magnesium ion, and 1CQP:A.

[0377]FIG. 46B: RasMol view of 1CQP:A, the I domain of integrin Alpha 2/Beta 1 in complex with a magnesium ion. The coloured balls represent the amino acids in 1CQP that comprise the MIDAS divalent cation site and are conserved in CAB01991.1 (AD5).

[0378]FIG. 46C: RasMol view of 1CQP:A, the I domain of integrin Alpha 2/Beta 1 in complex with a magnesium ion. The coloured balls represent the amino acids in 1CQP that are conserved in CAB01991.1 (AD5).

[0379]FIG. 46D: NCBI CDD search results for CAB01991.1 (AD5) as of Jul. 24, 2001.

[0380]FIG. 46E: NCBI CDD search results for residues 482-646 of CAB01991.1 (AD5) as of Jul. 24, 2001.

[0381]FIG. 47: Front page of the Biopendium™ Target Mining Interface. Search initiated using 1AOX:A.

[0382]FIG. 48A: Inpharmatica Genome Threader™ only results of search using 1AOX:A. The arrow points to Rv0368c.

[0383]FIG. 48B: PSI-Blast results from search using 1AOX:A.

[0384]FIG. 49: Redundant Sequence Display page for Rv0368c.

[0385]FIG. 50: NCBI protein report for Rv0368c (AD6).

[0386]FIG. 51: PFAM search results for Rv0368c (AD6).

[0387]FIG. 52A: Inpharmatica Genome Threader™ only results of search using Rv0368c (AD6). The arrows point to 1AOX. Reverse-maximised Psi-Blast identifies a homologue of Rv0368c, arrow points to BAA81233.1

[0388]FIG. 52B: PSI-Blast results from search using Rv0368c (AD6).

[0389]FIG. 53A: Sequence alignment of CAA17374.1 (Rv0368c; AD6), BAA81233.1 and 1AOX.

[0390]FIG. 53B: Alignment of CAA17374.1 (Rv0368c; AD6) and 1DGQ:A, 1IDO and 1QC5:A.

[0391]FIG. 54A: LigEye for 1AOX:A, which illustrates the sites of interaction of the magnesium ion, and 1AOX:A.

[0392]FIG. 54B: RasMol view of 1AOX:A, the I domain of integrin Alpha 2/Beta 1 in complex with a magnesium ion. The coloured balls represent the amino acids in 1AOX that comprise the MIDAS divalent cation site and are conserved in Rv0368c (AD6).

[0393]FIG. 54C: RasMol view of 1AOX:A, the I domain of integrin Alpha 2/Beta 1 in complex with a magnesium ion. The coloured balls represent the amino acids in 1AOX that are conserved in Rv0368c (AD6)

[0394]FIG. 54D: InterPro search results for Rv0368c (AD6) as of Jul. 24, 2001.

[0395]FIG. 54E: InterPro search results for residues 230-370 of Rv0368c (AD6) as of Jul. 24, 2001.

[0396]FIG. 54F: NCBI CDD search results for Rv0368c (AD6) as of Jul. 24, 2001.

[0397]FIG. 54G: NCBI CDD search results for residues 230-370 of Rv0368c (AD6) as of Jul. 24, 2001.

EXAMPLES Example 1: KIAA0301 (BAA20761.1; AD1)

[0398] In order to initiate a search for novel, distantly related integrins, an archetypal family member, Leukocyte Function Associated Molecule-1 (LFA), alpha subunit is chosen. More specifically, the search is initiated using a structure from the Protein Data Bank (PDB) which is operated by the Research Collaboratory for Structural Bioinformatics.

[0399] The structure chosen represents the I domain (insertion domain) of LFA-1, PDB code 1LFA:A (FIG. 1). Lymphocyte function-associated antigen 1 (LFA-1) is a leukocyte integrin that supports inflammatory and immune responses by mediating cell adhesion, the trafficking of leukocytes, and the augmentation of signalling through the T cell receptor. This integrin consists of a CD11a and a CD18 chain and binds to the cell surface ligands intercellular adhesion molecule 1 (ICAM-1), ICAM-2, and ICAM-3. Mutational studies indicate that ICAM-1 interacts with LFA-1 through a module of approximately 200 residues designated the I domain that is located in CD11. The I domain is the site of interaction between integrins and intercellular adhesion molecules. Integrin I domains are homologous to the A-domains present in von Willebrand factor, several collagen and complement proteins, and cartilage matrix protein, all proteins with adhesive functions (Huth, J. R., et al., Proc Natl Acad Sci U.S.A. 2000 97(10):5231-6).

[0400] A search of the Biopendium™ for homologues of 1LFA takes place and returns 559 Inpharmatica Genome Threader™ results (selection given in FIG. 2A) and 595 PSI-Blast results (selection in FIG. 2B). The 559 Genome Threader™ results include examples of other I domain containing integrins, such as H. sapiens MAC-1 and LFA-1 as well as Collagen alpha 1 and Von Willebrand Factor. Among the known I domain containing adhesion molecules/proteins appears a protein of apparently unknown function, “Not Given” (BAA20761.1; AD1, FIG. 2A).

[0401] The Inpharmatica Genome Threader™ has identified residues 1836-1950 of a sequence, BAA20761.1 (AD1), as having an equivalent structure to residues 5-114 of the I domain of LFA-1 (PDB code 1LFA:A), the known interaction domain between LFA-1 and ICAM. Having a structure similar to this domain suggests that BAA20761.1 (AD1) is a protein that functions in cellular adhesion. The Inpharmatica Genome Threader™ identifies this with 95% confidence.

[0402] PSI-Blast (FIG. 2B) is unable to identify this relationship; it is only the Inpharmatica Genome Threader™ that is able to identify residues 1836-1950 of BAA20761.1 (AD1) as having an I domain. PSI-Blast does identify LFA-1 itself and other related integrins with varying degrees of probability (E value) as would be expected.

[0403] In order to view what is known in the public domain databases about BAA20761.1 (AD1), the Redundant Sequence Display Page (FIG. 3) is viewed. BAA20761.1 (AD1) is a Homo sapiens sequence, its GenBank protein ID is BAA20761.1, its gene name is KIAA0301 and it is 2047 amino acids in length. There are no associated PROSITE or PRINTS hits for this sequence. PROSITE and PRINTS are databases that help to describe proteins of similar families. Returning zero hits from both databases means that BAA20761.1 (AD1) is unidentifiable as an I domain containing adhesion molecule using PROSITE or PRINTS.

[0404] The National Centre for Biotechnology Information (NCBI) GenBank protein database is viewed to examine if there is any further information that is known in the public domain relating to BAA20761.1 (AD1). This is the U.S. public domain database for protein and gene sequence deposition (FIG. 4). BAA20761.1 was cloned by a group of scientists in Chiba, Japan (Nagase, T. et al, (1997) DNA Res. 4(2): 141-150). There is no further annotation for BAA20761.1 except that the BAA20761.1 gene was cloned from brain tissue. The public domain information for this gene does not annotate it as an integrin or an I domain-containing protein, or indeed, contain any suggestion whatsoever for the function of this protein.

[0405] In order to identify whether any other public domain annotation vehicle is able to annotate BAA20761.1 as an I domain containing protein, the BAA20761.1 protein sequence is searched against the Protein Family Database of Alignment and HMM's (PFAM) database (FIG. 5). The results identify that BAA20761.1 has no identifiable PFAMs. It may have a Von Willebrand domain (VWA) but this is below the threshold of credibility: the certainty of this is very low (E=0.82) and as such is not reliable. PFAM does not identify BAA20761.1 (AD 1) as having an I domain.

[0406] Therefore using all public domain annotation tools BAA20761.1 (AD1) is not annotated as a protein involved in adhesion through the presence of an I domain. Only the Inpharmatica Genome Threader™ is able to annotate this protein as possessing an I domain.

[0407] The reverse search is now carried out. BAA20761.1 (KIAA0301; AD1) is now used as the query sequence in the Biopendium™. The Inpharmatica Genome Threader™ identifies 30 bits (FIG. 6A) while PSI-Blast returns 39 hits (FIG. 6B). The Inpharmatica Genome Threader™ (FIG. 6A, arrow {circle over (1)}) identifies residues 1832-2036 of BAA20761.1 (AD1) as having a structure the same as the I domain of the integrin Alpha 2-Beta 2 (PDB code: 1AOX:A) with 100% confidence. The Inpharmatica Genome Threader™ (FIG. 6A, arrow {circle over (2)}) also identifies residues 1836-2036 of BAA20761.1 (AD1) as having a structure the same as the I-domain of the integrin MAC-1 (PDB code: 1IDO) with 100% confidence. The Inpharmatica Genome Threader™ (FIG. 6A, arrow {circle over (3)}) also identifies residues 1836-1950 of BAA20761.1 (AD I) as having a structure the same as the I-domain of the integrin LFA-1 (PDB code: 1ZOO:A) with 95% confidence. Thus a region from residues 1832-1836 to residues 1836-1950 of BAA20761.1 (AD1) has been identified as adopting an equivalent fold to a range of I-domains including those of the adhesion molecules Integrin Alpha2, MAC-1, and LFA-1. Forward PSI-Blast does not return this result. PSI-Blast is only able to identify this relationship in the negative iteration, which the Biopendium™ computes through its all-by-all calculation. It is only the Inpharmatica Genome Threader™ and negative iteration PSI-Blast that is able to identify this relationship.

[0408] Among the Integrins I domains that the Inpharmatica Genome Threader™ returns is the I domain from Integrin MAC-1 (also known as CR3; PDB code: 1IDO), and the I domain from Integrin Alpha 2-Beta 1 (1AOX:B, 1AOX:A). These are chosen (highlighted) against which to view the sequence alignment of BAA20761.1 (the AD1 polypeptide which also has the identifier CAB86660.1). Viewing the alignment (FIG. 7A) of the query protein against the proteins identified as being of a similar structure helps to visualize the areas of homology. FIG. 7A illustrates the point that the divalent cation binding residues of 1AOX (Ser153, Ser155 and Asp254) are conserved as Ser1843, Ser1845 and Asp1948 in BAA20761.1 (the AD1 polypeptide which also has the identifier CAB86660.1). Furthermore, FIG. 7A also illustrates that the metal ion binding residues of 1IDO (Ser142, Ser144 and Thr209) are conserved as Ser1843, Ser1845 and Thr1912 in BAA20761.1 (the AD1 polypeptide which also has the identifier CAB86660.1). Thus BAA20761.1 (the AD1 polypeptide which also has the identifier CAB86660.1) has two potential metal ion binding triads (Ser1843, Ser1845 and Asp1948) or(Ser1843, Ser1845 and Thr1912).

[0409]FIG. 7B shows the Genome Threader™ alignment of BAA20761.1 (the AD1 polypeptide which also has the identifier CAB86660.1) with the Integrin LFA-1 I-domain (1ZOO:A). FIG. 7B illustrates that the metal ion binding residues of 1ZOO:A (Ser139, Ser141 and Asp239) are conserved as Ser1843, Ser1845 and Asp1948 in BAA20761.1 (the AD1 polypeptide which also has the identifier CAB86660.1).

[0410] In order to ensure that the protein identified is a homologue of the query sequence, the visualisation program LigEye (FIG. 8A) and RasMol (FIG. 8B) are used. These visualization tools identify the active site of known protein structures by indicating the amino acids with which known small molecule inhibitors interact at the active site. These interactions are through either a direct hydrogen bond or hydrophobic interactions. In this manner one can see if the active site fold/structure is conserved between the identified homologue and the chosen protein of known structure.

[0411] This visualisation is shown with 1AOX, which illustrates the sites of interaction of a magnesium ion with the I domain of Integrin Alpha 2-Beta 1 (FIG. 8A). The magnesium ion sees 3 different amino acids in the I domain of 1AOX. The three amino acids of 1AOX (SER153, SER155, and Asp254) are conserved in BAA20761.1 (FIG. 8B, ball structures). FIG. 8C further identifies the amino acids that are conserved in 1AOX and BAA20761.1. The conservation of amino acids indicates that the fold is identical. This indicates that indeed as predicted by the Inpharmatica Genome Threader™, BAA20761.1 (AD1) folds in a similar manner to 1AOX and as such is identified as an I domain containing protein.

[0412] Inpharmatica's Reverse Maximised Psi-Blast identifies two homologues of AD1 (FIG. 8D, arrows) in D. melanogaster, AAF58612.1 and AAF58611.1. The sequence identity between these homologues and AD1 is relatively low, 36% and 25% respectively. Neither of these homologues are annotated as having an I domain. FIG. 8E shows an alignment between AD1 (BAA20761.1) CAA97671.1, AAF58612.1 and 1AOX:B. Although these sequences have diverged signifigantly we see that the functional I domain residues of 1AOX, Ser153, Ser155 and Asp254 are absolutely conserved in the homologues. This indicates that these residues are of functional importance to the protein, indicating that BAA20761.1 does indeed contain an I domain. Residues which are essential for the function of a protein will be conserved in homologues of that protein. Thus the precise conservation of identified functional I domain residues strongly supports the annotation of BAA20761.1 as an I domain containing protein.

[0413]FIG. 9 is a report generated from the NCBI UniGene database. This database is a collection of expressed sequence tags (ESTs). As this is a database of expressed sequences from a range of tissues from the human body, it can be used to give a general tissue distribution for a protein provided that its sequence is present in the database. BAA20761.1 (AD1) is presented in the database and is expressed in a wide range of tissues.

[0414] Although the UniGene database gives a rough idea of tissue distribution the Serial Analysis of Gene Expression (SAGE) database gives a direct count of how many times the gene appears in the tissues that have been analysed. FIG. 10 shows a list of all the tissues in the SAGE database. FIG. 11A is a report generated from the SAGE database for BAA20761.1 (AD1), which shows a fairly low level of expression (tags per million) predominately in brain tissue. SAGE tag TACCTGAAGT shows the most striking observation in SAGE DUKE BB542 normal cerebellum library. It is upregulated in this tissue indicating that expression of BAA20761.1 (AD1) may play a role in brain cellular function, both normal and diseased.

[0415]FIG. 11B shows the InterPro results for BAA20761.1 (AD1) as of Jul. 24, 2001. InterPro is a public domain annotation tool which combines PROSITE pattern, PROSITE profile, PRINTS and PFAM. InterPro returns two hits. (only the second hit is reported when residues 1832-2036 of BAA20761.1 (AD1), rather than full-length sequence, is inputted into InterPro, see FIG. 11C). The first of the two hits is to the PROSITE profile PS50079, which annotates residues 249-266 of BAA20761.1 (AD1) as being a nuclear localisation signal. A nuclear localisation signal would appear to be inconsistent with a role for BAA20761.1 (AD1) as an adhesion molecule. However, the nuclear localisation signal annotation can be discounted since PS50079 is known to have a high false positive rate, see FIG. 11D. The second InterPro result annotates residues 1835-2034 of BAA20761.1 (AD1) as possessing a von Willebrand factor/I-domain (PROSITE profile PS50234). This public domain annotation of BAA20761.1 (AD1) as possessing an I-domain only became available in September 2000 (see FIG. 11E). Thus this public domain annotation can be considered supporting evidence for the Genome Threader™ annotation of a region including, at the most, residue 1832 to residue 2036 of BAA20761.1 (AD 1), and at the least, residue 1836 to residue 1950 of BAA20761.1 (AD1) as being an I-domain and functioning as an adhesion molecule.

[0416]FIG. 11F shows the NCBI Conserved Domain Database (CDD) results for BAA20761.1 (AD1) as of Jul. 24, 2001. CDD returns one hit. (An identical hit is reported when residues 1832-2036 of BAA20761.1 (AD1), rather than the full-length sequence, is inputted into CDD, see FIG. 11G). The match is to the smart00327 profile which annotates residues 1833-1986 of BAA20761.1 (AD1) as possessing a von Willebrand factor/I-domain (smart00327). This public domain annotation of BAA20761.1 (AD1) as possessing an I-domain only became available on Jun. 30, 2001 (see FIG. 11H). Thus this public domain annotation can be considered supporting evidence for the Genome Threader™ annotation of a region including, at the most, residue 1832 to residue 2036 of BAA20761.1 (AD1), and at the least, residue 1836 to residue 1950 of BAA20761.1 (AD1) as being an I-domain and functioning as an adhesion molecule.

Example 2 G7c (CAB52192.1)

[0417] To initiate the search, the I domain (insertion domain) of LFA-1, PDB code 1LFA:A (FIG. 12) is again chosen.

[0418] Among the known I domain containing adhesion molecules/proteins appears a protein of apparently unknown function, G7c (CAB52192.1; AD2, FIG. 13A). The Inpharmatica Genome Threader™ has identified residues 20-126 of this sequence as having a structure similar to the I domain of LFA-1 (PDB code 1LFA:A), the known interaction domain between LFA-1 and ICAM. Having a structure similar to this I domain suggests that G7c (AD2) is a protein that functions in cellular adhesion. The Inpharmatica Genome Threader™ identifies this with 98% confidence.

[0419] PSI-Blast (FIG. 13B) is unable to identify this relationship; it is only the Inpharmatica Genome Threader™ that is able to identify CAB52192.1 (AD2) as having an I domain. PSI-Blast does identify LFA-1 itself and other related integrins with varying degrees of probability (E value) as would be expected.

[0420] In order to view what is known in the public domain databases about CAB52192.1 (AD2), the Redundant Sequence Display Page (FIG. 14) is viewed. G7c (AD2) is a Homo sapiens sequence, its GenBank protein ID is CAB52192.1, and it is 536 amino acids in length. There are no associated PROSITE or PRINTS hits for this sequence. PROSITE and PRINTS are databases that help to describe proteins of similar families. Returning 0 hits from both databases means that BAA20761.1 (AD2) is unidentifiable as an I domain containing adhesion molecule using PROSITE or PRINTS.

[0421] The National Center for Biotechnology Information (NCBI) GenBank protein database is viewed to examine if there is any further information that is known in the public domain relating to CAB52192.1 (AD2). This is the U.S. public domain database for protein and gene sequence deposition (FIG. 15A). Several groups have cloned CAB52192.1 but its function remains unknown. CAB52192.1 (AD2) is a gene sequence located in the human major histocompatibility complex (MHC). The public domain information for this gene does not annotate it as an integrin or an I domain-containing protein. Snoek et al. (J. Immunol. 1998 160(1):266-72; FIG. 15B herein) identify the G7c (AD2) gene as being located in a MHC recombinatorial hot spot that is associated with a number of disease susceptibility loci, including susceptibility to cleft palate, experimental autoimmune allergic orchitis, and chemically induced alveolar lung tumours. Defects in adhesion molecules could explain all of these disorders.

[0422] In order to identify whether any other public domain annotation vehicle is able to annotate CAB52192.1 (AD2) as an I domain containing protein, the CAB52192.1 protein sequence is searched against the Protein Family Database of Alignment and HMM's (PFAM) database (FIG. 16). The results identify that CAB52192.1 (AD2) has no identifiable PFAMs of high quality (PFAM-A) hits. It does identify a PFAM-B hit, but these are of low quality and unknown function. PFAM does not identify CAB52192.1 (AD2) as having an I domain. Therefore using all public domain annotation tools CAB52192.1 (AD2) is not annotated as a protein involved in adhesion through the presence of an I domain. Only the Inpharmatica Genome Threader™ is able to annotate it as having an I domain. Interestingly, public domain literature (FIG. 15B) implicates G7c (AD2) in several disease processes in which adhesion molecules are known to be important.

[0423] The reverse search is now carried out. CAB52192.1 (G7c; AD2) is now used as the query sequence in the Biopendium™. The Inpharmatica Genome Threader™ identifies 22 hits (FIG. 17A) while PSI-Blast returns 16 hits (FIG. 17B). The Inpharmatica Genome Threader™ (FIG. 17A, arrow {circle over (1)}) identifies residues 10-126 of CAB52192.1 (AD2) as having a structure the same as the I-domain of the Integrin LFA-1 (1LFA:B) with a confidence of 98%. The Inpharmatica Genome Threader™ (FIG. 17A, arrow {circle over (2)}) also identifies residues 20-105 of CAB52192.1 (AD2) as having a structure the same as the I-domain of the Integrin MAC-1 (1JLM) with a confidence of 92%. Thus a region from residues 10-20 to residues 105-126 of CAB52192.1 (AD2) has been identified as adopting an equivalent fold to a range of I-domains including those of the adhesion molecules LFA-1 and MAC-1.

[0424] Forward PSI-Blast does not return this result. PSI-Blast is only able to identify a relationship with von Willebrand factor (CAB37672.1) in the negative iteration, which the Biopendium™ computes through its all by all calculation. Interestingly, reverse maximised Psi-Blast identifies a homologue of AD2 in C. elegans, CAA87336.1. Therefore, it is only the Inpharmatica Genome Threader™ and negative iteration PSI-Blast that is able to identify the I domain of CAB52192.1.

[0425] Among the I-domains that the Inpharmatica Genome Threader™ returns is the I-domain of LFA (1LFA:B). 1LFA:B is chosen against which to view the sequence alignment of BAA20761.1 (AD2). Viewing the alignment (FIG. 18A) of the query protein against the proteins identified as being of a similar structure helps to visualize the areas of homology. FIG. 18A illustrates the point that the divalent cation binding residues of 1LFA;B (Ser139, Ser141, and Asp239) are conserved as Thr25 (a conservative substitution), Ser27 and Asp119, respectively, in BAA20761.1 (AD2).

[0426]FIG. 18B shows the alignment of BAA20761.1 (AD2) with another set of LFA-1 structures (1CQP:A and 1CQP:B). FIG. 18B reinforces the point that the divalent cation binding residues of LFA-1 (1CQP:A and 1CQP:B) are conserved in CAB52192.1 (AD2). The alignment on FIG. 18B also shows that the C. elegans homologue CAA87336.1 has th functionally important divalent cation binding residues conserved. This indicates that these residues are of functional importance to the protein, indicating that CAB52192.1 does indeed contain an I domain. Residues which are essential for the function of a protein will be conserved in homologues of that protein. Thus the precise conservation of identified functional I domain residues strongly supports the annotation of CAB52192.1 as an I domain-containing protein.

[0427]FIG. 18C shows the alignment of BAA20761.1 (AD2) with the Integrin MAC-1 (1JLM). FIG. 18C illustrates the point that the divalent cation binding residues of MAC-1 (Ser142, Ser144, and Asp242) are conserved as Thr25 (a conservative substitution), Ser27 and Asp119, respectively, in BAA20761.1 (AD2).

[0428] In order to ensure that the protein identified is a homologue of the query sequence LigEye (FIG. 19A) and RasMol (FIG. 19B) are used. These visualization tools identify the active site of known protein structures by indicating the amino acids that known small molecule inhibitors interact with at the active site. These interactions are through either a direct hydrogen bond or hydrophobic interactions. In this manner, one can see if the active site fold/structure is conserved between the identified homologue and the chosen protein of known structure. This is shown with 1CQP, which illustrates the sites of interaction of a magnesium ion with the I domain of lymphocyte function-associated antigen (FIG. 19A). The magnesium ion sees 3 different amino acids in the I domain of LFA-1 (1CQP). The three amino acids of LFA-1 (SER139, SER141, and Asp239) are partially conserved in CAB52192.1 (AD2) (a threonine substitutes for SER139 in CAB52192.1, FIG. 19B, ball structures). FIG. 19C further identifies the amino acids that are conserved in LFA-1 (1CQP) and CAB52192.1. The conservation of amino acids indicates that the fold is very similar. This indicates that indeed as predicted by the Inpharmatica Genome Threader™, CAB52162.1 (AD2) folds in a similar manner to 1LFA and as such is identified as an I domain containing protein.

[0429] The Serial Analysis of Gene Expression (SAGE) database, curated through the NCBI, gives a direct count of how many times a gene appears in the tissues that they have analysed. FIG. 20 shows a list of all the tissues in the SAGE database. FIG. 21A is a report generated from the SAGE database for G7c (CAB52192.1; AD2), which shows a fairly low level of expression (tags per million) and is present in only a few of the SAGE libraries. This may indicate a very limited tissue distribution or very low levels of expression.

[0430]FIG. 21B shows the InterPro results for CAB52162.1 (AD2) as of Jul. 24, 2001. InterPro is a public domain annotation tool which combines PROSITE pattern, PROSITE profile, PRINTS and PFAM. InterPro returns no hits. (no hits are also reported when residues 10-126 of CAB52162.1 (AD2), rather than full-length sequence, is inputted into InterPro, see FIG. 21C). The fact that InterPro returns no results for CAB52162.1 (AD2) on the Jul. 24, 2001 demonstrates that on the date of PCT filing, CAB52162.1 (AD2) could still only be annotated as an adhesion molecule by Inpharmatica Genome Threader™.

[0431]FIG. 21D shows the NCBI Conserved Domain Database (CDD) results for CAB52162.1 (AD2) as of Jul. 24, 2001. CDD returns no hits. (no hits are also reported when residues 10-126 of CAB52162.1 (AD2), rather than the full-length sequence, is inputted into CDD, see FIG. 21E). The fact that CDD returns no results for CAB52162.1 (AD2) on the Jul. 24, 2001 demonstrates that on the date of PCT filing, CAB52162.1 (AD2) could still only be annotated as an adhesion molecule by Inpharmatica Genome Threader™.

Example 3 KIAA0564 (AD3)

[0432] In order to initiate a search for novel, distantly related integrins, an archetypal family member, Leukocyte Function Associated Molecule-1 (LFA), alpha subunit is chosen. More specifically, the search is initiated using a structure from the Protein Data Bank (PDB) which is operated by the Research Collaboratory for Structural Bioinformatics.

[0433] The structure chosen represents the I domain (insertion domain) of LFA-1, PDB code 1LFA:A (FIG. 22). Lymphocyte function-associated antigen 1 (LFA-1) is a leukocyte integrin that supports inflammatory and immune responses by mediating cell adhesion, the trafficking of leukocytes, and the augmentation of signalling through the T cell receptor. This integrin consists of a CD11a and a CD18 chain and binds to the cell surface ligands intercellular adhesion molecule 1 (ICAM-1), ICAM-2, and ICAM-3. Mutational studies indicate that ICAM-I interacts with LFA-1 through a module of approximately 200 residues designated the I domain that is located in CD11. The I domain is the site of interaction between integrins and intercellular adhesion molecules. Integrin I domains are homologous to the A-domains present in von Willebrand factor, several collaggen and complement proteins, and cartilage matrix protein, all proteins with adhesive functions (Huth, J. R. , et al. Proc Natl Acad Sci USA. 2000 97(10):5231-6).

[0434] A search of the Biopendium for homologues of 1LFA takes place and returns 557 Inpharmatica Genome Threader™ results (selection given in FIG. 23A) and 420 PSI-Blast results (selection in FIG. 23B). The 557 Genome Threader™ results include examples of other I domain containing integrins, such as H. sapiens MAC-1 and LFA-1 as well as Collagen alpha 1 and Von Willebrand Factor. Among the known I domain containing adhesion molecules/proteins appears a protein of apparently unknown function, KIAA0564 (BAA25490.1; AD3, FIG. 23A).

[0435] The Inpharmatica Genome Threader™ has thus identified residues 1248-1403 of a sequence, KIAA0564 (AD3), as having an equivalent structure to residues 2-140 of the I domain of LFA-1 (1LFA:A), the known interaction domain between LFA-1 and ICAM. Having a structure similar to this domain suggests that KIAA0564 (AD3) is a protein that functions in cellular adhesion. The Inpharmatica Genome Threader™ identifies this with 100% confidence.

[0436] PSI-Blast (FIG. 23B) is unable to identify this relationship; it is only the Inpharmatica Genome Threader™ that is able to identify residues 1248-1403 of KIAA0564 (AD3) as having an I domain. PSI-Blast does identify LFA-1 itself and other related integrins with varying degrees of probability (E value) as would be expected.

[0437] In order to view what is known in the public domain databases about KIAA0564 (AD3), the Redundant Sequence Display Page (FIG. 24) is viewed. KIAA0564 (AD3) is a Homo sapiens sequence, its GenBank protein ID is BAA25490.1 and it is 2047 amino acids in length. There are no associated PROSITE or PRINTS hits for this sequence. PROSITE and PRINTS are databases that help to describe proteins of similar families. Returning zero hits from both databases means that KIAA0564 (AD3) is unidentifiable as an I domain containing adhesion molecule using PROSITE or PRINTS.

[0438] The National Centre for Biotechnology Information (NCBI) GenBank protein database is viewed to examine if there is any further information that is known in the public domain relating to KIAA0564 (AD3). This is the U.S. public domain database for protein and gene sequence deposition (FIG. 25). KIAA0564 was cloned by a group of scientists in Chiba, Japan (Nagase, T. et al, (1998) DNA Res. 5(1), 31-39). There is no further annotation for KIAA0564 except that the KIAA0564 gene was cloned from brain tissue. The public domain information for this gene does not annotate it as an integrin or an I domain-containing protein, or indeed, contain any suggestion whatsoever for the function of this protein.

[0439] In order to identify whether any other public domain annotation vehicle is able to annotate KIAA0564 as an I domain containing protein, the KIAA0564 protein sequence is searched against the Protein Family Database of Alignment and HMM's (PFAM) database (FIG. 26). The results identify that KIAA0564 has no identifiable PFAMs. It may have a Von Willebrand domain (VWA) but this is below the threshold of credibility: the certainty of this is very low (E=0.77) and as such is not reliable. PFAM does not identify KIAA0564 (AD3) as having an I domain.

[0440] Therefore using all public domain annotation tools KIAA0564 (AD3) is not annotated as a protein involved in adhesion through the presence of an I domain. Only the Inpharmatica Genome Threader™ is able to annotate this protein as possessing an I domain.

[0441] The reverse search is now carried out. KIAA0564 (BAA25490.1; AD3) is now used as the query sequence in the Biopendium™. The Inpharmatica Genome Threader™ identifies 182 hits (FIG. 27A) while PSI-Blast returns 2188 hits (FIG. 27B). The Inpharmatica Genome Threader™ (FIG. 27A, arrow {circle over (1)}) identifies residues 1248-1403 of KIAA0564 (AD3) as having a structure the same as the I domain of the integrin LFA-1 (1LFA:A) with a confidence of 100%. The Inpharmatica Genome Threader™ (FIG. 27A, arrow {circle over (2)}) also identifies residues 1253-1432 of KIAA0564 (AD3) as having a structure the same as the I domain of the integrin MAC-1 (1BHO:2) with a confidence of 100%. Thus a region from residues 1248-1253 to residues 1403-1432 of KIAA0564 (AD3) has been identified as adopting an equivalent fold to a range of I-domains including those of the adhesion molecules LFA-1 and MAC-1.

[0442] PSI-Blast does not return this result. It is only the Inpharmatica Genome Threader™ and that is able to identify this relationship.

[0443] Among the integrin I domains that the Inpharmatica Genome Threader™ returns is the I domain from integrin LFA-1 (1LFA:A). This is chosen (highlighted) against which to view the sequence alignment of KIAA0564 (AD3). Viewing the alignment (FIG. 28A) of the query protein against the proteins identified as being of a similar structure helps to visualize the areas of homology. FIG. 28A illustrates the point that the divalent cation binding residues of 1LFA:A (Ser139, Ser141, and Asp239) is conserved as Ser1258, Ser1260 and Asp1367, respectively, in KIAA0564 (AD3).

[0444]FIG. 28B shows the Genome Threader™alignment of KIAA0564 (AD3) with the Integrin MAC-1 I-domain (1BHO:2). FIG. 28B illustrates that the metal binding residues of 1BHO:2 (Ser442, Ser444 and Asp542) are conserved as Ser1258, Ser1260 and Asp1367, respectively, in KIAA0564 (AD3).

[0445] In order to ensure that the protein identified is a homologue of the query sequence, the visualisation program LigEye (FIG. 29A) and RasMol (FIG. 29B) are used. These visualisation tools identify the active site of known protein structures by indicating the amino acids with which known small molecule inhibitors interact at the active site. These interactions are through either a direct hydrogen bond or hydrophobic interactions. In this manner one can see if the active site fold/structure is conserved between the identified homologue and the chosen protein of known structure.

[0446] This visualisation is shown with 1LFA, which illustrates the sites of interaction of a mangenese (MN) ion with the I domain of integrin Alpha 2-Beta 1 (FIG. 29A). The MN ion sees 3 different amino acids in the I domain of 1LFA. The three amino acids of 1LFA (SER139, SER141, and Asp239) are conserved in KIAA0564 (FIG. 29B, ball structures). FIG. 29C further identifies the amino acids that are conserved in 1LFA and KIAA0564 conservation occurs throughout the structure though it is especially marked in the metal ion binding region and the central core of the protein. The conservation of amino acids indicates that the fold is identical. This indicates that indeed as predicted by the Inpharmatica Genome Threader™, KIAA0564 (AD3) folds in a similar manner to 1LFA and as such is identified as an I domain containing protein.

[0447] The Serial Analysis of Gene Expression (SAGE) database gives a direct count of how many times the gene appears in the tissues that have been analysed. FIG. 30A is a report generated from the SAGE database for KIAA0564 (AD3), which shows a fairly low level of expression (tags per million) in a variety of tissues.

[0448]FIG. 30B shows the NCBI Conserved Domain Database (CDD) results for KIAA0564 (AD3) as of Jul. 24, 2001. CDD returns one hit. (An identical hit is reported when residues 1248-1432 of KIAA0564 (AD3), rather than the full-length sequence, is inputted into CDD, see FIG. 30C). The match is to the smart00327 profile which annotates residues 1248-1432 of KIAA0564 (AD3) as possessing a von Willebrand factor/I-domain (smart00327). This public domain annotation of KIAA0564 (AD3) as possessing an I-domain only became available on Jun. 30, 2001 (see FIG. 11H). Thus this public domain annotation can be considered supporting evidence for the Genome Threader™ annotation of a region including, at the most, residue 1248 to residue 1432 of KIAA0564 (AD3), and at the least, residue 1253 to residue 1403 of KIAA0564 (AD3) as being an I-domain and functioning as an adhesion molecule.

Example 4 NG37 (AD4)

[0449] In order to initiate a search for novel, distantly related integrins, an archetypal family member, Mac-1, is chosen. More specifically, the search is initiated using a structure from the Protein Data Bank (PDB) which is operated by the Research Collaboratory for Structural Bioinformatics.

[0450] The structure chosen represents the I domain (insertion domain) of Mac-1, PDB code 1BHO:1 (FIG. 31). This integrin consists of a CD11b alpha chain and a beta chain. Mac-1 binds to receptors via a module of approximately 200 residues designated the I domain that is located in CD11b. The I domain is the site of interaction between integrins and intercellular adhesion molecules. Integrin I domains are homologous to the A-domains present in von Willebrand factor, several collaggen and complement proteins, and cartilage matrix protein, all proteins with adhesive functions (Huth, J. R. , et al., Proc Natl Acad Sci USA. 2000 May 9;97(10):5231-6).

[0451] A search of the Biopendium for homologues of 1BHO:1 takes place and returns 621 Inpharmatica Genome Threader™ results (selection given in FIG. 32A) and 431 PSI-Blast results (selection in FIG. 32B). The 621 Genome Threader™ results include examples of other I domain-containing integrins, such as LFA-1 as well as Collagen alpha 1 and Von Willebrand Factor. Among the known I domain containing adhesion molecules/proteins appears a protein of apparently unknown function, NG37 (AAD21820.1; AD4, FIG. 32A).

[0452] The Inpharmatica Genome Threader™ has thus identified residues 318-422 of a sequence, NG37 (AD4), as having an equivalent structure to residues 6-116 of the I domain of MAC-1 (1BHO:1), the known interaction domain of MAC-1. Having a structure similar to this domain suggests that NG37 (AD4) is a protein that functions in cellular adhesion. The Inpharmatica Genome Threader™ identifies this with 97.8% confidence.

[0453] PSI-Blast (FIG. 32B) is unable to identify this relationship; it is only the Inpharmatica Genome Threader™ that is able to identify residues 318-422 of NG37 (AD4) as having an I domain. PSI-Blast does identify MAC-1 itself and other related integrins with varying degrees of probability (E value) as would be expected.

[0454] In order to view what is known in the public domain databases about NG37 (AD4), the Redundant Sequence Display Page (FIG. 33) is viewed. NG37 (AD4) is a Homo sapiens sequence, its GenBank protein ID is AAD21820.1 and it is 852 amino acids in length. There are no associated PROSITE or PRINTS hits for this sequence. PROSITE and PRINTS are databases that help to describe proteins of similar families. Returning zero hits from both databases means that NG37 (AD4) is unidentifiable as an I domain containing adhesion molecule using PROSITE or PRINTS.

[0455] The National Centre for Biotechnology Information (NCBI) GenBank protein database is viewed to examine if there is any further information that is known in the public domain relating to NG37 (AD4). This is the U.S. public domain database for protein and gene sequence deposition (FIG. 34). NG37 was cloned by a group of scientists at the University of Washington (Unpublished). There is no further annotation for NG37 except that the NG37 gene was cloned the human major histocompatibility complex class III region. The public domain information for this gene does not annotate it as an integrin or an I domain-containing protein, or indeed, contain any suggestion whatsoever for the function of this protein other than it originates from the major histocompatibility complex class III region.

[0456] In order to identify whether any other public domain annotation vehicle is able to annotate NG37 as an I domain containing protein, the NG37 protein sequence is searched against the Protein Family Database of Alignment and HMM's (PFAM) database (FIG. 35). PFAM does not identify NG37 (AD4) as having an I domain or any other functional information.

[0457] Therefore using all public domain annotation tools NG37 (AD4) is not annotated as a protein involved in adhesion through the presence of an I domain. Only the Inpharmatica Genome Threader™ is able to annotate this protein as possessing an I domain.

[0458] The reverse search is now carried out. NG37 (AAD21820.1; AD4) is now used as the query sequence in the Biopendium™. The Inpharmatica Genome Threader™ identifies 96 hits (FIG. 36A) while PSI-Blast returns 22 hits (FIG. 36B). The Inpharmatica Genome Threader™ (FIG. 36A, arrow {circle over (1)}) identifies residues 308-424 of NG37 (AD4) as having a structure the same as the I domain of the Integrin LFA-1 (1CQP:A). PSI-Blast does not return this result. PSI-Blast is only able to identify this relationship in the negative iteration, which the Biopendium™ computes through its all by all calculation.

[0459] It is only the Inpharmatica Genome Threader™ and negative iteration PSI-Blast that is able to identify this relationship.

[0460] Among the integrin I domains that the Inpharmatica Genome Threader™ (FIG. 36A, arrow {circle over (2)}) returns is the I domain from integrin LFA-1 (1CQP:A). Reverse maximised PSI-Blast (FIG. 27A, arrow {circle over (2)}) identifies a homologue of AAD21820.1 in C. elegans, CAA87336.1. These are chosen (highlighted) against which to view the sequence alignment of NG37 (AD4). Viewing the alignment (FIG. 37) of the query protein against the proteins identified as being of a similar structure helps to visualize the areas of homology. FIG. 37 illustrates the point that the divalent cation binding residues of 1CQP:A and 1CQP:B (Ser139, Ser141 and Asp239 are conserved as Thr323 (conservative substitution), Ser325 and Asp417 in NG37 (AD4). This divalent ion binding region, termed the MIDAS (metal ion-dependent adhesion site) motif is highly conserved in I domain containing integrins. It plays an important role in integrin activation. The motif consists of a DXSXS consensus sequence and conserved aspartate and threonine residues which bind metal ions to provide an adhesion site.

[0461]FIG. 37 shows the conservation of ASP137 and SER141 of the DXSXS consensus sequence. SER139 the other member of the sequence is replaced by THR which is likely to be functionally equivalent, ASP239, the other metal ion ligand, is also conserved. These residues are also precisley conserved in the C. elegans homologue, CAA87336.1. This indicates that these residues are of functional importance to the protein, indicating that AAD21820.1 does indeed contain an I domain. Residues which are essential for the function of a protein will be conserved in homologues of that protein. Thus the precise conservation of identified functional I domain residues strongly supports the annotation of AAD21820.1 as an I domain-containing protein.

[0462] In order to ensure that the protein identified is a homologue of the query sequence, the visualisation program LigEye (FIG. 38A) and RasMol (FIG. 38B) are used. These visualization tools identify the active site of known protein structures by indicating the amino acids with which known small molecule inhibitors interact at the active site. These interactions are through either a direct hydrogen bond or hydrophobic interactions. In this manner one can see if the active site fold/structure is conserved between the identified homologue and the chosen protein of known structure.

[0463] This visualisation is shown with 1CQP, which illustrates the sites of interaction of a magnesium ion with the I domain of integrin LFA-1 (FIG. 38A). The magnesium ion sees 3 different amino acids in the I domain of LFA-1. The three amino acids of LFA-1 (SER139, SER141, and ASP239) are conserved in NG37 though SER139 is substituted by THR (FIG. 38B, ball structures). FIG. 38C further identifies the amino acids that are conserved in LFA-1 and NG37. The conservation of amino acids indicates that the fold is identical. This indicates that indeed as predicted by the Inpharmatica Genome Threader™, NG37 (AD4) folds in a similar manner to LFA-1 and as such is identified as an I domain-containing protein.

[0464]FIG. 38D shows the InterPro results for NG37 (AD4) as of Jul. 24, 2001. InterPro is a public domain annotation tool which combines PROSITE pattern, PROSITE profile, PRINTS and PFAM. InterPro returns no hits. (no hits are also reported when residues 308-424 of NG37 (AD4), rather than full-length sequence, is inputted into InterPro, see FIG. 38E). The fact that InterPro returns no results for NG37 (AD4) on the Jul. 24, 2001 demonstrates that on the date of PCT filing, NG37 (AD4) could still only be annotated as an adhesion molecule by Inpharmatica Genome Threader™.

[0465]FIG. 38F shows the NCBI Conserved Domain Database (CDD) results for NG37 (AD4) as of Jul. 24, 2001. CDD returns no hits. (no hits are also reported when residues 308-424 of NG37 (AD4), rather than the full-length sequence, is inputted into CDD, see FIG. 38G). The fact that CDD returns no results for NG37 (AD4) on the Jul. 24, 2001 demonstrates that on the date of PCT filing, NG37 (AD4) could still only be annotated as an adhesion molecule by Inpharmatica Genome Threader™.

Example 5: CAB01991.1 (AD5)

[0466] In order to initiate a search for novel, distantly related integrins, an archetypal family member, alpha 2 beta 1, is chosen. More specifically, the search is initiated using a structure from the Protein Data Bank (PDB) which is operated by the Research Collaboratory for Structural Bioinformatics.

[0467] The structure chosen represents the I domain (insertion domain) of alpha 2 beta 1, PDB code 1AOX:A (FIG. 39). Alpha 2 beta 1 is expressed on a variety of cell types and acts as the collagen receptor on endothelial and epithelial cells. This integrin consists of a beta 1 and an alpha 2 chain and binds to collagen fibres in the extracellular matrix. Mutational studies indicate that the I domain that is located in the alpha 2 chain is the site of collagen binding. Integrin I domains are homologous to the A-domains present in von Willebrand factor, several collagen and complement proteins, and cartilage matrix protein, all proteins with adhesive functions (Huth, J. R., et al., Proc Natl Acad Sci USA. 2000 97(10):5231-6).

[0468] A search of the Biopendium for homologues of 1AOX:A takes place and returns 529 Inpharmatica Genome Threader™ results (selection given in FIG. 40A) and 646 PSI-Blast results (selection in FIG. 40B). The 529 Genome Threader™ results include examples of other I domain containing integrins, such as LFA-1 as well as Collagen alpha 1 and Von Willebrand Factor. Among the known I domain containing adhesion molecules/proteins appears a protein of apparently unknown function, (FIG. 40A) CAB01991.1 (AD5).

[0469] The Inpharmatica Genome Threader™ has thus identified a sequence, CAB01991.1 (AD5), as having an equivalent structure to the I domain of integrin alpha 2 beta 1, the known interaction domain between it and collagen. Having a structure similar to this domain suggests that CAB01991.1 (AD5) is a protein that functions in cellular adhesion. The Inpharmatica Genome Threader™ identifies this with 99.72% confidence.

[0470] PSI-Blast (FIG. 40B) is unable to identify this relationship; it is only the Inpharmatica Genome Threader™ that is able to identify CAB01991.1 (AD5) as having an I domain. PSI-Blast does identify other related integrins with varying degrees of probability (E value) as would be expected.

[0471] In order to view what is known in the public domain databases about CAB01991.1 (AD5), the Redundant Sequence Display Page is viewed (FIG. 41). CAB01991.1 (AD5) is a Mycobacterium tuberculosis sequence, and is 672 amino acids in length. There are no associated PROSITE or PRINTS hits for the sequences. PROSITE and PRINTS are databases that help to describe proteins of similar families. Returning zero hits from both databases means that CAB01991.1 (AD5) is unidentifiable as an I domain-containing adhesion molecule using PROSITE or PRINTS.

[0472] The National Centre for Biotechnology Information (NCBI) GenBank protein database is viewed to examine if there is any further information that is known in the public domain relating to CAB01991.1 (AD5). This is the U.S. public domain database for protein and gene sequence deposition (FIG. 42). CAB01991.1 (AD5) is derived from part of the Mycobacterium tuberculosis genome sequenced by the Sanger Centre at Cambridge and other members of the Mycobacterium tuberculosis genome sequencing team (Cole, S. T. et al Nature 393(6685):537-544 (1998). The public domain information for CAB01991.1 (AD5) does not annotate it as an integrin or I domain-containing protein, or indeed, contain any suggestion whatsoever for the function of this protein.

[0473] In order to identify whether any other public domain annotation vehicle is able to annotate CAB01991.1 (AD5) as I domain-containing proteins, the CAB01991.1 (AD5) protein sequence is searched against the Protein Family Database of Alignment and HMM's (PFAM) database (FIG. 43). The results identify that CAB01991.1 (AD5) has no identifiable PFAM-A matches.

[0474] Therefore using all public domain annotation tools CAB01991.1 (AD5) cannot be annotated as a protein involved in adhesion through the presence of an I domain. Only the Inpharmatica Genome Threader™ is able to annotate this protein as possessing an I domain.

[0475] The reverse search is now carried out. CAB01991.1 (AD5) is now used as the query sequence in the Biopendium™. The Inpharmatica Genome Threader™ identifies 439 hits (Selection in FIG. 44A) while PSI-Blast returns 330 hits (Selection FIG. 44B).

[0476] The Inpharmatica Genome Threader™ (FIG. 44A, arrow {circle over (1)}) identifies residues 484-646 of CAB01991.1 (AD5) as having a structure the same as the I domain of the integrin LFA-1 (1CQP:A) with a confidence of 100%. The Inpharmatica Genome Threader™ (FIG. 44A, arrow {circle over (2)}) also identifies residues 482-646 of CAB01991.1 (AD5) as having a structure the same as the I domain of the integrin MAC-1 (1BHO:2) with a confidence of 100%. Thus a region from residues 482-484 to residue 646 of CAB01991.1 (AD5) has been identified as adopting an equivalent fold to a range of I-domains including those of the adhesion molecules LFA-1 and MAC-1. PSI-Blast is only able to return this result above iteration seven and in the negative iteration, which the Biopendium™ computes through its all by all calculation. It is only the Inpharmatica Genome Threader™ and negative iteration PSI-Blast that is able to confidently identify the relationship between CAB01991.1 (AD5) and the I domain. Reverse maximised PSI-Blast (FIG. 44A, arrow {circle over (3)}) identifies a homologue of CAB01991.1 in D. radiodurans, AAF11936.1, annotated as conserved hypothetical protein.

[0477] Among the integrin I domains that the Inpharmatica Genome Threader™ returns is the I domain from integrin LFA-1 (1CQP:A and 1CQP:B). These structures and AAF1 1936.1 are chosen against which to view the sequence alignment of CAB01991.1 (AD5). Viewing the alignment (FIG. 45A) of the query protein against the protein identified as being of a similar structure helps to visualize the areas of homology. FIG. 45A illustrates the point that the divalent cation binding residues of 1CQP:A and 1CQP:B (Ser139, Ser141 and Asp239) are conserved as Ser491, Ser493, and Asp579 in CAB01991.1 (AD5).

[0478]FIG. 45B shows the Genome Threader™ alignment of CAB01991.1 (which has the alternative identifier P71551; AD5) with the Integrin MAC-1 I-domain (1BHO:2). FIG. 45B illustrates that the metal ion binding residues of 1BHO:2 (Ser442, Ser444 and Asp542) are conserved as Ser 491, Ser493 and Asp579 in CAB01991.1 (AD5).

[0479] This divalent ion binding region, termed the MIDAS (metal ion-dependent adhesion site) motif is highly conserved in I domain containing integrins. It plays an important role in integrin activation. The motif consists of a DXSXS consensus sequence and conserved aspartate and threonine residues, which bind metal ions to provide an adhesion site.

[0480] Thus the precise conservation of identified functional I domain residues strongly supports the annotation of CAB01991.1 as an I domain-containing protein.

[0481] In order to ensure that the protein identified is a homologue of the query sequence, the visualisation program LigEye (FIG. 46A) and RasMol (FIG. 46B) are used. These visualization tools identify the active site of known protein structures by indicating the amino acids with which known small molecule inhibitors interact at the active site. These interactions are through either a direct hydrogen bond or hydrophobic interactions. In this manner one can see if the active site fold/structure is conserved between the identified homologue and the chosen protein of known structure.

[0482] This visualisation is shown with 1CQP, which illustrates the sites of interaction of a magnesium ion with the I domain of integrin LFA-1 (FIG. 46A). The magnesium ion sees 3 different amino acids in the I domain of LFA-1. These three amino acids of LFA-1 (SER139, SER141, and ASP239) are conserved in CAB01991.1 (AD5) (FIG. 46B, ball structures). FIG. 46C further identifies the amino acids that are conserved between 1CQP and CAB01991.1 (AD5). The conservation of amino acids indicates that the fold is identical. This indicates that indeed as predicted by the Inpharmatica Genome Threader™, CAB01991.1 (AD5) folds in a similar manner to 1AOX and as such is identified as an I domain-containing protein.

[0483]FIG. 46D shows the NCBI Conserved Domain Database (CDD) results for CAB01991.1 (AD5) as of Jul. 24, 2001. CDD returns no hits. (no hits are also reported when residues 482-646 of CAB01991.1 (AD5), rather than the full-length sequence, is inputted into CDD, see FIG. 46E). The fact that CDD returns no results for CAB01991.1 (AD5) on the Jul. 24, 2001 demonstrates that on the date of PCT filing, CAB01991.1 (AD5) could still only be annotated as an adhesion molecule by Inpharmatica Genome Threader™.

Example 6: Rv0368c (AD6)

[0484] In order to initiate a search for novel, distantly related integrins, an archetypal family member, alpha 2 beta 1, is chosen. More specifically, the search is initiated using a structure from the Protein Data Bank (PDB) which is operated by the Research Collaboratory for Structural Bioinformatics.

[0485] The structure chosen represents the I domain (insertion domain) of alpha 2 beta 1, PDB code 1AOX:A (FIG. 47). Alpha 2 beta 1 is expressed on a variety of cell types and acts as the collagen receptor on endothelial and epithelial cells. This integrin consists of a beta 1 and an alpha 2 chain and binds to collagen fibres in the extracellular matrix. Mutational studies indicate that the I domain that is located in the alpha 2 chain is the site of collagen binding. Integrin I domains are homologous to the A-domains present in von Willebrand factor, several collagen and complement proteins, and cartilage matrix protein, all proteins with adhesive functions (Huth, J. R., et al., Proc Natl Acad Sci USA. 2000 97(10):5231-6).

[0486] A search of the Biopendium for homologues of 1AOX:A takes place and returns 529 Inpharmatica Genome Threader™ results (selection given in FIG. 48A) and 674 PSI-Blast results (selection in FIG. 48B). The 529 Genome Threader results include examples of other I domain containing integrins, such as LFA-1 as well as Collagen alpha 1 and Von Willebrand Factor. Among the known I domain containing adhesion molecules/proteins appears a protein of apparently unknown function, Rv0368c (CAA17374.1; AD6) FIG. 48A).

[0487] The Inpharmatica Genome Threader™ has thus identified residues230-370 of a sequence, Rv0368c (AD6) as having a structure similar to residues 8-157 of the I domain of integrin alpha 2 beta 1 (1AOX:A), the known interaction domain between it and collagen. Having a structure similar to this domain suggests that Rv0368c (AD6) is a protein that functions in cellular adhesion. The Inpharmatica Genome Threader™ identifies this with 100% confidence.

[0488] PSI-Blast (FIG. 48B) is unable to identify this relationship; it is only the Inpharmatica Genome Threader™ that is able to identify residues 8-157 of Rv0368c (AD6) as having an I domain. PSI-Blast does identify other related integrins with varying degrees of probability (E value) as would be expected.

[0489] In order to view what is known in the public domain databases about Rv0368c (AD6), the Redundant Sequence Display Page is viewed (FIG. 49). Rv0368c (AD6) is a Mycobacterium tuberculosis sequence, and is 403 amino acids in length. There are no associated PROSITE or PRINTS hits for the sequence. PROSITE and PRINTS are databases that help to describe proteins of similar families. Returning zero hits from both databases means that Rv0368c (AD6) is unidentifiable as an I domain containing adhesion molecule using PROSITE or PRINTS.

[0490] The National Centre for Biotechnology Information (NCBI) GenBank protein database is viewed to examine if there is any further information that is known in the public domain relating to Rv0368c (AD6). This is the U.S. public domain database for protein and gene sequence deposition (FIG. 50). Rv0368c (AD6) is derived from part of the Mycobacterium tuberculosis genome sequenced by the Sanger Centre at Cambridge and other members of the Mycobacterium tuberculosis genome sequencing team (Cole, S. T. et al Nature 393 (6685):537-544 (1998). A similarity is noted between Rv0368c and another protein of unknown function, but no functional annotation for this protein is given. The public domain information for this gene does not annotate it as an integrin or I domain-containing protein, or indeed, contain any suggestion whatsoever for the function of this protein.

[0491] In order to identify whether any other public domain annotation vehicle is able to annotate Rv0368c (AD6) as an I domain containing protein, the Rv0368c (AD6) protein sequence is searched against the Protein Family Database of Alignment and HMM's (PFAM) database (FIG. 51). The results identify that Rv0368c (AD6) has no identifiable PFAM-A matches. The PFAM-B match has no functional information.

[0492] Therefore using all public domain annotation tools Rv0368c (AD6) is not annotated as a protein involved in adhesion through the presence of an I domain. Only the Inpharmatica Genome Threader™ is able to annotate this protein as possessing an I domain.

[0493] The reverse search is now carried out. Rv0368c (AD6) is now used as the query sequence in the Biopendium™. The Inpharmatica Genome Threader™ identifies 114 hits (FIG. 52A) while PSI-Blast returns 102 hits (FIG. 52B).

[0494] The Inpharmatica Genome Threader™ (FIG. 52A, arrow {circle over (1)}) identifies residues 230-370 of Rv0368c (AD6) as having a structure the same as the I domain of the Integrin Alpha2 (1AOX:A) with 100% confidence. The Inpharmatica Genome Threader™ (FIG. 52A, arrow {circle over (2)}) also identifies residues 230-352 of Rv0368c (AD6) as having a structure the same as the I domain of the Integrin MAC-1 (1IDO) with 100% confidence. The Inpharmatica Genome Threader™ (FIG. 52A, arrow {circle over (3)}) also identifies residues 230-340 of Rv0368c (AD6) as having a structure the same as the I domain of the Integrin LFA-1 (1DGQ:A) with 99% confidence. The Inpharmatica Genome Threader™ (FIG. 52A, arrow {circle over (4)}) also identifies residues 230-339 of Rv0368c (AD6) as having a structure the same as the I domain of the Integrin Alphal (1QC5:A) with 99% confidence. Thus a region from residue 230 to residues 339-370 of Rv0368c (AD6) has been identified as adopting an equivalent fold to a range of I-domains including those of the adhesion molecules Integrin Alpha2, MAC-1, LFA-1 and Integrin Alpha1.

[0495] PSI-Blast does not return this result, and only finds matches to other proteins of unknown function. PSI-blast is able to identify a homologue of Rv0368c (AD6) in A. pernix, BAA81233.1. It is only the Inpharmatica Genome Threader™ and negative iteration PSI-Blast that is able to confidently identify the relationship between Rv0368c (AD6) and the I domain.

[0496] Among the integrin I domains that the Inpharmatica Genome Threader™ returns is the I domain from integrin Alpha 2/Beta 1 (1AOX:A). This structure and BAA81233.1 are chosen against which to view the sequence alignment of Rv0368c (AD6). Viewing the alignment (FIG. 53A) of the query protein against the proteins identified as being of a similar structure helps to visualize the areas of homology. FIG. 53A illustrates the point that the divalent cation binding residues of 1AOX:A (Ser153, Ser155 and Asp254) are conserved as Ser237, Ser239 and Asp330 in Rv0368c (AD6). This divalent ion binding region, termed the MIDAS (metal ion-dependent adhesion site) motif is highly conserved in I domain-containing integrins. It plays an important role in integrin activation. The motif consists of a DXSXS consensus sequence and conserved aspartate and threonine residues, which bind metal ions to provide an adhesion site.

[0497]FIG. 53A shows the conservation of the ASP151, SER153 and SER155 consensus sequence, the other metal ion ligand, ASP254, is also conserved and the fifth member of the MIDAS motif, THR221, is also conserved. Precise conservation of those residues is also observed in BAA81233.1. This indicates that these residues are of functional importance to the protein, indicating that Rv0368c (AD6) does indeed contain an I domain. Residues which are essential for the function of a protein will be conserved in homologues of that protein.

[0498]FIG. 53B shows the Genome threader™ alignment of Rv0368c (AD6) with the I-domains of LFA-1 (1DGQ:A), MAC-1 (1IDO) and Alpha1 (1QC5:A). FIG. 53B illustrates that the metal ion binding residues of 1DGQ:A (Ser139, Ser141 and Asp239) are conserved as Ser237, Ser239 and Asp330 in Rv0368c (AD6). FIG. 53B also illustrates that the metal ion binding residues of 1QC5:A (Ser42, Ser44 and Asp143) are conserved as Ser237, Ser239 and Asp330 in Rv0368c (AD6). FIG. 53B also illustrates that the metal ion binding residues of 1IDO (Ser142, Ser144 and Thr209) are conserved as Ser237, Ser239 and Thr302 in Rv0368c (AD6). Thus Rv0368c (AD6) has two potential metal ion binding triads (Ser237, Ser239 and Asp330) or (Ser237, Ser239 and Thr302).

[0499] Thus the precise conservation of identified functional I domain residues strongly supports the annotation of Rv0368c (AD6) as an I domain-containing protein.

[0500] In order to ensure that the protein identified is a homologue of the query sequence, the visualisation program LigEye (FIG. 54A) and RasMol (FIG. 54B) are used. These visualization tools identify the active site of known protein structures by indicating the amino acids with which known small molecule inhibitors interact at the active site. These interactions are through either a direct hydrogen bond or hydrophobic interactions. In this manner one can see if the active site fold/structure is conserved between the identified homologue and the chosen protein of known structure.

[0501] This visualisation is shown with 1AOX, which illustrates the sites of interaction of a magnesium ion with the I domain of integrin Alpha 2-Beta 1 (FIG. 54A). The magnesium ion sees 3 different amino acids in the I domain of 1AOX. These three amino acids of 1AOX (SER153, SER155, and ASP254) are conserved in Rv0368c (AD6) (FIG. 54B, ball structures). FIG. 54C farther identifies the amino acids that are conserved between 1AOX and Rv0368c (AD6). The conservation of amino acids indicates that the fold is identical. This indicates that indeed as predicted by the Inpharmatica Genome Threader™, Rv0368c (AD6) folds in a similar manner to 1AOX and as such is identified as an I domain-containing protein.

[0502]FIG. 54D shows the InterPro results for Rv0368c (AD6) as of Jul. 24, 2001. InterPro is a public domain annotation tool which combines PROSITE pattern, PROSITE profile, PRINTS and PFAM. InterPro returns a hit to a lipocalin, but in a different region to the region of Rv0368c that is annotated herein as possessing activity as an adhesion molecule (the same hit is not reported when residues 230-370 of Rv0368c (AD6), rather than full-length sequence, is inputted into InterPro, see FIG. 54E). The fact that InterPro returns no adhesion molecule hits for Rv0368c (AD6) on the Jul. 24, 2001 demonstrates that on the date of PCT filing, Rv0368c (AD6) could still only be annotated as an adhesion molecule by Inpharmatica Genome Threader™.

[0503]FIG. 54F shows the NCBI Conserved Domain Database (CDD) results for Rv0368c (AD6) as of Jul. 24, 2001. CDD returns no bits. (no hits are also reported when residues 230-370 of Rv0368c (AD6), rather than the full-length sequence, is inputted into CDD, see FIG. 54G). The fact that CDD returns no results for Rv0368c (AD6) on the Jul. 24, 2001 demonstrates that on the date of PCT filing, Rv0368c (AD6) could still only be annotated as an adhesion molecule by Inpharmatica Genome Threader™.

[0504] The invention will now be further described by way of the following numbered paragraphs:

[0505] 1. A polypeptide, which polypeptide: has the amino acid sequence as recited in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO: 10 or SEQ ID NO: 12;

[0506] is a fragment thereof having adhesion molecule activity or having an antigenic determinant in common with the polypeptide of (i); or

[0507] is a functional equivalent of (i) or (ii).

[0508] 2. A polypeptide which is a fragment according to paragraph 1(ii), which includes the adhesion molecule region of the AD1 polypeptide, said adhesion molecule region being defined as including, at the most, between residues 1832 and 2036 inclusive, or at the least, between residues 1836 and 1950 inclusive, of the amino acid sequence recited in SEQ ID NO:2, wherein said fragment possesses the catalytic residues Ser1843, Ser1845 and Asp1912, or equivalent residues, or the trio Ser1843, Ser1845 and Thr1912, or equivalent residues, and possesses adhesion molecule activity.

[0509] 3. A polypeptide which is a functional equivalent according to paragraph 1(iii), is homologous to the amino acid sequence as recited in SEQ ID NO:2, possesses the catalytic residues Ser1843, Ser1845 and Asp 1912, or equivalent residues, or the trio Ser1843, Ser1845 and Thr1912, or equivalent residues, and has adhesion molecule activity.

[0510] 4. A polypeptide according to paragraph 3, wherein said functional equivalent is homologous to the adhesion molecule region of the AD1 polypeptide.

[0511] 5. A polypeptide which is a fragment according to paragraph 1(ii), which includes the adhesion molecule region of the AD2 polypeptide, said adhesion molecule region being defined as including, at the most, between residue 10 and residue 126, and at the least, between residue 20 and residue 105 of the amino acid sequence recited in SEQ ID NO:4, wherein said fragment possesses the catalytic residues Thr25, Ser27 and Asp119, or equivalent residues, and possesses adhesion molecule activity.

[0512] 6. A polypeptide which is a functional equivalent according to paragraph 1(iii), is homologous to the amino acid sequence as recited in SEQ ID NO:4, possesses the catalytic residues Thr25, Ser27 and Asp 119, or equivalent residues, and has adhesion molecule activity.

[0513] 7. A polypeptide according to paragraph 6, wherein said functional equivalent is homologous to the adhesion molecule region of the AD2 polypeptide.

[0514] 8. A polypeptide which is a fragment according to paragraph 1(ii), which includes the adhesion molecule region of the AD3 polypeptide, said adhesion molecule region being defined as including, at the most, between residue 1248 and residue 1432, and at the least, between residue 1253 and residue 1403 of the amino acid sequence recited in SEQ ID NO:6, wherein said fragment possesses the catalytic residues Ser1258, Ser1260 and Asp1367, or equivalent residues, and possesses adhesion molecule activity.

[0515] 9. A polypeptide which is a functional equivalent according to paragraph 1(iii), is homologous to the amino acid sequence as recited in SEQ ID NO:6, possesses the catalytic residues Ser1258, Ser1260 and Asp1367, or equivalent residues, and has adhesion molecule activity.

[0516] 10. A polypeptide according to paragraph 9, wherein said functional equivalent is homologous to the adhesion molecule region of the AD3 polypeptide.

[0517] 11. A polypeptide which is a fragment according to paragraph 1(ii), which includes the adhesion molecule region of the AD4 polypeptide, said adhesion molecule region being defined as including between residue 308 and residue 424 of the amino acid sequence recited in SEQ ID NO:8, wherein said fragment possesses the catalytic residues Thr323, Ser325 and Asp417, or equivalent residues, and possesses adhesion molecule activity.

[0518] 12. A polypeptide which is a functional equivalent according to paragraph 1(iii), is homologous to the amino acid sequence as recited in SEQ ID NO:8, possesses the catalytic residues Thr323, Ser325 and Asp417, or equivalent residues, and has adhesion molecule activity.

[0519] 13. A polypeptide according to paragraph 12, wherein said functional equivalent is homologous to the adhesion molecule region of the AD4 polypeptide.

[0520] 14. A polypeptide which is a fragment according to paragraph 1(ii), which includes the adhesion molecule region of the AD5 polypeptide, said adhesion molecule region being defined as including, at the most, between residue 482 and residue 646, and at the least; between residue 484 and residue 646 of the amino acid sequence recited in SEQ ID NO:10, wherein said fragment possesses the catalytic residues Ser491, Ser493 and Asp579, or equivalent residues, and possesses adhesion molecule activity.

[0521] 15. A polypeptide which is a functional equivalent according to paragraph 1(iii), is homologous to the amino acid sequence as recited in SEQ ID NO:10, possesses the catalytic residues Ser491, Ser493 and Asp579, or equivalent residues, and has adhesion molecule activity.

[0522] 16. A polypeptide according to paragraph 15, wherein said functional equivalent is homologous to the adhesion molecule region of the AD5 polypeptide.

[0523] 17. A polypeptide which is a fragment according to paragraph 1(ii), which includes the adhesion molecule region of the AD6 polypeptide, said adhesion molecule region being defined as including, at the most, between residue 230 and residue 370, and at the least, between residue 230 and residue 339 of the amino acid sequence recited in SEQ ID NO:12, wherein said fragment possesses the catalytic residues Ser237, Ser239 and Asp330, or equivalent residues; or the trio of Ser237, Ser239 and Thr302, or equivalent residues, and possesses adhesion molecule activity.

[0524] 18. A polypeptide which is a functional equivalent according to paragraph 1(iii), is homologous to the amino acid sequence as recited in SEQ ID NO:12, possesses the catalytic residues Ser237, Ser239 and Asp330, or equivalent residues; or the trio of Ser237, Ser239 and Thr302, or equivalent residues, and has adhesion molecule activity.

[0525] 19. A polypeptide according to paragraph 18, wherein said functional equivalent is homologous to the adhesion molecule region of the AD6 polypeptide.

[0526] 20. A fragment or functional equivalent according to any one of paragraphs 1-19, which has greater than 30% sequence identity with an amino acid sequence as recited in any one of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO: 10 and SEQ ID NO:12, or with a fragment thereof that possesses adhesion molecule activity, preferably greater than 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98% or 99% sequence identity, as determined using BLAST version 2.1.3 using the default parameters specified by the NCBI (the National Center for Biotechnology Information; http://www.ncbi.nlm.nih.gov/) [Blosum 62 matrix; gap open penalty=11 and gap extension penalty=I].

[0527] 21. A functional equivalent according to any one of paragraphs 1-19, which exhibits significant structural homology with a polypeptide having the amino acid sequence given in any one of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10 and SEQ ID NO:12, or with a fragment thereof that possesses adhesion molecule activity.

[0528] 22. A fragment as recited in paragraph 1, 2, 5, 8, 11, 14, 17 or 20, having an antigenic determinant in common with the polypeptide of paragraph 1(i), which consists of 7 or more (for example, 8, 10, 12, 14, 16, 18, 20 or more) amino acid residues from the sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10 or SEQ ID NO:12.

[0529] 23. A purified nucleic acid molecule which encodes a polypeptide according to any one of the preceding paragraphs.

[0530] 24. A purified nucleic acid molecule according to paragraph 23, which has the nucleic acid sequence as recited in SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9 or SEQ ID NO: 11, or is a redundant equivalent or fragment thereof.

[0531] 25. A fragment of a purified nucleic acid molecule according to paragraph 23 or paragraph 24, which comprises, at the most, between nucleotides 5495 and 6109, and at the least, between nucleotides 5507 and 5851 of SEQ ID NO:1, or is a redundant equivalent thereof.

[0532] 26. A fragment of a purified nucleic acid molecule according to paragraph 23 or paragraph 24, which comprises, at the most, between nucleotides 30 and 380, and at the least, between nucleotides 60 and 317 of SEQ ID NO:3, or is a redundant equivalent thereof.

[0533] 27. A fragment of a purified nucleic acid molecule according to paragraph 23 or paragraph 24, which comprises, at the most, between nucleotides 3744 and 4298, and at the least, between nucleotides 3759 and 4211 of SEQ ID NO:5, or is a redundant equivalent thereof.

[0534] 28. A fragment of a purified nucleic acid molecule according to paragraph 23 or paragraph 24, which comprises between nucleotides 922 and 1272 of SEQ ID NO:7, or is a redundant equivalent thereof.

[0535] 29. A fragment of a purified nucleic acid molecule according to paragraph 23 or paragraph 24, which comprises, at the most, between nucleotides 1444 and 1938, and at the least, between nucleotides 1450 and 1938 of SEQ ID NO:9, or is a redundant equivalent thereof.

[0536] 30. A fragment of a purified nucleic acid molecule according to paragraph 23 or paragraph 24, which comprises, at the most, between nucleotides 688 and 1110, and at the least, between nucleotides 688 and 1017 of SEQ ID NO: 11, or is a redundant equivalent thereof.

[0537] 31. A purified nucleic acid molecule which hydridizes under high stringency conditions with a nucleic acid molecule according to any one of paragraphs 23-30.

[0538] 32. A vector comprising a nucleic acid molecule as recited in any one of paragraphs 23-31.

[0539] 33. A host cell transformed with a vector according to paragraph 32.

[0540] 34. A ligand which binds specifically to, and which preferably inhibits the adhesion molecule activity of, a polypeptide according to any one of paragraphs 1-22.

[0541] 35. A ligand according to paragraph 34, which is an antibody.

[0542] 36. A compound that either increases or decreases the level of expression or activity of a polypeptide according to any one of paragraphs 1-22.

[0543] 37. A compound according to paragraph 36 that binds to a polypeptide according to any one of paragraphs 1-22 without inducing any of the biological effects of the polypeptide.

[0544] 38. A compound according to paragraph 36 or paragraph 37, which is a natural or modified substrate, ligand, enzyme, receptor or structural or functional mimetic.

[0545] 39. A polypeptide according to any one of paragraphs 1-22, a nucleic acid molecule according to any one of paragraphs 23-31, a vector according to paragraph 32, a ligand according to paragraph 34 or 35, or a compound according to any one of paragraphs 36-38, for use in therapy or diagnosis of disease.

[0546] 40. A method of diagnosing a disease in a patient, comprising assessing the level of expression of a natural gene encoding a polypeptide according to any one of paragraphs 1-22, or assessing the activity of a polypeptide according to any one of paragraph 1-22, in tissue from said patient and comparing said level of expression or activity to a control level, wherein a level that is different from said control level is indicative of disease.

[0547] 41. A method according to paragraph 40 that is carried out in vitro.

[0548] 42. A method according to paragraph 40 or paragraph 41, which comprises the steps of (a) contacting a ligand according to paragraph 34 or paragraph 35 with a biological sample under conditions suitable for the formation of a ligand-polypeptide complex; and (b) detecting said complex.

[0549] 43. A method according to paragraph 40 or paragraph 41, comprising the steps of:

[0550] a. contacting a sample of tissue from the patient with a nucleic acid probe under stringent conditions that allow the formation of a hybrid complex between a nucleic acid molecule according to any one of paragraphs 23-31 and the probe;

[0551] b. contacting a control sample with said probe under the same conditions used in step a); and

[0552] c. detecting the presence of hybrid complexes in said samples;

[0553] wherein detection of levels of the hybrid complex in the patient sample that differ from levels of the hybrid complex in the control sample is indicative of disease.

[0554] 44. A method according to paragraph 40 or paragraph 41, comprising:

[0555] a. contacting a sample of nucleic acid from tissue of the patient with a nucleic acid primer under stringent conditions that allow the formation of a hybrid complex between a nucleic acid molecule according to any one of paragraphs 23-31 and the primer;

[0556] b. contacting a control sample with said primer under the same conditions used in step a); and

[0557] c. amplifying the sampled nucleic acid; and

[0558] d. detecting the level of amplified nucleic acid from both patient and control samples;

[0559] wherein detection of levels of the amplified nucleic acid in the patient sample that differ significantly from levels of the amplified nucleic acid in the control sample is indicative of disease.

[0560] 45. A method according to paragraph 40 or paragraph 41 comprising:

[0561] a. obtaining a tissue sample from a patient being tested for disease;

[0562] b. isolating a nucleic acid molecule according to any one of paragraphs 23-31 from said tissue sample; and

[0563] c. diagnosing the patient for disease by detecting the presence of a mutation which is associated with disease in the nucleic acid molecule as an indication of the disease.

[0564] 46. The method of paragraph 45, further comprising amplifying the nucleic acid molecule to form an amplified product and detecting the presence or absence of a mutation in the amplified product.

[0565] 47. The method of either paragraph 45 or 46, wherein the presence or absence of the mutation in the patient is detected by contacting said nucleic acid molecule with a nucleic acid probe that hybridises to said nucleic acid molecule under stringent conditions to form a hybrid double-stranded molecule, the hybrid double-stranded molecule having an unhybridised portion of the nucleic acid probe strand at any portion corresponding to a mutation associated with disease; and detecting the presence or absence of an unhybridised portion of the probe strand as an indication of the presence or absence of a disease-associated mutation.

[0566] 48. A method according to any one of paragraphs 40-47, wherein said disease is a cardiovascular disease, including atherosclerosis, ischaemia, restenosis, reperfusion injury, sepsis; a haematological disease such as leukaemia; a blood clotting disorder, such as thrombosis; cancer, including lung, prostate, breast, colorectal and brain tumours, metastasis; an inflammatory disease such as rhinitis; a gastrointestinal disease, including inflammatory bowel disease, ulcerative colitis, Crohn's disease; a respiratory disease, including asthma; chronic obstructive pulmonary disease (COPD); respiratory distress syndrome; pulmonary fibrosis; immune disorders, including autoimmune diseases, rheumatoid arthritis, transplant rejection; allergy; liver diseases, such as cirrhosis; endocrine diseases, such as diabetes; bone diseases such as osteoporosis; neurological diseases, including stroke, multiple sclerosis, spinal cord injury; burns and wound healing; bacterial infection, particularly Mycobacterium tuberculosis infection, and virus infection.

[0567] 49. Use of a polypeptide according to any one of paragraphs 1-22 as an adhesion molecule.

[0568] 50. Use of a nucleic acid molecule according to any one of paragraphs 23-31 to express a protein that possesses adhesion molecule activity.

[0569] 51. A method for effecting cell-cell adhesion, utilising a polypeptide according to any one of paragraphs 1-22.

[0570] 52. A pharmaceutical composition comprising a polypeptide according to any one of paragraphs 1-22, a nucleic acid molecule according to any one of paragraphs 23-31, a vector according to paragraph 32, a ligand according to paragraph 34 or 35, or a compound according to any one of paragraphs 36-38.

[0571] 53. A vaccine composition comprising a polypeptide according to any one of paragraphs 1-22 or a nucleic acid molecule according to any one of paragraphs 23-31.

[0572] 54. A polypeptide according to any one of paragraphs 1-22, a nucleic acid molecule according to any one of paragraphs 23-31, a vector according to paragraph 32, a ligand according to paragraph 34 or 35, a compound according to any one of paragraphs 36-38, or a pharmaceutical composition according to paragraph 52 for use in the manufacture of a medicament for the treatment of a cardiovascular disease, including atherosclerosis, ischaemia, restenosis, reperfusion injury, sepsis; a haematological disease such as leukaemia; a blood clotting disorder, such as thrombosis; cancer, including lung, prostate, breast, colorectal and brain tumours, metastasis; an inflammatory disease such as rhinitis; a gastrointestinal disease, including inflammatory bowel disease, ulcerative colitis, Crohn's disease; a respiratory disease, including asthma; chronic obstructive pulmonary disease (COPD); respiratory distress syndrome; pulmonary fibrosis; immune disorders, including autoimmune diseases, rheumatoid arthritis, transplant rejection; allergy; liver diseases, such as cirrhosis; endocrine diseases, such as diabetes; bone diseases such as osteoporosis; neurological diseases, including stroke, multiple sclerosis, spinal cord injury; burns and wound healing; bacterial infection, particularly Mycobacterium tuberculosis infection, or a virus infection.

[0573] 55. A method of treating a disease in a patient, comprising administering to the patient a polypeptide according to any one of paragraphs 1-22, a nucleic acid molecule according to any one of paragraphs 23-31, a vector according to paragraph 32, a ligand according to paragraph 34 or 35, a compound according to any one of paragraphs 36-38, or a pharmaceutical composition according to paragraph 52.

[0574] 56. A method according to paragraph 55, wherein, for diseases in which the expression of the natural gene or the activity of the polypeptide is lower in a diseased patient when compared to the level of expression or activity in a healthy patient, the polypeptide, nucleic acid molecule, vector, ligand, compound or composition administered to the patient is an agonist.

[0575] 57. A method according to paragraph 55, wherein, for diseases in which the expression of the natural gene or activity of the polypeptide is higher in a diseased patient when compared to the level of expression or activity in a healthy patient, the polypeptide, nucleic acid molecule, vector, ligand, compound or composition administered to the patient is an antagonist.

[0576] 58. A method of monitoring the therapeutic treatment of disease in a patient, comprising monitoring over a period of time the level of expression or activity of a polypeptide according to any one of paragraphs 1-22, or the level of expression of a nucleic acid molecule according to any one of paragraphs 23-31 in tissue from said patient, wherein altering said level of expression or activity over the period of time towards a control level is indicative of regression of said disease.

[0577] 59. A method for the identification of a compound that is effective in the treatment and/or diagnosis of disease, comprising contacting a polypeptide according to any one of paragraphs 1-22, a nucleic acid molecule according to any one of paragraphs 23-31, or a host cell according to paragraph 33 with one or more compounds suspected of possessing binding affinity for said polypeptide or nucleic acid molecule, and selecting a compound that binds specifically to said nucleic acid molecule or polypeptide.

[0578] 60. A kit useful for diagnosing disease comprising a first container containing a nucleic acid probe that hybridises under stringent conditions with a nucleic acid molecule according to any one of paragraphs 23-31; a second container containing primers useful for amplifying said nucleic acid molecule; and instructions for using the probe and primers for facilitating the diagnosis of disease.

[0579] 61. The kit of paragraph 60, further comprising a third container holding an agent for digesting unhybridised RNA.

[0580] 62. A kit comprising an array of nucleic acid molecules, at least one of which is a nucleic acid molecule according to any one of paragraphs 23-31.

[0581] 63. A kit comprising one or more antibodies that bind to a polypeptide as recited in any one of paragraphs 1-22; and a reagent useful of the detection of a binding reaction between said antibody and said polypeptide.

[0582] 64. A transgenic or knockout non-human animal that has been transformed to express higher, lower or absent levels of a polypeptide according to any one of paragraphs 1-22.

[0583] 65. A method for screening for a compound effective to treat disease, by contacting a non-human transgenic animal according to paragraph 64 with a candidate compound and determining the effect of the compound on the disease of the animal.

1 57 1 7651 DNA Homo sapiens 1 aagcggcctg tatagataca ggagcaggaa ctctaggaca gccctgagtg aagaggagga 60 ggaagaacgg gagttcagaa aacagttccc cctgcatgaa aaggactttg cagatatttt 120 ggtgcagcca acgttggagg agaacaaagg aacttcagat gggcaagaag aggaagcagg 180 cacaaaccca gctctcctct cccagaattc aatgcaggca gtaatgctga tacaccagca 240 attgtgtctc aactttgctc gatccctctg gtatcaacag actctgccgc cacatgaagc 300 aaagcattac ctcagcctgt ttctgtcttg ctatcagact ggggcatcgc ttgtgacaca 360 cttctacccc ctgatgggag ttgaactgaa tgaccgactc ttgggcagcc aacttttggc 420 ctgtaccctc tcccataaca ctctttttgg ggaggcaccc tcagacctga tggtgaaacc 480 tgatgggccc tatgacttct accagcatcc caatgttcca gaagcacggc agtgtcaacc 540 tgtgcttcaa ggtttctcag aggctgtcag tcacttgcta caggactggc cagaacaccc 600 agcgcttgaa cagctcctgg ttgtaatgga cagaattcgt agtttcccac tttccagtcc 660 catctcaaag ttcctgaatg gcttagagat ccttctggca aaggcacagg attgggagga 720 aaatgcaagt cgagctttgt ctttgcggaa acatcttgat ttgatcagtc agatgatcat 780 tcggtggcgt aaactggagc tgaactgctg gtccatgagt ttggataata ctatgaagcg 840 ccacaccgag aaatccacca agcactggtt ctccatctat cagatgcttg agaagcacat 900 gcaggaacaa acagaagaac aggaagatga caaacagatg accttgatgt tgctggtcag 960 cacattacaa gcatttattg aaggatcctc gctgggagag ttccatgtgc gacttcagat 1020 gttactggtt ttccattgtc atgtcttgct gatgccacag gttgaaggaa aggattcact 1080 ttgcagtgtt ctatggaatt tgtaccatta ttacaagcaa ttctttgacc gggtccaggc 1140 caaaattgtg gaacttcgtt cccccctaga aaaagaactt aaagaatttg ttaagatttc 1200 caagtggaat gatgtcagct tctggtccat taagcaatct gtagaaaaga cacacaggac 1260 actctttaaa ttcatgaaga aatttgaagc agtcctgagt gaaccctgcc ggtcatccct 1320 ggtggagagt gacaaggaag aacagcctga ctttttgccc aggccaacag atggagctgc 1380 aagtgaactg tcttccattc agaatctgaa cagggcactg agggagaccc tgttagccca 1440 accagcagct gggcaggcca caattccaga gtggtgtcag ggcgctgctc cttccggctt 1500 ggaaggggag cttctgcgtc gcttgccaaa gctcaggaaa cgcatgagga agatgtgcct 1560 gacgttcatg aaggagagcc ccctgcctcg ccttgtggag ggccttgatc agttcacagg 1620 tgaagtgatt tcctctgtga gtgagctgca gagcttaaag gtggaaccct ctgcagagaa 1680 ggagaagcag cggtcagaag ccaagcacat tctcatgcaa aaacagcgag ctttgtcaga 1740 cctctttaaa caccttgcaa aaattggttt gtcgtatcgc aaaggtcttg cttgggcccg 1800 ttcaaaaaac cctcaagaga tgcttcatct tcacccatta gatctccaga gcgcattgtc 1860 catcgtcagc agcactcagg aggctgattc taggctgctt acagaaatct cgtcttcatg 1920 ggatggatgc cagaagtatt tttatcgctc tcttgcacgg catgccaggc ttaacgcagc 1980 actagcaact cctgccaagg aaatgggcat gggcaacgtg gagaggtgca gagggttctc 2040 agcacatttg atgaagatgc tcgtccgaca gcggcgctcc ctgaccacgc tcagtgagca 2100 gtggatcatc ctcaggaacc tcctcagctg tgtgcaagag attcacagca ggctgatggg 2160 gccccaggcc taccccgtgg ccttcccccc tcaggatggc gtgcagcagt ggacagagcg 2220 cctgcagcac ctggccatgc agtgccagat cctgcttgag cagctctcct ggctcctcca 2280 gtgctgcccc agtgtagggc cagctccagg ccatggcaat gtccaggtac tggggcagcc 2340 tcctggcccc tgcctggaag gaccagaact tagcaaggga caactttgtg gagtagtgct 2400 ggacctaatt ccttccaatc tgagctaccc atctccaata cctggaagtc agctgccctc 2460 tggttgccgg atgcggaaac aggatcacct ttggcaacag tcaactacga gattaacaga 2520 gatgctaaaa accattaaaa cagtgaaagc tgacgtcgac aaaattagac agcagtcttg 2580 tgagactctc tttcattctt ggaaagattt tgaagtttgc tcttctgcgc tgagttgctt 2640 gtcccaggtg tcagttcatt tgcagggcct agagtccttg ttcattcttc cagggatgga 2700 ggttgagcaa agagactcac aaatggcact agttgaaagt ctggaatatg taagaggaga 2760 aattagtaaa gccatggctg actttactac ctggaagacc catctgctta cttcagatag 2820 ccaaggagga aatcaaatgt tggacgaagg atttgtggaa gatttttcag agcaaatgga 2880 aattgccatc cgagccatcc tctgtgccat ccagaactta gaagaaagaa agaatgaaaa 2940 agcagaggag aacactgacc aagcaagccc acaagaagat tatgcaggct ttgagagact 3000 gcaatcagga catctaacaa aactcttaga ggatgacttc tgggccgatg tgagcacttt 3060 gcacgtgcag aaaataattt ctgccatctc cgagctgttg gagaggctga aatcgtacgg 3120 tgaggatggc acagcagcaa agcacctgtt cttcagccaa tcctgttcct tgctggtgcg 3180 cctggtgccg gtcctctcca gctactcaga cctcgtcctc ttcttcctga ccatgtcttt 3240 agcaactcac cgtagtactg caaagctgct ctctgtgctt gcccaggtct ttacagagct 3300 tgcccagaag ggattttgct tgcccaaaga atttatggaa gattcagctg gagagggagc 3360 aactgagttc catgactatg agggaggtgg aattggagaa ggcgagggca tgaaggatgt 3420 gagtgaccag atcggaaatg aagaacaggt ggaagataca tttcagaagg gtcaagaaaa 3480 agacaaagag gatcctgatt caaaatctga tattaagggc gaggataatg ccattgagat 3540 gtcggaagat tttgatggga aaatgcatga tggggagctt gaagaacaag aagaggatga 3600 tgagaaatca gatagtgagg gcggagacct ggataaacac atgggcgatc tcaatggtga 3660 ggaagctgac aaactagatg agaggctttg gggtgatgat gatgaggagg aagatgagga 3720 ggaagaagac aataaaactg aagaaacagg accaggaatg gatgaggaag attctgaact 3780 tgttgctaaa gatgacaact tggatagtgg caattcaaac aaagataaaa gccagcaaga 3840 taagaaggaa gaaaaggaag aagcagaagc tgatgatggt ggacaaggtg aagacaaaat 3900 taatgaacaa atagatgaga gggactatga tgaaaatgag gtggaccctt accatggcaa 3960 tcaggaaaag gtgccagaac ccgaggcttt ggaccttcca gatgacttga accttgacag 4020 tgaagacaag aatggtggtg aggacaccga caatgaagaa ggagaagaag agaatccttt 4080 ggagataaaa gaaaaaccag aagaagcagg tcatgaagct gaggaaagag gagagaccga 4140 gaccgaccag aacgaaagtc agagtccaca ggagcctgag gaaggcccca gtgaagatga 4200 caaggcagaa ggggaagagg aaatggacac aggagctgat gaccaagatg gagatgctgc 4260 tcagcatcct gaagaacact ctgaggagca gcagcagtct gtggaggaaa aagacaagga 4320 agccgatgaa gaaggtggag agaatggccc tgctgaccaa ggtttccagc cccaggagga 4380 agaagaacgg gaggactctg atacagagga gcaggtgcca gaggctttgg agaggaagga 4440 gcatgcctcc tgtgggcaga ctggtgtgga gaacatgcag aacacacagg ccatggagct 4500 ggctggggcc gcacctgaga aggagcaggg gaaagaggaa cacggaagtg gagctgcaga 4560 tgcaaaccag gcagaaggcc atgaatcgaa tttcattgcc cagttggcct cccagaagca 4620 caccaggaaa aacacacaga gttttaagag gaaacctggg caggctgaca atgaacgttc 4680 catgggtgat cacaatgagc gtgtgcacaa gaggctgagg actgtggata cggacagcca 4740 tgccgagcag gggccagctc agcagcccca ggcccaggtg gaggatgcag atgcattcga 4800 gcacattaaa caaggcagtg acgcatacga tgcacagacc tatgatgtgg ccagcaaaga 4860 acagcaacag tctgcaaaag actctggcaa agatcaggaa gaggaggaga tagaggacac 4920 ccttatggac acagaggagc aggaggagtt caaagcagca gacgtggagc agctgaagcc 4980 agaggaaatc aagtcgggca ccacagcacc cttgggcttt gatgagatgg aagtggagat 5040 ccaaactgtt aaaacagagg aagaccaaga ccccagaaca gacaaagccc ataaggagac 5100 agaaaatgag aaaccagaaa gaagccgaga gtctaccatt catacagctc atcaattcct 5160 catggacacg atcttccagc cctttttaaa agatgtcaat gagctaagac aggagctgga 5220 gagacagctg gaaatgtggc agccacgtga atctggaaac ccagaggagg agaaggttgc 5280 agctgagatg tggcagagtt acctgatctt aacagcgcct ctttcacaac ggttatgtga 5340 agagcttcgt ctcatattag agcctaccca ggcagccaag ctgaaaggag actatcgaac 5400 tgggaaacga ctaaacatac ggaaagtcat tccatacatt gctagtcaat ttcggaaaga 5460 caagatttgg cttcgaagga ccaagcccag taaacgccag tatcagattt gtttggctat 5520 cgatgactct tctagtatgg tagacaatca taccaagcag cttgcatttg aatctttggc 5580 tgtgattgga aatgctctaa ccctcctgga agtgggtcag attgcagtgt gtagttttgg 5640 agaatctgta aagctgttac acccatttca tgagcagttc agtgattact ctgggtccca 5700 gattctacgt ctctgcaaat tccaacaaaa gaaaaccaag attgctcagt ttctagagtc 5760 tgttgccaac atgtttgcag ctgctcagca gctctcgcag aacatcagtt cagaaactgc 5820 acaactcctc ctggtagtct ctgatgggcg aggccttttc cttgagggca aagaaagagt 5880 cctggcagca gttcaggctg cccggaatgc aaatatcttt gtcatctttg ttgtattgga 5940 caatcccagt tcacgggatt ctatcttgga cattaaagta ccgatattta aaggacctgg 6000 agagatgcct gaaatccgat cctacatgga agagttccca ttcccatact atatcattct 6060 tcgagatgta aacgcacttc ctgagacact cagcgatgcc ctcagacagt ggtttgagtt 6120 ggtgacagcc tctgaccacc catagaacag aaagaagagt ccaaagtgag acttaactgt 6180 ggtcagaagg tcacattgct tacccaggtg ctcccttttg gacaactaca aaaaatttta 6240 ttgtaatatt tttattttac aacgtgatct tacagcctac agaatgctct ctggctcccg 6300 gctttgcctg ggctgaggtt tttataccaa acctggaagc agcagcaggt gcctgaactc 6360 gtaactagag aagagttatc cttcttccct gccttggaag ccctggcctg ggaggaggtc 6420 ataccccacc gttggagccc agctgcctgt tttcttttgc aggggatctg ggcacctgtg 6480 ccttgaggag atgctgccag gagcatggga ctctgacagt cctttgtata aaggactaaa 6540 gggagctgcc cttttgaccc tgttctaagc tctgccttgc caagcccata gtgtgtgccc 6600 aaaagctgtc aagtggccaa gacagctcgt ttctggagag tatgagggtg tgttttctta 6660 ttgtgaaagg aactaccttc tcttagaggg taggaagaat gtggtgtgtg tgtgttctca 6720 taaagcaact ggacattata ggtgcccagg tcatctataa aaacgatcct tgggctgtgt 6780 aaaaatgaag tggcttttca gtatcctctt tcacacttgc tgcttcggga gactatgcaa 6840 tgatgggaag gtgattgccc ctttatttca ttcagtgcca tggtccctgt tgttgtagta 6900 atttatttgt ttagttcatt tttttttttc ttaacagtca aggggaagag tgattcctca 6960 cactgctttc aagctggact gagccagtct cattctggga aagaaacgct gtgtccagaa 7020 ctcagcagct ccatctattt tttccagtcg aaagaaactg atctttaggc agtttttact 7080 tggccagaaa gcagtgctga atacttgaaa ctgtgtgctc tgttctactt aatgttctgt 7140 cagaatgttc ttttgtaggc agtatgtcat gatgtaatca tctatctcct tgtctgtttc 7200 caagttacac tgtgaagtct gcgacccttt tgaggtggtc atcaaagaca cagattcctt 7260 gtttaaccaa gtgtcccaaa gcatgtacct gaagttatat cattttttat tctaaaaagc 7320 tatgcagctt atattctgaa aactattaaa acatatacca ctgttgttga tgtaatttgt 7380 gactcttctt aatggaagat gacaggattg taaaaggtat gctaggggac tgatcttctc 7440 tgctggatca gtcagtcagc tgttactagt tgatgctgtg ctaacatgat cccctcctac 7500 ttccatgttg ctcttactac aaaggttatc atttgcattt atgtccatgg taggctgagc 7560 tataatatgc tggctttgca gcagaatgaa aaggatgagt tggtgtagcc ttataaggag 7620 gcttataaaa ataaattatc ctccataaat g 7651 2 2047 PRT Homo sapiens 2 Ser Gly Leu Tyr Arg Tyr Arg Ser Arg Asn Ser Arg Thr Ala Leu Ser 1 5 10 15 Glu Glu Glu Glu Glu Glu Arg Glu Phe Arg Lys Gln Phe Pro Leu His 20 25 30 Glu Lys Asp Phe Ala Asp Ile Leu Val Gln Pro Thr Leu Glu Glu Asn 35 40 45 Lys Gly Thr Ser Asp Gly Gln Glu Glu Glu Ala Gly Thr Asn Pro Ala 50 55 60 Leu Leu Ser Gln Asn Ser Met Gln Ala Val Met Leu Ile His Gln Gln 65 70 75 80 Leu Cys Leu Asn Phe Ala Arg Ser Leu Trp Tyr Gln Gln Thr Leu Pro 85 90 95 Pro His Glu Ala Lys His Tyr Leu Ser Leu Phe Leu Ser Cys Tyr Gln 100 105 110 Thr Gly Ala Ser Leu Val Thr His Phe Tyr Pro Leu Met Gly Val Glu 115 120 125 Leu Asn Asp Arg Leu Leu Gly Ser Gln Leu Leu Ala Cys Thr Leu Ser 130 135 140 His Asn Thr Leu Phe Gly Glu Ala Pro Ser Asp Leu Met Val Lys Pro 145 150 155 160 Asp Gly Pro Tyr Asp Phe Tyr Gln His Pro Asn Val Pro Glu Ala Arg 165 170 175 Gln Cys Gln Pro Val Leu Gln Gly Phe Ser Glu Ala Val Ser His Leu 180 185 190 Leu Gln Asp Trp Pro Glu His Pro Ala Leu Glu Gln Leu Leu Val Val 195 200 205 Met Asp Arg Ile Arg Ser Phe Pro Leu Ser Ser Pro Ile Ser Lys Phe 210 215 220 Leu Asn Gly Leu Glu Ile Leu Leu Ala Lys Ala Gln Asp Trp Glu Glu 225 230 235 240 Asn Ala Ser Arg Ala Leu Ser Leu Arg Lys His Leu Asp Leu Ile Ser 245 250 255 Gln Met Ile Ile Arg Trp Arg Lys Leu Glu Leu Asn Cys Trp Ser Met 260 265 270 Ser Leu Asp Asn Thr Met Lys Arg His Thr Glu Lys Ser Thr Lys His 275 280 285 Trp Phe Ser Ile Tyr Gln Met Leu Glu Lys His Met Gln Glu Gln Thr 290 295 300 Glu Glu Gln Glu Asp Asp Lys Gln Met Thr Leu Met Leu Leu Val Ser 305 310 315 320 Thr Leu Gln Ala Phe Ile Glu Gly Ser Ser Leu Gly Glu Phe His Val 325 330 335 Arg Leu Gln Met Leu Leu Val Phe His Cys His Val Leu Leu Met Pro 340 345 350 Gln Val Glu Gly Lys Asp Ser Leu Cys Ser Val Leu Trp Asn Leu Tyr 355 360 365 His Tyr Tyr Lys Gln Phe Phe Asp Arg Val Gln Ala Lys Ile Val Glu 370 375 380 Leu Arg Ser Pro Leu Glu Lys Glu Leu Lys Glu Phe Val Lys Ile Ser 385 390 395 400 Lys Trp Asn Asp Val Ser Phe Trp Ser Ile Lys Gln Ser Val Glu Lys 405 410 415 Thr His Arg Thr Leu Phe Lys Phe Met Lys Lys Phe Glu Ala Val Leu 420 425 430 Ser Glu Pro Cys Arg Ser Ser Leu Val Glu Ser Asp Lys Glu Glu Gln 435 440 445 Pro Asp Phe Leu Pro Arg Pro Thr Asp Gly Ala Ala Ser Glu Leu Ser 450 455 460 Ser Ile Gln Asn Leu Asn Arg Ala Leu Arg Glu Thr Leu Leu Ala Gln 465 470 475 480 Pro Ala Ala Gly Gln Ala Thr Ile Pro Glu Trp Cys Gln Gly Ala Ala 485 490 495 Pro Ser Gly Leu Glu Gly Glu Leu Leu Arg Arg Leu Pro Lys Leu Arg 500 505 510 Lys Arg Met Arg Lys Met Cys Leu Thr Phe Met Lys Glu Ser Pro Leu 515 520 525 Pro Arg Leu Val Glu Gly Leu Asp Gln Phe Thr Gly Glu Val Ile Ser 530 535 540 Ser Val Ser Glu Leu Gln Ser Leu Lys Val Glu Pro Ser Ala Glu Lys 545 550 555 560 Glu Lys Gln Arg Ser Glu Ala Lys His Ile Leu Met Gln Lys Gln Arg 565 570 575 Ala Leu Ser Asp Leu Phe Lys His Leu Ala Lys Ile Gly Leu Ser Tyr 580 585 590 Arg Lys Gly Leu Ala Trp Ala Arg Ser Lys Asn Pro Gln Glu Met Leu 595 600 605 His Leu His Pro Leu Asp Leu Gln Ser Ala Leu Ser Ile Val Ser Ser 610 615 620 Thr Gln Glu Ala Asp Ser Arg Leu Leu Thr Glu Ile Ser Ser Ser Trp 625 630 635 640 Asp Gly Cys Gln Lys Tyr Phe Tyr Arg Ser Leu Ala Arg His Ala Arg 645 650 655 Leu Asn Ala Ala Leu Ala Thr Pro Ala Lys Glu Met Gly Met Gly Asn 660 665 670 Val Glu Arg Cys Arg Gly Phe Ser Ala His Leu Met Lys Met Leu Val 675 680 685 Arg Gln Arg Arg Ser Leu Thr Thr Leu Ser Glu Gln Trp Ile Ile Leu 690 695 700 Arg Asn Leu Leu Ser Cys Val Gln Glu Ile His Ser Arg Leu Met Gly 705 710 715 720 Pro Gln Ala Tyr Pro Val Ala Phe Pro Pro Gln Asp Gly Val Gln Gln 725 730 735 Trp Thr Glu Arg Leu Gln His Leu Ala Met Gln Cys Gln Ile Leu Leu 740 745 750 Glu Gln Leu Ser Trp Leu Leu Gln Cys Cys Pro Ser Val Gly Pro Ala 755 760 765 Pro Gly His Gly Asn Val Gln Val Leu Gly Gln Pro Pro Gly Pro Cys 770 775 780 Leu Glu Gly Pro Glu Leu Ser Lys Gly Gln Leu Cys Gly Val Val Leu 785 790 795 800 Asp Leu Ile Pro Ser Asn Leu Ser Tyr Pro Ser Pro Ile Pro Gly Ser 805 810 815 Gln Leu Pro Ser Gly Cys Arg Met Arg Lys Gln Asp His Leu Trp Gln 820 825 830 Gln Ser Thr Thr Arg Leu Thr Glu Met Leu Lys Thr Ile Lys Thr Val 835 840 845 Lys Ala Asp Val Asp Lys Ile Arg Gln Gln Ser Cys Glu Thr Leu Phe 850 855 860 His Ser Trp Lys Asp Phe Glu Val Cys Ser Ser Ala Leu Ser Cys Leu 865 870 875 880 Ser Gln Val Ser Val His Leu Gln Gly Leu Glu Ser Leu Phe Ile Leu 885 890 895 Pro Gly Met Glu Val Glu Gln Arg Asp Ser Gln Met Ala Leu Val Glu 900 905 910 Ser Leu Glu Tyr Val Arg Gly Glu Ile Ser Lys Ala Met Ala Asp Phe 915 920 925 Thr Thr Trp Lys Thr His Leu Leu Thr Ser Asp Ser Gln Gly Gly Asn 930 935 940 Gln Met Leu Asp Glu Gly Phe Val Glu Asp Phe Ser Glu Gln Met Glu 945 950 955 960 Ile Ala Ile Arg Ala Ile Leu Cys Ala Ile Gln Asn Leu Glu Glu Arg 965 970 975 Lys Asn Glu Lys Ala Glu Glu Asn Thr Asp Gln Ala Ser Pro Gln Glu 980 985 990 Asp Tyr Ala Gly Phe Glu Arg Leu Gln Ser Gly His Leu Thr Lys Leu 995 1000 1005 Leu Glu Asp Asp Phe Trp Ala Asp Val Ser Thr Leu His Val Gln Lys 1010 1015 1020 Ile Ile Ser Ala Ile Ser Glu Leu Leu Glu Arg Leu Lys Ser Tyr Gly 1025 1030 1035 1040 Glu Asp Gly Thr Ala Ala Lys His Leu Phe Phe Ser Gln Ser Cys Ser 1045 1050 1055 Leu Leu Val Arg Leu Val Pro Val Leu Ser Ser Tyr Ser Asp Leu Val 1060 1065 1070 Leu Phe Phe Leu Thr Met Ser Leu Ala Thr His Arg Ser Thr Ala Lys 1075 1080 1085 Leu Leu Ser Val Leu Ala Gln Val Phe Thr Glu Leu Ala Gln Lys Gly 1090 1095 1100 Phe Cys Leu Pro Lys Glu Phe Met Glu Asp Ser Ala Gly Glu Gly Ala 1105 1110 1115 1120 Thr Glu Phe His Asp Tyr Glu Gly Gly Gly Ile Gly Glu Gly Glu Gly 1125 1130 1135 Met Lys Asp Val Ser Asp Gln Ile Gly Asn Glu Glu Gln Val Glu Asp 1140 1145 1150 Thr Phe Gln Lys Gly Gln Glu Lys Asp Lys Glu Asp Pro Asp Ser Lys 1155 1160 1165 Ser Asp Ile Lys Gly Glu Asp Asn Ala Ile Glu Met Ser Glu Asp Phe 1170 1175 1180 Asp Gly Lys Met His Asp Gly Glu Leu Glu Glu Gln Glu Glu Asp Asp 1185 1190 1195 1200 Glu Lys Ser Asp Ser Glu Gly Gly Asp Leu Asp Lys His Met Gly Asp 1205 1210 1215 Leu Asn Gly Glu Glu Ala Asp Lys Leu Asp Glu Arg Leu Trp Gly Asp 1220 1225 1230 Asp Asp Glu Glu Glu Asp Glu Glu Glu Glu Asp Asn Lys Thr Glu Glu 1235 1240 1245 Thr Gly Pro Gly Met Asp Glu Glu Asp Ser Glu Leu Val Ala Lys Asp 1250 1255 1260 Asp Asn Leu Asp Ser Gly Asn Ser Asn Lys Asp Lys Ser Gln Gln Asp 1265 1270 1275 1280 Lys Lys Glu Glu Lys Glu Glu Ala Glu Ala Asp Asp Gly Gly Gln Gly 1285 1290 1295 Glu Asp Lys Ile Asn Glu Gln Ile Asp Glu Arg Asp Tyr Asp Glu Asn 1300 1305 1310 Glu Val Asp Pro Tyr His Gly Asn Gln Glu Lys Val Pro Glu Pro Glu 1315 1320 1325 Ala Leu Asp Leu Pro Asp Asp Leu Asn Leu Asp Ser Glu Asp Lys Asn 1330 1335 1340 Gly Gly Glu Asp Thr Asp Asn Glu Glu Gly Glu Glu Glu Asn Pro Leu 1345 1350 1355 1360 Glu Ile Lys Glu Lys Pro Glu Glu Ala Gly His Glu Ala Glu Glu Arg 1365 1370 1375 Gly Glu Thr Glu Thr Asp Gln Asn Glu Ser Gln Ser Pro Gln Glu Pro 1380 1385 1390 Glu Glu Gly Pro Ser Glu Asp Asp Lys Ala Glu Gly Glu Glu Glu Met 1395 1400 1405 Asp Thr Gly Ala Asp Asp Gln Asp Gly Asp Ala Ala Gln His Pro Glu 1410 1415 1420 Glu His Ser Glu Glu Gln Gln Gln Ser Val Glu Glu Lys Asp Lys Glu 1425 1430 1435 1440 Ala Asp Glu Glu Gly Gly Glu Asn Gly Pro Ala Asp Gln Gly Phe Gln 1445 1450 1455 Pro Gln Glu Glu Glu Glu Arg Glu Asp Ser Asp Thr Glu Glu Gln Val 1460 1465 1470 Pro Glu Ala Leu Glu Arg Lys Glu His Ala Ser Cys Gly Gln Thr Gly 1475 1480 1485 Val Glu Asn Met Gln Asn Thr Gln Ala Met Glu Leu Ala Gly Ala Ala 1490 1495 1500 Pro Glu Lys Glu Gln Gly Lys Glu Glu His Gly Ser Gly Ala Ala Asp 1505 1510 1515 1520 Ala Asn Gln Ala Glu Gly His Glu Ser Asn Phe Ile Ala Gln Leu Ala 1525 1530 1535 Ser Gln Lys His Thr Arg Lys Asn Thr Gln Ser Phe Lys Arg Lys Pro 1540 1545 1550 Gly Gln Ala Asp Asn Glu Arg Ser Met Gly Asp His Asn Glu Arg Val 1555 1560 1565 His Lys Arg Leu Arg Thr Val Asp Thr Asp Ser His Ala Glu Gln Gly 1570 1575 1580 Pro Ala Gln Gln Pro Gln Ala Gln Val Glu Asp Ala Asp Ala Phe Glu 1585 1590 1595 1600 His Ile Lys Gln Gly Ser Asp Ala Tyr Asp Ala Gln Thr Tyr Asp Val 1605 1610 1615 Ala Ser Lys Glu Gln Gln Gln Ser Ala Lys Asp Ser Gly Lys Asp Gln 1620 1625 1630 Glu Glu Glu Glu Ile Glu Asp Thr Leu Met Asp Thr Glu Glu Gln Glu 1635 1640 1645 Glu Phe Lys Ala Ala Asp Val Glu Gln Leu Lys Pro Glu Glu Ile Lys 1650 1655 1660 Ser Gly Thr Thr Ala Pro Leu Gly Phe Asp Glu Met Glu Val Glu Ile 1665 1670 1675 1680 Gln Thr Val Lys Thr Glu Glu Asp Gln Asp Pro Arg Thr Asp Lys Ala 1685 1690 1695 His Lys Glu Thr Glu Asn Glu Lys Pro Glu Arg Ser Arg Glu Ser Thr 1700 1705 1710 Ile His Thr Ala His Gln Phe Leu Met Asp Thr Ile Phe Gln Pro Phe 1715 1720 1725 Leu Lys Asp Val Asn Glu Leu Arg Gln Glu Leu Glu Arg Gln Leu Glu 1730 1735 1740 Met Trp Gln Pro Arg Glu Ser Gly Asn Pro Glu Glu Glu Lys Val Ala 1745 1750 1755 1760 Ala Glu Met Trp Gln Ser Tyr Leu Ile Leu Thr Ala Pro Leu Ser Gln 1765 1770 1775 Arg Leu Cys Glu Glu Leu Arg Leu Ile Leu Glu Pro Thr Gln Ala Ala 1780 1785 1790 Lys Leu Lys Gly Asp Tyr Arg Thr Gly Lys Arg Leu Asn Ile Arg Lys 1795 1800 1805 Val Ile Pro Tyr Ile Ala Ser Gln Phe Arg Lys Asp Lys Ile Trp Leu 1810 1815 1820 Arg Arg Thr Lys Pro Ser Lys Arg Gln Tyr Gln Ile Cys Leu Ala Ile 1825 1830 1835 1840 Asp Asp Ser Ser Ser Met Val Asp Asn His Thr Lys Gln Leu Ala Phe 1845 1850 1855 Glu Ser Leu Ala Val Ile Gly Asn Ala Leu Thr Leu Leu Glu Val Gly 1860 1865 1870 Gln Ile Ala Val Cys Ser Phe Gly Glu Ser Val Lys Leu Leu His Pro 1875 1880 1885 Phe His Glu Gln Phe Ser Asp Tyr Ser Gly Ser Gln Ile Leu Arg Leu 1890 1895 1900 Cys Lys Phe Gln Gln Lys Lys Thr Lys Ile Ala Gln Phe Leu Glu Ser 1905 1910 1915 1920 Val Ala Asn Met Phe Ala Ala Ala Gln Gln Leu Ser Gln Asn Ile Ser 1925 1930 1935 Ser Glu Thr Ala Gln Leu Leu Leu Val Val Ser Asp Gly Arg Gly Leu 1940 1945 1950 Phe Leu Glu Gly Lys Glu Arg Val Leu Ala Ala Val Gln Ala Ala Arg 1955 1960 1965 Asn Ala Asn Ile Phe Val Ile Phe Val Val Leu Asp Asn Pro Ser Ser 1970 1975 1980 Arg Asp Ser Ile Leu Asp Ile Lys Val Pro Ile Phe Lys Gly Pro Gly 1985 1990 1995 2000 Glu Met Pro Glu Ile Arg Ser Tyr Met Glu Glu Phe Pro Phe Pro Tyr 2005 2010 2015 Tyr Ile Ile Leu Arg Asp Val Asn Ala Leu Pro Glu Thr Leu Ser Asp 2020 2025 2030 Ala Leu Arg Gln Trp Phe Glu Leu Val Thr Ala Ser Asp His Pro 2035 2040 2045 3 1610 DNA Homo sapiens 3 tcctgggaga cagggatttc tccaggctgc tggacatcac cccagcctcc agcctgagct 60 ttgtcctgga caccacgggc agcatgggtg aggagatcaa cgctgccaaa atccaggctc 120 gccaccttgt ggagcagcgg agaggcagcc ccatggagcc tgtccactat gtcctggtgc 180 cttttcatga cccagggttc ggccctgtct ttacaaccag tgaccctgac agcttctggc 240 agcagcttaa tgagatccat gccttggggg gtggagacga gcctgagatg tgcctgtcag 300 ccctgcagct ggccctgctg cacacacctc cactctcaga tatctttgtc ttcacggatg 360 cctcccccaa ggatgccttt ctcaccaacc aggtggaatc cctgactcag gagcggcgct 420 gccgggtaac attcctggtg actgaagata catcaagggt tcagggtcga gctcggcgtg 480 agatcttgtc ccctctgcgt tttgagccat acaaagcagt ggccctggcc tcaggaggag 540 aggtgatctt caccaaagac cagcacattc gagacgtggc agccattgtt ggggagagca 600 tggctgccct ggtgactctt cccctggacc ctcctgttgt ggtgcctggg cagccacttg 660 tgttcagcgt ggatgggctg ctccagaaga tcacagtccg gatccacgga gacatcagca 720 gcttctggat caagaaccct gcaggggtct cccagggcca ggagaagcgg gggtcctcta 780 gtcacactcg ccgctttggg cagttctgga tggtgaccat ggatgaccct ccacagacag 840 gaacctggga gatccaggtc acagctgagg acacccctgg ggtgagagtg caagcccaga 900 cctccctgga cttcctcttc cactttggga tccccatgga ggatggaccc caccctggcc 960 tctaccccct gactcagcca gttgcaggtc ttcagaccca gctgctggta gaagtgacag 1020 ggttgggttc cagagccaat cctggggatc ctcagccgca tttctcccac gtcatccttc 1080 gaggggtccc agagggtgcc gaactaggcc aggtgccctt ggagcccgtg ggacctccgg 1140 agcgaggtct cctcgcagcc tcgctgtcgc ccacgctgct gtccacccct agacccttct 1200 ccctggagct gattggccag gacgcagcgg ggcggcgcct gcacagggct gcccctcagc 1260 ctagcactgt agtccctgtc cttctggagc ttagtggccc ctcgggtttc ttggccccgg 1320 gcagcaaagt cccgctcagt ctccgcatcg ccagcttctc gggccctcag gatcttgacc 1380 ttaggacttt cgtcaacccc agcttctccc tcacctccaa cctctccagg gctcacctgg 1440 aactgaatga gtgcctgggg cccgctgtgg ctggaggtcc cagattcagc ggccccggat 1500 tccgtggtga tggtgactgt gactgcaggg ggacgagaag ccaacccagt acccccgact 1560 cgtgctttct ccggctcctg gtatcgcccc agccccgcag gaccggcaca 1610 4 536 PRT Homo sapiens 4 Leu Gly Asp Arg Asp Phe Ser Arg Leu Leu Asp Ile Thr Pro Ala Ser 1 5 10 15 Ser Leu Ser Phe Val Leu Asp Thr Thr Gly Ser Met Gly Glu Glu Ile 20 25 30 Asn Ala Ala Lys Ile Gln Ala Arg His Leu Val Glu Gln Arg Arg Gly 35 40 45 Ser Pro Met Glu Pro Val His Tyr Val Leu Val Pro Phe His Asp Pro 50 55 60 Gly Phe Gly Pro Val Phe Thr Thr Ser Asp Pro Asp Ser Phe Trp Gln 65 70 75 80 Gln Leu Asn Glu Ile His Ala Leu Gly Gly Gly Asp Glu Pro Glu Met 85 90 95 Cys Leu Ser Ala Leu Gln Leu Ala Leu Leu His Thr Pro Pro Leu Ser 100 105 110 Asp Ile Phe Val Phe Thr Asp Ala Ser Pro Lys Asp Ala Phe Leu Thr 115 120 125 Asn Gln Val Glu Ser Leu Thr Gln Glu Arg Arg Cys Arg Val Thr Phe 130 135 140 Leu Val Thr Glu Asp Thr Ser Arg Val Gln Gly Arg Ala Arg Arg Glu 145 150 155 160 Ile Leu Ser Pro Leu Arg Phe Glu Pro Tyr Lys Ala Val Ala Leu Ala 165 170 175 Ser Gly Gly Glu Val Ile Phe Thr Lys Asp Gln His Ile Arg Asp Val 180 185 190 Ala Ala Ile Val Gly Glu Ser Met Ala Ala Leu Val Thr Leu Pro Leu 195 200 205 Asp Pro Pro Val Val Val Pro Gly Gln Pro Leu Val Phe Ser Val Asp 210 215 220 Gly Leu Leu Gln Lys Ile Thr Val Arg Ile His Gly Asp Ile Ser Ser 225 230 235 240 Phe Trp Ile Lys Asn Pro Ala Gly Val Ser Gln Gly Gln Glu Lys Arg 245 250 255 Gly Ser Ser Ser His Thr Arg Arg Phe Gly Gln Phe Trp Met Val Thr 260 265 270 Met Asp Asp Pro Pro Gln Thr Gly Thr Trp Glu Ile Gln Val Thr Ala 275 280 285 Glu Asp Thr Pro Gly Val Arg Val Gln Ala Gln Thr Ser Leu Asp Phe 290 295 300 Leu Phe His Phe Gly Ile Pro Met Glu Asp Gly Pro His Pro Gly Leu 305 310 315 320 Tyr Pro Leu Thr Gln Pro Val Ala Gly Leu Gln Thr Gln Leu Leu Val 325 330 335 Glu Val Thr Gly Leu Gly Ser Arg Ala Asn Pro Gly Asp Pro Gln Pro 340 345 350 His Phe Ser His Val Ile Leu Arg Gly Val Pro Glu Gly Ala Glu Leu 355 360 365 Gly Gln Val Pro Leu Glu Pro Val Gly Pro Pro Glu Arg Gly Leu Leu 370 375 380 Ala Ala Ser Leu Ser Pro Thr Leu Leu Ser Thr Pro Arg Pro Phe Ser 385 390 395 400 Leu Glu Leu Ile Gly Gln Asp Ala Ala Gly Arg Arg Leu His Arg Ala 405 410 415 Ala Pro Gln Pro Ser Thr Val Val Pro Val Leu Leu Glu Leu Ser Gly 420 425 430 Pro Ser Gly Phe Leu Ala Pro Gly Ser Lys Val Pro Leu Ser Leu Arg 435 440 445 Ile Ala Ser Phe Ser Gly Pro Gln Asp Leu Asp Leu Arg Thr Phe Val 450 455 460 Asn Pro Ser Phe Ser Leu Thr Ser Asn Leu Ser Arg Ala His Leu Glu 465 470 475 480 Leu Asn Glu Cys Leu Gly Pro Ala Val Ala Gly Gly Pro Arg Phe Ser 485 490 495 Gly Pro Gly Phe Arg Gly Asp Gly Asp Cys Asp Cys Arg Gly Thr Arg 500 505 510 Ser Gln Pro Ser Thr Pro Asp Ser Cys Phe Leu Arg Leu Leu Val Ser 515 520 525 Pro Gln Pro Arg Arg Thr Gly Thr 530 535 5 5688 DNA Homo sapiens 5 taggatacaa catagaacct attatgctct atcaggatat gacagcgcgt gatctgctac 60 agcagagata cacccttcca aatggagaca ctgcctggcg gtcctcaccc cttgtgaatg 120 ctgctctgga aggcaagctg gtcctgctgg atggcattca ccgggtgaat gcgggcacgc 180 ttgctgtatt gcaaaggtta atccatgatc gagagctaag cctctatgat ggttctaggc 240 tgctgagaga agacaggtat atgcgtttaa aggaggagct gcaactgtct gatgaacagc 300 tacagaagag atccattttt cctatccatc cctccttcag aatcattgcc ttggcagaac 360 cccctgttat tggaagcaca gcacaccagt ggctgggacc agaattctta accatgttct 420 ttttccatta catgaaacca cttgtgaaaa gtgaagaaat ccaagtgatt aaggaaaagg 480 tcccaaatgt acctcaggaa gctctggata agttattatc atttacacac aaactcagag 540 aaacacagga tccaacggca caatcattag cggcatcact ttctaccaga caactgttgc 600 gaatttctcg tcggctgtca cagtatccta atgaaaatct tcacagtgct gttactaaag 660 cctgcctttc caggttttta cccagtcttg ctaggtcagc attagaaaaa aatctggcag 720 atgctacaat agaaataaat actgatgaca atttggagcc agaactgaag gattacaaat 780 gtgaagtaac atctggaact ctgaggattg gtgctgttag tgcaccgatc tataatgcac 840 atgagaaaat gaaagtgcct gatgttcttt tctatgacaa cattcagcat gtgatagtga 900 tggaagatat gctgaaagac tttctccttg gagaacactt attattggtt ggcaaccagg 960 gtgtaggaaa aaacaagatt gttgacagat tccttcacct gctcaacaga ccccgagaat 1020 atattcagct acacagggat accacagtac aaactcttac gcttcagcct tcggttaaag 1080 acggacttat tgtatatgaa gactcacctt tggttaaagc agtaaagttg ggtcatattc 1140 tggtagtaga tgaggctgac aaagctccaa caaatgtcac gtgtatttta aaaactctag 1200 tagaaaatgg agaaatgatt ctagcagatg gaagacgcat tgttgcaaat tctgctaatg 1260 tgaatggaag agaaaatgtt gtagtgattc atcctgattt taggatgatt gttctggcaa 1320 atagacctgg atttcctttc ctaggcaatg atttcttcgg taccttaggt gatattttta 1380 gctgccatgc agttgataac cccaaacccc actcggagct cgagatgctc agacagtatg 1440 gaccaaatgt gcctgagccc atccttcaga agcttgtggc tgcctttgga gagctgagga 1500 gtttggctga ccaagggatt attaactatc cttattctac cagagaagtt gtcaacatag 1560 tcaaacattt acagaaattt ccgactgaag gtctctccag tgtagttcga aatgtgtttg 1620 actttgattc ctacaacaat gacatgaggg agatattgat taacacttta cacaaatacg 1680 ggatacctat cggagcaaag cctaccagtg tgcagctggc aaaggagttg actctgccag 1740 aacaaacgtt catgggctac tggacaattg gtcaggcaag aagtgggatg caaaaactct 1800 tgtgtccagt ggaaactcat catatagaca taaagggtcc agcacttata aatatacagg 1860 agtatccaat agaaagacat gaagaaagat ccctaaactt tactgaagaa tgtgcctcat 1920 ggagaatacc attggatgaa attaatataa tctgtgacat tgctacatca catgaaaatg 1980 agcaaaatac tctctatgta gttacatgca atcccgcttc cctgtacttt atgaatatga 2040 ctgggaaaag tggcttcttt gtggactttt ttgatatctt cccaagaaca gccaatggcg 2100 tttggcaccc ttttgtgaca gtggcaccgc tgggaagtcc tctcaaaggt caagtggttc 2160 tccatgagca gcagagtaat gttatcctgt tgttagatac tactggccgg gcccttcatc 2220 gtctcatcct cccttccgag aagtttacat ctaagaaacc tttctggtgg aacaaagaag 2280 aagctgaaac ttataaaatg tgtaaagaat tttcacacaa aaactggctg gtgttctaca 2340 aagaaaaagg gaacagcctg actgtgctgg atgttctaga agggcgaact cacaccatct 2400 cacttcccat caacctcaag acagttttcc ttgtagcaga ggacaaatgg cttctggtgg 2460 agagcaaaac aaatcagaaa tatcttttaa ctaagcctgc acacatcgaa tctgagggta 2520 gtggggtttg ccagttgtat gtgctgaaag aggagccgcc cagcacaggg tttggagtta 2580 cacaagaaac agagttcagc atacctcata aaatttccag tgatcaacta tcatctgaac 2640 atctaagttc agctgtggaa caaaagattg cctctcccaa cagaattctc tcagatgaga 2700 aaaattatgc tacaatagtt gttggttttc cagatctcat gtcacccagt gaagtttatt 2760 cttggaagag accatcatct ttgcataaac gaagtggcac tgatacatca ttctatagag 2820 gaaagaagaa aagggggact ccaaaacaaa gcaattgtgt gactctttta gatacgaatc 2880 aggtagtgag gattttaccc ccaggagaag tccctctaaa agatatctac ccaaaagatg 2940 ttactcctcc acaaacatct ggttatatag aagtcactga tcttcaatca aagaaactcc 3000 gatatatccc tattcccaga tcagaatctc tctcgccgta taccacatgg ctgtcgacca 3060 tttcagacac agatgcactg ctggctgagt gggacaaaag cggtgttgtt actgttgata 3120 tgggaggtca catcaggctt tgggaaactg gacttgaacg tctgcagcga tcactcatgg 3180 aatggagaaa catgattgga caagatgaca gaaatatgca gataacaatc aacagagaca 3240 gtggtgaaga tgtaagctcc cccaaacacg ggaaggagga cccagacaac atgcctcacg 3300 tgggcggcaa cacttgggct ggcggaacag ggggaagaga cacggcaggc ctgggtggca 3360 aaggaggccc ttaccggctg gatgcaggcc atacggtgta ccaggtctct caggctgaga 3420 aagatgcagt tcccgaagag gtcaagagag ctgctagaga gatgggccag agagcattcc 3480 agcagaggct aaaggagatc caaatgagtg aatacgatgc tgcaacctat gaaaggtttt 3540 caggtgctgt tcggcgacag gtgcactccc tccgaatcat cctggataat ttacaggcta 3600 aaggtaaaga aagacaatgg ctaagacatc aagctactgg agaattagat gatgccaaga 3660 tcattgatgg gctgactgga gaaaaagcca tctacaaacg tcggggtgag ctggagccac 3720 aacttggcag cccacaacag aaacccaagc gtctgcgcct ggtggtagat gtgtctggta 3780 gcatgtaccg tttcaacagg atggatggcc ggcttgagcg cacaatggag gctgtgtgta 3840 tggtcatgga agccttcgag aactatgagg agaagttcca gtatgacatc gttggacact 3900 ctggagatgg ctacaacatt ggtctggttc caatgaacaa aatccccaag gacaataagc 3960 aaagactaga aattctgaag acaatgcatg cccactctca gttctgcatg agtggggacc 4020 acacgttaga agggacagaa catgccatca aggaaattgt caaagaagaa gctgatgagt 4080 actttgtcat agtcttgagt gatgcaaatc tgtcacgata tggaatacat cctgctaagt 4140 ttgctcaaat cctcacaaga gaccctcaag taaatgcttt tgccattttt attggctctt 4200 taggtgatca agcaaccagg cttcagagaa ctttaccagc tggtcggtct ttcgttgcca 4260 tggataccaa ggatatccct cagattttac aacagatctt cacctccacc atgttgtcga 4320 gtgtctaaga agtgcccttc atcaccctga tgacaccagg atttgaaata agacaggaat 4380 aaagagtatt ctgaaaaaaa gaagatatgg atgaagtgaa cccatgcagt gactggatga 4440 ttccggcatt cctgggtctt cctacacttg ctccgtaatg agaattcaga gaagcagcca 4500 gaaggagact taaacatgga aagatactcc actgatgagt ttagaagtga ttagggcaag 4560 ctagttgacc tgcactttat caaaggttgg ggttaaagga aggtggtttt gagaactatg 4620 tgtttggtct atttccaaaa acctgagggg gagaaaatac tttgcttttg ccttaacaca 4680 tcatctggtc acgttagaaa agtgacccca tcaaactgag cctttgatgt cacattctga 4740 cacaagatgc aagtctgtgc aaaacccacc aaaatgctcc tatccaacaa ttatttttat 4800 tttctccctg ctctgtattg accagaaaac aatgatttta taatatttaa cccaccaaaa 4860 agtccctcca acagcaatat cttatgaaag gctggctgtt ctcaataatt tcattttctt 4920 ggccaaagcc aaaaggaatc aaaaaatcct tggagtgctt gcctttccac gtgactttta 4980 aaaggctctt aaagagcaaa tgtcctcttc tccttgctgc tagagtggga ggagaaagat 5040 gtcttgcctt aaaagtttac tgtttcttct gttcttctag catctctcaa aaaattcaca 5100 gtactccatt ttggggtcca aactgtaatg ctcaaaataa taaatgctta cacgaaaatt 5160 atttattgag aatattcata taaaaattac ctaaagcaaa gtaaaaaaag taaaatcaag 5220 gtggtatatt tgaagtgaat ggtgattgga aatttttagc tgtaacaaaa agaaagaaaa 5280 caactttttt taaagcctca ttctcttttc tttcaaaatg taccttattc ccacacactc 5340 ttgggctgac ctttatttta tcaataagct caatattact ttgtttaaaa taagatgctt 5400 cagcaaaagt cattctctct ttaaccatat aatttaaaaa ctcctcttca cgattgatag 5460 caaaatcaga aacgttaggg caccagtgag ttgaaaaaac tggtcttaag ttggaaaaac 5520 tattattaat aatattatcc tatccatcca tatctattga aattgtacag gtccataatt 5580 tcattttaat taattatagg aaagaagaaa agataatacc catttgttct atcacccctc 5640 tccctatcat taactatcaa ataaataaat aaaagcaatc tgatttcc 5688 6 1441 PRT Homo sapiens 6 Gly Tyr Asn Ile Glu Pro Ile Met Leu Tyr Gln Asp Met Thr Ala Arg 1 5 10 15 Asp Leu Leu Gln Gln Arg Tyr Thr Leu Pro Asn Gly Asp Thr Ala Trp 20 25 30 Arg Ser Ser Pro Leu Val Asn Ala Ala Leu Glu Gly Lys Leu Val Leu 35 40 45 Leu Asp Gly Ile His Arg Val Asn Ala Gly Thr Leu Ala Val Leu Gln 50 55 60 Arg Leu Ile His Asp Arg Glu Leu Ser Leu Tyr Asp Gly Ser Arg Leu 65 70 75 80 Leu Arg Glu Asp Arg Tyr Met Arg Leu Lys Glu Glu Leu Gln Leu Ser 85 90 95 Asp Glu Gln Leu Gln Lys Arg Ser Ile Phe Pro Ile His Pro Ser Phe 100 105 110 Arg Ile Ile Ala Leu Ala Glu Pro Pro Val Ile Gly Ser Thr Ala His 115 120 125 Gln Trp Leu Gly Pro Glu Phe Leu Thr Met Phe Phe Phe His Tyr Met 130 135 140 Lys Pro Leu Val Lys Ser Glu Glu Ile Gln Val Ile Lys Glu Lys Val 145 150 155 160 Pro Asn Val Pro Gln Glu Ala Leu Asp Lys Leu Leu Ser Phe Thr His 165 170 175 Lys Leu Arg Glu Thr Gln Asp Pro Thr Ala Gln Ser Leu Ala Ala Ser 180 185 190 Leu Ser Thr Arg Gln Leu Leu Arg Ile Ser Arg Arg Leu Ser Gln Tyr 195 200 205 Pro Asn Glu Asn Leu His Ser Ala Val Thr Lys Ala Cys Leu Ser Arg 210 215 220 Phe Leu Pro Ser Leu Ala Arg Ser Ala Leu Glu Lys Asn Leu Ala Asp 225 230 235 240 Ala Thr Ile Glu Ile Asn Thr Asp Asp Asn Leu Glu Pro Glu Leu Lys 245 250 255 Asp Tyr Lys Cys Glu Val Thr Ser Gly Thr Leu Arg Ile Gly Ala Val 260 265 270 Ser Ala Pro Ile Tyr Asn Ala His Glu Lys Met Lys Val Pro Asp Val 275 280 285 Leu Phe Tyr Asp Asn Ile Gln His Val Ile Val Met Glu Asp Met Leu 290 295 300 Lys Asp Phe Leu Leu Gly Glu His Leu Leu Leu Val Gly Asn Gln Gly 305 310 315 320 Val Gly Lys Asn Lys Ile Val Asp Arg Phe Leu His Leu Leu Asn Arg 325 330 335 Pro Arg Glu Tyr Ile Gln Leu His Arg Asp Thr Thr Val Gln Thr Leu 340 345 350 Thr Leu Gln Pro Ser Val Lys Asp Gly Leu Ile Val Tyr Glu Asp Ser 355 360 365 Pro Leu Val Lys Ala Val Lys Leu Gly His Ile Leu Val Val Asp Glu 370 375 380 Ala Asp Lys Ala Pro Thr Asn Val Thr Cys Ile Leu Lys Thr Leu Val 385 390 395 400 Glu Asn Gly Glu Met Ile Leu Ala Asp Gly Arg Arg Ile Val Ala Asn 405 410 415 Ser Ala Asn Val Asn Gly Arg Glu Asn Val Val Val Ile His Pro Asp 420 425 430 Phe Arg Met Ile Val Leu Ala Asn Arg Pro Gly Phe Pro Phe Leu Gly 435 440 445 Asn Asp Phe Phe Gly Thr Leu Gly Asp Ile Phe Ser Cys His Ala Val 450 455 460 Asp Asn Pro Lys Pro His Ser Glu Leu Glu Met Leu Arg Gln Tyr Gly 465 470 475 480 Pro Asn Val Pro Glu Pro Ile Leu Gln Lys Leu Val Ala Ala Phe Gly 485 490 495 Glu Leu Arg Ser Leu Ala Asp Gln Gly Ile Ile Asn Tyr Pro Tyr Ser 500 505 510 Thr Arg Glu Val Val Asn Ile Val Lys His Leu Gln Lys Phe Pro Thr 515 520 525 Glu Gly Leu Ser Ser Val Val Arg Asn Val Phe Asp Phe Asp Ser Tyr 530 535 540 Asn Asn Asp Met Arg Glu Ile Leu Ile Asn Thr Leu His Lys Tyr Gly 545 550 555 560 Ile Pro Ile Gly Ala Lys Pro Thr Ser Val Gln Leu Ala Lys Glu Leu 565 570 575 Thr Leu Pro Glu Gln Thr Phe Met Gly Tyr Trp Thr Ile Gly Gln Ala 580 585 590 Arg Ser Gly Met Gln Lys Leu Leu Cys Pro Val Glu Thr His His Ile 595 600 605 Asp Ile Lys Gly Pro Ala Leu Ile Asn Ile Gln Glu Tyr Pro Ile Glu 610 615 620 Arg His Glu Glu Arg Ser Leu Asn Phe Thr Glu Glu Cys Ala Ser Trp 625 630 635 640 Arg Ile Pro Leu Asp Glu Ile Asn Ile Ile Cys Asp Ile Ala Thr Ser 645 650 655 His Glu Asn Glu Gln Asn Thr Leu Tyr Val Val Thr Cys Asn Pro Ala 660 665 670 Ser Leu Tyr Phe Met Asn Met Thr Gly Lys Ser Gly Phe Phe Val Asp 675 680 685 Phe Phe Asp Ile Phe Pro Arg Thr Ala Asn Gly Val Trp His Pro Phe 690 695 700 Val Thr Val Ala Pro Leu Gly Ser Pro Leu Lys Gly Gln Val Val Leu 705 710 715 720 His Glu Gln Gln Ser Asn Val Ile Leu Leu Leu Asp Thr Thr Gly Arg 725 730 735 Ala Leu His Arg Leu Ile Leu Pro Ser Glu Lys Phe Thr Ser Lys Lys 740 745 750 Pro Phe Trp Trp Asn Lys Glu Glu Ala Glu Thr Tyr Lys Met Cys Lys 755 760 765 Glu Phe Ser His Lys Asn Trp Leu Val Phe Tyr Lys Glu Lys Gly Asn 770 775 780 Ser Leu Thr Val Leu Asp Val Leu Glu Gly Arg Thr His Thr Ile Ser 785 790 795 800 Leu Pro Ile Asn Leu Lys Thr Val Phe Leu Val Ala Glu Asp Lys Trp 805 810 815 Leu Leu Val Glu Ser Lys Thr Asn Gln Lys Tyr Leu Leu Thr Lys Pro 820 825 830 Ala His Ile Glu Ser Glu Gly Ser Gly Val Cys Gln Leu Tyr Val Leu 835 840 845 Lys Glu Glu Pro Pro Ser Thr Gly Phe Gly Val Thr Gln Glu Thr Glu 850 855 860 Phe Ser Ile Pro His Lys Ile Ser Ser Asp Gln Leu Ser Ser Glu His 865 870 875 880 Leu Ser Ser Ala Val Glu Gln Lys Ile Ala Ser Pro Asn Arg Ile Leu 885 890 895 Ser Asp Glu Lys Asn Tyr Ala Thr Ile Val Val Gly Phe Pro Asp Leu 900 905 910 Met Ser Pro Ser Glu Val Tyr Ser Trp Lys Arg Pro Ser Ser Leu His 915 920 925 Lys Arg Ser Gly Thr Asp Thr Ser Phe Tyr Arg Gly Lys Lys Lys Arg 930 935 940 Gly Thr Pro Lys Gln Ser Asn Cys Val Thr Leu Leu Asp Thr Asn Gln 945 950 955 960 Val Val Arg Ile Leu Pro Pro Gly Glu Val Pro Leu Lys Asp Ile Tyr 965 970 975 Pro Lys Asp Val Thr Pro Pro Gln Thr Ser Gly Tyr Ile Glu Val Thr 980 985 990 Asp Leu Gln Ser Lys Lys Leu Arg Tyr Ile Pro Ile Pro Arg Ser Glu 995 1000 1005 Ser Leu Ser Pro Tyr Thr Thr Trp Leu Ser Thr Ile Ser Asp Thr Asp 1010 1015 1020 Ala Leu Leu Ala Glu Trp Asp Lys Ser Gly Val Val Thr Val Asp Met 1025 1030 1035 1040 Gly Gly His Ile Arg Leu Trp Glu Thr Gly Leu Glu Arg Leu Gln Arg 1045 1050 1055 Ser Leu Met Glu Trp Arg Asn Met Ile Gly Gln Asp Asp Arg Asn Met 1060 1065 1070 Gln Ile Thr Ile Asn Arg Asp Ser Gly Glu Asp Val Ser Ser Pro Lys 1075 1080 1085 His Gly Lys Glu Asp Pro Asp Asn Met Pro His Val Gly Gly Asn Thr 1090 1095 1100 Trp Ala Gly Gly Thr Gly Gly Arg Asp Thr Ala Gly Leu Gly Gly Lys 1105 1110 1115 1120 Gly Gly Pro Tyr Arg Leu Asp Ala Gly His Thr Val Tyr Gln Val Ser 1125 1130 1135 Gln Ala Glu Lys Asp Ala Val Pro Glu Glu Val Lys Arg Ala Ala Arg 1140 1145 1150 Glu Met Gly Gln Arg Ala Phe Gln Gln Arg Leu Lys Glu Ile Gln Met 1155 1160 1165 Ser Glu Tyr Asp Ala Ala Thr Tyr Glu Arg Phe Ser Gly Ala Val Arg 1170 1175 1180 Arg Gln Val His Ser Leu Arg Ile Ile Leu Asp Asn Leu Gln Ala Lys 1185 1190 1195 1200 Gly Lys Glu Arg Gln Trp Leu Arg His Gln Ala Thr Gly Glu Leu Asp 1205 1210 1215 Asp Ala Lys Ile Ile Asp Gly Leu Thr Gly Glu Lys Ala Ile Tyr Lys 1220 1225 1230 Arg Arg Gly Glu Leu Glu Pro Gln Leu Gly Ser Pro Gln Gln Lys Pro 1235 1240 1245 Lys Arg Leu Arg Leu Val Val Asp Val Ser Gly Ser Met Tyr Arg Phe 1250 1255 1260 Asn Arg Met Asp Gly Arg Leu Glu Arg Thr Met Glu Ala Val Cys Met 1265 1270 1275 1280 Val Met Glu Ala Phe Glu Asn Tyr Glu Glu Lys Phe Gln Tyr Asp Ile 1285 1290 1295 Val Gly His Ser Gly Asp Gly Tyr Asn Ile Gly Leu Val Pro Met Asn 1300 1305 1310 Lys Ile Pro Lys Asp Asn Lys Gln Arg Leu Glu Ile Leu Lys Thr Met 1315 1320 1325 His Ala His Ser Gln Phe Cys Met Ser Gly Asp His Thr Leu Glu Gly 1330 1335 1340 Thr Glu His Ala Ile Lys Glu Ile Val Lys Glu Glu Ala Asp Glu Tyr 1345 1350 1355 1360 Phe Val Ile Val Leu Ser Asp Ala Asn Leu Ser Arg Tyr Gly Ile His 1365 1370 1375 Pro Ala Lys Phe Ala Gln Ile Leu Thr Arg Asp Pro Gln Val Asn Ala 1380 1385 1390 Phe Ala Ile Phe Ile Gly Ser Leu Gly Asp Gln Ala Thr Arg Leu Gln 1395 1400 1405 Arg Thr Leu Pro Ala Gly Arg Ser Phe Val Ala Met Asp Thr Lys Asp 1410 1415 1420 Ile Pro Gln Ile Leu Gln Gln Ile Phe Thr Ser Thr Met Leu Ser Ser 1425 1430 1435 1440 Val 7 2559 DNA Homo sapiens 7 atgctcccca cggaggtccc ccaatcccac ccgggcccct cagcgttgct tctgctgcag 60 ctgttgctgc cccccacatc tgccttcttc cccaacatct ggagcctgct ggctgcccct 120 ggctccatca cccaccaaga cctaactgag gaggcagcgc tcaacgtcac cctgcagctc 180 ttcctggagc agccaccccc aggccgcccc cctcttcgtc ttgaggactt cctgggtcga 240 acactccttg ctgatgacct ctttgccgcc tactttggac ctggttcttc tcggcggttc 300 cgagcagcct taggtgaggt gtctcgtgcc aatgcagccc aggacttcct gccaacttcc 360 aggaatgacc ccgacctgca ctttgatgct gagcgactgg gtcagggacg cgcgcgcctg 420 gtaggggctc tgcgggagac cgtggtggca gccagggccc ttgaccacac cctggctcgc 480 cagcgcctcg gggctgcact tcatgccctg caggatttct acagtcatag caactgggtg 540 gagctgggcg agcagcagcc acaccctcac ctcctctggc caaggcagga gctccagaac 600 ctggcacaag tggccgatcc tacctgctcc gattgcgagg agttgagctg ccccaggaat 660 tggctgggct tcacactcct cacctctggc tactttggaa ctcatccccc gaaacctcca 720 gggaaatgta gccacggggg ccattttgac cggagcagct cccagccacc gaggggaggc 780 atcaacaagg acagcacatc cccaggcttc tcccctcacc acatgctgca cctccaggct 840 gcaaaactgg cccttctagc ctccatccag gccttcagcc ttctgcgaag ccgcctggga 900 gacagggatt tctccaggct gctggacatc accccagcct ccagcctgag ctttgtcctg 960 gacaccacgg gcagcatggg tgaggagatc aacgctgcca aaatccaggc tcgccacctt 1020 gtggagcagc ggagaggcag ccccatggag cctgtccact atgtcctggt gccttttcat 1080 gacccagggt tcggccctgt ctttacaacc agtgaccctg acagcttctg gcaacagctt 1140 aatgagatcc atgccttggg gggtggagac gagcctgaga tgtgcctgtc agccctgcag 1200 ctggccctgc tgcacacacc tccactctca gatatctttg tcttcacgga tgcctccccc 1260 aaggatgcct ttctcaccaa ccaggtggaa tccctgactc aggagcggcg ctgccgggta 1320 acattcctgg tgactgaaga tacatcaagg gttcagggtc gagctcggcg tgagatcttg 1380 tcccctctgc gttttgagcc atacaaagca gtggccctgg cctcaggagg agaggtgatc 1440 ttcaccaaag accagcacat tcgagacgtg gcagccattg ttggggagag catggctgcc 1500 ctggtgactc ttcccctgga ccctcctgtt gtggtgcctg ggcagccact tgtgttcagc 1560 gtggatgggc tgctccagaa gatcacagtc cggatccacg gagacatcag cagcttctgg 1620 atcaagaacc ctgcaggggt ctcccagggc caggaggaag gcgggggtcc tctaggtcac 1680 actcgccgct ttgggcagtt ctggatggtg accatggatg accctccaca gacaggaacc 1740 tgggagatcc aggtcacagc tgaggacacc cctggggtga gagtgcaagc ccagacctcc 1800 ctggacttcc tcttccactt tgggatcccc atggaggatg gaccccaccc tggcctctac 1860 cccctgactc agccagttgc aggtcttcag acccagctgc tggtagaagt gacagggttg 1920 ggttccagag ccaatcctgg ggatcctcag ccgcatttct cccacgtcat ccttcgaggg 1980 gtcccagagg gtgccgaact aggccaggtg cccttggagc ccgtgggacc tccggagcga 2040 ggtctcctcg cagcctcgct gtcgcccacg ctgctgtcca cccctagacc cttctccctg 2100 gagctgattg gccaggacgc agcggggcgg cgcctgcaca gggctgcccc tcagcctagc 2160 actgtagtcc ctgtccttct ggagcttagt ggcccctcgg gtttcttggc cccgggcagc 2220 aaagtcccgc tcagtctccg catcgccagc ttctcgggcc ctcaggatct tgaccttagg 2280 actttcgtca accccagctt ctccctcacc tccaacctct ccagggctca cctggaactg 2340 aatgagtcgg cctggggccg cctgtggctg gaggtcccag attcagcggc cccggattcc 2400 gtggtgatgg tgactgtgac tgcaggggga cgagaagcca acccagtacc cccgactcat 2460 gctttcctcc ggctcctggt atcggcccca gccccgcagg tgaggaacta ctactttcca 2520 tcacagggac cggcacacca cccctaccgg ctcatctga 2559 8 852 PRT Homo sapiens 8 Met Leu Pro Thr Glu Val Pro Gln Ser His Pro Gly Pro Ser Ala Leu 1 5 10 15 Leu Leu Leu Gln Leu Leu Leu Pro Pro Thr Ser Ala Phe Phe Pro Asn 20 25 30 Ile Trp Ser Leu Leu Ala Ala Pro Gly Ser Ile Thr His Gln Asp Leu 35 40 45 Thr Glu Glu Ala Ala Leu Asn Val Thr Leu Gln Leu Phe Leu Glu Gln 50 55 60 Pro Pro Pro Gly Arg Pro Pro Leu Arg Leu Glu Asp Phe Leu Gly Arg 65 70 75 80 Thr Leu Leu Ala Asp Asp Leu Phe Ala Ala Tyr Phe Gly Pro Gly Ser 85 90 95 Ser Arg Arg Phe Arg Ala Ala Leu Gly Glu Val Ser Arg Ala Asn Ala 100 105 110 Ala Gln Asp Phe Leu Pro Thr Ser Arg Asn Asp Pro Asp Leu His Phe 115 120 125 Asp Ala Glu Arg Leu Gly Gln Gly Arg Ala Arg Leu Val Gly Ala Leu 130 135 140 Arg Glu Thr Val Val Ala Ala Arg Ala Leu Asp His Thr Leu Ala Arg 145 150 155 160 Gln Arg Leu Gly Ala Ala Leu His Ala Leu Gln Asp Phe Tyr Ser His 165 170 175 Ser Asn Trp Val Glu Leu Gly Glu Gln Gln Pro His Pro His Leu Leu 180 185 190 Trp Pro Arg Gln Glu Leu Gln Asn Leu Ala Gln Val Ala Asp Pro Thr 195 200 205 Cys Ser Asp Cys Glu Glu Leu Ser Cys Pro Arg Asn Trp Leu Gly Phe 210 215 220 Thr Leu Leu Thr Ser Gly Tyr Phe Gly Thr His Pro Pro Lys Pro Pro 225 230 235 240 Gly Lys Cys Ser His Gly Gly His Phe Asp Arg Ser Ser Ser Gln Pro 245 250 255 Pro Arg Gly Gly Ile Asn Lys Asp Ser Thr Ser Pro Gly Phe Ser Pro 260 265 270 His His Met Leu His Leu Gln Ala Ala Lys Leu Ala Leu Leu Ala Ser 275 280 285 Ile Gln Ala Phe Ser Leu Leu Arg Ser Arg Leu Gly Asp Arg Asp Phe 290 295 300 Ser Arg Leu Leu Asp Ile Thr Pro Ala Ser Ser Leu Ser Phe Val Leu 305 310 315 320 Asp Thr Thr Gly Ser Met Gly Glu Glu Ile Asn Ala Ala Lys Ile Gln 325 330 335 Ala Arg His Leu Val Glu Gln Arg Arg Gly Ser Pro Met Glu Pro Val 340 345 350 His Tyr Val Leu Val Pro Phe His Asp Pro Gly Phe Gly Pro Val Phe 355 360 365 Thr Thr Ser Asp Pro Asp Ser Phe Trp Gln Gln Leu Asn Glu Ile His 370 375 380 Ala Leu Gly Gly Gly Asp Glu Pro Glu Met Cys Leu Ser Ala Leu Gln 385 390 395 400 Leu Ala Leu Leu His Thr Pro Pro Leu Ser Asp Ile Phe Val Phe Thr 405 410 415 Asp Ala Ser Pro Lys Asp Ala Phe Leu Thr Asn Gln Val Glu Ser Leu 420 425 430 Thr Gln Glu Arg Arg Cys Arg Val Thr Phe Leu Val Thr Glu Asp Thr 435 440 445 Ser Arg Val Gln Gly Arg Ala Arg Arg Glu Ile Leu Ser Pro Leu Arg 450 455 460 Phe Glu Pro Tyr Lys Ala Val Ala Leu Ala Ser Gly Gly Glu Val Ile 465 470 475 480 Phe Thr Lys Asp Gln His Ile Arg Asp Val Ala Ala Ile Val Gly Glu 485 490 495 Ser Met Ala Ala Leu Val Thr Leu Pro Leu Asp Pro Pro Val Val Val 500 505 510 Pro Gly Gln Pro Leu Val Phe Ser Val Asp Gly Leu Leu Gln Lys Ile 515 520 525 Thr Val Arg Ile His Gly Asp Ile Ser Ser Phe Trp Ile Lys Asn Pro 530 535 540 Ala Gly Val Ser Gln Gly Gln Glu Glu Gly Gly Gly Pro Leu Gly His 545 550 555 560 Thr Arg Arg Phe Gly Gln Phe Trp Met Val Thr Met Asp Asp Pro Pro 565 570 575 Gln Thr Gly Thr Trp Glu Ile Gln Val Thr Ala Glu Asp Thr Pro Gly 580 585 590 Val Arg Val Gln Ala Gln Thr Ser Leu Asp Phe Leu Phe His Phe Gly 595 600 605 Ile Pro Met Glu Asp Gly Pro His Pro Gly Leu Tyr Pro Leu Thr Gln 610 615 620 Pro Val Ala Gly Leu Gln Thr Gln Leu Leu Val Glu Val Thr Gly Leu 625 630 635 640 Gly Ser Arg Ala Asn Pro Gly Asp Pro Gln Pro His Phe Ser His Val 645 650 655 Ile Leu Arg Gly Val Pro Glu Gly Ala Glu Leu Gly Gln Val Pro Leu 660 665 670 Glu Pro Val Gly Pro Pro Glu Arg Gly Leu Leu Ala Ala Ser Leu Ser 675 680 685 Pro Thr Leu Leu Ser Thr Pro Arg Pro Phe Ser Leu Glu Leu Ile Gly 690 695 700 Gln Asp Ala Ala Gly Arg Arg Leu His Arg Ala Ala Pro Gln Pro Ser 705 710 715 720 Thr Val Val Pro Val Leu Leu Glu Leu Ser Gly Pro Ser Gly Phe Leu 725 730 735 Ala Pro Gly Ser Lys Val Pro Leu Ser Leu Arg Ile Ala Ser Phe Ser 740 745 750 Gly Pro Gln Asp Leu Asp Leu Arg Thr Phe Val Asn Pro Ser Phe Ser 755 760 765 Leu Thr Ser Asn Leu Ser Arg Ala His Leu Glu Leu Asn Glu Ser Ala 770 775 780 Trp Gly Arg Leu Trp Leu Glu Val Pro Asp Ser Ala Ala Pro Asp Ser 785 790 795 800 Val Val Met Val Thr Val Thr Ala Gly Gly Arg Glu Ala Asn Pro Val 805 810 815 Pro Pro Thr His Ala Phe Leu Arg Leu Leu Val Ser Ala Pro Ala Pro 820 825 830 Gln Val Arg Asn Tyr Tyr Phe Pro Ser Gln Gly Pro Ala His His Pro 835 840 845 Tyr Arg Leu Ile 850 9 2019 DNA Mycobacterium tuberculosis 9 atggctaagt ctgatggtga cgacccgctg cgcccggctt cgccgcgctt gcgatcgtca 60 cgacggcact cgctacgcta ctcggcgtac accggcgggc ccgacccgct ggccccgccg 120 gtggatctgc gggatgcgct ggaacagatt ggccaagacg tcatggcggg cgcctcgccg 180 cgccgggcgc tgtccgagct gctgcggcgg ggcaccagga acctgaccgg cgccgaccgg 240 ctggcggccg aggtgaaccg ccgccgacgg gagttgttgc gccgcaacaa cttagatggc 300 accttgcagg agatcaagaa gctgctcgac gaggccgtgc tggccgaacg caaggagctg 360 gcccgcgcgc tagacgacga cgcccgcttc gccgagctgc agctggacgc gcttccggcc 420 tcgccggcca aggcagtaca ggagctggcc gaataccgct ggcgcagcgg gcaggcccgc 480 gaaaagtatg agcagatcaa ggatttgctc ggccgtgagc tgctcgacca acgctttgcc 540 ggcatgaagc aggcgcttgc cggtgccacc gacgacgatc gccggcgggt caccgagatg 600 ctcgacgacc tcaacgacct gttggataag cacgcccgcg gtgaagatac gcagcgggac 660 ttcgacgagt tcatgaccaa gcacggcgag ttcttcccgg agaacccgcg caacgtcgag 720 gagctgctgg actcgctggc caagcgagcc gccgccgcgc agcggttccg caacagcctg 780 agccaggaac agcgggacga gctggacgcg ttggcgcagc aggcatttgg ctctccggcg 840 ttgatgcggg cgctggaccg tttggatgcg catctgcagg ccgcccgtcc cggcgaagac 900 tggaccggct cgcagcagtt ctccggtgat aatccgttcg gcatggggga aggcacccag 960 gcgctggccg acattgccga gctggagcag ctggccgagc agctgtcgca gagctatccg 1020 ggcgccagca tggacgatgt cgacctggac gcgctggccc gtcagctcgg cgaccaggcc 1080 gccgtcgacg cccggacgct ggctgaattg gaacgcgcgc tggtcaatca gggcttcctg 1140 gaccgcggtt ccgacggcca gtggcggctc tcgccgaagg ccatgcgccg cctcggcgaa 1200 acggcgttac gcgatgtggc gcaacaactt tccgggcgcc acggcgagcg tgatcaccgg 1260 cgtgccggcg ccgcgggcga gctgaccggt gcgacgcggc cctggcagtt cggcgacacc 1320 gagccgtggc acgtcgcccg cacgctgacc aatgccgtgc tgcgccaagc cgcggccgtg 1380 catgaccgca tccggatcac cgtcgaggat gtcgaggtcg ccgagaccga aacgcgcacc 1440 caggccgctg ttgcgttgtt ggtggacacc tcgttttcga tggtgatgga gaatcgctgg 1500 ttgccgatga agcgcacggc gctggcgctg caccacctgg tgtgcacccg gttccgctcg 1560 gatgccttgc agatcatcgc gtttgggcgc tacgcccgca cggtgacggc ggccgagctg 1620 acggggttgg cgggtgtcta cgagcagggc accaacctgc accatgcgct cgcgctggcc 1680 ggccggcacc tgcgccggca cgcaggcgcc cagcccgtgg tgctggtggt gaccgacggc 1740 gagccgaccg cccacctgga ggacttcgac ggcgacggta cgtcggtgtt ctttgattac 1800 ccgccccatc cgcgcaccat cgcccacacc gtgcgcgggt ttgacgacat ggcgcggctg 1860 ggtgcgcagg tgacgatctt ccggttgggc agtgaccccg gtctggctcg gttcattgac 1920 caggttgcgc gacgggtgca gggccgcgtg gtggtgcccg atctcgacgg gctgggcgcg 1980 gcggtggtgg gcgactacct gcgcttccgg cggcgctag 2019 10 672 PRT Mycobacterium tuberculosis 10 Met Ala Lys Ser Asp Gly Asp Asp Pro Leu Arg Pro Ala Ser Pro Arg 1 5 10 15 Leu Arg Ser Ser Arg Arg His Ser Leu Arg Tyr Ser Ala Tyr Thr Gly 20 25 30 Gly Pro Asp Pro Leu Ala Pro Pro Val Asp Leu Arg Asp Ala Leu Glu 35 40 45 Gln Ile Gly Gln Asp Val Met Ala Gly Ala Ser Pro Arg Arg Ala Leu 50 55 60 Ser Glu Leu Leu Arg Arg Gly Thr Arg Asn Leu Thr Gly Ala Asp Arg 65 70 75 80 Leu Ala Ala Glu Val Asn Arg Arg Arg Arg Glu Leu Leu Arg Arg Asn 85 90 95 Asn Leu Asp Gly Thr Leu Gln Glu Ile Lys Lys Leu Leu Asp Glu Ala 100 105 110 Val Leu Ala Glu Arg Lys Glu Leu Ala Arg Ala Leu Asp Asp Asp Ala 115 120 125 Arg Phe Ala Glu Leu Gln Leu Asp Ala Leu Pro Ala Ser Pro Ala Lys 130 135 140 Ala Val Gln Glu Leu Ala Glu Tyr Arg Trp Arg Ser Gly Gln Ala Arg 145 150 155 160 Glu Lys Tyr Glu Gln Ile Lys Asp Leu Leu Gly Arg Glu Leu Leu Asp 165 170 175 Gln Arg Phe Ala Gly Met Lys Gln Ala Leu Ala Gly Ala Thr Asp Asp 180 185 190 Asp Arg Arg Arg Val Thr Glu Met Leu Asp Asp Leu Asn Asp Leu Leu 195 200 205 Asp Lys His Ala Arg Gly Glu Asp Thr Gln Arg Asp Phe Asp Glu Phe 210 215 220 Met Thr Lys His Gly Glu Phe Phe Pro Glu Asn Pro Arg Asn Val Glu 225 230 235 240 Glu Leu Leu Asp Ser Leu Ala Lys Arg Ala Ala Ala Ala Gln Arg Phe 245 250 255 Arg Asn Ser Leu Ser Gln Glu Gln Arg Asp Glu Leu Asp Ala Leu Ala 260 265 270 Gln Gln Ala Phe Gly Ser Pro Ala Leu Met Arg Ala Leu Asp Arg Leu 275 280 285 Asp Ala His Leu Gln Ala Ala Arg Pro Gly Glu Asp Trp Thr Gly Ser 290 295 300 Gln Gln Phe Ser Gly Asp Asn Pro Phe Gly Met Gly Glu Gly Thr Gln 305 310 315 320 Ala Leu Ala Asp Ile Ala Glu Leu Glu Gln Leu Ala Glu Gln Leu Ser 325 330 335 Gln Ser Tyr Pro Gly Ala Ser Met Asp Asp Val Asp Leu Asp Ala Leu 340 345 350 Ala Arg Gln Leu Gly Asp Gln Ala Ala Val Asp Ala Arg Thr Leu Ala 355 360 365 Glu Leu Glu Arg Ala Leu Val Asn Gln Gly Phe Leu Asp Arg Gly Ser 370 375 380 Asp Gly Gln Trp Arg Leu Ser Pro Lys Ala Met Arg Arg Leu Gly Glu 385 390 395 400 Thr Ala Leu Arg Asp Val Ala Gln Gln Leu Ser Gly Arg His Gly Glu 405 410 415 Arg Asp His Arg Arg Ala Gly Ala Ala Gly Glu Leu Thr Gly Ala Thr 420 425 430 Arg Pro Trp Gln Phe Gly Asp Thr Glu Pro Trp His Val Ala Arg Thr 435 440 445 Leu Thr Asn Ala Val Leu Arg Gln Ala Ala Ala Val His Asp Arg Ile 450 455 460 Arg Ile Thr Val Glu Asp Val Glu Val Ala Glu Thr Glu Thr Arg Thr 465 470 475 480 Gln Ala Ala Val Ala Leu Leu Val Asp Thr Ser Phe Ser Met Val Met 485 490 495 Glu Asn Arg Trp Leu Pro Met Lys Arg Thr Ala Leu Ala Leu His His 500 505 510 Leu Val Cys Thr Arg Phe Arg Ser Asp Ala Leu Gln Ile Ile Ala Phe 515 520 525 Gly Arg Tyr Ala Arg Thr Val Thr Ala Ala Glu Leu Thr Gly Leu Ala 530 535 540 Gly Val Tyr Glu Gln Gly Thr Asn Leu His His Ala Leu Ala Leu Ala 545 550 555 560 Gly Arg His Leu Arg Arg His Ala Gly Ala Gln Pro Val Val Leu Val 565 570 575 Val Thr Asp Gly Glu Pro Thr Ala His Leu Glu Asp Phe Asp Gly Asp 580 585 590 Gly Thr Ser Val Phe Phe Asp Tyr Pro Pro His Pro Arg Thr Ile Ala 595 600 605 His Thr Val Arg Gly Phe Asp Asp Met Ala Arg Leu Gly Ala Gln Val 610 615 620 Thr Ile Phe Arg Leu Gly Ser Asp Pro Gly Leu Ala Arg Phe Ile Asp 625 630 635 640 Gln Val Ala Arg Arg Val Gln Gly Arg Val Val Val Pro Asp Leu Asp 645 650 655 Gly Leu Gly Ala Ala Val Val Gly Asp Tyr Leu Arg Phe Arg Arg Arg 660 665 670 11 1212 DNA Mycobacterium tuberculosis 11 atggccaccc ctgcactgtt gccgggcgtc gacctcgcgg cgttcgcggc agcgctggca 60 gcgcgccttc gcgacgccgg gataccggtg tccgccagcg gtcaagcgag tttggtgcag 120 gcgttgcagc agttggtgcc gcgtacgccg gcggcgctgt attggggcgc gcggttgacc 180 ctggtcagcc gtgtagacga actggccacg ttcgatgcgg tattcgcttc gctgttcggg 240 gtatttggca gcgccgaacc cgacggtgcc aaccgcccac caccgcccat tgcaggcccg 300 cgcacaccgg tggccggcgt cgggcaccgc gccaagcggc gatcttgtgc cgcccaagcc 360 cagaatctgc cctgggatac tcgctcgctg acgatggcca gcgccggtca gggcggaccc 420 agccgcacac tgcccgatgt cctgcccagc cgcattgtcg cccgggccga cgagccattc 480 gaccagttcg atcccgacga tctgcgtctg ctcggcgcct ggctggaggc cacgatggcg 540 cgctggccgc ggcggcgcag catgcgattc gagtccagcc cgcacggcaa gcgcatcgac 600 ctgcgggcga cgatgaacgc gtcgcggtcg actggctggg agtcggtgct gttggcacgg 660 atccggcccc gccgacgccc caggcgggtg ctcctgctct gcgatgtgag ccgctcgatg 720 cagccctacg ccgccatcta tctgcgtctg atgcgggcgg cggtgctgcg ccgggcaggg 780 ggccacccgg aggttttcgc gttttcgacg tcgctgactc gacttacctc ggtgctgtct 840 catcgctcgg ccgagatggc gctacatcgg gccaacgcta gggtgaccga ccgctacggc 900 ggtacgttca tcggccgtag tgtcgccgcc ctgctggccc cgccgcatgg caacgcgtta 960 cgcggcgcgg tggtgatcat cgcctccgac ggctgggaca gcgatccgcc cgacgtgttg 1020 gtgcacgcac tgaccagggt gcgtcgccgc gccgagttgc tggtctggct gaaccctcgc 1080 gcggcacatc cggagttcca gccgcgtgcc ggttcgatgg cggcggcgct gccctattgc 1140 gacctgttcc tgccggcgca ctcgctggcc ggcctgcacc agttgctgct ggcgctggcc 1200 ggtgcccgct ag 1212 12 403 PRT Mycobacterium tuberculosis 12 Met Ala Thr Pro Ala Leu Leu Pro Gly Val Asp Leu Ala Ala Phe Ala 1 5 10 15 Ala Ala Leu Ala Ala Arg Leu Arg Asp Ala Gly Ile Pro Val Ser Ala 20 25 30 Ser Gly Gln Ala Ser Leu Val Gln Ala Leu Gln Gln Leu Val Pro Arg 35 40 45 Thr Pro Ala Ala Leu Tyr Trp Gly Ala Arg Leu Thr Leu Val Ser Arg 50 55 60 Val Asp Glu Leu Ala Thr Phe Asp Ala Val Phe Ala Ser Leu Phe Gly 65 70 75 80 Val Phe Gly Ser Ala Glu Pro Asp Gly Ala Asn Arg Pro Pro Pro Pro 85 90 95 Ile Ala Gly Pro Arg Thr Pro Val Ala Gly Val Gly His Arg Ala Lys 100 105 110 Arg Arg Ser Cys Ala Ala Gln Ala Gln Asn Leu Pro Trp Asp Thr Arg 115 120 125 Ser Leu Thr Met Ala Ser Ala Gly Gln Gly Gly Pro Ser Arg Thr Leu 130 135 140 Pro Asp Val Leu Pro Ser Arg Ile Val Ala Arg Ala Asp Glu Pro Phe 145 150 155 160 Asp Gln Phe Asp Pro Asp Asp Leu Arg Leu Leu Gly Ala Trp Leu Glu 165 170 175 Ala Thr Met Ala Arg Trp Pro Arg Arg Arg Ser Met Arg Phe Glu Ser 180 185 190 Ser Pro His Gly Lys Arg Ile Asp Leu Arg Ala Thr Met Asn Ala Ser 195 200 205 Arg Ser Thr Gly Trp Glu Ser Val Leu Leu Ala Arg Ile Arg Pro Arg 210 215 220 Arg Arg Pro Arg Arg Val Leu Leu Leu Cys Asp Val Ser Arg Ser Met 225 230 235 240 Gln Pro Tyr Ala Ala Ile Tyr Leu Arg Leu Met Arg Ala Ala Val Leu 245 250 255 Arg Arg Ala Gly Gly His Pro Glu Val Phe Ala Phe Ser Thr Ser Leu 260 265 270 Thr Arg Leu Thr Ser Val Leu Ser His Arg Ser Ala Glu Met Ala Leu 275 280 285 His Arg Ala Asn Ala Arg Val Thr Asp Arg Tyr Gly Gly Thr Phe Ile 290 295 300 Gly Arg Ser Val Ala Ala Leu Leu Ala Pro Pro His Gly Asn Ala Leu 305 310 315 320 Arg Gly Ala Val Val Ile Ile Ala Ser Asp Gly Trp Asp Ser Asp Pro 325 330 335 Pro Asp Val Leu Val His Ala Leu Thr Arg Val Arg Arg Arg Ala Glu 340 345 350 Leu Leu Val Trp Leu Asn Pro Arg Ala Ala His Pro Glu Phe Gln Pro 355 360 365 Arg Ala Gly Ser Met Ala Ala Ala Leu Pro Tyr Cys Asp Leu Phe Leu 370 375 380 Pro Ala His Ser Leu Ala Gly Leu His Gln Leu Leu Leu Ala Leu Ala 385 390 395 400 Gly Ala Arg 13 200 PRT Unknown Organism Description of Unknown Organism VWA domain peptide 13 Asp Ile Val Phe Leu Leu Asp Gly Ser Gly Ser Ile Gly Ser Gln Asn 1 5 10 15 Phe Glu Arg Val Lys Asp Phe Val Glu Arg Val Val Glu Arg Leu Asp 20 25 30 Val Gly Pro Arg Asp Lys Lys Glu Glu Asp Ala Val Arg Val Gly Leu 35 40 45 Val Gln Tyr Ser Asp Asn Val Arg Thr Glu Ile Lys Phe Lys Leu Asn 50 55 60 Asp Tyr Gln Asn Lys Asp Glu Val Leu Gln Ala Leu Gln Lys Ile Arg 65 70 75 80 Tyr Glu Asp Tyr Tyr Gly Gly Gly Gly Thr Asn Thr Gly Ala Ala Leu 85 90 95 Gln Tyr Val Val Arg Asn Leu Phe Thr Glu Ala Ser Gly Ser Arg Ile 100 105 110 Glu Pro Val Ala Glu Glu Gly Ala Pro Lys Val Leu Val Val Leu Thr 115 120 125 Asp Gly Arg Ser Gln Asp Asp Pro Ser Pro Thr Ile Asp Ile Arg Asp 130 135 140 Val Leu Asn Glu Leu Lys Lys Glu Ala Gly Val Glu Val Phe Ala Ile 145 150 155 160 Gly Val Gly Asn Ala Asp Asn Asn Asn Leu Glu Glu Leu Arg Glu Ile 165 170 175 Ala Ser Lys Pro Asp Asp His Val Phe Lys Val Ser Asp Phe Glu Ala 180 185 190 Leu Asp Thr Leu Gln Glu Leu Leu 195 200 14 15 PRT Unknown Organism Description of Unknown Organism Q12019 Pfam-B 16328 peptide 14 Asp Asp Tyr Glu Ala Asp Phe Arg Lys Leu Phe Pro Asp Tyr Glu 1 5 10 15 15 13 PRT Unknown Organism Description of Unknown Organism Q9YTL7 Pfam-B 1 peptide 15 Glu Glu Asn Lys Lys Lys Gly Asp Gly Glu Glu Asp Glu 1 5 10 16 240 PRT Unknown Organism Description of Unknown Organism Q12019 Pfam-B 16328 peptide 16 Phe Ser Ser Glu Leu Lys Ser Gly Ala Ile Ile Thr Thr Ile Leu Ser 1 5 10 15 Glu Asp Leu Lys Asn Thr Arg Ile Glu Glu Leu Lys Ser Gly Ser Leu 20 25 30 Ser Ala Val Ile Asn Thr Leu Asp Ala Glu Thr Gln Ser Phe Lys Asn 35 40 45 Thr Glu Val Phe Gly Asn Ile Asp Phe Tyr His Asp Phe Ser Ile Pro 50 55 60 Glu Phe Gln Lys Ala Gly Asp Ile Ile Glu Thr Val Leu Lys Ser Val 65 70 75 80 Leu Lys Leu Leu Lys Gln Trp Pro Glu His Ala Thr Leu Lys Glu Leu 85 90 95 Tyr Arg Val Ser Gln Glu Phe Leu Asn Tyr Pro Ile Lys Thr Pro Leu 100 105 110 Ala Arg Gln Leu Gln Lys Ile Glu Gln Ile Tyr Thr Tyr Leu Ala Glu 115 120 125 Trp Glu Lys Tyr Ala Ser Ser Glu Val Ser Leu Asn Asn Thr Val Lys 130 135 140 Leu Ile Thr Asp Leu Ile Val Ser Trp Arg Lys Leu Glu Leu Arg Thr 145 150 155 160 Trp Lys Gly Leu Phe Asn Ser Glu Asp Ala Lys Thr Arg Lys Ser Ile 165 170 175 Gly Lys Trp Trp Phe Tyr Leu Tyr Glu Ser Ile Val Ile Ser Asn Phe 180 185 190 Val Ser Glu Lys Lys Glu Thr Ala Pro Asn Ala Thr Leu Leu Val Ser 195 200 205 Ser Leu Asn Leu Phe Phe Ser Lys Ser Thr Leu Gly Glu Phe Asn Ala 210 215 220 Arg Leu Asp Leu Val Lys Ala Phe Tyr Lys His Ile Gln Leu Ile Gly 225 230 235 240 17 184 PRT Homo sapiens 17 Asp Ser Asp Ile Ala Phe Leu Ile Asp Gly Ser Gly Ser Ile Ile Pro 1 5 10 15 His Asp Phe Arg Arg Met Lys Glu Phe Val Ser Thr Val Met Glu Gln 20 25 30 Leu Lys Lys Ser Lys Thr Leu Phe Ser Leu Met Gln Tyr Ser Glu Glu 35 40 45 Phe Arg Ile His Phe Thr Phe Lys Glu Phe Gln Asn Asn Pro Asn Pro 50 55 60 Arg Ser Leu Val Lys Pro Ile Thr Gln Leu Leu Gly Arg Thr His Thr 65 70 75 80 Ala Thr Gly Ile Arg Lys Val Val Arg Glu Leu Phe Asn Ile Thr Asn 85 90 95 Gly Ala Arg Lys Asn Ala Phe Lys Ile Leu Val Val Ile Thr Asp Gly 100 105 110 Glu Lys Phe Gly Asp Pro Leu Gly Tyr Glu Asp Val Ile Pro Glu Ala 115 120 125 Asp Arg Glu Gly Val Ile Arg Tyr Val Ile Gly Val Gly Asp Ala Phe 130 135 140 Arg Ser Glu Lys Ser Arg Gln Glu Leu Asn Thr Ile Ala Ser Lys Pro 145 150 155 160 Pro Arg Asp His Val Phe Gln Val Asn Asn Phe Glu Ala Leu Lys Thr 165 170 175 Ile Gln Asn Gln Leu Arg Glu Lys 180 18 201 PRT Homo sapiens 18 Ser Cys Pro Ser Leu Ile Asp Val Val Val Val Cys Asp Glu Ser Asn 1 5 10 15 Ser Ile Tyr Pro Trp Asp Ala Val Lys Asn Phe Leu Glu Lys Phe Val 20 25 30 Gln Gly Leu Asp Ile Gly Pro Thr Lys Thr Gln Val Gly Leu Ile Gln 35 40 45 Tyr Ala Asn Asn Pro Arg Val Val Phe Asn Leu Asn Thr Tyr Lys Thr 50 55 60 Lys Glu Glu Met Ile Val Ala Thr Ser Gln Thr Ser Gln Tyr Gly Gly 65 70 75 80 Asp Leu Thr Asn Thr Phe Gly Ala Ile Gln Tyr Ala Arg Lys Tyr Ala 85 90 95 Tyr Ser Ala Ala Ser Gly Gly Arg Arg Ser Ala Thr Lys Val Met Val 100 105 110 Val Val Thr Asp Gly Glu Ser His Asp Gly Ser Met Leu Lys Ala Val 115 120 125 Ile Asp Gln Cys Asn His Asp Asn Ile Leu Arg Phe Gly Ile Ala Val 130 135 140 Leu Gly Tyr Leu Asn Arg Asn Ala Leu Asp Thr Lys Asn Leu Ile Lys 145 150 155 160 Glu Ile Lys Ala Ile Ala Ser Ile Pro Thr Glu Arg Tyr Phe Phe Asn 165 170 175 Val Ser Asp Glu Ala Ala Leu Leu Glu Lys Ala Gly Thr Leu Gly Glu 180 185 190 Gln Ile Phe Ser Ile Glu Gly Gly Thr 195 200 19 201 PRT Homo sapiens 19 Arg Ser Ser Cys Pro Ser Leu Ile Asp Val Val Val Val Cys Asp Glu 1 5 10 15 Ser Asn Ser Ile Tyr Pro Trp Asp Ala Val Lys Asn Phe Leu Glu Lys 20 25 30 Phe Val Gln Gly Leu Asp Ile Gly Pro Thr Lys Thr Gln Val Gly Leu 35 40 45 Ile Gln Tyr Ala Asn Asn Pro Arg Val Val Phe Asn Leu Asn Thr Tyr 50 55 60 Lys Thr Lys Glu Glu Met Ile Val Ala Thr Ser Gln Thr Ser Gln Tyr 65 70 75 80 Gly Gly Asp Leu Thr Asn Thr Phe Gly Ala Ile Gln Tyr Ala Arg Lys 85 90 95 Tyr Ala Tyr Ser Ala Ala Ser Gly Gly Arg Arg Ser Ala Thr Lys Val 100 105 110 Met Val Val Val Thr Asp Gly Glu Ser His Asp Gly Ser Met Leu Lys 115 120 125 Ala Val Ile Asp Gln Cys Asn His Asp Asn Ile Leu Arg Phe Gly Ile 130 135 140 Ala Val Leu Gly Tyr Leu Asn Arg Asn Ala Leu Asp Thr Lys Asn Leu 145 150 155 160 Ile Lys Glu Ile Lys Ala Ile Ala Ser Ile Pro Thr Glu Arg Tyr Phe 165 170 175 Phe Asn Val Ser Asp Glu Ala Ala Leu Leu Glu Lys Ala Gly Thr Leu 180 185 190 Gly Glu Gln Ile Phe Ser Ile Glu Gly 195 200 20 183 PRT Homo sapiens 20 Gly Asn Val Asp Leu Val Phe Leu Phe Asp Gly Ser Met Ser Leu Gln 1 5 10 15 Pro Asp Glu Phe Gln Lys Ile Leu Asp Phe Met Lys Asp Val Met Lys 20 25 30 Lys Leu Ser Asn Thr Ser Tyr Gln Phe Ala Ala Val Gln Phe Ser Thr 35 40 45 Ser Tyr Lys Thr Glu Phe Asp Phe Ser Asp Tyr Val Lys Arg Lys Asp 50 55 60 Pro Asp Ala Leu Leu Lys His Val Lys His Met Leu Leu Leu Thr Asn 65 70 75 80 Thr Phe Gly Ala Ile Asn Tyr Val Ala Thr Glu Val Phe Arg Glu Glu 85 90 95 Leu Gly Ala Arg Pro Asp Ala Thr Lys Val Leu Ile Ile Ile Thr Asp 100 105 110 Gly Glu Ala Thr Asp Ser Gly Asn Ile Asp Ala Ala Lys Asp Ile Ile 115 120 125 Arg Tyr Ile Ile Gly Ile Gly Lys His Phe Gln Thr Lys Glu Ser Gln 130 135 140 Glu Thr Leu His Lys Phe Ala Ser Lys Pro Ala Ser Glu Phe Val Lys 145 150 155 160 Ile Leu Asp Thr Phe Glu Lys Leu Lys Asp Leu Phe Thr Glu Leu Gln 165 170 175 Lys Lys Ile Tyr Val Ile Glu 180 21 4910 PRT Saccharomyces cerevisiae 21 Met Ser Gln Asp Arg Ile Leu Leu Asp Leu Asp Val Val Asn Gln Arg 1 5 10 15 Leu Ile Leu Phe Asn Ser Ala Phe Pro Ser Asp Ala Ile Glu Ala Pro 20 25 30 Phe His Phe Ser Asn Lys Glu Ser Thr Ser Glu Asn Leu Asp Asn Leu 35 40 45 Ala Gly Thr Ile Leu His Ser Arg Ser Ile Thr Gly His Val Phe Leu 50 55 60 Tyr Lys His Ile Phe Leu Glu Ile Val Ala Arg Trp Ile Lys Asp Ser 65 70 75 80 Lys Lys Lys Asp Tyr Val Leu Val Ile Glu Lys Leu Ala Ser Ile Ile 85 90 95 Thr Ile Phe Pro Val Ala Met Pro Leu Ile Glu Asp Tyr Leu Asp Lys 100 105 110 Glu Asn Asp His Phe Ile Thr Ile Leu Gln Asn Pro Ser Thr Gln Lys 115 120 125 Asp Ser Asp Met Phe Lys Ile Leu Leu Ala Tyr Tyr Arg Leu Leu Tyr 130 135 140 His Asn Lys Glu Val Phe Ala Arg Phe Ile Gln Pro Asp Ile Leu Tyr 145 150 155 160 Gln Leu Val Asp Leu Leu Thr Lys Glu Gln Glu Asn Gln Val Val Ile 165 170 175 Phe Leu Ala Leu Lys Val Leu Ser Leu Tyr Leu Asp Met Gly Glu Lys 180 185 190 Thr Leu Asn Asp Met Leu Asp Thr Tyr Ile Lys Ser Arg Asp Ser Leu 195 200 205 Leu Gly His Phe Glu Gly Asp Ser Gly Ile Asp Tyr Ser Phe Leu Glu 210 215 220 Leu Asn Glu Ala Lys Arg Cys Ala Asn Phe Ser Lys Leu Pro Ser Val 225 230 235 240 Pro Glu Cys Phe Thr Ile Glu Lys Lys Ser Ser Tyr Phe Ile Ile Glu 245 250 255 Pro Gln Asp Leu Ser Thr Lys Val Ala Ser Ile Cys Gly Val Ile Val 260 265 270 Pro Lys Val His Thr Ile His Asp Lys Val Phe Tyr Pro Leu Thr Phe 275 280 285 Val Pro Thr His Lys Thr Val Ser Ser Leu Arg Gln Leu Gly Arg Lys 290 295 300 Ile Gln Asn Ser Thr Pro Ile Met Leu Ile Gly Lys Ala Gly Ser Gly 305 310 315 320 Lys Thr Phe Leu Ile Asn Glu Leu Ser Lys Tyr Met Gly Cys His Asp 325 330 335 Ser Ile Val Lys Ile His Leu Gly Glu Gln Thr Asp Ala Lys Leu Leu 340 345 350 Ile Gly Thr Tyr Thr Ser Gly Asp Lys Pro Gly Thr Phe Glu Trp Arg 355 360 365 Ala Gly Val Leu Ala Thr Ala Val Lys Glu Gly Arg Trp Val Leu Ile 370 375 380 Glu Asp Ile Asp Lys Ala Pro Thr Asp Val Leu Ser Ile Leu Leu Ser 385 390 395 400 Leu Leu Glu Lys Arg Glu Leu Thr Ile Pro Ser Arg Gly Glu Thr Val 405 410 415 Lys Ala Ala Asn Gly Phe Gln Leu Ile Ser Thr Val Arg Ile Asn Glu 420 425 430 Asp His Gln Lys Asp Ser Ser Asn Lys Ile Tyr Asn Leu Asn Met Ile 435 440 445 Gly Met Arg Ile Trp Asn Val Ile Glu Leu Glu Glu Pro Ser Glu Glu 450 455 460 Asp Leu Thr His Ile Leu Ala Gln Lys Phe Pro Ile Leu Thr Asn Leu 465 470 475 480 Ile Pro Lys Leu Ile Asp Ser Tyr Lys Asn Val Lys Ser Ile Tyr Met 485 490 495 Asn Thr Lys Phe Ile Ser Leu Asn Lys Gly Ala His Thr Arg Val Val 500 505 510 Ser Val Arg Asp Leu Ile Lys Leu Cys Glu Arg Leu Asp Ile Leu Phe 515 520 525 Lys Asn Asn Gly Ile Asn Lys Pro Asp Gln Leu Ile Gln Ser Ser Val 530 535 540 Tyr Asp Ser Ile Phe Ser Glu Ala Ala Asp Cys Phe Ala Gly Ala Ile 545 550 555 560 Gly Glu Phe Lys Ala Leu Glu Pro Ile Ile Gln Ala Ile Gly Glu Ser 565 570 575 Leu Asp Ile Ala Ser Ser Arg Ile Ser Leu Phe Leu Thr Gln His Val 580 585 590 Pro Thr Leu Glu Asn Leu Asp Asp Ser Ile Lys Ile Gly Arg Ala Val 595 600 605 Leu Leu Lys Glu Lys Leu Asn Ile Gln Lys Lys Ser Met Asn Ser Thr 610 615 620 Leu Phe Ala Phe Thr Asn His Ser Leu Arg Leu Met Glu Gln Ile Ser 625 630 635 640 Val Cys Ile Gln Met Thr Glu Pro Val Leu Leu Val Gly Glu Thr Gly 645 650 655 Thr Gly Lys Thr Thr Val Val Gln Gln Leu Ala Lys Met Leu Ala Lys 660 665 670 Lys Leu Thr Val Ile Asn Val Ser Gln Gln Thr Glu Thr Gly Asp Leu 675 680 685 Leu Gly Gly Tyr Lys Pro Val Asn Ser Lys Thr Val Ala Val Pro Ile 690 695 700 Gln Glu Asn Phe Glu Thr Leu Phe Asn Ala Thr Phe Ser Leu Lys Lys 705 710 715 720 Asn Glu Lys Phe His Lys Met Leu His Arg Cys Phe Asn Lys Asn Gln 725 730 735 Trp Lys Asn Val Val Lys Leu Trp Asn Glu Ala Tyr Lys Met Ala Gln 740 745 750 Ser Ile Leu Lys Ile Thr Asn Thr Glu Asn Glu Asn Glu Asn Ala Lys 755 760 765 Lys Lys Lys Arg Arg Leu Asn Thr His Glu Lys Lys Leu Leu Leu Asp 770 775 780 Lys Trp Ala Asp Phe Asn Asp Ser Val Lys Lys Phe Glu Ala Gln Ser 785 790 795 800 Ser Ser Ile Glu Asn Ser Phe Val Phe Asn Phe Val Glu Gly Ser Leu 805 810 815 Val Lys Thr Ile Arg Ala Gly Glu Trp Leu Leu Leu Asp Glu Val Asn 820 825 830 Leu Ala Thr Ala Asp Thr Leu Glu Ser Ile Ser Asp Leu Leu Thr Glu 835 840 845 Pro Asp Ser Arg Ser Ile Leu Leu Ser Glu Lys Gly Asp Ala Glu Pro 850 855 860 Ile Lys Ala His Pro Asp Phe Arg Ile Phe Ala Cys Met Asn Pro Ala 865 870 875 880 Thr Asp Val Gly Lys Arg Asp Leu Pro Met Gly Ile Arg Ser Arg Phe 885 890 895 Thr Glu Ile Tyr Val His Ser Pro Glu Arg Asp Ile Thr Asp Leu Leu 900 905 910 Ser Ile Ile Asp Lys Tyr Ile Gly Lys Tyr Ser Val Ser Asp Glu Trp 915 920 925 Val Gly Asn Asp Ile Ala Glu Leu Tyr Leu Glu Ala Lys Lys Leu Ser 930 935 940 Asp Asn Asn Thr Ile Val Asp Gly Ser Asn Gln Lys Pro His Phe Ser 945 950 955 960 Ile Arg Thr Leu Thr Arg Thr Leu Leu Tyr Val Thr Asp Ile Ile His 965 970 975 Ile Tyr Gly Leu Arg Arg Ser Leu Tyr Asp Gly Phe Cys Met Ser Phe 980 985 990 Leu Thr Leu Leu Asp Gln Lys Ser Glu Ala Ile Leu Lys Pro Val Ile 995 1000 1005 Glu Lys Phe Thr Leu Gly Arg Leu Lys Asn Val Lys Ser Ile Met Ser 1010 1015 1020 Gln Thr Pro Pro Ser Pro Gly Pro Asp Tyr Val Gln Phe Lys His Tyr 1025 1030 1035 1040 Trp Met Lys Lys Gly Pro Asn Thr Ile Gln Glu Gln Ala His Tyr Ile 1045 1050 1055 Ile Thr Pro Phe Val Glu Lys Asn Met Met Asn Leu Val Arg Ala Thr 1060 1065 1070 Ser Gly Lys Arg Phe Pro Val Leu Ile Gln Gly Pro Thr Ser Ser Gly 1075 1080 1085 Lys Thr Ser Met Ile Lys Tyr Leu Ala Asp Ile Thr Gly His Lys Phe 1090 1095 1100 Val Arg Ile Asn Asn His Glu His Thr Asp Leu Gln Glu Tyr Leu Gly 1105 1110 1115 1120 Thr Tyr Val Thr Asp Asp Thr Gly Lys Leu Ser Phe Lys Glu Gly Val 1125 1130 1135 Leu Val Glu Ala Leu Arg Lys Gly Tyr Trp Ile Val Leu Asp Glu Leu 1140 1145 1150 Asn Leu Ala Pro Thr Asp Val Leu Glu Ala Leu Asn Arg Leu Leu Asp 1155 1160 1165 Asp Asn Arg Glu Leu Phe Ile Pro Glu Thr Gln Glu Val Val His Pro 1170 1175 1180 His Pro Asp Phe Leu Leu Phe Ala Thr Gln Asn Pro Pro Gly Ile Tyr 1185 1190 1195 1200 Gly Gly Arg Lys Ile Leu Ser Arg Ala Phe Arg Asn Arg Phe Leu Glu 1205 1210 1215 Leu His Phe Asp Asp Ile Pro Gln Asp Glu Leu Glu Ile Ile Leu Arg 1220 1225 1230 Glu Arg Cys Gln Ile Ala Pro Ser Tyr Ala Lys Lys Ile Val Glu Val 1235 1240 1245 Tyr Arg Gln Leu Ser Ile Glu Arg Ser Ala Ser Arg Leu Phe Glu Gln 1250 1255 1260 Lys Asn Ser Phe Ala Thr Leu Arg Asp Leu Phe Arg Trp Ala Leu Arg 1265 1270 1275 1280 Asp Ala Val Gly Tyr Glu Gln Leu Ala Ala Ser Gly Tyr Met Leu Leu 1285 1290 1295 Ala Glu Arg Cys Arg Thr Pro Gln Glu Lys Val Thr Val Lys Lys Thr 1300 1305 1310 Leu Glu Lys Val Met Lys Val Lys Leu Asp Met Asp Gln Tyr Tyr Ala 1315 1320 1325 Ser Leu Glu Asp Lys Ser Leu Glu Ala Ile Gly Ser Val Thr Trp Thr 1330 1335 1340 Lys Gly Met Arg Arg Leu Ser Val Leu Val Ser Ser Cys Leu Lys Asn 1345 1350 1355 1360 Lys Glu Pro Val Leu Leu Val Gly Glu Thr Gly Cys Gly Lys Thr Thr 1365 1370 1375 Ile Cys Gln Leu Leu Ala Gln Phe Met Gly Arg Glu Leu Ile Thr Leu 1380 1385 1390 Asn Ala His Gln Asn Thr Glu Thr Gly Asp Ile Leu Gly Ala Gln Arg 1395 1400 1405 Pro Val Arg Asn Arg Ser Glu Ile Gln Tyr Lys Leu Ile Lys Ser Leu 1410 1415 1420 Lys Thr Ala Leu Asn Ile Ala Asn Asp Gln Asp Val Asp Leu Lys Glu 1425 1430 1435 1440 Leu Leu Gln Leu Tyr Ser Lys Ser Asp Asn Lys Asn Ile Ala Glu Asp 1445 1450 1455 Val Gln Leu Glu Ile Gln Lys Leu Arg Asp Ser Leu Asn Val Leu Phe 1460 1465 1470 Glu Trp Ser Asp Gly Pro Leu Ile Gln Ala Met Arg Thr Gly Asn Phe 1475 1480 1485 Phe Leu Leu Asp Glu Ile Ser Leu Ala Asp Asp Ser Val Leu Glu Arg 1490 1495 1500 Leu Asn Ser Val Leu Glu Pro Glu Arg Ser Leu Leu Leu Ala Glu Gln 1505 1510 1515 1520 Gly Ser Ser Asp Ser Leu Val Thr Ala Ser Glu Asn Phe Gln Phe Phe 1525 1530 1535 Ala Thr Met Asn Pro Gly Gly Asp Tyr Gly Lys Lys Glu Leu Ser Pro 1540 1545 1550 Ala Leu Arg Asn Arg Phe Thr Glu Ile Trp Val Pro Ser Met Glu Asp 1555 1560 1565 Phe Asn Asp Val Asn Met Ile Val Ser Ser Arg Leu Leu Glu Asp Leu 1570 1575 1580 Lys Asp Leu Ala Asn Pro Ile Val Lys Phe Ser Glu Trp Phe Gly Lys 1585 1590 1595 1600 Lys Leu Gly Gly Gly Asn Ala Thr Ser Gly Val Ile Ser Leu Arg Asp 1605 1610 1615 Ile Leu Ala Trp Val Glu Phe Ile Asn Lys Val Phe Pro Lys Ile Gln 1620 1625 1630 Asn Lys Ser Thr Ala Leu Ile Gln Gly Ala Ser Met Val Phe Ile Asp 1635 1640 1645 Ala Leu Gly Thr Asn Asn Thr Ala Tyr Leu Ala Glu Asn Glu Asn Asp 1650 1655 1660 Leu Lys Ser Leu Arg Thr Glu Cys Ile Ile Gln Leu Leu Lys Leu Cys 1665 1670 1675 1680 Gly Asp Asp Leu Glu Leu Gln Gln Ile Glu Thr Asn Glu Ile Ile Val 1685 1690 1695 Thr Gln Asp Glu Leu Gln Val Gly Met Phe Lys Ile Pro Arg Phe Pro 1700 1705 1710 Asp Ala Gln Ser Ser Ser Phe Asn Leu Thr Ala Pro Thr Thr Ala Ser 1715 1720 1725 Asn Leu Val Arg Val Val Arg Ala Met Gln Val His Lys Pro Ile Leu 1730 1735 1740 Leu Glu Gly Ser Pro Gly Val Gly Lys Thr Ser Leu Ile Thr Ala Leu 1745 1750 1755 1760 Ala Asn Ile Thr Gly Asn Lys Leu Thr Arg Ile Asn Leu Ser Glu Gln 1765 1770 1775 Thr Asp Leu Val Asp Leu Phe Gly Ala Asp Ala Pro Gly Glu Arg Ser 1780 1785 1790 Gly Glu Phe Leu Trp His Asp Ala Pro Phe Leu Arg Ala Met Lys Lys 1795 1800 1805 Gly Glu Trp Val Leu Leu Asp Glu Met Asn Leu Ala Ser Gln Ser Val 1810 1815 1820 Leu Glu Gly Leu Asn Ala Cys Leu Asp His Arg Gly Glu Ala Tyr Ile 1825 1830 1835 1840 Pro Glu Leu Asp Ile Ser Phe Ser Cys His Pro Asn Phe Leu Val Phe 1845 1850 1855 Ala Ala Gln Asn Pro Gln Tyr Gln Gly Gly Gly Arg Lys Gly Leu Pro 1860 1865 1870 Lys Ser Phe Val Asn Arg Phe Ser Val Val Phe Ile Asp Met Leu Thr 1875 1880 1885 Ser Asp Asp Leu Leu Leu Ile Ala Lys His Leu Tyr Pro Ser Ile Glu 1890 1895 1900 Pro Asp Ile Ile Ala Lys Met Ile Lys Leu Met Ser Thr Leu Glu Asp 1905 1910 1915 1920 Gln Val Cys Lys Arg Lys Leu Trp Gly Asn Ser Gly Ser Pro Trp Glu 1925 1930 1935 Phe Asn Leu Arg Asp Thr Leu Arg Trp Leu Lys Leu Leu Asn Gln Tyr 1940 1945 1950 Ser Ile Cys Glu Asp Val Asp Val Phe Asp Phe Val Asp Ile Ile Val 1955 1960 1965 Lys Gln Arg Phe Arg Thr Ile Ser Asp Lys Asn Lys Ala Gln Leu Leu 1970 1975 1980 Ile Glu Asp Ile Phe Gly Lys Phe Ser Thr Lys Glu Asn Phe Phe Lys 1985 1990 1995 2000 Leu Thr Glu Asp Tyr Val Gln Ile Asn Asn Glu Val Ala Leu Arg Asn 2005 2010 2015 Pro His Tyr Arg Tyr Pro Ile Thr Gln Asn Leu Phe Pro Leu Glu Cys 2020 2025 2030 Asn Val Ala Val Tyr Glu Ser Val Leu Lys Ala Ile Asn Asn Asn Trp 2035 2040 2045 Pro Leu Val Leu Val Gly Pro Ser Asn Ser Gly Lys Thr Glu Thr Ile 2050 2055 2060 Arg Phe Leu Ala Ser Ile Leu Gly Pro Arg Val Asp Val Phe Ser Met 2065 2070 2075 2080 Asn Ser Asp Ile Asp Ser Met Asp Ile Leu Gly Gly Tyr Glu Gln Val 2085 2090 2095 Asp Leu Thr Arg Gln Ile Ser Tyr Ile Thr Glu Glu Leu Thr Asn Ile 2100 2105 2110 Val Arg Glu Ile Ile Ser Met Asn Met Lys Leu Ser Pro Asn Ala Thr 2115 2120 2125 Ala Ile Met Glu Gly Leu Asn Leu Leu Lys Tyr Leu Leu Asn Asn Ile 2130 2135 2140 Val Thr Pro Glu Lys Phe Gln Asp Phe Arg Asn Arg Phe Asn Arg Phe 2145 2150 2155 2160 Phe Ser His Leu Glu Gly His Pro Leu Leu Lys Thr Met Ser Met Asn 2165 2170 2175 Ile Glu Lys Met Thr Glu Ile Ile Thr Lys Glu Ala Ser Val Lys Phe 2180 2185 2190 Glu Trp Phe Asp Gly Met Leu Val Lys Ala Val Glu Lys Gly His Trp 2195 2200 2205 Leu Ile Leu Asp Asn Ala Asn Leu Cys Ser Pro Ser Val Leu Asp Arg 2210 2215 2220 Leu Asn Ser Leu Leu Glu Ile Asp Gly Ser Leu Leu Ile Asn Glu Cys 2225 2230 2235 2240 Ser Gln Glu Asp Gly Gln Pro Arg Val Leu Lys Pro His Pro Asn Phe 2245 2250 2255 Arg Leu Phe Leu Thr Met Asp Pro Lys Tyr Gly Glu Leu Ser Arg Ala 2260 2265 2270 Met Arg Asn Arg Gly Val Glu Ile Tyr Ile Asp Glu Leu His Ser Arg 2275 2280 2285 Ser Thr Ala Phe Asp Arg Leu Thr Leu Gly Phe Glu Leu Gly Glu Asn 2290 2295 2300 Ile Asp Phe Val Ser Ile Asp Asp Gly Ile Lys Lys Ile Lys Leu Asn 2305 2310 2315 2320 Glu Pro Asp Met Ser Ile Pro Leu Lys His Tyr Val Pro Ser Tyr Leu 2325 2330 2335 Ser Arg Pro Cys Ile Phe Ala Gln Val His Asp Ile Leu Leu Leu Ser 2340 2345 2350 Asp Glu Glu Pro Ile Glu Glu Ser Leu Ala Ala Val Ile Pro Ile Ser 2355 2360 2365 His Leu Gly Glu Val Gly Lys Trp Ala Asn Asn Val Leu Asn Cys Thr 2370 2375 2380 Glu Tyr Ser Glu Lys Lys Ile Ala Glu Arg Leu Tyr Val Phe Ile Thr 2385 2390 2395 2400 Phe Leu Thr Asp Met Gly Val Leu Glu Lys Ile Asn Asn Leu Tyr Lys 2405 2410 2415 Pro Ala Asn Leu Lys Phe Gln Lys Ala Leu Gly Leu His Asp Lys Gln 2420 2425 2430 Leu Thr Glu Glu Thr Val Ser Leu Thr Leu Asn Glu Tyr Val Leu Pro 2435 2440 2445 Thr Val Ser Lys Tyr Ser Asp Lys Ile Lys Ser Pro Glu Ser Leu Tyr 2450 2455 2460 Leu Leu Ser Ser Leu Arg Leu Leu Leu Asn Ser Leu Asn Ala Leu Lys 2465 2470 2475 2480 Leu Ile Asn Glu Lys Ser Thr His Gly Lys Ile Asp Glu Leu Thr Tyr 2485 2490 2495 Ile Glu Leu Ser Ala Ala Ala Phe Asn Gly Arg His Leu Lys Asn Ile 2500 2505 2510 Pro Arg Ile Pro Ile Phe Cys Ile Leu Tyr Asn Ile Leu Thr Val Met 2515 2520 2525 Ser Glu Asn Leu Lys Thr Glu Ser Leu Phe Cys Gly Ser Asn Gln Tyr 2530 2535 2540 Gln Tyr Tyr Trp Asp Leu Leu Val Ile Val Ile Ala Ala Leu Glu Thr 2545 2550 2555 2560 Ala Val Thr Lys Asp Glu Ala Arg Leu Arg Val Tyr Lys Glu Leu Ile 2565 2570 2575 Asp Ser Trp Ile Ala Ser Val Lys Ser Lys Ser Asp Ile Glu Ile Thr 2580 2585 2590 Pro Phe Leu Asn Ile Asn Leu Glu Phe Thr Asp Val Leu Gln Leu Ser 2595 2600 2605 Arg Gly His Ser Ile Thr Leu Leu Trp Asp Ile Phe Arg Lys Asn Tyr 2610 2615 2620 Pro Thr Thr Ser Asn Ser Trp Leu Ala Phe Glu Lys Leu Ile Asn Leu 2625 2630 2635 2640 Ser Glu Lys Phe Asp Lys Val Arg Leu Leu Gln Phe Ser Glu Ser Tyr 2645 2650 2655 Asn Ser Ile Lys Asp Leu Met Asp Val Phe Arg Leu Leu Asn Asp Asp 2660 2665 2670 Val Leu Asn Asn Lys Leu Ser Glu Phe Asn Leu Leu Leu Ser Lys Leu 2675 2680 2685 Glu Asp Gly Ile Asn Glu Leu Glu Leu Ile Ser Asn Lys Phe Leu Asn 2690 2695 2700 Lys Arg Lys His Tyr Phe Ala Asp Glu Phe Asp Asn Leu Ile Arg Tyr 2705 2710 2715 2720 Thr Phe Ser Val Asp Thr Ala Glu Leu Ile Lys Glu Leu Ala Pro Ala 2725 2730 2735 Ser Ser Leu Ala Thr Gln Lys Leu Thr Lys Leu Ile Thr Asn Lys Tyr 2740 2745 2750 Asn Tyr Pro Pro Ile Phe Asp Val Leu Trp Thr Glu Lys Asn Ala Lys 2755 2760 2765 Leu Thr Ser Phe Thr Ser Thr Ile Phe Ser Ser Gln Phe Leu Glu Asp 2770 2775 2780 Val Val Arg Lys Ser Asn Asn Leu Lys Ser Phe Ser Gly Asn Gln Ile 2785 2790 2795 2800 Lys Gln Ser Ile Ser Asp Ala Glu Leu Leu Leu Ser Ser Thr Ile Lys 2805 2810 2815 Cys Ser Pro Asn Leu Leu Lys Ser Gln Met Glu Tyr Tyr Lys Asn Met 2820 2825 2830 Leu Leu Ser Trp Leu Arg Lys Val Ile Asp Ile His Val Gly Gly Asp 2835 2840 2845 Cys Leu Lys Leu Thr Leu Lys Glu Leu Cys Ser Leu Ile Glu Glu Lys 2850 2855 2860 Thr Ala Ser Glu Thr Arg Val Thr Phe Ala Glu Tyr Ile Phe Pro Ala 2865 2870 2875 2880 Leu Asp Leu Ala Glu Ser Ser Lys Ser Leu Glu Glu Leu Gly Glu Ala 2885 2890 2895 Trp Ile Thr Phe Gly Thr Gly Leu Leu Leu Leu Phe Val Pro Asp Ser 2900 2905 2910 Pro Tyr Asp Pro Ala Ile His Asp Tyr Val Leu Tyr Asp Leu Phe Leu 2915 2920 2925 Lys Thr Lys Thr Phe Ser Gln Asn Leu Met Lys Ser Trp Arg Asn Val 2930 2935 2940 Arg Lys Val Ile Ser Gly Asp Glu Glu Ile Phe Thr Glu Lys Leu Ile 2945 2950 2955 2960 Asn Thr Ile Ser Asp Asp Asp Ala Pro Gln Ser Pro Arg Val Tyr Arg 2965 2970 2975 Thr Gly Met Ser Ile Asp Ser Leu Phe Asp Glu Trp Met Ala Phe Leu 2980 2985 2990 Ser Ser Thr Met Ser Ser Arg Gln Ile Lys Glu Leu Val Ser Ser Tyr 2995 3000 3005 Lys Cys Asn Ser Asp Gln Ser Asp Arg Arg Leu Glu Met Leu Gln Gln 3010 3015 3020 Asn Ser Ala His Phe Leu Asn Arg Leu Glu Ser Gly Tyr Ser Lys Phe 3025 3030 3035 3040 Ala Asp Leu Asn Asp Ile Leu Ala Gly Tyr Ile Tyr Ser Ile Asn Phe 3045 3050 3055 Gly Phe Asp Leu Leu Lys Leu Gln Lys Ser Lys Asp Arg Ala Ser Phe 3060 3065 3070 Gln Ile Ser Pro Leu Trp Ser Met Asp Pro Ile Asn Ile Ser Cys Ala 3075 3080 3085 Glu Asn Val Leu Ser Ala Tyr His Glu Leu Ser Arg Phe Phe Lys Lys 3090 3095 3100 Gly Asp Met Glu Asp Thr Ser Ile Glu Lys Val Leu Met Tyr Phe Leu 3105 3110 3115 3120 Thr Leu Phe Lys Phe His Lys Arg Asp Thr Asn Leu Leu Glu Ile Phe 3125 3130 3135 Glu Ala Ala Leu Tyr Thr Leu Tyr Ser Arg Trp Ser Val Arg Arg Phe 3140 3145 3150 Arg Gln Glu Gln Glu Glu Asn Glu Lys Ser Asn Met Phe Lys Phe Asn 3155 3160 3165 Asp Asn Ser Asp Asp Tyr Glu Ala Asp Phe Arg Lys Leu Phe Pro Asp 3170 3175 3180 Tyr Glu Asp Thr Ala Leu Val Thr Asn Glu Lys Asp Ile Ser Ser Pro 3185 3190 3195 3200 Glu Asn Leu Asp Asp Ile Tyr Phe Lys Leu Ala Asp Thr Tyr Ile Ser 3205 3210 3215 Val Phe Asp Lys Asp His Asp Ala Asn Phe Ser Ser Glu Leu Lys Ser 3220 3225 3230 Gly Ala Ile Ile Thr Thr Ile Leu Ser Glu Asp Leu Lys Asn Thr Arg 3235 3240 3245 Ile Glu Glu Leu Lys Ser Gly Ser Leu Ser Ala Val Ile Asn Thr Leu 3250 3255 3260 Asp Ala Glu Thr Gln Ser Phe Lys Asn Thr Glu Val Phe Gly Asn Ile 3265 3270 3275 3280 Asp Phe Tyr His Asp Phe Ser Ile Pro Glu Phe Gln Lys Ala Gly Asp 3285 3290 3295 Ile Ile Glu Thr Val Leu Lys Ser Val Leu Lys Leu Leu Lys Gln Trp 3300 3305 3310 Pro Glu His Ala Thr Leu Lys Glu Leu Tyr Arg Val Ser Gln Glu Phe 3315 3320 3325 Leu Asn Tyr Pro Ile Lys Thr Pro Leu Ala Arg Gln Leu Gln Lys Ile 3330 3335 3340 Glu Gln Ile Tyr Thr Tyr Leu Ala Glu Trp Glu Lys Tyr Ala Ser Ser 3345 3350 3355 3360 Glu Val Ser Leu Asn Asn Thr Val Lys Leu Ile Thr Asp Leu Ile Val 3365 3370 3375 Ser Trp Arg Lys Leu Glu Leu Arg Thr Trp Lys Gly Leu Phe Asn Ser 3380 3385 3390 Glu Asp Ala Lys Thr Arg Lys Ser Ile Gly Lys Trp Trp Phe Tyr Leu 3395 3400 3405 Tyr Glu Ser Ile Val Ile Ser Asn Phe Val Ser Glu Lys Lys Glu Thr 3410 3415 3420 Ala Pro Asn Ala Thr Leu Leu Val Ser Ser Leu Asn Leu Phe Phe Ser 3425 3430 3435 3440 Lys Ser Thr Leu Gly Glu Phe Asn Ala Arg Leu Asp Leu Val Lys Ala 3445 3450 3455 Phe Tyr Lys His Ile Gln Leu Ile Gly Leu Arg Ser Ser Lys Ile Ala 3460 3465 3470 Gly Leu Leu His Asn Thr Ile Lys Phe Tyr Tyr Gln Phe Lys Pro Leu 3475 3480 3485 Ile Asp Glu Arg Ile Thr Asn Gly Lys Lys Ser Leu Glu Lys Glu Ile 3490 3495 3500 Asp Asp Ile Ile Leu Leu Ala Ser Trp Lys Asp Val Asn Val Asp Ala 3505 3510 3515 3520 Leu Lys Gln Ser Ser Arg Lys Ser His Asn Asn Leu Tyr Lys Ile Val 3525 3530 3535 Arg Lys Tyr Arg Asp Leu Leu Asn Gly Asp Ala Lys Thr Ile Ile Glu 3540 3545 3550 Ala Gly Leu Leu Tyr Ser Asn Glu Asn Lys Leu Lys Leu Pro Thr Leu 3555 3560 3565 Lys Gln His Phe Tyr Glu Asp Pro Asn Leu Glu Ala Ser Lys Asn Leu 3570 3575 3580 Val Lys Glu Ile Ser Thr Trp Ser Met Arg Ala Ala Pro Leu Arg Asn 3585 3590 3595 3600 Ile Asp Thr Val Ala Ser Asn Met Asp Ser Tyr Leu Glu Lys Ile Ser 3605 3610 3615 Ser Gln Glu Phe Pro Asn Phe Ala Asp Leu Ala Ser Asp Phe Tyr Ala 3620 3625 3630 Glu Ala Glu Arg Leu Arg Lys Glu Thr Pro Asn Val Tyr Thr Lys Glu 3635 3640 3645 Asn Lys Lys Arg Leu Ala Tyr Leu Lys Thr Gln Lys Ser Lys Leu Leu 3650 3655 3660 Gly Asp Ala Leu Lys Glu Leu Arg Arg Ile Gly Leu Lys Val Asn Phe 3665 3670 3675 3680 Arg Glu Asp Ile Gln Lys Val Gln Ser Ser Thr Thr Thr Ile Leu Ala 3685 3690 3695 Asn Ile Ala Pro Phe Asn Asn Glu Tyr Leu Asn Ser Ser Asp Ala Phe 3700 3705 3710 Phe Phe Lys Ile Leu Asp Leu Leu Pro Lys Leu Arg Ser Ala Ala Ser 3715 3720 3725 Asn Pro Ser Asp Asp Ile Pro Val Ala Ala Ile Glu Arg Gly Met Ala 3730 3735 3740 Leu Ala Gln Ser Leu Met Phe Ser Leu Ile Thr Val Arg His Pro Leu 3745 3750 3755 3760 Ser Glu Phe Thr Asn Asp Tyr Cys Lys Ile Asn Gly Met Met Leu Asp 3765 3770 3775 Leu Glu His Phe Thr Cys Leu Lys Gly Asp Ile Val His Ser Ser Leu 3780 3785 3790 Lys Ala Asn Val Asp Asn Val Arg Leu Phe Glu Lys Trp Leu Pro Ser 3795 3800 3805 Leu Leu Asp Tyr Ala Ala Gln Thr Leu Ser Val Ile Ser Lys Tyr Ser 3810 3815 3820 Ala Thr Ser Glu Gln Gln Lys Ile Leu Leu Asp Ala Lys Ser Thr Leu 3825 3830 3835 3840 Ser Ser Phe Phe Val His Phe Asn Ser Ser Arg Ile Phe Asp Ser Ser 3845 3850 3855 Phe Ile Glu Ser Tyr Ser Arg Phe Glu Leu Phe Ile Asn Glu Leu Leu 3860 3865 3870 Lys Lys Leu Glu Asn Ala Lys Glu Thr Gly Asn Ala Phe Val Phe Asp 3875 3880 3885 Ile Ile Ile Glu Trp Ile Lys Ala Asn Lys Gly Gly Pro Ile Lys Lys 3890 3895 3900 Glu Gln Lys Arg Gly Pro Ser Val Glu Asp Val Glu Gln Ala Phe Arg 3905 3910 3915 3920 Arg Thr Phe Thr Ser Ile Ile Leu Ser Phe Gln Lys Val Ile Gly Asp 3925 3930 3935 Gly Ile Glu Ser Ile Ser Glu Thr Asp Asp Asn Trp Leu Ser Ala Ser 3940 3945 3950 Phe Lys Lys Val Met Val Asn Val Lys Leu Leu Arg Ser Ser Val Val 3955 3960 3965 Ser Lys Asn Ile Glu Thr Ala Leu Ser Leu Leu Lys Asp Phe Asp Phe 3970 3975 3980 Thr Thr Thr Glu Ser Ile Tyr Val Lys Ser Val Ile Ser Phe Thr Leu 3985 3990 3995 4000 Pro Val Ile Thr Arg Tyr Tyr Asn Ala Met Thr Val Val Leu Glu Arg 4005 4010 4015 Ser Arg Ile Tyr Tyr Thr Asn Thr Ser Arg Gly Met Tyr Ile Leu Ser 4020 4025 4030 Thr Ile Leu His Ser Leu Ala Lys Asn Gly Phe Cys Ser Pro Gln Pro 4035 4040 4045 Pro Ser Glu Glu Val Asp Asp Lys Asn Leu Gln Glu Gly Thr Gly Leu 4050 4055 4060 Gly Asp Gly Glu Gly Ala Gln Asn Asn Asn Lys Asp Val Glu Gln Asp 4065 4070 4075 4080 Glu Asp Leu Thr Glu Asp Ala Gln Asn Glu Asn Lys Glu Gln Gln Asp 4085 4090 4095 Lys Asp Glu Arg Asp Asp Glu Asn Glu Asp Asp Ala Val Glu Met Glu 4100 4105 4110 Gly Asp Met Ala Gly Glu Leu Glu Asp Leu Ser Asn Gly Glu Glu Asn 4115 4120 4125 Asp Asp Glu Asp Thr Asp Ser Glu Glu Glu Glu Leu Asp Glu Glu Ile 4130 4135 4140 Asp Asp Leu Asn Glu Asp Asp Pro Asn Ala Ile Asp Asp Lys Met Trp 4145 4150 4155 4160 Asp Asp Lys Ala Ser Asp Asn Ser Lys Glu Lys Asp Thr Asp Gln Asn 4165 4170 4175 Leu Asp Gly Lys Asn Gln Glu Glu Asp Val Gln Ala Ala Glu Asn Asp 4180 4185 4190 Glu Gln Gln Arg Asp Asn Lys Glu Gly Gly Asp Glu Asp Pro Asn Ala 4195 4200 4205 Pro Glu Asp Gly Asp Glu Glu Ile Glu Asn Asp Glu Asn Ala Glu Glu 4210 4215 4220 Glu Asn Asp Val Gly Glu Gln Glu Asp Glu Val Lys Asp Glu Glu Gly 4225 4230 4235 4240 Glu Asp Leu Glu Ala Asn Val Pro Glu Ile Glu Thr Leu Asp Leu Pro 4245 4250 4255 Glu Asp Met Asn Leu Asp Ser Glu His Glu Glu Ser Asp Glu Asp Val 4260 4265 4270 Asp Met Ser Asp Gly Met Pro Asp Asp Leu Asn Lys Glu Glu Val Gly 4275 4280 4285 Asn Glu Asp Glu Glu Val Lys Gln Glu Ser Gly Ile Glu Ser Asp Asn 4290 4295 4300 Glu Asn Asp Glu Pro Gly Pro Glu Glu Asp Ala Gly Glu Thr Glu Thr 4305 4310 4315 4320 Ala Leu Asp Glu Glu Glu Gly Ala Glu Glu Asp Val Asp Met Thr Asn 4325 4330 4335 Asp Glu Gly Lys Glu Asp Glu Glu Asn Gly Pro Glu Glu Gln Ala Met 4340 4345 4350 Ser Asp Glu Glu Glu Leu Lys Gln Asp Ala Ala Met Glu Glu Asn Lys 4355 4360 4365 Glu Lys Gly Gly Glu Gln Asn Thr Glu Gly Leu Asp Gly Val Glu Glu 4370 4375 4380 Lys Ala Asp Thr Glu Asp Ile Asp Gln Glu Ala Ala Val Gln Gln Asp 4385 4390 4395 4400 Ser Gly Ser Lys Gly Ala Gly Ala Asp Ala Thr Asp Thr Gln Glu Gln 4405 4410 4415 Asp Asp Val Gly Gly Ser Gly Thr Thr Gln Asn Thr Tyr Glu Glu Asp 4420 4425 4430 Gln Glu Asp Val Thr Lys Asn Asn Glu Glu Ser Arg Glu Glu Ala Thr 4435 4440 4445 Ala Ala Leu Lys Gln Leu Gly Asp Ser Met Lys Glu Tyr His Arg Arg 4450 4455 4460 Arg Gln Asp Ile Lys Glu Ala Gln Thr Asn Gly Glu Glu Asp Glu Asn 4465 4470 4475 4480 Leu Glu Lys Asn Asn Glu Arg Pro Asp Glu Phe Glu His Val Glu Gly 4485 4490 4495 Ala Asn Thr Glu Thr Asp Thr Gln Ala Leu Gly Ser Ala Thr Gln Asp 4500 4505 4510 Gln Leu Gln Thr Ile Asp Glu Asp Met Ala Ile Asp Asp Asp Arg Glu 4515 4520 4525 Glu Gln Glu Val Asp Gln Lys Glu Leu Val Glu Asp Ala Asp Asp Glu 4530 4535 4540 Lys Met Asp Ile Asp Glu Glu Glu Met Leu Ser Asp Ile Asp Ala His 4545 4550 4555 4560 Asp Ala Asn Asn Asp Val Asp Ser Lys Lys Ser Gly Phe Ile Gly Lys 4565 4570 4575 Arg Lys Ser Glu Glu Asp Phe Glu Asn Glu Leu Ser Asn Glu His Phe 4580 4585 4590 Ser Ala Asp Gln Glu Asp Asp Ser Glu Ile Gln Ser Leu Ile Glu Asn 4595 4600 4605 Ile Glu Asp Asn Pro Pro Asp Ala Ser Ala Ser Leu Thr Pro Glu Arg 4610 4615 4620 Ser Leu Glu Glu Ser Arg Glu Leu Trp His Lys Ser Glu Ile Ser Thr 4625 4630 4635 4640 Ala Asp Leu Val Ser Arg Leu Gly Glu Gln Leu Arg Leu Ile Leu Glu 4645 4650 4655 Pro Thr Leu Ala Thr Lys Leu Lys Gly Asp Tyr Lys Thr Gly Lys Arg 4660 4665 4670 Leu Asn Met Lys Arg Ile Ile Pro Tyr Ile Ala Ser Gln Phe Arg Lys 4675 4680 4685 Asp Lys Ile Trp Leu Arg Arg Thr Lys Pro Ser Lys Arg Gln Tyr Gln 4690 4695 4700 Ile Met Ile Ala Leu Asp Asp Ser Lys Ser Met Ser Glu Ser Lys Cys 4705 4710 4715 4720 Val Lys Leu Ala Phe Asp Ser Leu Cys Leu Val Ser Lys Thr Leu Thr 4725 4730 4735 Gln Leu Glu Ala Gly Gly Leu Ser Ile Val Lys Phe Gly Glu Asn Ile 4740 4745 4750 Lys Glu Val His Ser Phe Asp Gln Gln Phe Ser Asn Glu Ser Gly Ala 4755 4760 4765 Arg Ala Phe Gln Trp Phe Gly Phe Gln Glu Thr Lys Thr Asp Val Lys 4770 4775 4780 Lys Leu Val Ala Glu Ser Thr Lys Ile Phe Glu Arg Ala Arg Ala Met 4785 4790 4795 4800 Val His Asn Asp Gln Trp Gln Leu Glu Ile Val Ile Ser Asp Gly Ile 4805 4810 4815 Cys Glu Asp His Glu Thr Ile Gln Lys Leu Val Arg Arg Ala Arg Glu 4820 4825 4830 Asn Lys Ile Met Leu Val Phe Val Ile Ile Asp Gly Ile Thr Ser Asn 4835 4840 4845 Glu Ser Ile Leu Asp Met Ser Gln Val Asn Tyr Ile Pro Asp Gln Tyr 4850 4855 4860 Gly Asn Pro Gln Leu Lys Ile Thr Lys Tyr Leu Asp Thr Phe Pro Phe 4865 4870 4875 4880 Glu Phe Tyr Val Val Val His Asp Ile Ser Glu Leu Pro Glu Met Leu 4885 4890 4895 Ser Leu Ile Leu Arg Gln Tyr Phe Thr Asp Leu Ala Ser Ser 4900 4905 4910 22 446 PRT Drosophila melanogaster 22 Met Asp Gln Thr Glu Ala Glu Glu Tyr Gln His Val Lys Glu Pro Lys 1 5 10 15 Asn Ser Asp Lys Thr Thr Leu Asp Asn Ala Thr Glu Glu Gln Ser Lys 20 25 30 Lys Ile Gln His Gln Glu Asp Glu Pro Pro Asn Glu Glu Glu Ile Glu 35 40 45 Ala Glu Asn Val Asp Glu Leu Met Glu Ala Glu Glu Pro Ala Val Asp 50 55 60 Pro Glu Asp Asp Ala Glu Leu Glu Gln Leu Gly Ala Glu Lys Thr Glu 65 70 75 80 Gln Lys Ser Asp Lys Pro Ser Lys Thr Glu Lys Ser Lys Glu Gln Leu 85 90 95 Glu Thr Pro Glu Gly Met Glu Ile Glu Gly Glu Val Val Leu Thr Met 100 105 110 Thr Val Pro Arg Ser Ser Glu Thr Thr Ala His Ser Asn Ser Glu Ile 115 120 125 Leu Leu Asp Lys Ser Ser His Ala Glu Asp Leu Ser Ser Ala Glu Gln 130 135 140 Ile Glu Leu Arg Gln Gln Tyr Gln Lys Gln Leu Thr Thr Phe Arg Val 145 150 155 160 Ala Gln Pro Glu His Glu Asp Tyr Glu Thr Trp Gln Gly Ile Ser Asn 165 170 175 Arg Met Thr Gln Asn Ala Arg Glu Leu Cys Glu Gln Leu Arg Leu Ile 180 185 190 Leu Glu Pro Thr Lys Cys Thr Arg Leu Lys Gly Asp Tyr Arg Thr Gly 195 200 205 Arg Arg Ile Asn Met Lys Lys Ile Ile Pro Tyr Ile Ala Ser Gln Phe 210 215 220 Arg Lys Asp Lys Ile Trp Leu Arg Arg Thr Lys Pro Ala Gln Arg Asp 225 230 235 240 Tyr Lys Ile Thr Ile Ala Ile Asp Asp Ser Lys Ser Met His His Asn 245 250 255 Asn Ser Lys Thr Leu Thr Leu Glu Ala Ile Ser Leu Val Ser Gln Ala 260 265 270 Leu Thr Leu Leu Glu Ser Gly Arg Leu Ser Ile Val Ser Phe Gly Glu 275 280 285 Ala Pro Gln Ile Ile Leu Asn His Thr Glu Gln Phe Asp Gly Pro Arg 290 295 300 Leu Val Asn Ala Leu Asn Phe Ala Gln Asp Lys Thr Lys Ile Ala Gly 305 310 315 320 Leu Leu Asn Phe Ile Arg Thr Ala Asn Ala Glu Glu Ser Gly Thr Gly 325 330 335 Gly Asp Asn Gly Leu Phe Glu Asn Leu Leu Leu Ile Leu Ser Asp Gly 340 345 350 Arg Asn Ile Phe Ser Glu Gly Ala Gln Asn Val Lys Asn Ala Ile Lys 355 360 365 Leu Ala Arg Leu Gln Arg Ile Phe Leu Val Tyr Ile Ile Ile Asp Asn 370 375 380 Pro Asp Asn Lys Asn Ser Ile Leu Asp Ile Gln His Val Ala Val Asn 385 390 395 400 Ala Asp Gly Ser Val Asn Ile Asn Ser Tyr Leu Asp Ser Phe Pro Phe 405 410 415 Pro Tyr Tyr Val Ile Val Arg Asp Leu Asn Gln Leu Pro Leu Val Leu 420 425 430 Ser Glu Ala Met Arg Gln Trp Phe Glu Leu Val Asn Ser Glu 435 440 445 23 10 DNA Artificial Sequence Description of Artificial Sequence SAGE library tag 23 acatactgcc 10 24 10 DNA Artificial Sequence Description of Artificial Sequence SAGE library tag 24 ggcgatctca 10 25 10 DNA Artificial Sequence Description of Artificial Sequence SAGE library tag 25 gtaggctgag 10 26 10 DNA Artificial Sequence Description of Artificial Sequence SAGE library tag 26 tacctgaagt 10 27 10 DNA Artificial Sequence Description of Artificial Sequence Oligonucleotide tag not found in some SAGE libraries 27 gcactgaatg 10 28 10 DNA Artificial Sequence Description of Artificial Sequence Oligonucleotide tag not found in some SAGE libraries 28 ggactctgac 10 29 10 DNA Artificial Sequence Description of Artificial Sequence Oligonucleotide tag not found in some SAGE libraries 29 gggactctac 10 30 150 PRT Unknown Organism Description of Unknown Organism VWA domain peptide 30 Pro Leu Asp Val Val Phe Leu Leu Asp Gly Ser Gly Ser Met Gly Gly 1 5 10 15 Asn Arg Phe Glu Leu Ala Lys Glu Phe Val Leu Lys Leu Val Glu Gln 20 25 30 Leu Asp Ile Gly Pro Arg Gly Asp Arg Val Gly Leu Val Thr Phe Ser 35 40 45 Ser Asp Ala Arg Val Leu Phe Pro Leu Asn Asp Ser Gln Ser Lys Asp 50 55 60 Ala Leu Leu Glu Ala Leu Ala Asn Leu Ser Tyr Ser Leu Gly Gly Gly 65 70 75 80 Thr Asn Leu Gly Ala Ala Leu Glu Tyr Ala Leu Glu Asn Leu Phe Ser 85 90 95 Glu Ser Ala Gly Ser Arg Arg Gly Ala Pro Lys Val Leu Ile Leu Ile 100 105 110 Thr Asp Gly Glu Ser Asn Asp Gly Gly Glu Asp Ile Leu Lys Ala Ala 115 120 125 Lys Glu Leu Lys Arg Ser Gly Val Lys Val Phe Val Val Gly Val Gly 130 135 140 Asn Ala Val Asp Glu Glu 145 150 31 180 PRT Unknown Organism Description of Unknown Organism VWA domain peptide 31 Pro Leu Asp Val Val Phe Leu Leu Asp Gly Ser Gly Ser Met Gly Gly 1 5 10 15 Asn Arg Phe Glu Leu Ala Lys Glu Phe Val Leu Lys Leu Val Glu Gln 20 25 30 Leu Asp Ile Gly Pro Arg Gly Asp Arg Val Gly Leu Val Thr Phe Ser 35 40 45 Ser Asp Ala Arg Val Leu Phe Pro Leu Asn Asp Ser Gln Ser Lys Asp 50 55 60 Ala Leu Leu Glu Ala Leu Ala Asn Leu Ser Tyr Ser Leu Gly Gly Gly 65 70 75 80 Thr Asn Leu Gly Ala Ala Leu Glu Tyr Ala Leu Glu Asn Leu Phe Ser 85 90 95 Glu Ser Ala Gly Ser Arg Arg Gly Ala Pro Lys Val Leu Ile Leu Ile 100 105 110 Thr Asp Gly Glu Ser Asn Asp Gly Gly Glu Asp Ile Leu Lys Ala Ala 115 120 125 Lys Glu Leu Lys Arg Ser Gly Val Lys Val Phe Val Val Gly Val Gly 130 135 140 Asn Ala Val Asp Glu Glu Glu Leu Lys Lys Leu Ala Ser Ala Pro Gly 145 150 155 160 Gly Val Phe Ala Val Glu Asp Leu Pro Glu Leu Leu Asp Leu Leu Ile 165 170 175 Asp Leu Leu Leu 180 32 370 PRT Mus musculus 32 Asp Ile Thr Pro Ala Ser Ser Leu Ser Phe Val Leu Asp Thr Thr Gly 1 5 10 15 Ser Met Gly Glu Glu Ile Asn Ala Ala Lys Ile Gln Ala Arg Arg Ile 20 25 30 Val Glu Gln Arg Gln Gly Ser Pro Met Glu Pro Val Phe Tyr Ile Leu 35 40 45 Val Pro Phe His Asp Pro Gly Phe Gly Pro Val Phe Thr Thr Ser Asp 50 55 60 Pro Asp Ser Phe Trp Gln Lys Leu Asn Glu Ile His Ala Leu Gly Gly 65 70 75 80 Gly Asp Glu Pro Glu Met Cys Leu Ser Ala Leu Glu Leu Ala Leu Leu 85 90 95 His Thr Pro Pro Leu Ser Asp Ile Phe Val Phe Thr Asp Ala Ser Pro 100 105 110 Lys Asp Ala Leu Leu Thr Asn Arg Val Glu Ser Leu Thr Arg Glu Arg 115 120 125 Arg Cys Arg Val Thr Phe Leu Val Thr Glu Asp Pro Ser Arg Thr Gly 130 135 140 Gly Arg Arg Arg Arg Glu Ala Leu Ser Pro Leu Arg Phe Glu Pro Tyr 145 150 155 160 Glu Ala Ile Ala Arg Ala Ser Gly Gly Glu Val Ile Phe Thr Lys Asp 165 170 175 Gln Tyr Ile Gln Asp Val Ala Ala Ile Val Gly Glu Ser Met Ala Gly 180 185 190 Leu Val Thr Leu Pro Leu Asp Pro Pro Val Phe Thr Pro Gly Glu Pro 195 200 205 Cys Val Phe Ser Val Asp Ser Leu Leu Trp Gln Val Thr Val Arg Met 210 215 220 His Gly Asp Ile Ser Ser Phe Trp Ile Lys Ser Pro Ala Gly Val Ser 225 230 235 240 Gln Gly Pro Glu Glu Gly Ile Gly Pro Leu Gly His Thr Arg Arg Phe 245 250 255 Gly Gln Phe Trp Thr Val Thr Met Thr Asp Pro Pro Arg Thr Gly Thr 260 265 270 Trp Glu Ile Gln Val Ala Ala Ala Gly Thr Pro Arg Val Arg Val Gln 275 280 285 Ala Gln Thr Ser Leu Asp Phe Leu Phe His Phe Gly Ile Ser Val Glu 290 295 300 Asp Gly Pro His Pro Gly Leu Tyr Pro Leu Thr Gln Pro Val Ala Gly 305 310 315 320 Leu Gln Thr Gln Leu Leu Val Glu Val Thr Gly Leu Thr Ser Arg Gln 325 330 335 Lys Leu Val Gly Gly Gln Pro Gln Phe Ser His Val Val Leu Arg Arg 340 345 350 Val Pro Glu Gly Thr Gln Leu Gly Arg Val Ser Leu Glu Pro Val Gly 355 360 365 Pro Pro 370 33 182 PRT Homo sapiens 33 Gly Asn Val Asp Leu Val Phe Leu Phe Asp Gly Ser Met Ser Leu Gln 1 5 10 15 Pro Asp Glu Phe Gln Lys Ile Leu Asp Phe Met Lys Asp Val Met Lys 20 25 30 Lys Leu Ser Asn Thr Ser Tyr Gln Phe Ala Ala Val Gln Phe Ser Thr 35 40 45 Ser Tyr Lys Thr Glu Phe Asp Phe Ser Asp Tyr Val Lys Arg Lys Asp 50 55 60 Pro Asp Ala Leu Leu Lys His Val Lys His Met Leu Leu Leu Thr Asn 65 70 75 80 Thr Phe Gly Ala Ile Asn Tyr Val Ala Thr Glu Val Phe Arg Glu Glu 85 90 95 Leu Gly Ala Arg Pro Asp Ala Thr Lys Val Leu Ile Ile Ile Thr Asp 100 105 110 Gly Glu Ala Thr Asp Ser Gly Asn Ile Asp Ala Ala Lys Asp Ile Ile 115 120 125 Arg Tyr Ile Ile Gly Ile Gly Lys His Phe Gln Thr Lys Glu Ser Gln 130 135 140 Glu Thr Leu His Lys Phe Ala Ser Lys Pro Ala Ser Glu Phe Val Lys 145 150 155 160 Ile Leu Asp Thr Phe Glu Lys Leu Lys Asp Leu Phe Thr Glu Leu Gln 165 170 175 Lys Lys Ile Tyr Val Ile 180 34 5198 PRT Caenorhabditis elegans 34 Met Gly Arg Ser Pro Ser Trp Leu Tyr Gly Val Leu Gly Leu Leu Leu 1 5 10 15 Leu Ala Thr Thr Cys Ser Ser Val Asn Asp Asp Lys Asn Asp Pro Thr 20 25 30 Gly Lys Ser Ser Leu Ala Phe Val Phe Asp Ile Thr Gly Ser Met Phe 35 40 45 Asp Asp Leu Val Gln Val Arg Glu Gly Ala Ala Lys Ile Phe Lys Thr 50 55 60 Val Met Ala Gln Arg Glu Lys Leu Ile Tyr Asn Tyr Ile Met Val Pro 65 70 75 80 Phe His Asp Pro Tyr Leu Gly Glu Ile Ile Asn Thr Thr Asp Ser Thr 85 90 95 Tyr Phe Met Arg Gln Leu Ser Lys Val Tyr Val His Gly Gly Gly Asp 100 105 110 Cys Pro Glu Lys Thr Leu Thr Gly Ile Leu Lys Ala Leu Gln Ile Ser 115 120 125 Leu Pro Ser Ser Phe Ile Tyr Val Phe Thr Asp Ala Arg Ser Lys Asp 130 135 140 Tyr His Leu Glu Asp Glu Val Leu Asn Thr Ile Gln Glu Lys Gln Ser 145 150 155 160 Ser Val Val Phe Val Met Thr Gly Asp Cys Gly Asn Arg Thr His Pro 165 170 175 Gly Phe Arg Thr Tyr Glu Lys Ile Ala Ala Ala Ser Phe Gly Gln Val 180 185 190 Phe His Leu Glu Lys Ser Asp Val Ser Thr Val Leu Glu Tyr Val Arg 195 200 205 His Ala Val Lys Gln Lys Lys Val His Leu Met Tyr Glu Ala Arg Glu 210 215 220 Arg Gly Gly Thr Val Ser Arg Asn Ile Pro Val Asp Lys His Leu Ser 225 230 235 240 Glu Leu Thr Ile Ser Leu Ser Gly Asp Lys Asp Asp Ser Asp Asn Leu 245 250 255 Asp Ile Val Leu Arg Asp Pro Glu Gly Arg Thr Val Asp Lys Arg Leu 260 265 270 Tyr Ser Lys Glu Gly Gly Thr Ile Asp Leu Lys Asn Val Lys Leu Ile 275 280 285 Arg Leu Lys Asp Pro Ser Pro Gly Val Trp Thr Val Asn Thr Asn Ser 290 295 300 Arg Leu Lys His Thr Ile Arg Val Phe Gly His Gly Ala Val Asp Phe 305 310 315 320 Lys Tyr Gly Phe Ala Ser Arg Pro Leu Asp Arg Ile Glu Leu Ala Arg 325 330 335 Pro Arg Pro Val Leu Asn Gln Asp Thr Tyr Leu Leu Ile Asn Met Thr 340 345 350 Gly Leu Ile Pro Pro Gly Thr Val Gly Glu Ile Asp Leu Val Asp Tyr 355 360 365 His Gly His Ser Leu Tyr Lys Ala Val Ala Ser Pro His Arg Thr Asn 370 375 380 Pro Asn Met Tyr Phe Ala Gly Pro Phe Val Pro Pro Lys Gly Leu Phe 385 390 395 400 Phe Val Arg Val Gln Gly Tyr Asp Glu Asp Asn Tyr Glu Phe Met Arg 405 410 415 Ile Ala Pro Thr Ala Ile Gly Ser Val Ile Val Gly Gly Pro Arg Ala 420 425 430 Phe Met Ser Pro Ile His Gln Glu Phe Val Gly Arg Asp Leu Asn Leu 435 440 445 Ser Cys Thr Val Glu Ser Ala Ser Ala Tyr Thr Ile Tyr Trp Val Lys 450 455 460 Thr Gly Glu Asp Ile Ile Gly Gly Pro Leu Phe Tyr His Asn Thr Asp 465 470 475 480 Thr Ser Val Trp Thr Ile Pro Glu Leu Ser Leu Lys Asp Ala Gly Glu 485 490 495 Tyr Glu Cys Arg Val Ile Ser Asn Asn Gly Asn Tyr Ser Val Lys Thr 500 505 510 Arg Val Glu Thr Arg Glu Ser Pro Pro Glu Ile Phe Gly Val Arg Asn 515 520 525 Val Ser Val Pro Leu Gly Glu Ala Ala Phe Leu His Cys Ser Thr Arg 530 535 540 Ser Ala Gly Glu Val Glu Ile Arg Trp Thr Arg Tyr Gly Ala Thr Val 545 550 555 560 Phe Asn Gly Pro Asn Thr Glu Arg Asn Pro Thr Asn Gly Thr Leu Lys 565 570 575 Ile His His Val Thr Arg Ala Asp Ala Gly Val Tyr Glu Cys Met Ala 580 585 590 Arg Asn Ala Gly Gly Met Ser Thr Arg Lys Met Arg Leu Asp Ile Met 595 600 605 Glu Pro Pro Ser Val Lys Val Thr Pro Gln Asp Val Tyr Phe Asn Met 610 615 620 Arg Glu Gly Val Asn Leu Ser Cys Glu Ala Met Gly Asp Pro Lys Pro 625 630 635 640 Glu Val His Trp Tyr Phe Lys Gly Arg His Leu Leu Asn Asp Tyr Lys 645 650 655 Tyr Gln Val Gly Gln Asp Ser Lys Phe Leu Tyr Ile Arg Asp Ala Thr 660 665 670 His His Asp Glu Gly Thr Tyr Glu Cys Arg Ala Met Ser Gln Ala Gly 675 680 685 Gln Ala Arg Asp Thr Thr Asp Leu Met Leu Ala Thr Pro Pro Lys Val 690 695 700 Glu Ile Ile Gln Asn Lys Met Met Val Gly Arg Gly Asp Arg Val Ser 705 710 715 720 Phe Glu Cys Lys Thr Ile Arg Gly Lys Pro His Pro Lys Ile Arg Trp 725 730 735 Phe Lys Asn Gly Lys Asp Leu Ile Lys Pro Asp Asp Tyr Ile Lys Ile 740 745 750 Asn Glu Gly Gln Leu His Ile Met Gly Ala Lys Asp Glu Asp Ala Gly 755 760 765 Ala Tyr Ser Cys Val Gly Glu Asn Met Ala Gly Lys Asp Val Gln Val 770 775 780 Ala Asn Leu Ser Val Gly Arg Val Pro Thr Ile Ile Glu Ser Pro His 785 790 795 800 Thr Val Arg Val Asn Ile Glu Arg Gln Val Thr Leu Gln Cys Leu Ala 805 810 815 Val Gly Ile Pro Pro Pro Glu Ile Glu Trp Gln Lys Gly Asn Val Leu 820 825 830 Leu Ala Thr Leu Asn Asn Pro Arg Tyr Thr Gln Leu Ala Asp Gly Asn 835 840 845 Leu Leu Ile Thr Asp Ala Gln Ile Glu Asp Gln Gly Gln Phe Thr Cys 850 855 860 Ile Ala Arg Asn Thr Tyr Gly Gln Gln Ser Gln Ser Thr Thr Leu Met 865 870 875 880 Val Thr Gly Leu Val Ser Pro Val Leu Gly His Val Pro Pro Glu Glu 885 890 895 Gln Leu Ile Glu Gly Gln Asp Leu Thr Leu Ser Cys Val Val Val Leu 900 905 910 Gly Thr Pro Lys Pro Ser Ile Val Trp Ile Lys Asp Asp Lys Pro Val 915 920 925 Glu Glu Gly Pro Thr Ile Lys Ile Glu Gly Gly Gly Ser Leu Leu Arg 930 935 940 Leu Arg Gly Gly Asn Pro Lys Asp Glu Gly Lys Tyr Thr Cys Ile Ala 945 950 955 960 Val Ser Pro Ala Gly Asn Ser Thr Leu His Ile Asn Val Gln Leu Ile 965 970 975 Lys Lys Pro Glu Phe Val Tyr Lys Pro Glu Gly Gly Ile Val Phe Lys 980 985 990 Pro Thr Ile Ser Gly Met Asp Glu Lys His Val Ala Val Val Asn Ser 995 1000 1005 Thr His Asp Val Leu Asp Gly Glu Gly Phe Ala Ile Pro Cys Val Val 1010 1015 1020 Ser Gly Thr Pro Pro Pro Ile Ile Thr Trp Tyr Leu Asp Gly Arg Pro 1025 1030 1035 1040 Ile Thr Pro Asn Ser Arg Asp Phe Thr Val Thr Ala Asp Asn Thr Leu 1045 1050 1055 Ile Val Arg Lys Ala Asp Lys Ser Tyr Ser Gly Val Tyr Thr Cys Gln 1060 1065 1070 Ala Thr Asn Ser Ala Gly Asp Asn Glu Gln Lys Thr Thr Ile Arg Ile 1075 1080 1085 Met Asn Thr Pro Met Ile Ser Pro Gly Gln Ser Ser Phe Asn Met Val 1090 1095 1100 Val Asp Asp Leu Phe Thr Ile Pro Cys Asp Val Tyr Gly Asp Pro Lys 1105 1110 1115 1120 Pro Val Ile Thr Trp Leu Leu Asp Asp Lys Pro Phe Thr Glu Gly Val 1125 1130 1135 Val Asn Glu Asp Gly Ser Leu Thr Ile Pro Asn Val Asn Glu Ala His 1140 1145 1150 Arg Gly Thr Phe Thr Cys His Ala Gln Asn Ala Ala Gly Asn Asp Thr 1155 1160 1165 Arg Thr Val Thr Leu Thr Val His Thr Thr Pro Thr Ile Asn Ala Glu 1170 1175 1180 Asn Gln Glu Lys Ile Ala Leu Gln Asn Asp Asp Ile Val Leu Glu Cys 1185 1190 1195 1200 Pro Ala Lys Ala Leu Pro Pro Pro Val Arg Leu Trp Thr Tyr Glu Gly 1205 1210 1215 Glu Lys Ile Asp Ser Gln Leu Ile Pro His Thr Ile Arg Glu Asp Gly 1220 1225 1230 Ala Leu Val Leu Gln Asn Val Lys Leu Glu Asn Thr Gly Val Phe Val 1235 1240 1245 Cys Gln Val Ser Asn Leu Ala Gly Glu Asp Ser Leu Ser Tyr Thr Leu 1250 1255 1260 Thr Val His Glu Lys Pro Lys Ile Ile Ser Glu Val Pro Gly Val Val 1265 1270 1275 1280 Asp Val Val Lys Gly Phe Thr Ile Glu Ile Pro Cys Arg Ala Thr Gly 1285 1290 1295 Val Pro Glu Val Ile Arg Thr Trp Asn Lys Asn Gly Ile Asp Leu Lys 1300 1305 1310 Met Asp Glu Lys Lys Phe Ser Val Asp Asn Leu Gly Thr Leu Arg Ile 1315 1320 1325 Tyr Glu Ala Asp Lys Asn Asp Ile Gly Asn Tyr Asn Cys Val Val Thr 1330 1335 1340 Asn Glu Ala Gly Thr Ser Gln Met Thr Thr His Val Asp Val Gln Glu 1345 1350 1355 1360 Pro Pro Ile Ile Leu Pro Ser Thr Gln Thr Asn Asn Thr Ala Val Val 1365 1370 1375 Gly Asp Arg Val Glu Leu Lys Cys Tyr Val Glu Ala Ser Pro Pro Ala 1380 1385 1390 Ser Val Thr Trp Phe Arg Arg Gly Ile Ala Ile Gly Thr Asp Thr Lys 1395 1400 1405 Gly Tyr Val Val Glu Ser Asp Gly Thr Leu Val Ile Gln Ser Ala Ser 1410 1415 1420 Val Glu Asp Ala Thr Ile Tyr Thr Cys Lys Ala Ser Asn Pro Ala Gly 1425 1430 1435 1440 Lys Ala Glu Ala Asn Leu Gln Val Thr Val Ile Ala Ser Pro Asp Ile 1445 1450 1455 Lys Asp Pro Asp Val Val Thr Gln Glu Ser Ile Lys Glu Ser His Pro 1460 1465 1470 Phe Ser Leu Tyr Cys Pro Val Phe Ser Asn Pro Leu Pro Gln Ile Ser 1475 1480 1485 Trp Tyr Leu Asn Asp Lys Pro Leu Ile Asp Asp Lys Thr Ser Trp Lys 1490 1495 1500 Thr Ser Asp Asp Lys Arg Lys Leu His Val Phe Lys Ala Lys Ile Thr 1505 1510 1515 1520 Asp Ser Gly Val Tyr Lys Cys Val Ala Arg Asn Ala Ala Gly Glu Gly 1525 1530 1535 Ser Lys Ser Phe Gln Val Glu Val Ile Val Pro Leu Asn Leu Asp Glu 1540 1545 1550 Ser Lys Tyr Lys Lys Lys Val Phe Ala Lys Glu Gly Glu Glu Val Thr 1555 1560 1565 Leu Gly Cys Pro Val Ser Gly Phe Pro Val Pro Gln Ile Asn Trp Val 1570 1575 1580 Val Asp Gly Thr Val Val Glu Pro Gly Lys Lys Tyr Lys Gly Ala Thr 1585 1590 1595 1600 Leu Ser Asn Asp Gly Leu Thr Leu His Phe Asp Ser Val Ser Val Lys 1605 1610 1615 Gln Glu Gly Asn Tyr His Cys Val Ala Gln Ser Lys Gly Asn Ile Leu 1620 1625 1630 Asp Ile Asp Val Glu Leu Ser Val Leu Ala Val Pro Ile Val Gly Glu 1635 1640 1645 Asp Asp Asn Leu Glu Val Phe Leu Gly Lys Asp Ile Ser Leu Ser Cys 1650 1655 1660 Asp Leu Gln Thr Glu Ser Asp Asp Lys Thr Thr Phe Val Trp Ser Ile 1665 1670 1675 1680 Asn Gly Ser Glu Ser Asp Arg Pro Asp Asn Val Gln Ile Pro Ser Asp 1685 1690 1695 Gly His Arg Leu Tyr Ile Thr Asp Ala Lys Pro Glu Asn Asn Gly Lys 1700 1705 1710 Tyr Met Cys Arg Val Thr Asn Ser Ala Gly Lys Ala Glu Arg Thr Leu 1715 1720 1725 Thr Leu Asp Val Leu Glu Pro Pro Val Phe Val Glu Pro Val Phe Glu 1730 1735 1740 Ala Asn Gln Lys Leu Ile Gly Asn Asn Pro Ile Ile Leu Gln Cys Gln 1745 1750 1755 1760 Val Thr Gly Asn Pro Lys Pro Thr Val Ile Trp Lys Ile Asp Gly Asn 1765 1770 1775 Asp Val Asp Lys Ser Trp Leu Phe Asp Glu Ser Leu Ser Leu Leu Arg 1780 1785 1790 Ile Glu Lys Leu Thr Gly Lys Ser Ala Gln Ile Ser Cys Thr Ala Glu 1795 1800 1805 Asn Lys Ala Gly Thr Ala Ser Arg Asp Phe Phe Ile Gln Asn Ile Ala 1810 1815 1820 Ala Pro Thr Phe Lys Asn Glu Gly Asp Gln Glu Thr Ile Phe Arg Glu 1825 1830 1835 1840 Ser Glu Thr Ile Thr Leu Asp Cys Pro Val Ser Leu Gly Asp Phe Gln 1845 1850 1855 Ile Thr Trp Met Lys Gln Gly Leu Pro Leu Thr Glu Asn Asp Ala Ile 1860 1865 1870 Phe Thr Leu Asp Asn Thr Arg Leu Thr Ile Leu Asn Ala Asn Arg Asp 1875 1880 1885 His Glu Asp Ile Tyr Thr Cys Val Ala Asn Asn Thr Ala Gly Gln Val 1890 1895 1900 Ser Lys Asp Phe Asp Val Val Val Gln Val Leu Pro Lys Ile Lys Asn 1905 1910 1915 1920 Ala Val Val Thr Leu Glu Ile Asn Glu Gly Glu Glu Ile Ile Leu Thr 1925 1930 1935 Cys Asp Ala Glu Gly Asn Pro Thr Pro Thr Ala Lys Trp Asp Phe Asn 1940 1945 1950 Gln Gly Asp Leu Pro Lys Glu Ala Val Phe Val Asn Asn Asn His Thr 1955 1960 1965 Val Val Val Asn Asn Val Thr Lys Tyr His Thr Gly Val Tyr Lys Cys 1970 1975 1980 Tyr Ala Thr Asn Lys Val Gly Gln Ala Val Lys Thr Ile Asn Val His 1985 1990 1995 2000 Val Arg Thr Lys Pro Arg Phe Glu Ser Gly Leu Thr Glu Ser Glu Leu 2005 2010 2015 Thr Val Asn Leu Thr Arg Ser Ile Thr Leu Glu Cys Asp Val Asp Asp 2020 2025 2030 Ala Ile Gly Val Gly Ile Ser Trp Thr Val Asn Gly Lys Pro Phe Leu 2035 2040 2045 Ala Glu Thr Asp Gly Val Gln Thr Leu Ala Gly Gly Arg Phe Leu His 2050 2055 2060 Ile Val Ser Ala Lys Thr Asp Asp His Gly Ser Tyr Ala Cys Thr Val 2065 2070 2075 2080 Thr Asn Glu Ala Gly Val Ala Thr Lys Thr Phe Asn Leu Phe Val Gln 2085 2090 2095 Val Pro Pro Thr Ile Val Asn Glu Gly Gly Glu Tyr Thr Val Ile Glu 2100 2105 2110 Asn Asn Ser Leu Val Leu Pro Cys Glu Val Thr Gly Lys Pro Asn Pro 2115 2120 2125 Val Val Thr Trp Thr Lys Asp Gly Arg Pro Val Gly Asp Leu Lys Ser 2130 2135 2140 Val Gln Val Leu Ser Glu Gly Gln Gln Phe Lys Ile Val His Ala Glu 2145 2150 2155 2160 Ile Ala His Lys Gly Ser Tyr Ile Cys Met Ala Lys Asn Asp Val Gly 2165 2170 2175 Thr Ala Glu Ile Ser Phe Asp Val Asp Ile Ile Thr Arg Pro Met Ile 2180 2185 2190 Gln Lys Gly Ile Lys Asn Ile Val Thr Ala Ile Lys Gly Gly Ala Leu 2195 2200 2205 Pro Phe Lys Cys Pro Ile Asp Asp Asp Lys Asn Phe Lys Gly Gln Ile 2210 2215 2220 Ile Trp Leu Arg Asn Tyr Gln Pro Ile Asp Leu Glu Ala Glu Asp Ala 2225 2230 2235 2240 Arg Ile Thr Arg Leu Ser Asn Asp Arg Arg Leu Thr Ile Leu Asn Val 2245 2250 2255 Thr Glu Asn Asp Glu Gly Gln Tyr Ser Cys Arg Val Lys Asn Asp Ala 2260 2265 2270 Gly Glu Asn Ser Phe Asp Phe Lys Ala Thr Val Leu Val Pro Pro Thr 2275 2280 2285 Ile Ile Met Leu Asp Lys Asp Lys Asn Lys Thr Ala Val Glu His Ser 2290 2295 2300 Thr Val Thr Leu Ser Cys Pro Ala Thr Gly Lys Pro Glu Pro Asp Ile 2305 2310 2315 2320 Thr Trp Phe Lys Asp Gly Glu Ala Ile His Ile Glu Asn Ile Ala Asp 2325 2330 2335 Ile Ile Pro Asn Gly Glu Leu Asn Gly Asn Gln Leu Lys Ile Thr Arg 2340 2345 2350 Ile Lys Glu Gly Asp Ala Gly Lys Tyr Thr Cys Glu Ala Asp Asn Ser 2355 2360 2365 Ala Gly Ser Val Glu Gln Asp Val Asn Val Asn Val Ile Thr Ile Pro 2370 2375 2380 Lys Ile Glu Lys Asp Gly Ile Pro Ser Asp Tyr Glu Ser Gln Gln Asn 2385 2390 2395 2400 Glu Arg Val Val Ile Ser Cys Pro Val Tyr Ala Arg Pro Pro Ala Lys 2405 2410 2415 Ile Thr Trp Leu Lys Ala Gly Lys Pro Leu Gln Ser Asp Lys Phe Val 2420 2425 2430 Lys Thr Ser Ala Asn Gly Gln Lys Leu Tyr Leu Phe Lys Leu Arg Glu 2435 2440 2445 Thr Asp Ser Ser Lys Tyr Thr Cys Ile Ala Thr Asn Glu Ala Gly Thr 2450 2455 2460 Asp Lys Arg Asp Phe Lys Val Ser Met Leu Val Ala Pro Ser Phe Asp 2465 2470 2475 2480 Glu Pro Asn Ile Val Arg Arg Ile Thr Val Asn Ser Gly Asn Pro Ser 2485 2490 2495 Thr Leu His Cys Pro Ala Lys Gly Ser Pro Ser Pro Thr Ile Thr Trp 2500 2505 2510 Leu Lys Asp Gly Asn Ala Ile Glu Pro Asn Asp Arg Tyr Val Phe Phe 2515 2520 2525 Asp Ala Gly Arg Gln Leu Gln Ile Ser Lys Thr Glu Gly Ser Asp Gln 2530 2535 2540 Gly Arg Tyr Thr Cys Ile Ala Thr Asn Ser Val Gly Ser Asp Asp Leu 2545 2550 2555 2560 Glu Asn Thr Leu Glu Val Ile Ile Pro Pro Val Ile Asp Gly Glu Arg 2565 2570 2575 Arg Glu Ala Val Ala Val Ile Glu Gly Phe Ser Ser Glu Leu Phe Cys 2580 2585 2590 Asp Ser Asn Ser Thr Gly Val Asp Val Glu Trp Gln Lys Asp Gly Leu 2595 2600 2605 Thr Ile Asn Gln Asp Thr Leu Arg Gly Asp Ser Phe Ile Gln Ile Pro 2610 2615 2620 Ser Ser Gly Lys Lys Met Ser Phe Leu Ser Ala Arg Lys Ser Asp Ser 2625 2630 2635 2640 Gly Arg Tyr Thr Cys Ile Val Arg Asn Pro Ala Gly Glu Ala Arg Lys 2645 2650 2655 Leu Phe Asp Phe Ala Val Asn Asp Pro Pro Ser Ile Ser Asp Glu Leu 2660 2665 2670 Ser Ser Ala Asn Ile Gln Thr Ile Val Pro Tyr Tyr Pro Val Glu Ile 2675 2680 2685 Asn Cys Val Val Ser Gly Ser Pro His Pro Lys Val Tyr Trp Leu Phe 2690 2695 2700 Asp Asp Lys Pro Leu Glu Pro Asp Ser Ala Ala Tyr Glu Leu Thr Asn 2705 2710 2715 2720 Asn Gly Glu Thr Leu Lys Ile Val Arg Ser Gln Val Glu His Ala Gly 2725 2730 2735 Thr Tyr Thr Cys Glu Ala Gln Asn Asn Val Gly Lys Ala Arg Lys Asp 2740 2745 2750 Phe Leu Val Arg Val Thr Ala Pro Pro His Phe Glu Lys Glu Arg Glu 2755 2760 2765 Glu Val Val Ala Arg Val Gly Asp Thr Met Leu Leu Thr Cys Asn Ala 2770 2775 2780 Glu Ser Ser Val Pro Leu Ser Ser Val Tyr Trp His Ala His Asp Glu 2785 2790 2795 2800 Ser Val Gln Asn Gly Val Ile Thr Ser Lys Tyr Ala Ala Asn Glu Lys 2805 2810 2815 Thr Leu Asn Val Thr Asn Ile Gln Leu Asp Asp Glu Gly Phe Tyr Tyr 2820 2825 2830 Cys Thr Ala Val Asn Glu Ala Gly Ile Thr Lys Lys Phe Phe Lys Leu 2835 2840 2845 Ile Val Ile Glu Thr Pro Tyr Phe Leu Asp Gln Gln Lys Leu Tyr Pro 2850 2855 2860 Ile Ile Leu Gly Lys Arg Leu Thr Leu Asp Cys Ser Ala Thr Gly Thr 2865 2870 2875 2880 Pro Pro Pro Thr Ile Leu Phe Met Lys Asp Gly Lys Arg Leu Asn Glu 2885 2890 2895 Ser Asp Glu Val Asp Ile Ile Gly Ser Thr Leu Val Ile Asp Asn Pro 2900 2905 2910 Gln Lys Glu Val Glu Gly Arg Tyr Thr Cys Ile Ala Glu Asn Lys Ala 2915 2920 2925 Gly Arg Ser Glu Lys Asp Met Met Val Glu Val Leu Leu Pro Pro Lys 2930 2935 2940 Leu Ser Lys Glu Trp Ile Asn Val Glu Val Gln Ala Gly Asp Pro Leu 2945 2950 2955 2960 Thr Leu Glu Cys Pro Ile Glu Asp Thr Ser Gly Val His Ile Thr Trp 2965 2970 2975 Ser Arg Gln Phe Gly Lys Asp Gly Gln Leu Asp Met Arg Ala Gln Ser 2980 2985 2990 Ser Ser Asp Lys Ser Lys Leu Tyr Ile Met Gln Ala Thr Pro Glu Asp 2995 3000 3005 Ala Asp Ser Tyr Ser Cys Ile Ala Val Asn Asp Ala Gly Gly Ala Glu 3010 3015 3020 Ala Val Phe Gln Val Thr Val Asn Thr Pro Pro Lys Ile Phe Gly Asp 3025 3030 3035 3040 Ser Phe Ser Thr Thr Glu Ile Val Ala Asp Thr Thr Leu Glu Ile Pro 3045 3050 3055 Cys Arg Thr Glu Gly Ile Pro Pro Pro Glu Ile Ser Trp Phe Leu Asp 3060 3065 3070 Gly Lys Pro Ile Leu Glu Met Pro Gly Val Thr Tyr Lys Gln Gly Asp 3075 3080 3085 Leu Ser Leu Arg Ile Asp Asn Ile Lys Pro Asn Gln Glu Gly Arg Tyr 3090 3095 3100 Thr Cys Val Ala Glu Asn Lys Ala Gly Arg Ala Glu Gln Asp Thr Tyr 3105 3110 3115 3120 Val Glu Ile Ser Glu Pro Pro Arg Val Val Met Ala Ser Glu Val Met 3125 3130 3135 Arg Val Val Glu Gly Arg Gln Thr Thr Ile Arg Cys Glu Val Phe Gly 3140 3145 3150 Asn Pro Glu Pro Val Val Asn Trp Leu Lys Asp Gly Glu Pro Tyr Thr 3155 3160 3165 Ser Asp Leu Leu Gln Phe Ser Thr Lys Leu Ser Tyr Leu His Leu Arg 3170 3175 3180 Glu Thr Thr Leu Ala Asp Gly Gly Thr Tyr Thr Cys Ile Ala Thr Asn 3185 3190 3195 3200 Lys Ala Gly Glu Ser Gln Thr Thr Thr Asp Val Glu Val Leu Val Pro 3205 3210 3215 Pro Arg Ile Glu Asp Glu Glu Arg Val Leu Gln Gly Lys Glu Gly Asn 3220 3225 3230 Thr Tyr Met Val His Cys Gln Val Thr Gly Arg Pro Val Pro Tyr Val 3235 3240 3245 Thr Trp Lys Arg Asn Gly Lys Glu Ile Glu Gln Phe Asn Pro Val Leu 3250 3255 3260 His Ile Arg Asn Ala Thr Arg Ala Asp Glu Gly Lys Tyr Ser Cys Ile 3265 3270 3275 3280 Ala Ser Asn Glu Ala Gly Thr Ala Val Ala Asp Phe Leu Ile Asp Val 3285 3290 3295 Phe Thr Lys Pro Thr Phe Glu Thr His Glu Thr Thr Phe Asn Ile Val 3300 3305 3310 Glu Gly Glu Ser Ala Lys Ile Glu Cys Lys Ile Asp Gly His Pro Lys 3315 3320 3325 Pro Thr Ile Ser Trp Leu Lys Gly Gly Arg Pro Phe Asn Met Asp Asn 3330 3335 3340 Ile Ile Leu Ser Pro Arg Gly Asp Thr Leu Met Ile Leu Lys Ala Gln 3345 3350 3355 3360 Arg Phe Asp Gly Gly Leu Tyr Thr Cys Val Ala Thr Asn Ser Tyr Gly 3365 3370 3375 Asp Ser Glu Gln Asp Phe Lys Val Asn Val Tyr Thr Lys Pro Tyr Ile 3380 3385 3390 Asp Glu Thr Ile Asp Gln Thr Pro Lys Ala Val Ala Gly Gly Glu Ile 3395 3400 3405 Ile Leu Lys Cys Pro Val Leu Gly Asn Pro Thr Pro Thr Val Thr Trp 3410 3415 3420 Lys Arg Gly Asp Asp Ala Val Pro Asn Asp Ser Arg His Thr Ile Val 3425 3430 3435 3440 Asn Asn Tyr Asp Leu Lys Ile Asn Ser Val Thr Thr Glu Asp Ala Gly 3445 3450 3455 Gln Tyr Ser Cys Ile Ala Val Asn Glu Ala Gly Asn Leu Thr Thr His 3460 3465 3470 Tyr Ala Ala Glu Val Ile Gly Lys Pro Thr Phe Val Arg Lys Gly Gly 3475 3480 3485 Asn Leu Tyr Glu Val Ile Glu Asn Asp Thr Ile Thr Met Asp Cys Gly 3490 3495 3500 Val Thr Ser Arg Pro Leu Pro Ser Ile Ser Trp Phe Arg Gly Asp Lys 3505 3510 3515 3520 Pro Val Tyr Leu Tyr Asp Arg Tyr Ser Ile Ser Pro Asp Gly Ser His 3525 3530 3535 Ile Thr Ile Asn Lys Ala Lys Leu Ser Asp Gly Gly Lys Tyr Ile Cys 3540 3545 3550 Arg Ala Ser Asn Glu Ala Gly Thr Ser Asp Ile Asp Leu Ile Leu Lys 3555 3560 3565 Ile Leu Val Pro Pro Lys Ile Asp Lys Ser Asn Ile Ile Gly Asn Pro 3570 3575 3580 Leu Ala Ile Val Ala Arg Thr Ile Tyr Leu Glu Cys Pro Ile Ser Gly 3585 3590 3595 3600 Ile Pro Gln Pro Asp Val Ile Trp Thr Lys Asn Gly Met Asp Ile Asn 3605 3610 3615 Met Thr Asp Ser Arg Val Ile Leu Ala Gln Asn Asn Glu Thr Phe Gly 3620 3625 3630 Ile Glu Asn Val Gln Val Thr Asp Gln Gly Arg Tyr Thr Cys Thr Ala 3635 3640 3645 Thr Asn Arg Gly Gly Lys Ala Ser His Asp Phe Ser Leu Asp Val Leu 3650 3655 3660 Ser Pro Pro Glu Phe Asp Ile His Gly Thr Gln Pro Thr Ile Lys Arg 3665 3670 3675 3680 Glu Gly Asp Thr Ile Thr Leu Thr Cys Pro Ile Lys Leu Ala Glu Asp 3685 3690 3695 Ile Ala Asp Gln Val Met Asp Val Ser Trp Thr Lys Asp Ser Arg Ala 3700 3705 3710 Leu Asp Gly Asp Leu Thr Asp Asn Val Asp Ile Ser Asp Asp Gly Arg 3715 3720 3725 Lys Leu Thr Ile Ser Gln Ala Ser Leu Glu Asn Ala Gly Leu Tyr Thr 3730 3735 3740 Cys Ile Ala Leu Asn Arg Ala Gly Glu Ala Ser Leu Glu Phe Lys Val 3745 3750 3755 3760 Glu Ile Leu Ser Pro Pro Val Ile Asp Ile Ser Arg Asn Asp Val Gln 3765 3770 3775 Pro Gln Val Ala Val Asn Gln Pro Thr Ile Met Arg Cys Ala Val Thr 3780 3785 3790 Gly His Pro Phe Pro Ser Ile Lys Trp Leu Lys Asn Gly Lys Glu Val 3795 3800 3805 Thr Asp Asp Glu Asn Ile Arg Ile Val Glu Gln Gly Gln Val Leu Gln 3810 3815 3820 Ile Leu Arg Thr Asp Ser Asp His Ala Gly Lys Trp Ser Cys Val Ala 3825 3830 3835 3840 Glu Asn Asp Ala Gly Val Lys Glu Leu Glu Met Val Leu Asp Val Phe 3845 3850 3855 Thr Pro Pro Val Val Ser Val Lys Ser Asp Asn Pro Ile Lys Ala Leu 3860 3865 3870 Gly Glu Thr Ile Thr Leu Phe Cys Asn Ala Ser Gly Asn Pro Tyr Pro 3875 3880 3885 Gln Leu Lys Trp Ala Lys Gly Gly Ser Leu Ile Phe Asp Ser Pro Asp 3890 3895 3900 Gly Ala Arg Ile Ser Leu Lys Gly Ala Arg Leu Asp Ile Pro His Leu 3905 3910 3915 3920 Lys Lys Thr Asp Val Gly Asp Tyr Thr Cys Gln Ala Leu Asn Ala Ala 3925 3930 3935 Gly Thr Ser Glu Ala Ser Val Ser Val Asp Val Leu Val Pro Pro Glu 3940 3945 3950 Ile Asn Arg Asp Gly Ile Asp Met Ser Pro Arg Leu Pro Ala Gln Gln 3955 3960 3965 Ser Leu Thr Leu Gln Cys Leu Ala Gln Gly Lys Pro Val Pro Gln Met 3970 3975 3980 Arg Trp Thr Leu Asn Gly Thr Ala Leu Thr His Ser Thr Pro Gly Ile 3985 3990 3995 4000 Thr Val Ala Ser Asp Ser Thr Phe Ile Gln Ile Asn Asn Val Ser Leu 4005 4010 4015 Ser Asp Lys Gly Val Tyr Thr Cys Tyr Ala Glu Asn Val Ala Gly Ser 4020 4025 4030 Asp Asn Leu Met Tyr Asn Val Asp Val Val Gln Ala Pro Val Ile Ser 4035 4040 4045 Asn Gly Gly Thr Lys Gln Val Ile Glu Gly Glu Leu Ala Val Ile Glu 4050 4055 4060 Cys Leu Val Glu Gly Tyr Pro Ala Pro Gln Val Ser Trp Leu Arg Asn 4065 4070 4075 4080 Gly Asn Arg Val Glu Thr Gly Val Gln Gly Val Arg Tyr Val Thr Asp 4085 4090 4095 Gly Arg Met Leu Thr Ile Ile Glu Ala Arg Ser Leu Asp Ser Gly Ile 4100 4105 4110 Tyr Leu Cys Ser Ala Thr Asn Glu Ala Gly Ser Ala Gln Gln Ala Tyr 4115 4120 4125 Thr Leu Glu Val Leu Val Ser Pro Lys Ile Ile Thr Ser Thr Pro Gly 4130 4135 4140 Val Leu Thr Pro Ser Ser Gly Ser Lys Phe Ser Leu Pro Cys Ala Val 4145 4150 4155 4160 Arg Gly Tyr Pro Asp Pro Ile Ile Ser Trp Thr Leu Asn Gly Asn Asp 4165 4170 4175 Ile Lys Asp Gly Glu Asn Gly His Thr Ile Gly Ala Asp Gly Thr Leu 4180 4185 4190 His Ile Glu Lys Ala Glu Glu Arg His Leu Ile Tyr Glu Cys Thr Ala 4195 4200 4205 Lys Asn Asp Ala Gly Ala Asp Thr Leu Glu Phe Pro Val Gln Thr Ile 4210 4215 4220 Val Ala Pro Lys Ile Ser Thr Ser Gly Asn Arg Tyr Ile Asn Gly Ser 4225 4230 4235 4240 Glu Gly Thr Glu Thr Val Ile Lys Cys Glu Ile Glu Ser Glu Ser Ser 4245 4250 4255 Glu Phe Ser Trp Ser Lys Asn Gly Val Pro Leu Leu Pro Ser Asn Asn 4260 4265 4270 Leu Ile Phe Ser Glu Asp Tyr Lys Leu Ile Lys Ile Leu Ser Thr Arg 4275 4280 4285 Leu Ser Asp Gln Gly Glu Tyr Ser Cys Thr Ala Ala Asn Lys Ala Gly 4290 4295 4300 Asn Ala Thr Gln Lys Thr Asn Leu Asn Val Gly Val Ala Pro Lys Ile 4305 4310 4315 4320 Met Glu Arg Pro Arg Thr Gln Val Val His Lys Gly Asp Gln Val Thr 4325 4330 4335 Leu Trp Cys Glu Ala Ser Gly Val Pro Gln Pro Ala Ile Thr Trp Tyr 4340 4345 4350 Lys Asp Asn Glu Leu Leu Thr Asn Thr Gly Val Asp Glu Thr Ala Thr 4355 4360 4365 Thr Lys Lys Lys Ser Val Ile Phe Ser Ser Ile Ser Pro Ser Gln Ala 4370 4375 4380 Gly Val Tyr Thr Cys Lys Ala Glu Asn Trp Val Ala Ser Thr Glu Glu 4385 4390 4395 4400 Asp Ile Asp Leu Ile Val Met Ile Pro Pro Glu Val Val Pro Glu Arg 4405 4410 4415 Met Asn Val Ser Thr Asn Pro Arg Gln Thr Val Phe Leu Ser Cys Asn 4420 4425 4430 Ala Thr Gly Ile Pro Glu Pro Val Ile Ser Trp Met Arg Asp Ser Asn 4435 4440 4445 Ile Ala Ile Gln Asn Asn Glu Lys Tyr Gln Ile Leu Gly Thr Thr Leu 4450 4455 4460 Ala Ile Arg Asn Val Leu Pro Asp Asp Asp Gly Phe Tyr His Cys Ile 4465 4470 4475 4480 Ala Lys Ser Asp Ala Gly Gln Lys Ile Ala Thr Arg Lys Leu Ile Val 4485 4490 4495 Asn Lys Pro Ser Asp Arg Pro Ala Pro Ile Trp Val Glu Cys Asp Glu 4500 4505 4510 Lys Gly Lys Pro Lys Lys Thr Glu Tyr Met Ile Asp Arg Gly Asp Thr 4515 4520 4525 Pro Asp Asp Asn Pro Gln Leu Leu Pro Trp Lys Asp Val Glu Asp Ser 4530 4535 4540 Ser Leu Asn Gly Ser Ile Ala Tyr Arg Cys Met Pro Gly Pro Arg Ser 4545 4550 4555 4560 Ser Arg Thr Val Leu Leu His Ala Ala Pro Gln Phe Ile Val Lys Pro 4565 4570 4575 Lys Asn Thr Thr Ala Ala Ile Gly Ala Ile Val Glu Leu Arg Cys Ser 4580 4585 4590 Ala Ala Gly Pro Pro His Pro Thr Ile Thr Trp Ala Lys Asp Gly Lys 4595 4600 4605 Leu Ile Glu Asp Ser Lys Phe Glu Ile Ala Tyr Ser His Leu Lys Val 4610 4615 4620 Thr Leu Asn Ser Thr Ser Asp Ser Gly Glu Tyr Thr Cys Met Ala Gln 4625 4630 4635 4640 Asn Ser Val Gly Ser Ser Thr Val Ser Ala Phe Ile Asn Val Asp Asn 4645 4650 4655 Asn Ile Leu Pro Thr Pro Lys Pro Ser Ser Asn Gln Lys Asn Val Ala 4660 4665 4670 Val Ile Thr Cys Tyr Glu Arg Asn Gln Ala Tyr Ser Arg Gly Leu Thr 4675 4680 4685 Trp Glu Tyr Asn Gly Val Pro Met Pro Lys Asn Leu Ala Gly Ile His 4690 4695 4700 Phe Met Asn Asn Gly Ser Leu Val Ile Leu Asp Thr Ser Ser Leu Lys 4705 4710 4715 4720 Glu Gly Asp Leu Glu Leu Tyr Thr Cys Lys Val Arg Asn Arg Arg Arg 4725 4730 4735 His Ser Ile Pro His Leu Thr Ser Ala Phe Glu Gly Val Pro Glu Val 4740 4745 4750 Lys Thr Ile Asp Lys Val Glu Val Asn Asn Gly Asp Ser Val Val Leu 4755 4760 4765 Asp Cys Glu Val Thr Ser Asp Pro Leu Thr Thr His Val Val Trp Thr 4770 4775 4780 Lys Asn Asp Gln Lys Met Leu Asp Asp Asp Ala Ile Tyr Val Leu Pro 4785 4790 4795 4800 Asn Asn Ser Leu Val Leu Leu Asn Val Glu Lys Tyr Asp Glu Gly Val 4805 4810 4815 Tyr Lys Cys Val Ala Ser Asn Ser Ile Gly Lys Ala Phe Asp Asp Thr 4820 4825 4830 Gln Leu Asn Val Tyr Glu Gly Asp Phe Leu Pro Leu Thr Gly Phe Glu 4835 4840 4845 Gly Ser Gly Ile Asn Ile Asp Asp Ser Ser Asn Ala Gly Gly Ser Ser 4850 4855 4860 Arg Arg Glu Ala Tyr Lys Lys Glu Asn Glu Asp Ala Ser Thr Thr Thr 4865 4870 4875 4880 Ile Thr Thr Thr Ser Pro Thr Thr Thr Thr Thr Glu Thr Pro Leu Thr 4885 4890 4895 Thr Thr Ile Ile Pro Ala Leu Ile Thr Leu Pro Ala Lys Gln Tyr Pro 4900 4905 4910 Thr Asp Asp Tyr His Glu Gly Ser Ala Asn Asp Asp Gly Phe Gly Pro 4915 4920 4925 Thr Thr Gln Asp Ser Leu Phe Glu Phe Asn Pro Pro Leu His Pro Glu 4930 4935 4940 Ile Ser Val Val Asn Thr Asp Cys Ala Gly Thr Ile Asn Glu Asn Gly 4945 4950 4955 4960 Asp Cys Val Asp Lys Asp Gly Lys Thr His Asn Leu Lys Ile Leu Thr 4965 4970 4975 Gly Glu Asn His Cys Pro Glu Gly Phe Ala Met Asn Pro His Thr Arg 4980 4985 4990 Ile Cys Glu Asp Leu Asp Glu Cys Ala Phe Tyr Gln Pro Cys Asp Phe 4995 5000 5005 Glu Cys Ile Asn Tyr Asp Gly Gly Phe Gln Cys Asn Cys Pro Leu Gly 5010 5015 5020 Tyr Glu Leu Ala Glu Glu Gly Cys Arg Asp Val Asn Glu Cys Glu Ser 5025 5030 5035 5040 Val Arg Cys Glu Asp Gly Lys Ala Cys Phe Asn Gln Leu Gly Gly Tyr 5045 5050 5055 Glu Cys Ile Asp Asp Pro Cys Pro Ala Asn Tyr Ser Leu Val Asp Asp 5060 5065 5070 Arg Tyr Cys Glu Pro Glu Cys Glu Asn Cys Thr Ser Thr Pro Ile Gln 5075 5080 5085 Val His Met Leu Ala Ile Pro Ser Gly Leu Pro Ile Ser His Ile Ala 5090 5095 5100 Thr Leu Thr Ala Tyr Asp Lys Ser Gly Arg Val Leu Asn Asp Thr Thr 5105 5110 5115 5120 Tyr Ala Ile Ser Asp Thr Gly Ala Pro Leu Ala Arg Gly Arg Met Thr 5125 5130 5135 Ser Gly Pro Phe Thr Ile Lys Ala Val Lys Arg Gly His Ala Gln Val 5140 5145 5150 Trp Thr Asn Arg Val Leu Ala Ala Gly Asp His His Lys Val Arg Val 5155 5160 5165 Arg Ala His Ser Asp His Ala Thr Asn Glu Leu His Ala Pro Lys Glu 5170 5175 5180 Thr Asn Phe Leu Val Leu Ile Asn Val Gly Gln Tyr Pro Phe 5185 5190 5195 35 182 PRT Homo sapiens 35 Gly Asn Val Asp Leu Val Phe Leu Phe Asp Gly Ser Met Ser Leu Gln 1 5 10 15 Pro Asp Glu Phe Gln Lys Ile Leu Asp Phe Met Lys Asp Val Met Lys 20 25 30 Lys Leu Ser Asn Thr Ser Tyr Gln Phe Ala Ala Val Gln Phe Ser Thr 35 40 45 Ser Tyr Lys Thr Glu Phe Asp Phe Ser Asp Tyr Val Lys Trp Lys Asp 50 55 60 Pro Asp Ala Leu Leu Lys His Val Lys His Met Leu Leu Leu Thr Asn 65 70 75 80 Thr Phe Gly Ala Ile Asn Tyr Val Ala Thr Glu Val Phe Arg Glu Glu 85 90 95 Leu Gly Ala Arg Pro Asp Ala Thr Lys Val Leu Ile Ile Ile Thr Asp 100 105 110 Gly Glu Ala Thr Asp Ser Gly Asn Ile Asp Ala Ala Lys Asp Ile Ile 115 120 125 Arg Tyr Ile Ile Gly Ile Gly Lys His Phe Gln Thr Lys Glu Ser Gln 130 135 140 Glu Thr Leu His Lys Phe Ala Ser Lys Pro Ala Ser Glu Phe Val Lys 145 150 155 160 Ile Leu Asp Thr Phe Glu Lys Leu Lys Asp Leu Phe Thr Glu Leu Gln 165 170 175 Lys Lys Ile Tyr Val Ile 180 36 182 PRT Homo sapiens 36 Gly Asn Val Asp Leu Val Phe Leu Phe Asp Gly Ser Met Ser Leu Gln 1 5 10 15 Pro Asp Glu Phe Gln Lys Ile Leu Asp Phe Met Lys Asp Val Met Lys 20 25 30 Lys Leu Ser Asn Thr Ser Tyr Gln Phe Ala Ala Val Gln Phe Ser Thr 35 40 45 Ser Tyr Lys Thr Glu Phe Asp Phe Ser Asp Tyr Val Lys Trp Lys Asp 50 55 60 Pro Asp Ala Leu Leu Lys His Val Lys His Met Leu Leu Leu Thr Asn 65 70 75 80 Thr Phe Gly Ala Ile Asn Tyr Val Ala Thr Glu Val Phe Arg Glu Glu 85 90 95 Leu Gly Ala Arg Pro Asp Ala Thr Lys Val Leu Ile Ile Ile Thr Asp 100 105 110 Gly Glu Ala Thr Asp Ser Gly Asn Ile Asp Ala Ala Lys Asp Ile Ile 115 120 125 Arg Tyr Ile Ile Gly Ile Gly Lys His Phe Gln Thr Lys Glu Ser Gln 130 135 140 Glu Thr Leu His Lys Phe Ala Ser Lys Pro Ala Ser Glu Phe Val Lys 145 150 155 160 Ile Leu Asp Thr Phe Glu Lys Leu Lys Asp Leu Phe Thr Glu Leu Gln 165 170 175 Lys Lys Ile Tyr Val Ile 180 37 187 PRT Homo sapiens 37 Asp Ser Asp Ile Ala Phe Leu Ile Asp Gly Ser Gly Ser Ile Ile Pro 1 5 10 15 His Asp Phe Arg Arg Met Lys Glu Phe Val Ser Thr Val Met Glu Gln 20 25 30 Leu Lys Lys Ser Lys Thr Leu Phe Ser Leu Met Gln Tyr Ser Glu Glu 35 40 45 Phe Arg Ile His Phe Thr Phe Lys Glu Phe Gln Asn Asn Pro Asn Pro 50 55 60 Arg Ser Leu Val Lys Pro Ile Thr Gln Leu Leu Gly Arg Thr His Thr 65 70 75 80 Ala Thr Gly Ile Arg Lys Val Val Arg Glu Leu Phe Asn Ile Thr Asn 85 90 95 Gly Ala Arg Lys Asn Ala Phe Lys Ile Leu Val Val Ile Thr Asp Gly 100 105 110 Glu Lys Phe Gly Asp Pro Leu Gly Tyr Glu Asp Val Ile Pro Glu Ala 115 120 125 Asp Arg Glu Gly Val Ile Arg Tyr Val Ile Gly Val Gly Asp Ala Phe 130 135 140 Arg Ser Glu Lys Ser Arg Gln Glu Leu Asn Thr Ile Ala Ser Lys Pro 145 150 155 160 Pro Arg Asp His Val Phe Gln Val Asn Asn Phe Glu Ala Leu Lys Thr 165 170 175 Ile Gln Asn Gln Leu Arg Glu Lys Ile Phe Ala 180 185 38 10 DNA Artificial Sequence Description of Artificial Sequence SAGE library tag 38 gaggatggac 10 39 10 DNA Artificial Sequence Description of Artificial Sequence SAGE library tag 39 ctgcccgtgg 10 40 180 PRT Unknown Organism Description of Unknown Organism VWA domain peptide 40 Asp Ile Val Phe Leu Leu Asp Gly Ser Gly Ser Ile Gly Ser Gln Asn 1 5 10 15 Phe Glu Arg Val Lys Asp Phe Val Glu Arg Val Val Glu Arg Leu Asp 20 25 30 Val Gly Pro Arg Asp Lys Lys Glu Glu Asp Ala Val Arg Val Gly Leu 35 40 45 Val Gln Tyr Ser Asp Asn Val Arg Thr Glu Ile Lys Phe Lys Leu Asn 50 55 60 Asp Tyr Gln Asn Lys Asp Glu Val Leu Gln Ala Leu Gln Lys Ile Arg 65 70 75 80 Tyr Glu Asp Tyr Tyr Gly Gly Gly Gly Thr Asn Thr Gly Ala Ala Leu 85 90 95 Gln Tyr Val Val Arg Asn Leu Phe Thr Glu Ala Ser Gly Ser Arg Ile 100 105 110 Glu Pro Val Ala Glu Glu Gly Ala Pro Lys Val Leu Val Val Leu Thr 115 120 125 Asp Gly Arg Ser Gln Asp Asp Pro Ser Pro Thr Ile Asp Ile Arg Asp 130 135 140 Val Leu Asn Glu Leu Lys Lys Glu Ala Gly Val Glu Val Phe Ala Ile 145 150 155 160 Gly Val Gly Asn Ala Asp Asn Asn Asn Leu Glu Glu Leu Arg Glu Ile 165 170 175 Ala Ser Lys Pro 180 41 183 PRT Homo sapiens 41 Gly Asn Val Asp Leu Val Phe Leu Phe Asp Gly Ser Met Ser Leu Gln 1 5 10 15 Pro Asp Glu Phe Gln Lys Ile Leu Asp Phe Met Lys Asp Val Met Lys 20 25 30 Lys Leu Ser Asn Thr Ser Tyr Gln Phe Ala Ala Val Gln Phe Ser Thr 35 40 45 Ser Tyr Lys Thr Glu Phe Asp Phe Ser Asp Tyr Val Lys Arg Lys Asp 50 55 60 Pro Asp Ala Leu Leu Lys His Val Lys His Met Leu Leu Leu Thr Asn 65 70 75 80 Thr Phe Gly Ala Ile Asn Tyr Val Ala Thr Glu Val Phe Arg Glu Glu 85 90 95 Leu Gly Ala Arg Pro Asp Ala Thr Lys Val Leu Ile Ile Ile Thr Asp 100 105 110 Gly Glu Ala Thr Asp Ser Gly Asn Ile Asp Ala Ala Lys Asp Ile Ile 115 120 125 Arg Tyr Ile Ile Gly Ile Gly Lys His Phe Gln Thr Lys Glu Ser Gln 130 135 140 Glu Thr Leu His Lys Phe Ala Ser Lys Pro Ala Ser Glu Phe Val Lys 145 150 155 160 Ile Leu Asp Thr Phe Glu Lys Leu Lys Asp Leu Phe Thr Glu Leu Gln 165 170 175 Lys Lys Ile Tyr Val Ile Glu 180 42 190 PRT Homo sapiens MOD_RES (1) Variable amino acid 42 Xaa Ser Asp Ile Ala Phe Leu Ile Asp Gly Ser Gly Ser Ile Ile Pro 1 5 10 15 His Asp Phe Arg Arg Met Lys Glu Phe Val Ser Thr Val Met Glu Gln 20 25 30 Leu Lys Lys Ser Lys Thr Leu Phe Ser Leu Met Gln Tyr Ser Glu Glu 35 40 45 Phe Arg Ile His Phe Thr Phe Lys Glu Phe Gln Asn Asn Pro Asn Pro 50 55 60 Arg Ser Leu Val Lys Pro Ile Thr Gln Leu Leu Gly Arg Thr His Thr 65 70 75 80 Ala Thr Gly Ile Arg Lys Val Val Arg Glu Leu Phe Asn Ile Thr Asn 85 90 95 Gly Ala Arg Lys Asn Ala Phe Lys Ile Leu Val Val Ile Thr Asp Gly 100 105 110 Glu Lys Phe Gly Asp Pro Leu Gly Tyr Glu Asp Val Ile Pro Glu Ala 115 120 125 Asp Arg Glu Gly Val Ile Arg Tyr Val Ile Gly Val Gly Asp Ala Phe 130 135 140 Arg Ser Glu Lys Ser Arg Gln Glu Leu Asn Thr Ile Ala Ser Lys Pro 145 150 155 160 Pro Arg Asp His Val Phe Gln Val Asn Asn Phe Glu Ala Leu Lys Thr 165 170 175 Ile Gln Asn Gln Leu Arg Glu Lys Ile Phe Ala Ile Glu Gly 180 185 190 43 178 PRT Unknown Organism Description of Unknown Organism VWA domain peptide 43 Pro Leu Asp Val Val Phe Leu Leu Asp Gly Ser Gly Ser Met Gly Gly 1 5 10 15 Asn Arg Phe Glu Leu Ala Lys Glu Phe Val Leu Lys Leu Val Glu Gln 20 25 30 Leu Asp Ile Gly Pro Arg Gly Asp Arg Val Gly Leu Val Thr Phe Ser 35 40 45 Ser Asp Ala Arg Val Leu Phe Pro Leu Asn Asp Ser Gln Ser Lys Asp 50 55 60 Ala Leu Leu Glu Ala Leu Ala Asn Leu Ser Tyr Ser Leu Gly Gly Gly 65 70 75 80 Thr Asn Leu Gly Ala Ala Leu Glu Tyr Ala Leu Glu Asn Leu Phe Ser 85 90 95 Glu Ser Ala Gly Ser Arg Arg Gly Ala Pro Lys Val Leu Ile Leu Ile 100 105 110 Thr Asp Gly Glu Ser Asn Asp Gly Gly Glu Asp Ile Leu Lys Ala Ala 115 120 125 Lys Glu Leu Lys Arg Ser Gly Val Lys Val Phe Val Val Gly Val Gly 130 135 140 Asn Ala Val Asp Glu Glu Glu Leu Lys Lys Leu Ala Ser Ala Pro Gly 145 150 155 160 Gly Val Phe Ala Val Glu Asp Leu Pro Glu Leu Leu Asp Leu Leu Ile 165 170 175 Asp Leu 44 9 PRT Homo sapiens 44 Asn Leu Leu Gln Leu Leu Leu Glu Phe 1 5 45 44 PRT Mycobacterium tuberculosis 45 Arg Asn Asn Glu Asp Gly Thr Leu Gln Glu Ile Lys Lys Leu Leu Asp 1 5 10 15 Glu Ala Val Leu Ala Glu Arg Lys Glu Leu Ala Arg Ala Leu Asp Asp 20 25 30 Asp Ala Arg Phe Ala Glu Leu Gln Leu Asp Ala Leu 35 40 46 20 PRT Mycobacterium tuberculosis 46 Thr Gln Ala Leu Ala Asp Ile Ala Glu Leu Glu Gln Leu Ala Glu Gln 1 5 10 15 Ser Gln Ser Tyr 20 47 403 PRT Deinococcus radiodurans 47 Met Ala Arg Ile Thr Arg Tyr Ser Lys Phe Glu Gly Glu Leu Asp Gln 1 5 10 15 Leu Glu Ser Ser Glu Leu Met Gln Met Ile Gln Glu Ala Leu Leu Gly 20 25 30 Gln Gly Met Asn Asp Pro Trp Asp Pro Asp Pro Asn Ala Arg Pro Ser 35 40 45 Met Asp Asp Leu Phe Asp Ala Ile Leu Glu Ala Leu Ala Glu Arg Asn 50 55 60 Met Ile Pro Glu Glu Gln Leu Leu Glu Ala Leu Gln Ala Asp Asp Val 65 70 75 80 Arg Glu Thr Ala Leu Gly Gln Gln Ile Glu Arg Leu Met Asp Lys Leu 85 90 95 Gln Gln Asp Gly Phe Ile Arg Lys Glu Phe Gly Asp Glu Asp Gly Gln 100 105 110 Gly Gly Ala Gly Asn Pro Gly Glu Ala Thr Phe Gln Leu Thr Asp Lys 115 120 125 Ser Ile Asp Phe Leu Gly Tyr Lys Ser Leu Arg Asp Leu Met Gly Gly 130 135 140 Leu Gly Arg Ser Ser Ala Gly Ala His Asp Thr Arg Glu Tyr Ala Ser 145 150 155 160 Gly Val Glu Met Thr Gly Glu Leu Lys Asn Tyr Glu Phe Gly Asp Thr 165 170 175 Leu Asn Leu Asp Thr Thr Ala Thr Leu Gly Asn Val Ile Ser Lys Gly 180 185 190 Phe Asp Gln Leu Glu Glu Ala Asp Leu Val Ile Arg Gln Ala Glu Tyr 195 200 205 Ser Ser Ser Ala Ala Thr Val Val Met Leu Asp Cys Ser His Ser Met 210 215 220 Ile Leu Tyr Gly Glu Asp Arg Phe Thr Pro Ala Lys Gln Val Ala Leu 225 230 235 240 Ala Leu Ala His Leu Ile Arg Thr Gln Tyr Pro Gly Asp Thr Val Lys 245 250 255 Phe Val Leu Phe His Asp Ser Ala Glu Glu Val Pro Val Ser Lys Leu 260 265 270 Ala Gln Ala Gln Ile Gly Pro Tyr His Thr Asn Thr Ala Gly Gly Leu 275 280 285 Arg Leu Ala Gln Gln Leu Leu Lys Arg Glu Asn Lys Asp Met Lys Gln 290 295 300 Ile Val Met Ile Thr Asp Gly Lys Pro Ser Ala Leu Thr Leu Pro Asp 305 310 315 320 Gly Arg Ile Tyr Lys Asn Pro Tyr Gly Leu Asp Pro Tyr Val Leu Gly 325 330 335 Thr Thr Leu Arg Glu Val Ala Asn Cys Arg Arg Ser Gly Ile Gln Ile 340 345 350 Asn Thr Phe Met Leu Ala Arg Asp Pro Glu Leu Val Gly Phe Val Gln 355 360 365 Arg Val Ser Glu Met Thr Lys Gly Lys Ala Tyr Phe Thr Thr Pro Gln 370 375 380 Asn Ile Gly Gln Tyr Val Leu Gln Asp Phe Met Thr Asn Lys Thr Lys 385 390 395 400 Val Met Asn 48 190 PRT Homo sapiens MOD_RES (1) Variable amino acid 48 Xaa Ser Asp Ile Ala Phe Leu Ile Asp Gly Ser Gly Ser Ile Ile Pro 1 5 10 15 His Asp Phe Arg Arg Met Lys Glu Phe Val Ser Thr Val Met Glu Gln 20 25 30 Leu Lys Lys Ser Lys Thr Leu Phe Ser Leu Met Gln Tyr Ser Glu Glu 35 40 45 Phe Arg Ile His Phe Thr Phe Lys Glu Phe Gln Asn Asn Pro Asn Pro 50 55 60 Arg Ser Leu Val Lys Pro Ile Thr Gln Leu Leu Gly Arg Thr His Thr 65 70 75 80 Ala Thr Gly Ile Arg Lys Val Val Arg Glu Leu Phe Asn Ile Thr Asn 85 90 95 Gly Ala Arg Lys Asn Ala Phe Lys Ile Leu Val Val Ile Thr Asp Gly 100 105 110 Glu Lys Phe Gly Asp Pro Leu Gly Tyr Glu Asp Val Ile Pro Glu Ala 115 120 125 Asp Arg Glu Gly Val Ile Arg Tyr Val Ile Gly Val Gly Asp Ala Phe 130 135 140 Arg Ser Glu Lys Ser Arg Gln Glu Leu Asn Thr Ile Ala Ser Lys Pro 145 150 155 160 Pro Arg Asp His Val Phe Gln Val Asn Asn Phe Glu Ala Leu Lys Thr 165 170 175 Ile Gln Asn Gln Leu Arg Glu Lys Ile Phe Ala Ile Glu Gly 180 185 190 49 19 PRT Mycobacterium tuberculosis 49 Met Ala Thr Pro Ala Leu Leu Pro Gly Val Asp Leu Ala Ala Phe Phe 1 5 10 15 Ala Ala Ala 50 10 PRT Mycobacterium tuberculosis 50 Leu Ala Ala Glu Ala Ala Ala Leu Ala Ala 1 5 10 51 9 PRT Mycobacterium tuberculosis 51 Arg Ile Arg Pro Arg Arg Pro Arg Arg 1 5 52 17 PRT Mycobacterium tuberculosis 52 Pro Gly Val Asp Leu Ala Ala Glu Ala Ala Ala Leu Ala Ala Arg Leu 1 5 10 15 Arg 53 17 PRT Mycobacterium tuberculosis 53 Ala Thr Phe Asp Ala Val Phe Ala Ser Glu Phe Gly Tyr Glu Gly Ser 1 5 10 15 Ala 54 170 PRT Bradyrhizobium japonicum 54 Arg His Arg Pro Asp Ser Arg Gly Leu Arg Leu Asp Leu Arg Arg Thr 1 5 10 15 Leu Arg Ala Ser Leu Arg Thr Gly Gly Asp Ile Ile Asp Ile His Arg 20 25 30 Leu Gly Arg Ile Glu Lys Pro Ala Pro Ile Val Ala Leu Leu Asp Ile 35 40 45 Ser Gly Ser Met Asn Glu Tyr Thr Arg Leu Phe Leu His Phe Leu His 50 55 60 Ala Ile Gly Asp Ala Arg Lys Arg Val Ser Val Phe Leu Phe Gly Thr 65 70 75 80 Arg Leu Thr Asn Val Thr Arg Ala Leu Arg Gln Arg Asp Pro Asp Glu 85 90 95 Ala Leu Ala Ser Cys Ser Ala Ser Val Glu Asp Trp Ala Gly Gly Thr 100 105 110 Arg Ile Ser Ala Ser Leu His Asn Phe Asn Lys Leu Trp Ala Arg Arg 115 120 125 Val Leu Ser Gln Gly Ala Ile Val Leu Leu Ile Ser Asp Gly Leu Glu 130 135 140 Arg Glu Ala Asp Ser Arg Leu Ala Phe Glu Met Asp Arg Leu His Arg 145 150 155 160 Ser Cys Arg Arg Leu Ile Trp Leu Asn Pro 165 170 55 323 PRT Aeropyrum pernix 55 Met Gly Met Glu Asp Leu Glu Arg Leu Lys Gln Ala Leu Arg Ala Ala 1 5 10 15 Leu Ala Lys Asp Pro Gly Arg His Arg Leu Phe Asp Tyr Leu Phe Asp 20 25 30 Val Tyr Trp Arg Gly Ala Trp Thr Ala Val Gln Val Pro Gly Arg Arg 35 40 45 Ile Ala Val Arg Val Glu Val Glu Pro Gly Ser Pro Val Glu Arg Phe 50 55 60 Leu Ser Ile Tyr Ser Pro Val Glu Ala Ser Trp Gly Glu Pro Gly Val 65 70 75 80 Glu Pro Pro Ser Ala Ala Gln Ala Arg Ala Leu Tyr Arg Ser Leu Ala 85 90 95 Leu Leu Arg Arg Arg Leu Gly Leu Glu Glu Gly Arg Arg Arg Val Pro 100 105 110 Arg Arg Arg Gly Arg Ile Asp Phe Lys Arg Ser Met Arg Arg Ser Leu 115 120 125 Arg Thr Phe Gly Glu Thr Val Arg Leu Val Arg Ala Ser Arg Lys Arg 130 135 140 Ser Lys Thr Asp Ile Leu Val Leu Leu Asp Val Ser Asn Ser Met Lys 145 150 155 160 Asp Tyr Trp Pro Trp Ile Leu Gly Ile Leu Asn Ala Leu Arg Arg Leu 165 170 175 Pro Pro Gly Ser Tyr Glu Ala Phe Leu Phe Ser Thr Arg Leu Val Arg 180 185 190 Ala Thr Pro Met Val Glu Ala Ala Gly Gly Ala Glu Asp Leu Arg Arg 195 200 205 Leu Leu Ser Arg Val Glu Gly Leu Trp Gly Ser Gly Thr Arg Ile Ser 210 215 220 Gln Ser Val Glu Glu Leu Leu Glu Ser His Thr Pro Ala Leu His Arg 225 230 235 240 Gly Ala Ala Val Leu Val Phe Ser Asp Gly Trp Asp Leu Gly Asp Leu 245 250 255 Gly Arg Leu Ala Ser Ala Leu Ala Glu Leu Arg Arg Arg Ala Gly Phe 260 265 270 Leu Val Trp Val Thr Pro Glu Ser Pro Arg Arg Asp Ala Gly Gly Glu 275 280 285 Pro Ser Thr Met Arg Ile Ile Arg Arg His Ala Asp Leu Thr Ile Asp 290 295 300 Leu Glu Thr Leu Leu Asn Thr Arg Arg Leu Leu Arg Leu Leu Pro Arg 305 310 315 320 Ser Ser Ala 56 188 PRT Homo sapiens 56 Met Ala Ser Lys Gly Asn Val Asp Leu Val Phe Leu Phe Asp Gly Ser 1 5 10 15 Met Ser Leu Gln Pro Asp Glu Phe Gln Lys Ile Leu Asp Phe Met Lys 20 25 30 Asp Val Met Lys Lys Leu Ser Asn Thr Ser Tyr Gln Phe Ala Ala Val 35 40 45 Gln Phe Ser Thr Ser Tyr Lys Thr Glu Phe Asp Phe Ser Asp Tyr Val 50 55 60 Lys Trp Lys Asp Pro Asp Ala Leu Leu Lys His Val Lys His Met Leu 65 70 75 80 Leu Leu Thr Asn Thr Phe Gly Ala Ile Asn Tyr Val Ala Thr Glu Val 85 90 95 Phe Arg Glu Glu Leu Gly Ala Arg Pro Asp Ala Thr Lys Val Leu Ile 100 105 110 Ile Ile Thr Asp Gly Glu Ala Thr Asp Ser Gly Asn Ile Asp Ala Ala 115 120 125 Lys Asp Ile Ile Arg Tyr Ile Ile Gly Ile Gly Lys His Phe Gln Thr 130 135 140 Lys Glu Ser Gln Glu Thr Leu His Lys Phe Ala Ser Lys Pro Ala Ser 145 150 155 160 Glu Phe Val Lys Ile Leu Asp Thr Phe Glu Lys Leu Lys Asp Leu Phe 165 170 175 Thr Glu Leu Gln Lys Lys Ile Tyr Val Ile Glu Gly 180 185 57 192 PRT Homo sapiens 57 Ser Thr Gln Leu Asp Ile Val Ile Val Leu Asp Gly Ser Asn Ser Ile 1 5 10 15 Tyr Pro Trp Asp Ser Val Thr Ala Phe Leu Asn Asp Leu Leu Glu Arg 20 25 30 Met Asp Ile Gly Pro Lys Gln Thr Gln Val Gly Ile Val Gln Tyr Gly 35 40 45 Glu Asn Val Thr His Glu Phe Asn Leu Asn Lys Tyr Ser Ser Thr Glu 50 55 60 Glu Val Leu Val Ala Ala Lys Lys Ile Val Gln Arg Gly Gly Arg Gln 65 70 75 80 Thr Met Thr Ala Leu Gly Thr Asp Thr Ala Arg Lys Glu Ala Phe Thr 85 90 95 Glu Ala Arg Gly Ala Arg Arg Gly Val Lys Lys Val Met Val Ile Val 100 105 110 Thr Asp Gly Glu Ser His Asp Asn His Arg Leu Lys Lys Val Ile Gln 115 120 125 Asp Cys Glu Asp Glu Asn Ile Gln Arg Phe Ser Ile Ala Ile Leu Gly 130 135 140 Ser Tyr Asn Arg Gly Asn Leu Ser Thr Glu Lys Phe Val Glu Glu Ile 145 150 155 160 Lys Ser Ile Ala Ser Glu Pro Thr Glu Lys His Phe Phe Asn Val Ser 165 170 175 Asp Glu Ile Ala Leu Val Thr Ile Val Lys Thr Leu Gly Glu Arg Ile 180 185 190 

1. A polypeptide, which polypeptide: (i) has the amino acid sequence as recited in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO: 10 or SEQ ID NO: 12; (ii) is a fragment thereof having adhesion molecule activity or having an antigenic determinant in common with the polypeptide of (i); or (iii) is a functional equivalent of (i) or (ii).
 2. A polypeptide which is a fragment according to claim 1(ii), which includes the adhesion molecule region of the AD1 polypeptide, said adhesion molecule region being defined as including, at the most, between residues 1832 and 2036 inclusive, or at the least, between residues 1836 and 1950 inclusive, of the amino acid sequence recited in SEQ ID NO:2, wherein said fragment possesses the catalytic residues Ser1843, Ser1845 and Asp1912, or equivalent residues, or the trio Ser1843, Ser1845 and Thr1912, or equivalent residues, and possesses adhesion molecule activity.
 3. A polypeptide which is a functional equivalent according to claim 1(iii), is homologous to the amino acid sequence as recited in SEQ ID NO:2, possesses the catalytic residues Ser1843, Ser1845 and Asp1912, or equivalent residues, or the trio Ser1843, Ser1845 and Thr1912, or equivalent residues, and has adhesion molecule activity.
 4. A polypeptide according to claim 3, wherein said functional equivalent is homologous to the adhesion molecule region of the AD1 polypeptide.
 5. A polypeptide which is a fragment according to claim 1(ii), which includes the adhesion molecule region of the AD2 polypeptide, said adhesion molecule region being defined as including, at the most, between residue 10 and residue 126, and at the least, between residue 20 and residue 105 of the amino acid sequence recited in SEQ ID NO:4, wherein said fragment possesses the catalytic residues Thr25, Ser27 and Asp119, or equivalent residues, and possesses adhesion molecule activity.
 6. A polypeptide which is a functional equivalent according to claim 1(iii), is homologous to the amino acid sequence as recited in SEQ ID NO:4, possesses the catalytic residues Thr25, Ser27 and Asp119, or equivalent residues, and has adhesion molecule activity.
 7. A polypeptide according to claim 6, wherein said functional equivalent is homologous to the adhesion molecule region of the AD2 polypeptide.
 8. A polypeptide which is a fragment according to claim 1(ii), which includes the adhesion molecule region of the AD3 polypeptide, said adhesion molecule region being defined as including, at the most, between residue 1248 and residue 1432, and at the least, between residue 1253 and residue 1403 of the amino acid sequence recited in SEQ ID NO:6, wherein said fragment possesses the catalytic residues Ser1258, Ser1260 and Asp1367, or equivalent residues, and possesses adhesion molecule activity.
 9. A polypeptide which is a functional equivalent according to claim 1(iii), is homologous to the amino acid sequence as recited in SEQ ID NO:6, possesses the catalytic residues Ser1258, Ser1260 and Asp1367, or equivalent residues, and has adhesion molecule activity.
 10. A polypeptide according to claim 9, wherein said functional equivalent is homologous to the adhesion molecule region of the AD3 polypeptide.
 11. A polypeptide which is a fragment according to claim 1(ii), which includes the adhesion molecule region of the AD4 polypeptide, said adhesion molecule region being defined as including between residue 308 and residue 424 of the amino acid sequence recited in SEQ ID NO:8, wherein said fragment possesses the catalytic residues Thr323, Ser325 and Asp417, or equivalent residues, and possesses adhesion molecule activity.
 12. A polypeptide which is a functional equivalent according to claim 1(iii), is homologous to the amino acid sequence as recited in SEQ ID NO:8, possesses the catalytic residues Thr323, Ser325 and Asp417, or equivalent residues, and has adhesion molecule activity.
 13. A polypeptide according to claim 12, wherein said functional equivalent is homologous to the adhesion molecule region of the AD4 polypeptide.
 14. A polypeptide which is a fragment according to claim 1(ii), which includes the adhesion molecule region of the AD5 polypeptide, said adhesion molecule region being defined as including, at the most, between residue 482 and residue 646, and at the least; between residue 484 and residue 646 of the amino acid sequence recited in SEQ ID NO:10, wherein said fragment possesses the catalytic residues Ser491, Ser493 and Asp579, or equivalent residues, and possesses adhesion molecule activity.
 15. A polypeptide which is a functional equivalent according to claim 1(iii), is homologous to the amino acid sequence as recited in SEQ ID NO:10, possesses the catalytic residues Ser491, Ser493 and Asp579, or equivalent residues, and has adhesion molecule activity.
 16. A polypeptide according to claim 15, wherein said functional equivalent is homologous to the adhesion molecule region of the AD5 polypeptide.
 17. A polypeptide which is a fragment according to claim 1(ii), which includes the adhesion molecule region of the AD6 polypeptide, said adhesion molecule region being defined as including, at the most, between residue 230 and residue 370, and at the least, between residue 230 and residue 339 of the amino acid sequence recited in SEQ ID NO:12, wherein said fragment possesses the catalytic residues Ser237, Ser239 and Asp330, or equivalent residues; or the trio of Ser237, Ser239 and Thr302, or equivalent residues, and possesses adhesion molecule activity.
 18. A polypeptide which is a functional equivalent according to claim 1(iii), is homologous to the amino acid sequence as recited in SEQ ID NO:12, possesses the catalytic residues Ser237, Ser239 and Asp330, or equivalent residues; or the trio of Ser237, Ser239 and Thr302, or equivalent residues, and has adhesion molecule activity.
 19. A polypeptide according to claim 18, wherein said functional equivalent is homologous to the adhesion molecule region of the AD6 polypeptide.
 20. A fragment or functional equivalent according to any one of claims 1-19, which has greater than 30% sequence identity with an amino acid sequence as recited in any one of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO: 10 and SEQ ID NO:12, or with a fragment thereof that possesses adhesion molecule activity, preferably greater than 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98% or 99% sequence identity, as determined using BLAST version 2.1.3 using the default parameters specified by the National Center for Biotechnology Information.
 21. A functional equivalent according to claim 1, which exhibits significant structural homology with a polypeptide having the amino acid sequence given in any one of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10 and SEQ ID NO:12, or with a fragment thereof that possesses adhesion molecule activity.
 22. A fragment as recited in claim 1, having an antigenic determinant in common with the polypeptide of claim 1(i), which consists of 7 or more amino acid residues from the sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10 or SEQ ID NO:12.
 23. A purified nucleic acid molecule which encodes a polypeptide according to claim
 1. 24. A purified nucleic acid molecule according to claim 23, which has the nucleic acid sequence as recited in SEQ ID NO: 1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9 or SEQ ID NO: 11, or is a redundant equivalent or fragment thereof.
 25. A fragment of a purified nucleic acid molecule according to claim 23, which comprises, at the most, between nucleotides 5495 and 6109, and at the least, between nucleotides 5507 and 5851 of SEQ ID NO:1, or is a redundant equivalent thereof.
 26. A fragment of a purified nucleic acid molecule according to claim 23, which comprises, at the most, between nucleotides 30 and 380, and at the least, between nucleotides 60 and 317 of SEQ ID NO:3, or is a redundant equivalent thereof.
 27. A fragment of a purified nucleic acid molecule according to claim 23, which comprises, at the most, between nucleotides 3744 and 4298, and at the least, between nucleotides 3759 and 4211 of SEQ ID NO:5, or is a redundant equivalent thereof.
 28. A fragment of a purified nucleic acid molecule according to claim 23, which comprises between nucleotides 922 and 1272 of SEQ ID NO:7, or is a redundant equivalent thereof.
 29. A fragment of a purified nucleic acid molecule according to claim 23, which comprises, at the most, between nucleotides 1444 and 1938, and at the least, between nucleotides 1450 and 1938 of SEQ ID NO:9, or is a redundant equivalent thereof.
 30. A fragment of a purified nucleic acid molecule according to claim 23, which comprises, at the most, between nucleotides 688 and 1110, and at the least, between nucleotides 688 and 1017 of SEQ ID NO: 11, or is a redundant equivalent thereof.
 31. A purified nucleic acid molecule which hydridizes under high stringency conditions with a nucleic acid molecule according to claim
 23. 32. A vector comprising a nucleic acid molecule as recited in claim
 23. 33. A host cell transformed with a vector according to claim
 32. 34. A ligand which binds specifically to, and which preferably inhibits the adhesion molecule activity of, a polypeptide according to claim
 1. 35. A ligand according to claim 34, which is an antibody.
 36. A compound that either increases or decreases the level of expression or activity of a polypeptide according to claim
 1. 37. A compound that either increases or decreases the level of expression or activity of a polypeptide according to claim 1, wherein the compound binds to the polypeptide without inducing any of the biological effects of the polypeptide.
 38. A compound according to claim 36, which is a natural or modified substrate, ligand, enzyme, receptor or structural or functional mimetic.
 39. A polypeptide according to claim 1, for use in therapy or diagnosis of disease.
 40. A nucleic acid molecule according to claim 23, for use in therapy or diagnosis of disease.
 41. A vector according to claim 32, for use in therapy or diagnosis of disease.
 42. A ligand according to claim 34, for use in therapy or diagnosis of disease.
 43. A compound according claim 36, for use in therapy or diagnosis of disease.
 44. A method of diagnosing a disease in a patient, comprising assessing the level of expression of a natural gene encoding a polypeptide according to claim 1, or assessing the activity of a polypeptide according to claim 1, in tissue from said patient and comparing said level of expression or activity to a control level, wherein a level that is different to said control level is indicative of disease.
 45. A method according to claim 44 that is carried out in vitro.
 46. A method of diagnosing a disease in a patient, comprising assessing the level of expression of a natural gene encoding a polypeptide according to claim 1, or assessing the activity of a polypeptide according to claim 1, in tissue from said patient and comparing said level of expression or activity to a control level, wherein a level that is different to said control level is indicative of disease, wherein the method comprises the steps of (a) contacting a ligand which binds specifically to, and which preferably inhibits the adhesion molecule activity of, a polypeptide according to claim 1 with a biological sample under conditions suitable for the formation of a ligand-polypeptide complex; and (b) detecting said complex.
 47. A method of diagnosing a disease in a patient, comprising assessing the level of expression of a natural gene encoding a polypeptide according to claim 1, or assessing the activity of a polypeptide according to claim 1, in tissue from said patient and comparing said level of expression or activity to a control level, wherein a level that is different to said control level is indicative of disease, comprising the steps of: a) contacting a sample of tissue from the patient with a nucleic acid probe under stringent conditions that allow the formation of a hybrid complex between a nucleic acid molecule which encodes a polypeptide according to claim 1 and the probe; b) contacting a control sample with said probe under the same conditions used in step a); and c) detecting the presence of hybrid complexes in said samples; wherein detection of levels of the hybrid complex in the patient sample that differ from levels of the hybrid complex in the control sample is indicative of disease.
 48. A method of diagnosing a disease in a patient, comprising assessing the level of expression of a natural gene encoding a polypeptide according to claim 1, or assessing the activity of a polypeptide according to claim 1, in tissue from said patient and comparing said level of expression or activity to a control level, wherein a level that is different to said control level is indicative of disease, comprising: a) contacting a sample of nucleic acid from tissue of the patient with a nucleic acid primer under stringent conditions that allow the formation of a hybrid complex between a nucleic acid molecule which encodes a polypeptide according to claim 1 and the primer; b) contacting a control sample with said primer under the same conditions used in step a); and c) amplifying the sampled nucleic acid; and d) detecting the level of amplified nucleic acid from both patient and control samples; wherein detection of levels of the amplified nucleic acid in the patient sample that differ significantly from levels of the amplified nucleic acid in the control sample is indicative of disease.
 49. A method of diagnosing a disease in a patient, comprising assessing the level of expression of a natural gene encoding a polypeptide according to claim 1, or assessing the activity of a polypeptide according to claim 1, in tissue from said patient and comparing said level of expression or activity to a control level, wherein a level that is different to said control level is indicative of disease, comprising: a) obtaining a tissue sample from a patient being tested for disease; b) isolating a nucleic acid molecule which encodes a polypeptide according to claim 1 from said tissue sample; and c) diagnosing the patient for disease by detecting the presence of a mutation which is associated with disease in the nucleic acid molecule as an indication of the disease.
 50. The method of claim 49, further comprising amplifying the nucleic acid molecule to form an amplified product and detecting the presence or absence of a mutation in the amplified product.
 51. The method of either claim 49, wherein the presence or absence of the mutation in the patient is detected by contacting said nucleic acid molecule with a nucleic acid probe that hybridises to said nucleic acid molecule under stringent conditions to form a hybrid double-stranded molecule, the hybrid double-stranded molecule having an unhybridised portion of the nucleic acid probe strand at any portion corresponding to a mutation associated with disease; and detecting the presence or absence of an unhybridised portion of the probe strand as an indication of the presence or absence of a disease-associated mutation.
 52. A method according to claim 44, wherein said disease is a cardiovascular disease, atherosclerosis, ischaemia, restenosis, reperfusion injury, sepsis, a haematological disease, leukaemia, a blood clotting disorder, thrombosis, cancer, lung cancer, prostate cancer, breast cancer, colorectal tumors, brain tumors, metastasis, an inflammatory disease, rhinitis, a gastrointestinal disease, inflammatory bowel disease, ulcerative colitis, Crohn's disease, a respiratory disease, asthma, chronic obstructive pulmonary disease (COPD), respiratory distress syndrome, pulmonary fibrosis, immune disorders, autoimmune diseases, rheumatoid arthritis, transplant rejection, allergy, liver diseases, cirrhosis, endocrine diseases, diabetes, bone diseases, osteoporosis, neurological diseases, stroke, multiple sclerosis, spinal cord injury, burns, wound healing, bacterial infection, or virus infection.
 53. The method of claim 52, wherein the bacterial infection is a Mycobacterium tuberculosis infection.
 54. A method of using a polypeptide according to claim 1 as an adhesion molecule.
 55. A method of using a nucleic acid molecule according to claim 23 to express a protein that possesses adhesion molecule activity.
 56. A method for effecting cell-cell adhesion, utilizing a polypeptide according to claim
 1. 57. A pharmaceutical composition comprising a polypeptide according to claim
 1. 58. A pharmaceutical composition comprising a nucleic acid molecule according to claim
 23. 59. A pharmaceutical composition comprising a vector according to claim
 32. 60. A pharmaceutical composition comprising a ligand according to claim
 34. 61. A pharmaceutical composition comprising a compound according to claim
 36. 62. A vaccine composition comprising a polypeptide according to claim
 1. 63. A vaccine composition comprising a nucleic acid molecule according to claim
 23. 64. A pharmaceutical composition according to claim 57 for use in the manufacture of a medicament for the treatment of a cardiovascular disease, atherosclerosis, ischaemia, restenosis, reperfusion injury, sepsis, a haematological disease, leukaemia, a blood clotting disorder, thrombosis, cancer, lung cancer, prostate cancer, breast cancer, colorectal tumors, brain tumors, metastasis, an inflammatory disease, rhinitis, a gastrointestinal disease, inflammatory bowel disease, ulcerative colitis, Crohn's disease, a respiratory disease, asthma, chronic obstructive pulmonary disease (COPD), respiratory distress syndrome, pulmonary fibrosis, immune disorders, autoimmune diseases, rheumatoid arthritis, transplant rejection, allergy, liver diseases, cirrhosis, endocrine diseases, diabetes, bone diseases, osteoporosis, neurological diseases, stroke, multiple sclerosis, spinal cord injury, burns, wound healing, bacterial infection, or virus infection.
 65. A polypeptide according to claim 1 for use in the manufacture of a medicament for the treatment of wherein said disease is a cardiovascular disease, atherosclerosis, ischaemia, restenosis, reperfusion injury, sepsis, a haematological disease, leukaemia, a blood clotting disorder, thrombosis, cancer, lung cancer, prostate cancer, breast cancer, colorectal tumors, brain tumors, metastasis, an inflammatory disease, rhinitis, a gastrointestinal disease, inflammatory bowel disease, ulcerative colitis, Crohn's disease, a respiratory disease, asthma, chronic obstructive pulmonary disease (COPD), respiratory distress syndrome, pulmonary fibrosis, immune disorders, autoimmune diseases, rheumatoid arthritis, transplant rejection, allergy, liver diseases, cirrhosis, endocrine diseases, diabetes, bone diseases, osteoporosis, neurological diseases, stroke, multiple sclerosis, spinal cord injury, burns, wound healing, bacterial infection, or virus infection.
 66. A nucleic acid molecule according to claim 23 for use in the manufacture of a medicament for the treatment of wherein said disease is a cardiovascular disease, atherosclerosis, ischaemia, restenosis, reperfusion injury, sepsis, a haematological disease, leukaemia, a blood clotting disorder, thrombosis, cancer, lung cancer, prostate cancer, breast cancer, colorectal tumors, brain tumors, metastasis, an inflammatory disease, rhinitis, a gastrointestinal disease, inflammatory bowel disease, ulcerative colitis, Crohn's disease, a respiratory disease, asthma, chronic obstructive pulmonary disease (COPD), respiratory distress syndrome, pulmonary fibrosis, immune disorders, autoimmune diseases, rheumatoid arthritis, transplant rejection, allergy, liver diseases, cirrhosis, endocrine diseases, diabetes, bone diseases, osteoporosis, neurological diseases, stroke, multiple sclerosis, spinal cord injury, burns, wound healing, bacterial infection, or virus infection.
 67. A vector according to claim 32 for use in the manufacture of a medicament for the treatment of a wherein said disease is a cardiovascular disease, atherosclerosis, ischaemia, restenosis, reperfusion injury, sepsis, a haematological disease, leukaemia, a blood clotting disorder, thrombosis, cancer, lung cancer, prostate cancer, breast cancer, colorectal tumors, brain tumors, metastasis, an inflammatory disease, rhinitis, a gastrointestinal disease, inflammatory bowel disease, ulcerative colitis, Crohn's disease, a respiratory disease, asthma, chronic obstructive pulmonary disease (COPD), respiratory distress syndrome, pulmonary fibrosis, immune disorders, autoimmune diseases, rheumatoid arthritis, transplant rejection, allergy, liver diseases, cirrhosis, endocrine diseases, diabetes, bone diseases, osteoporosis, neurological diseases, stroke, multiple sclerosis, spinal cord injury, burns, wound healing, bacterial infection, or virus infection.
 68. A ligand according to claim 34 for use in the manufacture of a medicament for the treatment of a wherein said disease is a cardiovascular disease, atherosclerosis, ischaemia, restenosis, reperfusion injury, sepsis, a haematological disease, leukaemia, a blood clotting disorder, thrombosis, cancer, lung cancer, prostate cancer, breast cancer, colorectal tumors, brain tumors, metastasis, an inflammatory disease, rhinitis, a gastrointestinal disease, inflammatory bowel disease, ulcerative colitis, Crohn's disease, a respiratory disease, asthma, chronic obstructive pulmonary disease (COPD), respiratory distress syndrome, pulmonary fibrosis, immune disorders, autoimmune diseases, rheumatoid arthritis, transplant rejection, allergy, liver diseases, cirrhosis, endocrine diseases, diabetes, bone diseases, osteoporosis, neurological diseases, stroke, multiple sclerosis, spinal cord injury, burns, wound healing, bacterial infection, or virus infection.
 69. A compound according to claim 36 for use in the manufacture of a medicament for the treatment of a wherein said disease is a cardiovascular disease, atherosclerosis, ischaemia, restenosis, reperfusion injury, sepsis, a haematological disease, leukaemia, a blood clotting disorder, thrombosis, cancer, lung cancer, prostate cancer, breast cancer, colorectal tumors, brain tumors, metastasis, an inflammatory disease, rhinitis, a gastrointestinal disease, inflammatory bowel disease, ulcerative colitis, Crohn's disease, a respiratory disease, asthma, chronic obstructive pulmonary disease (COPD), respiratory distress syndrome, pulmonary fibrosis, immune disorders, autoimmune diseases, rheumatoid arthritis, transplant rejection, allergy, liver diseases, cirrhosis, endocrine diseases, diabetes, bone diseases, osteoporosis, neurological diseases, stroke, multiple sclerosis, spinal cord injury, burns, wound healing, bacterial infection, or virus infection.
 70. The method of claim 64, wherein the bacterial infection is a Mycobacterium tuberculosis infection.
 71. The method of claim 65, wherein the bacterial infection is a Mycobacterium tuberculosis infection.
 72. The method of claim 66, wherein the bacterial infection is a Mycobacterium tuberculosis infection.
 73. The method of claim 67, wherein the bacterial infection is a Mycobacterium tuberculosis infection.
 74. The method of claim 68, wherein the bacterial infection is a Mycobacterium tuberculosis infection.
 75. The method of claim 69, wherein the bacterial infection is a Mycobacterium tuberculosis infection.
 76. A method of treating a disease in a patient, comprising administering to the patient a polypeptide according to claim
 1. 77. A method of treating a disease in a patient, comprising administering to the patient a nucleic acid molecule according to claim
 23. 78. A method of treating a disease in a patient, comprising administering to the patient a vector according to claim
 32. 79. A method of treating a disease in a patient, comprising administering to the patient a ligand according to claim
 34. 80. A method of treating a disease in a patient, comprising administering to the patient a compound according to claim
 36. 81. A method of treating a disease in a patient, comprising administering to the patient a pharmaceutical composition according to claim
 57. 82. A method according to claim 76, wherein, for diseases in which the expression of the natural gene or the activity of the polypeptide is lower in a diseased patient when compared to the level of expression or activity in a healthy patient, the polypeptide administered to the patient is an agonist or an antagonist.
 83. A method according to claim 77, wherein, for diseases in which the expression of the natural gene or the activity of the polypeptide is lower in a diseased patient when compared to the level of expression or activity in a healthy patient, the nucleic acid molecule administered to the patient is an agonist or an antagonist.
 84. A method according to claim 78, wherein, for diseases in which the expression of the natural gene or the activity of the polypeptide is lower in a diseased patient when compared to the level of expression or activity in a healthy patient, the vector administered to the patient is an agonist or an antagonist.
 85. A method according to claim 79, wherein, for diseases in which the expression of the natural gene or the activity of the polypeptide is lower in a diseased patient when compared to the level of expression or activity in a healthy patient, the ligand administered to the patient is an agonist or an antagonist.
 86. A method according to claim 80, wherein, for diseases in which the expression of the natural gene or the activity of the polypeptide is lower in a diseased patient when compared to the level of expression or activity in a healthy patient, the compound administered to the patient is an agonist or an antagonist.
 87. A method according to claim 81, wherein, for diseases in which the expression of the natural gene or the activity of the polypeptide is lower in a diseased patient when compared to the level of expression or activity in a healthy patient, the composition administered to the patient is an agonist or an antagonist.
 88. A method of monitoring the therapeutic treatment of disease in a patient, comprising monitoring over a period of time the level of expression or activity of a polypeptide according to claim 1, in tissue from said patient, wherein altering said level of expression or activity over the period of time towards a control level is indicative of regression of said disease.
 89. A method of monitoring the therapeutic treatment of disease in a patient, comprising monitoring over a period of time the level of expression of a nucleic acid molecule according to claim 23 in tissue from said patient, wherein altering said level of expression or activity over the period of time towards a control level is indicative of regression of said disease.
 90. A method for the identification of a compound that is effective in the treatment and/or diagnosis of disease, comprising contacting a polypeptide according to claim 1 with one or more compounds suspected of possessing binding affinity for said polypeptide, and selecting a compound that binds specifically to said polypeptide.
 91. A method for the identification of a compound that is effective in the treatment and/or diagnosis of disease, comprising contacting a nucleic acid molecule according to claim 23 with one or more compounds suspected of possessing binding affinity for nucleic acid molecule, and selecting a compound that binds specifically to said nucleic acid molecule.
 92. A method for the identification of a compound that is effective in the treatment and/or diagnosis of disease, comprising contacting a host cell according to claim 33 with one or more compounds suspected of possessing binding affinity for said nucleic acid molecule, and selecting a compound that binds specifically to said nucleic acid molecule.
 93. A kit useful for diagnosing disease comprising a first container containing a nucleic acid probe that hybridises under stringent conditions with a nucleic acid molecule according to claim 23; a second container containing primers useful for amplifying said nucleic acid molecule; and instructions for using the probe and primers for facilitating the diagnosis of disease.
 94. The kit of claim 93, further comprising a third container holding an agent for digesting unhybridised RNA.
 95. A kit comprising an array of nucleic acid molecules, at least one of which is a nucleic acid molecule according to claim
 23. 96. A kit comprising one or more antibodies that bind to a polypeptide as recited in claim 1; and a reagent useful for the detection of a binding reaction between said antibody and said polypeptide.
 97. A transgenic or knockout non-human animal that has been transformed to express higher, lower or absent levels of a polypeptide according to claim
 1. 98. A method for screening for a compound effective to treat disease, by contacting a non-human transgenic animal according to claim 97 with a candidate compound and determining the effect of the compound on the disease of the animal. 